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1. Amplification and Transduction of a Light Signal by 
Regulated Photo-Activated Catalysisa 
1.1. Introduction 
1.1.1. Photoinitiated Reactions 
 
The most well-known example of photoinitiated reactions in nature is the neuronal 
response triggered by a light signal in retinal cells. The photoreceptor Rhodopsin is 
composed of the 40-kDa apoprotein opsin and its chromophore, 11-cis-retinal, a 
derivative of vitamin A that acts as an inverse agonist in the rhodopsin ground state. 
Photon absorption by rhodopsin isomerizes the 11-cis chromophore to all-trans, 
which triggers a series of conformational changes in opsin and leads to an active 
state of rhodopsin.1 This means that retinal is the allosteric group of rhodopsin as its 
conformational change activates rhodopsin without taking place at the active site.2 
The active state of rhodopsin is responsible for binding the heterotrimeric G-protein 
of the rod cell, transducin (Gt), and for the catalysis of the uptake of guanosine 
triphosphate by the -subunit of Gt. Thereby it initiates the enzymatic cascade that 
leads to vision.3,4 
This signal amplification by allosteric catalysis (SAAC) is also achieved by several 
artificial systems to mimic biological signal transduction processes, in which a 
molecular recognition event of an external signal or analyte to a receptor is 
transduced into catalytically amplified chemical information. Using engineered 
enzymes,5 ribozymes6 or adjustable organic catalysis7,8 this concept was applied by 
several groups for analytical purposes.9 Artificial SAAC systems reported so far 
converted external chemical signals into amplified chemical output. This mimics the 
signal transduction pathway, for example of a membrane bound receptor with 
subsequent amplification of the response. 
Visual response, in which light stimulates a photoreceptor to activate a signal trans-
duction cascade resulting in amplified chemical output, is another biological model for 
signal amplifying catalysis. Examples of artificial light-induced signal amplifying 
catalysis are the classical photographic process (autocatalytic signal amplification),10  
                                                 
a
 Results of this chapter have been published: S.C. Ritter, B. König, Chem. Commun. 2006, 45, 4694. 
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and the hydrosilylation of alkynes, catalyzed by Pt(II)-complexes after initial 
irradiation11 or by Fe(II)- or Cr(III)-complexes under continuous irradiation 
(scheme 1).12 Such photoactivated catalysts include Pt(acac)2, (η2-Cyclopentadienyl) 
trialkylplatinum and iron- and chromium-carbonyl complexes. These catalysts are 
activated by irradiation with UV-light. Activation takes place as one of the ligands is 
lost in the presence of silanes (scheme 2). 
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Scheme 1: Light-activated hydrosilylation of alkynes. 
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Scheme 2: Pt(II)-catalyst in its inactive form and after activation with UV-light. 
However, due to uncontrolled polymerisation, these systems are not able to 
transform the initial light-signal into a specific chemical output signal, similar to photo-
initiated radical reactions. Further, it is still uncertain if a definite amount of light forms 
a corresponding amount of active catalyst. 
Another approach to use light to control chemical reactions is the light-dependent 
azobenzene isomerisation. This system mimics the function of rhodopsin, as its 
photoactivation is also based on a change of conformation. It has been used to 
design photo-adjustable catalysts and enzymes13,14 (fig. 1), which can be switched 
“on” and “off” as the cis- and the trans-conformer of azobenzene-catalysts show 
different absorption behaviour and also different catalytic activity.  
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Figure 1: Trans-isomer of a photo-adjustable bis-Zn(II)-BPA-complex for non-enzymatic hydrolisis 
of RNA (additional ligands in the coordination-sphere of Zn2+ are missing for better 
clarity). 
While the trans-isomer is absorbing in the UV-region between 300 nm and 400 nm, 
the cis-isomer shows absorption of visible light at about 450 nm.14,15 These systems 
show allosteric behaviour in their catalytic activity, but are also not able to amplify the 
light-signal, which can be called the allosteric effector, in a specific way. 
 
1.1.2. Scope 
 
To design an artificial system which is able to amplify and transduct an initial light 
signal into chemical output information, four fundamental conditions have to be 
fulfilled: 
1) A light-sensitive element (a chromophore) has to use the initial photo-signal to 
activate a catalytic system. This could be achieved by a photochemical 
reaction, by a change of structure, or by a change of redox-potential. Further, 
the chromophore should show a high molar extinction coefficient (log ε > 4) 
and a high quantum yield (Φ nearly 1) to enable efficient exploitation of light 
energy. 
2) The amount (concentration) of active catalyst formed by the irradiated 
chromophore has to depend on the amount of light (number of photons) in 
order to guarantee reproducable results. Naturally a linear relationship 
between both values is desirable. Short-listed catalysts include enzymes and 
transition-metal complexes such as ruthenium-, palladium-, platinum- or 
copper-complexes. 
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3) The catalyst has to show a high turnover number to enable a large 
amplification of the initial light-signal. 
4) The catalyzed reaction has to depend on the concentration of catalyst (a direct 
proportional relationship is desirable). Besides, the catalysis has to be a 
mono- or bi-molecular reaction to guarantee a fast and definite reaction-
process. Further, it should proceed as quickly as possible, without formation of 
by-products, and enable a simple read-out to allow for quick evaluation. 
Polymerisation reactions as well as multi-component reactions (MCR) must be 
excluded, as the former proceed uncontrolled, and the latter are too complex 
and possibly proceed too slowly. 
 
Although these requirements are quite demanding, the combination of the light-driven 
reduction of flavines (fulfills 1)) with the Cu(I)-catalyzed “click-chemistry” (fulfills 3) 
and 4)) promises to be a good approach to design such a “chemical photo-multiplier”. 
Fig. 2 summarizes the general signalling pathway. Initial excitation of the flavine-
chromophore in the presence of an electron donor leads to its photoreduction. The 
reduced chromophore allows for the conversion of an inactive catalyst precursor 
(Cu2+) into an active catalyst (Cu+). The active catalyst then amplifies and converts 
the signal into a chemical output. The number of received photons is correlated with 
the amount of active catalyst generated, which is translated into the reaction rate of 
the conversion from substrate to product. 
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Figure 2: General signal-transduction pathway of a photoreceptor showing allosteric behaviour. 
Riboflavine tetraacetate (1)16 was used as redoxactive chromophore receiving the 
light signal. In the presence of a sacrificial electron donor, e.g. benzyl alcohol or 
triethylamine, excited flavin 1* undergoes photoreduction to give 1-H2 
(scheme 3).17,24 The quantum yield of this well-known process is in the order of 0.4.18 
Under the experimental conditions dihydroflavin (1-H2) is expected to have a 
sufficient redox potential to reduce Cu2+ to Cu+.19 Finally, the Cu(I)-catalyzed 
cycloaddition of an alkyne with an azide produces the chemical output of the 
cascade. 
 
1.2. Main Part 
1.2.1. The Light-Driven Flavine Redox System 
 
Upon irradiation with visible light (λ > 420 nm), flavines are excited from the ground-
state into the n,pi*-triplet-state,20,21,22 which is involved with a large change in redox-
potential.23 In the presence of a suitable reducing agent (sacrificial electron donor), 
like benzyl alcohols,22,24,25 amines,26 and thiols,27 the excited flavine is reduced to 
dihydroflavine (scheme 3). The presence of oxygen must be strictly excluded to avoid 
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formation of flavin-hydroperoxides and reoxidation of 1-H2 to 1.21,24,28 These 
processes would, in the end, prevent the reduction of Cu2+ by 1-H2. 
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Scheme 3: Reversible flavine-redoxsystem enabling the photo-regulated formation of Cu+. 
The photoreduction of 1 by several amines (NEt3, HNEt2 and BuNH2) and benzyl 
alcohol in different solvents (H2O, MeCN, tBuOH/H2O 2:1 and DMSO/H2O 1:1) was 
confirmed experimentally by UV/Vis-spectroscopy as the absorption spectrum of 1 
significantly differs from 1-H2 (fig. 3). 
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Figure 3: UV/Vis-spectra of 1 and 1-H2 in H2O (c = 5⋅10-5 mol/l). 1-H2 was generated by irradiation 
with visible light in the presence of benzyl alcohol. 
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While 1 shows a characteristic peak at 456 nm, the absorption of 1-H2 in the visual 
region is rather insignificant. Also, the absorption at 384 nm becomes weaker after 
reduction. These results match the spectroscopic behaviour of similar flavines.29 
Results of photoreduction-reactions with 1 showed that 1-H2 is formed in aqueous 
solutions (100 % H2O, tBuOH/H2O 2:1 and DMSO/H2O 1:1) in the presence of 
amines (NEt3 and HNEt2) as well as benzyl alcohol. Carrying out the reaction in 
MeCN, photoreduction of 1 was observed only in the presence of amines (NEt3, 
HNEt2 and BuNH2), but not with benzyl alcohol. 
 
1.2.2. Generation of the Cu(I)-Catalyst 
 
In order to find out if 1-H2 is able to reduce Cu2+ to Cu+, mixtures of 1, various 
sacrificial electron donors and different Cu(II)-salts in four solvents (H2O, MeCN and 
mixtures of DMSO/H2O 1:1 and tBuOH/H2O 2:1) were irradiated with visible light (see 
experimental section, general procedure (GP) 1). As formation of Cu+ cannot be 
observed directly in solution, it is detected indirectly using its catalytic activity in the 
[2+3] dipolar cycloaddition reaction. A “click-reaction” that can easily be followed is 
the formation of triazole 4 from phenylacetylene (2) and benzylazide (3). 
N3
N
NN
+
Cu(I)
2 3 4
 
Scheme 3: Cu(I)-catalyzed triazole formation. 
To monitor the conversion, 4 can either be isolated from the reaction mixture (GP 2), 
or the resonance shift of the benzylic CH2-signal in the 1H-NMR-spectrum is used; 
the CH2-group of 2 shows a singlet at 4.33 ppm, whereas the corresponding signal of 
the CH2-group of the triazole-product appears at 5.55 ppm. Both peaks are 
unaffected by the signals of other components or by-products, neither at the 
beginning nor at the end of the reaction (fig. 4, 5). The conversion can then be 
determined from the peak areas (GP 3). 
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Figure 4: 1H-NMR (CDCl3) spectrum of a mixture of 1, 2, 3, BnOH and CuSO4 x 5 H2O without 
irradiation. Assignment of main signals is shown. 
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Figure 5: 1H-NMR-spectrum (CDCl3) of the reaction mixture after 280 min of irradiation with visible 
light. The arrow marks the growing resonance signal of the CH2-group of 4. 
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In aqueous solution as well as in DMSO/H2O 1:1 and tBuOH/H2O 2:1, the formation 
of 4, and therefore formation of Cu(I), was observed for mixtures of 1 with BnOH, 
NEt3 or HNEt2 as sacrificial electron donors and CuSO4 x 5 H2O or CuCl2 as Cu(II)-
sources (following GP 1 and GP 2). No reaction was observed if Cu(ClO4)2 x 6 H2O 
was used. A reason for this might be that the perchlorate-anion has a sufficient 
oxidation potential to oxidize either 1-H2 or Cu+.  
In acetonitrile solution, the number of Cu(II)-salts that can be tested is quite limited, 
as only CuCl2 and Cu(ClO4)2 x 6 H2O are soluble in MeCN. Results were the same 
as in aqueous solutions: only CuCl2 allowed formation of Cu+, but not the perchlorate 
salt. Sacrificial electron donors NEt3, HNEt2, BuNH2, ethylenediamine, BnOH, p-
methoxy-benzylalcohol and thiophenol were tested, but the formation of 4 could only 
be observed with NEt3.30 One possible explanation for this result is that the Cu2+/Cu+ 
redox potential strongly depends on the available ligands for copper complexation. 
Further, chelating ligands like EDTA or ethylenediamine cannot be used, as they 
stabilize Cu2+ and therefore shift the Cu2+/Cu+ redox potential to more negative 
values.8,31 
Knowing the fundamental conditions for the photo-regulated “click-reaction”, further 
parameters can be investigated:  
• How does the process of the reaction influence the time of irradiation and, 
therefore, the amount of light (= number of photons)? 
• How does the concentration of Cu(II)-salt and sacrificial electron donor 
influence the process of the reaction? 
• What is the influence of the solvent on the reaction? 
 
1.2.3. Light-Depending “Click-Reaction” in Aqueous Solution 
 
The dependence of the conversion on the concentration of Cu2+ and on the duration 
of irradiation was investigated. Mixtures of 1, 2, 3, BnOH and CuSO4 x 5 H2O (10, 25 
and 50 mol%) in tBuOH/H2O 2:1 were irradiated for up to 9 h following GP 1. To 
determine the amount of 4 formed after a certain reaction time, the triazole was 
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isolated from the reaction mixture (GP 2). Results shown in diagram 1 are average 
values obtained after three repititions. 
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Diagram 1: Formation of 4 depending on time of irradiation and amount of CuSO4 x 5 H2O. 
Diagram 1 clearly shows a dependence of formation of 4 on irradiation-time and 
concentration of Cu2+, but errors are too large to allow a quantitative interpretation. It 
should be noted that GP 2 is not a suitable method to obtain reliable data. For this 
reason the conversion in all subsequent experiments was monitored using GP 3. 
In a new experiment, the progress of the reaction in alternating periods of irradiation 
and stirring in the dark was investigated. The behaviour of the reaction in these 
conditions is more of interest, as Cu+ is not stable in aqueous solutions in the 
absence of any stabilizing ligands.32 For this reason, the reaction is expected to stop 
when irradiation is switched off. 
The reaction mixture (GP 1) was irradiated for 90 min, then stirred in the dark for 
130 min, irradiated again for 70 min and finally stirred in the dark for 130 min. 
Diagram 2 gives the reaction conversion versus time. Values were derived from 
threefold repitition. 
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Diagram 2: Progress of reaction conversion during periods of irradiation (red triangles, white 
background) and dark periods (black dots, grey background). 
The reaction clearly shows an induction period of approx. 50 min, a significant 
increase in the reaction rate upon irradiation and ceasing in the dark. These results 
confirm the previous expections. Thus, performed in aqueous media the reaction 
cascade shows light-dependent behaviour: the cycloaddition reaction proceeds only 
under continuous irradiation due to the instability of Cu+ in aqueous media. 
Therefore, this approach cannot be used to develop a system that amplifies an initial 
light signal. 
 
1.2.4. Light-Initiated “Click-Reaction” in Acetonitrile Solution 
 
Amplification of the initial light signal requires the produced Cu(I) to be active and 
stable for some time. The choice of solvent is therefore crucial. In acetonitrile the 
photochemically produced Cu(I) is sufficiently stable to catalyze the cycloaddition for 
extended periods after short irradiation times (15 s to 180 s). To facilitate the 
monitoring of the Cu(I)-catalyzed cycloaddition, a bimolecular reaction between 
suitable dyes was used, showing a change in the absorption- or emission-spectrum 
after triaziole formation. This approach will enable a quick and easy readout. 
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1.2.4.1. Synthesis and Spectroscopic Characteristics of Fluorescent Dyes for Cu(I)-
Catalyzed Cycloaddition Reaction 
 
One possible approach is to use a fluorescent resonance energy transfer (FRET) 
between two covalently connected fluorophores. Anslyn et al. reported about the 
application of this idea to determine the concentration of Pb(II)-cations in analytical 
probes. The reported system used a FRET occuring after the cycloaddition reaction 
between a coumarin-azide and an anthracene-alkyne.8 
In order to design a similar system with simple and cheap fluorescent dyes, alkyne- 
and azide-substituted fluorescein- and dansyl-derivatives were used. Fluorescein can 
easily be functionalized with electrophiles at one of its phenol groups, forming 
phenolethers.33 Dansyl-derivatives can easily be derived from the sulfonic acid 
chloride, using amines or alcohols. Fluorescence spectra of corresponding 
substituted fluoresceins show emission in polar solvents, like MeOH, between 
520 nm and 550 nm, when excited between 470 nm and 490 nm. Substituted dansyl-
sulfonamides show emission in non-polar solvents, like CHCl3, at about 480 nm after 
excitation at about 330 nm. Thus, if a FRET between both dyes occurs, then the 
excitation of the dansyl unit at 330 nm should result in the emission signal of the 
fluorescein unit at λ > 520 nm. 
The alkyne-substituent was coupled to the fluorescein moiety in a SN2 reaction using 
propargylbromide and fluorescein di-sodium salt. In order to cleave the formed 
propargyl ester without affecting the ether, the raw product was treated with aqueous 
NaOH in MeOH. Finally, the lactone was formed by addition of hydrochloric acid. The 
raw product had to be purified by column chromatography. Surprisingly, this led to a 
mixture of the desired compound 5 and the corresponding methyl ether 6. Separation 
of 5 from 6 was not possible using chromatographic methods. However, as 5 was 
soluble in diethylether while 6 was not, separation of both compounds was achieved. 
5 was obtained in a low yield of 15 %, whereas 6 could be obtained in a yield of 65 % 
(scheme 4). 
The mechanism of the formation of 6 could not be clarified. The use of MeOH as 
solvent during synthesis should not be the reason, as its replacement by THF or 
propargyl alcohol gave exclusively compound 6. 
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Scheme 4: Synthesis of alkyne-substituted fluorescein dye 5. 
Spectroscopic characteristics of 5 were as expected. Figure 6 shows absorption and 
emission spectrum of 5 in MeOH. 
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Figure 6: Absorption and emission spectrum of 5 in MeOH (c = 1.30 x 10-4 mol/L). 
In order to synthesize an azide-substituted dansyl derivative, dansyl chloride was 
reacted with 2-azido-ethylamine hydrochloride under basic conditions using NEt3. 
After a short workup, the desired dansyl derivative 7 could be obtained in almost 
quantitative yield (scheme 5). 
 14
S OO
Cl
N
N
+ N3H
H
H
S OO
N
N
H
N3
Cl
+
DCM
NEt3
r. t. 1 h
95 %
7
 
Scheme 5: Synthesis of dansyl azide 7. 
Spectroscopic characteristics of 7 in MeOH were not as expected. The fluorescence 
spectrum showed a strong red-shift of 39 nm of the emission wavelength compared 
to the value in CHCl3 (fig. 7). The absorption spectrum of 7 showed no considerable 
differences in MeOH or CHCl3. 
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Figure 7: Absorption spectrum of 7 in MeOH and emission spectrum in MeOH and CHCl3 (c = 
1.13 x 10-4 mol/L). For better clarity the differences in the emission intensity are not taken 
into consideration. 
Because of the shift of the emission signal of 7 to longer wavelengths in MeOH, a 
FRET between both dyes could not occur. The usage of non-polar solvents, like 
CHCl3, was not possible, as fluorescein derivatives show fluorescence only in polar 
media. To verify this hypothesis, the triazole product 8, from 5 and 7, was 
synthesized in a typical “click-reaction” (scheme 6). 
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Scheme 6: Synthesis of triaziole 8. 
As expected, the triazole 8 showed no FRET when excited at 336 nm – neither in 
MeOH nor in CHCl3. Spectral characteristics of 8 were simply the same as a 
equimolar mixture of 5 and 7 (fig. 8). This proved that there was no affection on the 
spectra of either dye after covalent connection. 
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Figure 8: Fluorescence spectra of 8 in MeOH (c = 1.13 x 10-4 mol/L). 
In order to check if an additional substituent at the sulfonamide nitrogen shifts the 
emission signal of 7 to shorter wavelengths, an electron-pushing and an electron-
withdrawing group were introduced at this position. As sulfonamides can be 
deprotonated quite easily (pKa (water)= 10 – 11.5),34 new derivatives are accessible 
by reaction with suitable electrophiles like acetylanhydride or benzyl bromide. 
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Scheme 7: Synthesis of two further dansyl derivatives 9 and 10. 
Scheme 7 shows the synthesis of the dansyl derivatives 9 and 10. Compound 10 
was synthesized using NEt3, which is a sufficiently strong base to deprotonate 7. The 
following reaction with acetanhydride was catalyzed using DMAP. In order to 
introduce the benzyl group, a non-nucleophilic base, like sodium hydride, had to be 
used. In both cases, the desired compounds were obtained in quantitative yields. 
Fluorescence spectra of 9 and 10 showed that neither the introduction of a benzyl 
group nor the acetylation gave the desired effect of a blue shift of the emission 
signal. The emission maximum of 9 is at 520 nm and therefore almost identical to 
that of 7. Further, the introduction of an acetyl group (compound 10) yielded exactly 
the opposite effect: the emission maximum was shifted to 560 nm. 
In the end the approach of generating a FRET between a fluorescein and a dansyl 
derivative was not successful. In order to use some of the synthesized compounds to 
monitor the process of a “click-reaction”, a different system was used. The working 
group of Finn used the intramolecular quenching of the fluorescence signal of a 
dansyl group by a dabsyl dye35 to determine the conversion of a Cu(I)-catalyzed 
cycloaddition reaction.36 Compound 7 could be used in a corresponding approach. 
After the “click-reaction” with the dabsyl derivative 11 (scheme 8) the triazole (12) did 
not show any fluorescence. Compounds 11 and 12 were synthesized as previously 
described.36 
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Scheme 8: Cu(I)-catalyzed cycloaddition used as indicator reaction. 
 
1.2.4.2. Kinetic Measurements of the Light-Initiated Cu(I)-Catalyzed Cycloaddition 
Reaction 
 
The reaction mixture of 7, 11 (each 0.4 mmol), 1 (4 mol%), NEt3 (1 eq) and CuCl2 
(8 mol%) in MeCN was irradiated under identical conditions (see GP 4) for various 
lengths of time (from 0 to 180 sec) and the reaction rate of the initiated Cu(I)-
catalyzed cycloaddition in the dark was monitored (diagram 3). The quenching of the 
fluorescence of 7 can even be followed with bare eyes (fig. 9). 
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Diagram 3: Decrease of emission intensity over 20 min of reaction time exemplary for one reaction 
(initial irradiation time: 180 s). Values were derived from 3 repititions. 
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Figure 9: Emission fading during the photoinitiated cycloaddition; initial irradiation time was 90 s; 
from left to right: emission of the solution after 1 min, 10 min and 20 min reaction time in 
the dark. 
A slow background reaction was observed without irradiation due to the spontaneous 
reduction of Cu2+ to Cu+ by NEt3. Experimental results showed that after addition of 
1 eq NEt3, enough Cu+ was generated from CuCl2 to start the cycloaddition reaction. 
However, within irradiation times of 30 to 180 s, a significant increase of the reaction 
rate was observed (diagram 4). 
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Diagram 4: Conversion vs. reaction time depending on time of initial irradiation. 
Of course, this background reaction is not desired. In order to slow this reaction down 
or even stop it completely, the dependence of this “dark reaction” on the 
concentration of NEt3 was investigated. Diagram 5 shows the reaction process 
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exemplary for two reactions with 1 eq and 0.1 eq NEt3. There is a significant drop of 
the reaction rate if catalytic amounts of sacrificial electron donor are used. 
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Diagram 5: Decrease of fluorescence of reaction batch with 1 eq and 0.1 eq NEt3. 
Considering that an equimolar relation between NEt3 and 1 is sufficient to enable 
formation from 1-H2, and the following reduction of Cu(II), the use of 0.1 eq NEt3 
should not slow down the light initiated reaction. Experimental results showed 
otherwise: the use of lower amounts of NEt3 slowed the light-initiated reaction more 
than the “dark reaction”. When 0.15 eq NEt3 or less was used, the light initiated 
reaction stopped completely (diagram 6). 
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Diagram 6: Fluorescence vs. reaction time after initial irradiation of 180 s with 0.1 eq NEt3. The arrow 
marks the addition of further 0.9 eq NEt3 after 72 min. 
However, after the addition of further 0.9 eq NEt3, the reaction started immediately, 
without any further irradiation. The reaction proceeded only insignificantly lower than 
the corresponding one with 1 eq NEt3. This means that upon irradiation, almost all 
sacrificial electron donor is used up, and formation of 1-H2 takes place. 1-H2 is stable 
+ 0.9 eq NEt3 
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in the reaction mixture for at least 70 min, but the dihydroflavine itself is not able to 
reduce Cu2+ to Cu+. Thus, the presence of NEt3 is essential, as it forms a Cu(II)-
amine complex. Exceptionally [Cu(NEt3)4]2+ can be reduced by 1-H2. This confirms 
the prior assumption in chapter [1.2.2.]. Thus, for all subsequent experiments 1 eq of 
NEt3 was used. 
To estimate the efficiency of the light to catalyst conversion of the reaction, the 
dependence of the reaction rate of formation of 12 on the Cu(I) concentration under 
the experimental conditions, was determined (GP 5). 
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Diagram 7: Dependence of the cycloaddition reaction rate on the Cu(I)-concentration. 
Diagram 7 shows the reaction rate with respect to the concentration of copper iodide. 
Reaction rates were calculated from linear region in conversion vs. time diagram (up 
to 40 % conversion). Results clearly show a linear dependence for the experimental 
conditions employed (MeCN as solvent; NEt3 as additive; low CuI-concentration of 
10-4 to 10-3 mol/L). Thus, the reaction rate is first order in Cu(I). For catalytic reactions 
in aqueous solution and concentrations > 10-2 mol/L, a binuclear Cu(I)-complex was 
previously proposed.37 
Now with information from diagram 4 and diagram 7, the dependence of the rate 
enhancement, as well as the dependence of the surplus Cu(I) formation on the 
amount of photons, can be determined (diagram 8).  
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Diagram 8: Acceleration of the initial reaction rate and conversion of Cu(II) to Cu(I) depending on the 
amount of light (data points are for irradiation-times of 0, 15, 30, 60, 90, 135 and 180 s). 
Results show that even without irradiation, already 22 % of Cu(II) is converted. 
Further, with short irradiation times (< 30 s), the background reaction becomes 
important, while longer irradiation (> 100 s) leads to a non-linear response of the 
photoreceptor due to bleaching of 1-H2,17b the formation of side-products instead of 
1-H2,21 and decreasing concentrations of the sacrificial electron donor and CuCl2 
(related flavin photoreactions showed a similar behaviour).22,24 
In order to improve the performance of the photoreceptor, concentrations of 1 and 
CuCl2 were varied. Under better reaction conditions, the course of the graph in 
diagram 8 should become steeper. In particular, the efficiency of the Cu(II)-
conversion is rather low – between 20 % and 60 %. Theoretically, larger 
concentrations of 1 (up to 15 mol%) should not only lead to more Cu(II)-conversion 
(and therefore a wider linear range), but also to shorter irradiation times. In contrast, 
experimental results showed that larger concentrations of 1 lead primarily to an 
acceleration of the background reaction. The reason for this is unknown. Use of 
lower amounts of 1 or varying the concentration of Cu(II) also showed no 
improvement in performance. Thus, reaction conditions with 1 eq NEt3, 4 mol% 1 and 
8 mol% of CuCl2 were found to be optimal. 
Results from diagram 8 give a quantum yield of the Cu(I) generation of 0.2 and an 
overall quantum yield of triazole-formation (which can also be called the overall 
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amplification factor of the reaction cascade) of up to 15 after 20 min reaction time. 
This corresponds to a turnover number of 70 for Cu+ after that time. 
 
1.3. Summary and Conclusions 
 
In summary, a simple catalytic system, which is able to translate a light signal into a 
chemical output with amplified response, was developed. The overall amplification 
factor is 15 after a reaction time of 20 min. Although its fidelity in terms of sensitivity 
and amplification is far from biological models, the results show that coupling optical 
and chemical processes allows for the processing and amplification of information. 
Mechanistic details of the reaction cascade like efficiency of formation of 1-H2, and 
Cu(I), as well as the dependence of the cycloaddition reaction on the Cu(I)-
concentration, were determined. With this information, reaction conditions were 
optimized to achieve best possible performance of this photoreceptor system. 
Reaction process was monitored using a literature-known system, which allowed a 
quick and easy optical readout. 
New fluorescent dyes containing alkyne- and azide-groups were synthesized. These 
compunds allow modular connection to a lot of substrates, such as labelling of 
proteins. 
The catalytic system also works in aqueous media, where the reaction cascade 
shows light-depending behaviour. This enables control of the reaction by simply 
turning a light-source “on” or “off”. 
 
1.4. Outlook 
 
Theoretically, if the quantum yield of the formation of dihydroflavine was 1, every 
photon would be able to generate up to two copper(I)-cations (scheme 3). The 
resulting quantum yield of Cu(I)-formation would be 2, if the reduction of Cu(II) took 
place without any undesired background reaction. Then the reported catalytic system 
would show an amplification factor up to 1000, if the turnover number of the Cu(I)-
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catalyst was also raised (larger concentration of substrates, longer reaction time). 
The main improvement to be made is to switch off the background reaction. This 
could be achieved by using different complexing ligands, which allow for the easy 
reduction of Cu2+ without participating in a redox reaction. Polydentate thio-ether 
ligands could fulfill these creteria.38 Another possibility is the use of a different amine 
base, e.g. diethylamine. To compensate the resulting change in the redox potential of 
the Cu2+/Cu+-system, a dihydroflavine with a more negative redox potential has to be 
used. This can be achieved by the introduction of an electron-pushing substituent at 
the 7- or 8-position of the isoalloxazine system.39 A further approach would be the 
change of the solvent to e.g. DMSO or THF, which allow for solvation of CuCl2. 
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1.5. Experimental Part 
1.5.1. General Information 
 
All reactions were performed under an inert atmosphere using standard Schlenk 
techniques. Acetonitrile (HPLC-grade, Baker) was freshly distilled over sodium 
hydride and P4O10.  
For irradiation a commercial available Osram daylight lamp (200 W, 220 V) was 
used. To exclude irradiation with UV-light a LOT-Oriel filter was used. To 
compensate fluctuations in electricity and, therefore, in the intensity of emitted light, 
experiments were repeated twice and each day at the same time. 
 
1.5.1.1. Spectroscopy 
 
Emission Spectroscopy 
Fluorescence measurements were done in acetonitrile (UV-grade, Baker or Merck) at 
25 °C in 1 cm quartz cuvettes (Hellma) and recorded on a Varian ‘Cary Eclipse’ 
fluorescence spectrophotometer. The excitation wavelength was 337 nm for all 
measurements and the internal photomultiplier voltage was adjusted to 700 V. The 
intensity of fluorescence of (7) was measured in a range of 420 nm to 650 nm. 
Concentration of (7)/(11) was 4 µmol/L or lower to avoid intermolecular quenching of 
fluorescence, which was observed at concentrations higher than 20 µmol/L. To 
determine the conversion of the reaction the decrease of intensity of the maximum 
fluorescence at 524 nm was observed. 
 
Absorption Spectroscopy 
Varian Cary BIO 50 UV/VIS/NIR Spectrometer. Use of a 1 cm quartz cell (Hellma) 
and Uvasol solvents (Merck or Baker). 
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NMR Spectra 
Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 K), Bruker Avance 400 
(1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), Bruker Avance 300 (1H: 300.1 MHz, 
13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ [ppm] relative to 
external standards (solvent residual peak). The spectra were analysed by first order, 
the coupling constants are given in Hertz [Hz]. Characterisation of the signals: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet, dd = 
double doublet, dt = double triplet, ddd = double double doublet. Integration is 
determined as the relative number of atoms. Assignment of signals in 13C-spectra 
was determined with DEPT-technique (pulse angle: 135 °) and given as (+) for CH3 
or CH, (-) for CH2 and (Cquat) for quaternary C. Error of reported values: chemical 
shift: 0.01 ppm for 1H-NMR, 0.1 ppm for 13C-NMR and 0.1 Hz for coupling constants. 
The solvent used is reported for each spectrum. 
 
Mass Spectra 
Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD), Finnigan MAT TSQ 7000 
(ESI). Xenon serves as the ionisation gas for FAB. 
 
IR Spectra 
Recorded with a Bio-Rad FTS 2000 MX FT-IR and Bio-Rad FT-IR FTS 155. 
 
1.5.1.2. Analysis 
 
Cyclic Voltammetry 
Measurements were carried out under an inert atmosphere of argon in degassed and 
dry MeCN. The electrodes used were platinum (counter electrode), glassy carbon 
(working electrode) and Ag/AgCl (reference). Scan rate: 20 mV/s; electrolyte: 
tetrabutylammonium hexafluorophosphate (c = 0.2 mol/L). Concentrations of 1 and 
Cu(II) amine complexes were 2.5 mmol/L. E0 values were determined versus Fc/Fc+ 
as internal reference ([E0] = ([Ea]+[Ec])/2). 
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1.5.1.3. Synthesis 
 
Melting Points were determined on a Tottoli micro melting point apparatus and are 
uncorrected. TLC analyses were performed on silica gel 60 F-254 with a 0.2 mm 
layer thickness. Detection via UV light at 254 nm / 366 nm or through discolouration 
with ninhydrin in EtOH was used. For preparative column-chromatography, Merck 
Geduran SI 60 silica gel was used. Commercially available solvents of standard 
quality were used. If otherwise stated, purification and drying was done according to 
accepted general procedures.40 Elemental analyses were carried out by the Center 
for Chemical Analysis of the Faculty of Natural Sciences of the University 
Regensburg. 
 
1.5.2. General Procedures 
 
GP 1 for reactions in water, DMSO/water 1:1, tBuOH/water 2:1: 
Under an atmosphere of argon 1000 mg of benzyl azide (7.50 mmol), 766 mg of 
phenyl acetylene (7.50 mmol), the organic solvent and 15.0 mmol (2 eq) of sacrificial 
electron donor (benzyl alcohol: 1620 mg, 1545 µl; NEt3: 1518 mg, 2091 µl; HNEt2: 
1097 mg, 1552 µl) were added into a Schlenk-flask. Then a solution of 0.75 mmol 
(10 mol%) Cu(II)-salt (CuSO4 x 5 H2O: 187 mg; CuCl2: 101 mg, Cu(ClO4)2 x 6 H2O: 
278 mg) in water was added. The total volume of solvent (-mixture) added was 22 ml. 
The mixture was degassed and saturated with argon three times (using the “pump-
and-freeze method”). After warming to 25 °C 163 mg of 1 (0.30 mmol, 4 mol%) were 
added and the mixture was stirred well. To keep the reaction temperature constant at 
25 °C the Schlenk-flask was placed into a thermostated water-bath. The mixture was 
irradiated for various lengths of time. 
 
GP 1 for reactions in MeCN: 
Under an atmosphere of argon 1000 mg of benzyl azide (7.50 mmol), 766 mg of 
phenyl acetylene (7.50 mmol), 15.0 mmol (2 eq) of sacrificial electron donor (benzyl 
alcohol: 1620 mg, 1545 µl; NEt3: 1518 mg, 2091 µl; HNEt2: 1097 mg, 1552 µl, 
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BuNH2: 1097 mg, 1483 µl; ethylenediamine: 902 mg, 1002 µl; p-methoxy-benzyl 
alcohol: 2072 mg, 1862 µl; thiophenol: 1653 mg, 1540 µl) and 12 ml of dry MeCN 
were added into a Schlenk-flask. Then a solution of 0.75 mmol (10 mol%) Cu(II)-salt 
(CuCl2: 101 mg; Cu(ClO4)2 x 6 H2O: 278 mg) in 10 ml MeCN was added. The mixture 
was degassed and saturated with argon three times (using the “pump-and-freeze 
method”). After warming to 25 °C, 163 mg of 1 (0.30 mmol, 4 mol%) were added and 
the mixture was stirred well. To keep the reaction temperature constant at 25 °C, the 
Schlenk-flask was placed into a thermostated water-bath. The mixture was irradiated 
for various time. 
 
GP 2: 
After irradiation the mixture was diluted with 30 ml water and extracted three times 
with 100 ml EE each time. The organic phase was dried over Na2SO4, concentrated 
at reduced pressure and well dried in vacuum. The remaining yellow solid was eluted 
over a short silica gel column with pure EE to seperate 4 from 1. The obtained 
solution was concentrated and dried in vacuum. This yielded 4 as a colourless 
crystalline solid. 
 
GP 3: 
Aliquots of 40 µl were taken every 10 minutes from the mixture and diluted with 
0.8 ml CDCl3. 40 µl of 30 % aqueous H2O2 were added to stop the reaction. After 
phase separation, a NMR-spectrum was recorded. 
 
GP 4: 
Azide 2 (127.8 mg, 400 µmol) was dissolved in a schlenk-tube in 5 ml of MeCN. 
Alkyne 3 (137.0 mg, 400 µmol) was dissolved in a schlenk-flask in 15 ml of MeCN. 
Both solutions were degassed and saturated with argon. Under exclusion of light, 1 
(8.7 mg, 16 µmol, 4 mol %), CuCl2 (4.3 mg, 32 µmol, 8 mol %) and 55.4 µl of NEt3 
(40.5 mg, 400 µmol) were added in this order to the azide-solution. The solution was 
stirred in the dark (for 120 s to 300 s) and then irradiated (for 0 s to 180 s). After 
irradiation the alkyne solution was added. The mixture was stirred well in the dark 
and aliquots of 20 µl were taken every minute. The samples were added to a solution 
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of 20 µl of 30 % aqueous H2O2 in 2000 µl MeCN to stop the reaction. Samples of 
60 µl of this solution were diluted with 3000 µl MeCN and emission spectra were 
recorded. 
To prevent reduction of the light intensity required for the photoreduction process, the 
alkyne compound was added after irradiation. Compound 11 showed a strong 
absorption signal in the blue-light region (λmax (log ε) = 442 nm (4.496), in acetonitrile 
solution) and therefore competed with 1, which showed a similar absorption 
behaviour between 400 and 500 nm (λmax (log ε) = 449 nm (3.953), in aqueous 
solution). The azide compound did not influence neither the absorption behaviour of 
1 nor the photoreduction process, as it showed no absorbance in the relevant region 
above 400 nm. 
 
GP 5: 
Azide 7 (63.9 mg, 200 µmol) was dissolved in a Schlenk tube in different amounts of 
MeCN (approx. 2.0 – 2.9 ml, depending on the volume of CuI solution, which was 
added later). Alkyne 11 (68.5 mg, 200 µmol) was dissolved in a Schlenk flask in 
7.0 ml of MeCN. Both solutions were degassed and saturated with argon. Then, 27.7 
µl of NEt3 (20.2 mg, 200 µmol) and various amounts (approx. 100 µL to 1000 µL) of a 
stock solution of 38.1 mg of CuI (200 µmol) in 20 ml degassed acetonitrile were 
added to the azide solution to ensure a constant overall volume. Finally, the alkyne 
solution was added. The mixture was stirred well and aliquots of 20 µl were taken 
every minute. The samples were added to a solution of 20 µl of 30 % aqueous H2O2 
in 2000 µl acetonitrile to stop the reaction. Samples of 60 µl of this solution were 
diluted with 3000 µl of acetonitrile to determine the emission spectra. 
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1.5.3. Synthesis of New Compounds 
 
Safety 
Sodium azide is toxic and can generate the extremely hazardous hydrazoic acid 
(volatile, toxic, explosive) if it gets in contact with acids. Organic azides with a 
saturated carbon:azide ratio of < 6 (such as azidoethylamine or azidopropylamine) 
may be heat and shock sensitive and should be handled carefully. Phenylacetylene 
is suspected to cause cancer. 
 
Chemicals 
Dansyl chloride, fluorescein di-sodium salt, 2-bromoethylamine hydrobromide, 
3-bromopropylamine hydrobromide, propargylamine and phenyl acetylene were 
obtained from Fluka Chemicals. Benzyl azide was synthesized from benzyl bromide 
and sodium azide. 
 
N
+
H
H
H
N3
Cl
 
2-azidoethylamine hydrochloride: 
The hydrobromide (2.0 g, 9.8 mmol) was dissolved in a saturated aqueous solution of 
NaN3 (2.6 g, 39.4 mmol, 4 eq) and heated to 90 °C for 16 h. CAUTION! as the 
solution is acidic this causes the formation of volatile and toxic HN3! After cooling the 
solution to room temperature NaOH was added to make the solution basic (pH > 10). 
This produces the free amine which was separated from all inorganic compounds by 
distillation under reduced pressure (100 mbar, bp: 50 – 60 °C). The distillate was an 
aqueous solution of the amine which was afterwards acidified with 6 N hydrochloric 
acid. Lyophilisation of this solution gave the desired compound as a colourless, 
hygroscopic solid (1.10 g, 92 %). 
1H-NMR (300 MHz, MeOD): δ = 3.12 (t, 3J = 5.6 Hz, 2 H), 3.75 (t, 3J = 5.6 Hz, 2 H); 
13C-NMR (75.5 MHz, MeOD): δ = 40.1 (–, 1 C), 49.5 (–, 1 C); MS (ESI, H2O/MeCN): 
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m/z (%) = 87.0 [MH+] (100), 127.9 [MH++MeCN] (17); IR (KBr): ν  [cm-1] = 3530, 
2988, 2145, 1605, 1498, 1276, 1148; MF: C2H7N4Cl; MW = 122.56 g/mol; 
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3-azidopropylamine hydrochloride: 
The hydrobromide (2.0 g, 9.8 mmol) was dissolved in a saturated aqueous solution of 
NaN3 (2.6 g, 39.4 mmol, 4 eq) and heated to 90 °C for 16 h. CAUTION! as the 
solution is acidic this causes the formation of volatile and toxic HN3! After cooling the 
solution to room temperature NaOH was added to make the solution basic (pH > 10). 
This produces the free amine which was separated from all inorganic compounds by 
distillation under reduced pressure (100 mbar, bp: 50 – 60 °C). The distillate was an 
aqueous solution of the amine which was afterwards acidified with 6 N hydrochloric 
acid. Lyophilisation of this solution gave the desired compound as a colourless, 
hygroscopic solid (1.1 g; 92 %). 
1H-NMR (300 MHz, MeOD): δ = 1.97 (tt, 3J = 6.6 Hz, 3J = 7.4 Hz, 2 H), 3.01 – 3.06 
(m, 2 H), 3.52 (t, 3J = 6.6 Hz, 2 H); 13C-NMR (75.5 MHz, MeOD): δ = 28.0 (–, 1 C), 
38.5 (–, 1 C), 49.6 (–, 1 C); MS (ESI, H2O/MeCN): m/z (%) = 101.0 [MH+] (100), 
142.0 [MH++MeCN] (13); IR (KBr): ν  [cm-1] = 3532, 2987, 2147, 1604, 1497, 1278, 
1149; MF: C3H9N4Cl; MW = 136.58 g/mol; 
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Propargylfluorescein (5) and Methylfluorescein (6): 
Fluorescein-disodium-salt (3.8 g, 10 mmol) was suspended in 100 ml DMF and 8.6 
ml of a solution of propargyl bromide in toluene (80 %, 11.9 g, 80 mmol) was added. 
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The mixture was stirred at r.t. for 24 h, then a reflux condenser was put on and the 
suspension was heated to 40 °C for further 24 h. After addition of 150 ml water, a 
precipitate fell out of solution. The mixture was extracted twice with 300 ml EE each 
time. In order to redissolve the precipitate completely the mixture had to be heated to 
approx. 40 °C. The organic layer was washed with 100 ml water, 50 ml brine and 
dried over Na2SO4. Removal of the solvent at reduced pressure and drying in 
vacuum gave a red solid which was suspended in 160 ml MeOH. After addition of 
25 ml aqueous NaOH (c = 2 mol/L) the solid dissolved slowly. The mixture was 
stirred at 40 °C for 4 h. The MeOH was evaporated at reduced pressure and 50 ml 
water was added. The aqueous solution was washed with diethylether (50 ml, twice). 
The organic layers were discarded. The aqueous layer was acidified to pH 2 with 
hydrochloric acid (c = 10 mol/L) to precipitate the product. The suspension was 
stirred at r.t. for 1 h and filtered. The residue was dissolved in 300 ml EE. The 
solution was washed with 100 ml water, 50 ml brine and dried over Na2SO4. Removal 
of the solvent and drying in vacuum gave a red solid which was purified by column 
chromatography (diethylether:PE = 2:1). This yielded a mixture of compound 5 and 6 
in a ratio of 15:65 (determined by 1H-NMR). To separate both compounds the yellow 
solid is treated with small amounts of diethyl ether several times. Solutions were 
checked by TLC (eluent: diethylether:PE = 2:1, Rf (5) = 0.38, Rf (6) = 0.35). Pure 
solutions of 5 were combined. Removal of the solvent and drying in vacuum finally 
yielded 555 mg of 5 (15 %, 1.5 mmol).  
 
Compound 5: 
Mp: 125 °C; 1H-NMR (300 MHz, DMSO-d6): δ = 3.64 (t, 4J = 2.2 Hz, 1 H, CH), 4.89 
(d, 4J = 2.2 Hz, 2 H, CH2), 6.57 (s, 1 H), 6.58 (s, 1 H), 6.66 – 6.77 (m, 3 H), 7.00 (d, 
4J = 2.5 Hz, 1 H), 7.30 (d, 3J = 7.7 Hz, 1 H), 7.72 (dt, 3J = 7.4 Hz, 4J = 1.1 Hz, 1 H), 
7.80 (dt, 3J = 7.5 Hz, 4J = 1.2 Hz, 1 H), 8.01 (d, 3J = 7.1 Hz, 1 H), 10.21 (bs, 1 H, 
OH); 13C-NMR (75.5 MHz, DMSO-d6): δ = 55.7 (–), 78.7 (+, alkyne-CH), 78.8 (Cquat, 
alkyne), 82.5 (Cquat), 101.7 (+), 102.1 (+), 109.3 (Cquat), 111.6 (Cquat), 112.3 (+), 112.8 
(+), 123.9 (+), 124.6 (+), 125.9 (Cquat), 128.9 (+), 129.0 (+), 130.1 (+), 135.6 (+), 
151.6 (Cquat), 151.6 (Cquat), 152.3 (Cquat), 158.7 (Cquat), 159.5 (Cquat), 168.6 (Cquat); MS 
(ESI, MeOH): m/z (%) = 371.1 [MH+] (100); UV (MeOH) λmax (log ε) = 453 nm 
(3.370), 478 nm (3.280); MF: C23H14O5; MW = 370.36 g/mol; 
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Compound 6: 
Mp: 135 °C; 1H-NMR (300 MHz, DMSO-d6): δ = 3.83 (s, 3 H, CH3), 6.57 (s, 1 H), 
6.58 (s, 1 H), 6.66 – 6.77 (m, 3 H), 6.93 (d, 4J = 2.5 Hz, 1 H), 7.29 (d, 3J = 7.7 Hz, 1 
H), 7.71 (dt, 3J = 7.4 Hz, 4J = 1.1 Hz, 1 H), 7.79 (dt, 3J = 7.5 Hz, 4J = 1.2 Hz, 1 H), 
8.00 (d, 3J = 7.1 Hz, 1 H), 10.22 (bs, 1 H, OH); 13C-NMR (75.5 MHz, DMSO-d6): δ = 
55.5 (+), 82.5 (Cquat), 100.7 (+), 102.1 (+), 109.3 (Cquat), 110.8 (Cquat), 112.3 (+), 
112.8 (+), 123.9 (+), 124.6 (+), 125.9 (Cquat), 128.9 (+), 129.0 (+), 130.1 (+), 135.6 
(+), 151.6 (Cquat), 151.6 (Cquat), 152.3 (Cquat), 159.5 (Cquat), 160.9 (Cquat), 168.6 (Cquat); 
MS (ESI, MeOH): m/z (%) = 347.1 [MH+] (100); UV (MeOH) λmax (log ε) = 453 nm 
(3.366), 478 nm (3.275); MF: C21H14O5; MW = 346.34 g/mol; 
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5-Dimethylamino-naphtalene-1-sulfonic acid (2-azido-ethyl)-amide (7): 
Dansyl chloride (864 mg, 3.2 mmol) was dissolved in 10 ml DCM. To this solution 
1.78 ml of NEt3 (1296 mg, 12.8 mmol, 4 eq) and 2-azido-ethylamine hydrochloride 
(785 mg, 6.4 mmol, 2 eq) were added. The mixture was stirred 1 h at room 
temperature and diluted with 40 ml DCM as TLC showed almost 100 % conversion. 
The solution was washed once with 50 ml of saturated aqueous solution of NaHCO3, 
dried over Na2SO4, filtered and concentrated at reduced pressure. The crude product 
was purified by column chromatography over a short silica gel column, eluting with 
EE:PE = 7:3. This gave the dansyl derivative 7 as light yellow oil, which crystallized 
after drying in vacuum (972 mg, 95 %). Rf (EE:PE = 1:3) = 0.30. 
1H-NMR (300 MHz, CDCl3): δ = 2.88 (s, 6 H, 2 CH3), 3.05 (dt, 3J = 5.8 Hz, 3J = 
6.3 Hz, 2 H, CH2), 3.28 (t, 3J = 5.8 Hz, 2 H, CH2), 5.43 (t, 3J = 6.3 Hz, 1 H, NH), 7.18 
(dd, 3J = 7.7 Hz, 4J = 1.0 Hz, 1 H), 7.48 – 7.58 (m, 2 H), 8.24 (dd, 3J = 7.3 Hz, 4J = 
1.3 Hz, 1 H), 8.29 (d, 3J = 8.8 Hz, 1 H), 8.55 (dt, 3J = 8.5 Hz, 4J = 1.1 Hz, 1 H); 
13C-NMR (75.5 MHz, CDCl3): δ = 41.3 (–), 44.4 (+), 49.8 (–), 114.3 (+), 117.5 (+), 
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122.1 (+), 127.6 (+), 128.4 (Cquat), 128.5 (+), 128.8 (Cquat), 129.7 (+), 133.5 (Cquat), 
150.9 (Cquat); MS (ESI, DCM/MeOH): m/z (%) = 320.2 [MH+] (100), 639.4 [2M+H+] 
(20); EA (C14H17N5SO2) calc.: C 52.65 H 5.37 N 21.93, found: C 52.71 H 5.44 N 
21.79; UV (MeOH) λmax (log ε) = 336 nm (3.684); MF: C14H17N5SO2; 
MW = 319.38 g/mol; 
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(5-Dimethylamino-naphtalene-1-sulfonic acid  [2-(4-methyl-[1,2,3]triazol-1-yl)-ethyl]-
amidyl)-fluorescein (8): 
The azide 7 (51 mg, 0.16 mmol) and the alkyne 5 (59 mg, 0.16 mmol) were dissolved 
in 4 ml EtOH and a solution of 63 mg sodium ascorbate (0.32 mmol, 2 eq) in 1 ml 
water was added. Finally a solution of 40 mg CuSO4 x 5 H2O (0.16 mmol, 1 eq) in 
0.5 ml water was added and the mixture was stirred at r.t. for 3 h. TLC after that time 
showed complete conversion. The mixture was diluted with 20 ml water and 
extracted with EE (50 ml, twice). The organic phases were combined, dried over 
Na2SO4 and concentrated at reduced pressure. The resulting orange solid was 
purified by column chromatography (DCM:MeOH = 98:2 to 95:5). This gave 8 as 
yellow solid in a yield of 101 mg (92 %, 0.15 mmol). Rf (DCM:MeOH = 97:3) = 0.2. 
1H-NMR (300 MHz, acetone-d6): δ = 2.87 (s, 6 H, 2 CH3), 3.44 – 3.50 (m, 2 H, CH2), 
4.80 (t, 3J = 5.9 Hz, 2 H, CH2), 5.13 (s, 2 H, CH2), 6.62 – 6.81 (m, 5 H), 6.99 – 7.01 
(m, 1H), 7.17 (t, 3J = 6.2 Hz, 1 H, NH), 7.23 – 7.28 (m, 2 H), 7.50 – 7.62 (m, 2 H), 
7.68 – 7.80 (m, 2 H), 7.84 (s, 1 H, triazole), 7.97 – 8.01 (m, 1 H), 8.21 (dd, 3J = 
7.4 Hz, 4J = 1.1 Hz, 1 H), 8.32 (d, 3J = 8.8 Hz, 1 H), 8.57 (d, 3J = 8.5 Hz, 1 H), 9.15 
(bs, 1 H, OH); Due to low solubility of 8 in all organic solvents and overlapping of too 
many signals 13C-NMR spectrum is not evaluable; MS (ESI, DCM/MeOH): m/z (%) = 
690.2 [MH+] (100); UV (MeOH) λmax (log ε) = 336 nm (3.688), 453 nm (3.375), 
478 nm (3.285); MF: C37H31N5SO7; MW = 689.74 g/mol; 
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5-Dimethylamino-naphtalene-1-sulfonic acid (2-azido-ethyl)-benzyl-amide (9): 
The dansyl derivative 7 (200 mg, 0.63 mmol) was dissolved in 3 ml dry DMF. The 
solution was cooled to 0 °C in an ice-bath. After addition of NaH (60 % suspension in 
paraffine, 28 mg, 0.69 mmol, 1.1 eq) 150 µl of benzyl bromide (214 mg, 1.25 mmol, 
2 eq) was added dropwise. The ice-bath was removed and the solution was stirred 
for 6 h while warming to room temperature. TLC after that time showed complete 
conversion. Water (20 ml) is added and the resulting mixture is extracted with EE 
(30 ml, twice). The organic layer is dried over Na2SO4 and solvent is removed at 
reduced pressure. This gave a brown oil which was purified by column 
chromatography (EE:PE = 8:2). Drying in vacuum yielded compound 9 as greenish 
yellow oil (254 mg, 0.62 mmol, 99 %). Rf (EE:PE = 1:3) = 0.37. 
1H-NMR (300 MHz, CDCl3): δ = 2.90 (s, 6 H, 2 CH3), 3.20 (t, 3J = 6.6 Hz, 2 H, 
N-CH2), 3.38 (t, 3J = 6.6 Hz, 2 H, CH2), 4.53 (s, 2 H, Bn-CH2), 7.17 – 7.28 (m, 6 H, 
arom. CH), 7.50 – 7.63 (m, 2 H), 8.26 (dd, 3J = 7.3 Hz, 4J = 1.2 Hz, 1 H), 8.38 (d, 3J = 
8.8 Hz, 1 H), 8.58 (dt, 3J = 8.5 Hz, 4J = 1.1 Hz, 1 H); 13C-NMR (75.5 MHz, CDCl3): δ =  
45.5 (+), 45.6 (–, N-CH2), 49.8 (–), 52.3 (–, Bn), 115.4 (+, 1 C), 119.3 (+, 1 C), 123.2 
(+, 1 C), 128.1 (+, 1 C), 128.4 (+, 1 C), 128.6 (+, 2 C), 128.8 (+, 2 C), 130.1 (+, 1 C), 
130.1 (Cquat, 1 C), 130.1 (Cquat, 1 C), 130.8 (+, 1 C), 134.6 (Cquat, 1 C), 135.7 (Cquat, 
1 C), 151.9 (Cquat); MS (ESI, DCM/MeOH): m/z (%) = 410.1 [MH+] (100), 819.5 
[2M+H+] (5); EA (C21H23N5SO2) calc.: C 61.59 H 5.66 N 17.10, found: C 61.72 H 5.74 
N 17.00; UV (MeOH) λmax (log ε) = 337 nm (3.694); MF: C21H23N5SO2; 
MW = 409.51 g/mol; 
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5-Dimethylamino-naphtalene-1-sulfonic acid acetyl-(2-azido-ethyl)-amide (10): 
The sulfonamide 7 (281 mg, 0.88 mmol) was dissolved in 12 ml dry DCM. After 
addition of 818 µl NEt3 (594 mg, 3.52 mmol, 4 eq), 333 µl acetanhydride (359 mg, 
3.52 mmol, 4 eq) and 11 mg DMAP (0.09 mmol, 10 mol%) the solution was stirred at 
room temeprature for 2 h. TLC after that time showed complete conversion. The 
solution was diluted with 200 ml DCM and washed with 100 ml sat. aqueous NaHCO3 
and 100 ml brine. The organic phase was dried over Na2SO4 and concentrated under 
reduced pressure. The resulting brown oil was purified by column chromatography 
(PE:EE = 8:2) to yield 314 mg of 10 as a yellow oil (0.87 mmol, 99 %). Rf (EE:PE = 
1:3) = 0.40. 
1H-NMR (300 MHz, CDCl3): δ = 2.32 (s, 3 H, CH3), 2.86 (s, 6 H, 2 CH3), 3.56 (t, 3J = 
6.6 Hz, 2 H, CH2), 4.09 (t, 3J = 6.6 Hz, 2 H, N-CH2), 7.18 (dd, 3J = 7.7 Hz, 4J = 
1.0 Hz, 1H), 7.51 – 7.60 (m, 2 H), 7.99 (d, 3J = 8.5 Hz, 1 H), 8.18 (dd, 3J = 7.4 Hz, 
4J = 1.4 Hz, 1 H), 8.60 (dt, 3J = 8.5 Hz, 4J = 1.1 Hz, 1 H); 13C-NMR (75.5 MHz, 
CDCl3): δ = 25.3 (+), 45.2 (–), 45.4 (+), 49.8 (–), 115.7 (+), 117.8 (+), 123.1 (+), 129.2 
(+), 129.5 (Cquat), 129.8 (+), 130.0 (Cquat), 132.0 (+), 134.2 (Cquat), 152.3 (Cquat); MS 
(ESI, DCM/MeOH): m/z (%) = 362.1 [MH+] (100); EA (C16H19N5SO3) calc.: C 53.17 
H 5.30 N 19.38, found: C 53.31 H 5.41 N 19.18; UV (MeOH) λmax (log ε) = 350 nm 
(3.577); MF: C16H19N5SO3; MW = 361.42 g/mol; 
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5-Dimethylamino-naphtalene-1-sulfonic acid [2-(4-{[4-(4-dimethylamino-phenylazo)-
benzenesolfonylamino]-methyl}-[1,2,3]triazol-1-yl)-ethyl]-amide (12): 
In a 500 mL round-bottomed flask compounds 7 (192 mg, 0.60 mmol) and 11 
(206 mg, 0.60 mmol) were dissolved in 60 mL DMSO. Water (30 mL) was added, 
followed by aqueous sodium ascorbate (0.2 mL of 1 M stock solution) and aqueous 
copper sulfate (0.6 mL of 100 mM stock solution). The reaction was followed by TLC, 
eluting with 1:1 PE:EE. After stirring overnight, the reaction was found to be 
complete, and 150 mL water was added to precipitate the product. After standing 
open to air for several hours, the orange solid was filtered and washed with water. 
The product was dried to give 314 mg of triazole 12 (0.48 mmol, 79 %). The orange 
solid was recrystallized from acetonitrile to give red crystals. 
1H-NMR (300 MHz, DMSO-d6): δ = 2.79 (s, 6 H, 2 CH3), 3.06 (s, 6 H, 2 CH3), 3.22 (t, 
3J = 6.0 Hz, 2 H, CH2), 4.00 (s, 2 H, CH2), 4.32 (t, 3J = 6.0 Hz, 2 H, CH2), 6.83 (d, 3J = 
9.3 Hz, 2 H), 7.21 (d, 3J = 7.4 Hz, 1 H), 7.54 – 7.62 (m, 2 H), 7.76 (s, 1 H), 7.83 (d, 3J 
= 9.1 Hz, 2 H), 7.88 – 7.95 (m, 4 H), 8.08 (dd, 3J = 7.3 Hz, 4J = 1.0 Hz, 1 H), 8.21 – 
8.24 (m, 3 H), 8.44 (d, 3J = 8.5 Hz, 1 H); 13C-NMR (75.5 MHz, DMSO-d6): δ = 37.9   
(–), 39.7 (+), 42.25 (–), 44.9 (+), 48.9 (–), 111.5 (+), 115.0 (+), 118.85 (+), 122.0 (+), 
123.4 (+), 123.51 (+), 125.3 (+), 127.8 (+), 128.3 (+), 128.8 (Cquat), 128.9 (Cquat), 
129.5 (+), 135.2 (Cquat), 140.0 (Cquat), 142.5 (Cquat), 142.9 (Cquat), 151.2 (Cquat), 153.0 
(Cquat), 154.4 (Cquat); MS (ESI, DCM/MeOH): m/z (%) = 662.3 [MH+] (100); EA 
(C31H35N9S2O4) calc.: C 56.26 H 5.33 N 19.05, found: C 56.34 H 5.38 N 19.19; UV 
(MeCN) λmax (log ε) = 337 nm (3.679), 443 nm (4.478); MF: C31H35N9S2O4; 
MW = 661.80 g/mol; 
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2. Target Guided Synthesis of Bidentate Metal Complex 
Receptors 
2.1. Introduction 
2.1.1. Target Guided Synthesis 
 
During the last 20 years there has been an immense progress in drug discovery. 
While at the beginning only small numbers of natural products and compounds, 
derived from classical organic synthesis, were investigated for their pharmaceutical 
application, nowadays large combinatorial libraries are tested by high-throughput 
screening.1 These developments are of course bound to as well huge improvements 
in methods for producing, handling, and screening large numbers of compounds.2,3,4,5 
Despite these achievements, there are still challenges, related to the synthesis, 
purification, and diversity of compound libraries as well as the pharmacological 
properties of their members.6,7 Further, combinatorial chemistry still does not exhaust 
its possibilities completely.8,9 In a given screen usually less than 1 % of all 
compounds in a library emerge to be active, which makes the search time 
consuming, expensive and thus inefficient. Therefore, methods for producing just the 
active compounds are highly desirable. Target-guided synthesis (TGS) seeks to 
address this challenge by using the target molecule itself for forming its own inhibitors 
from a collection of building block reagents. 
The approach is that only building blocks which interact with the separate binding 
sites on the protein’s surface will react with each other, if their reactive groups are in 
close proximity. This will result in highly potent protein-effectors as the resulting 
polydentate receptor simultaneously accesses multiple binding pockets within the 
protein. The newly formed inhibitors usually display much higher binding affinities for 
their biological targets than the individual components, since they simultaneously 
engage in multiple binding interactions.10 These target-guided approaches avoid the 
classical screening of large compound libraries. The hit identification can be as 
simple as determining whether a given combination of building blocks has resulted in 
a product. The following tests for determining the potency, bioavailability and toxicity 
of the effector, as well as the development of structure-activity relationships (SAR) 
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can then be limited to a small number of compounds. This means a huge 
improvement of the efficiency of the discovery process. 
The pioneer in TGS was Rideout et al., who observed a marked synergism between 
the cytotoxic effects of decanal and N-amino-guanidines, which was proposed to be 
due to the selfassembly of cytotoxic hydrazones inside cells.11,12 Since then, several 
approaches to target-guided synthesis have been explored which use different 
effects of the target on the receptor-formation:  
I. dynamic combinatorial chemistry 13 – 22  13,14,15,16,17,18,19,20,21,22 
II. stepwise target-guided synthesis 23 
III. kinetically controlled TGS 24 – 32 24,25,26,27,28,29,30,31,32 
 
I.) Dynamic combinatorial chemistry 
The dynamic combinatorial chemistry approach was introduced by Lehn et al.13 It is 
based on the principle of shifting a thermodynamical equilibrium. Building blocks, 
which react reversibly with each other, form a thermodynamically controlled mixture 
of products. In the presence of the target molecule, the equilibrium is shifted toward 
the compounds that show the highest affinity towards the effector. In order to identify 
all reaction products, the equilibrium has to be “frozen” (for example, by hydride 
reduction or by lowering the pH). Then, the analysis by HPLC, LC-MS or MS can be 
performed. Disadvantages are: the equilibrium can be affected not only by the target 
molecule, a complex mixture of several products has to be analyzed and the 
additional reaction step to “freeze” the equilibrium might be limiting the number of 
building blocks due to incompatible functional groups. 
 
II.) Stepwise target-guided synthesis 
The stepwise TGS makes only indirect use of the target molecule for effector 
synthesis and consists of three steps.23 First, a library of building blocks is screened 
to identify candidates that bind to the target. Then, the building blocks with the 
highest affinity are linked together, using conventional combinatorial chemistry 
approaches. The resulting library of “divalent” effectors is then screened to find 
receptors with a high binding constant, using traditional assays. Disadvantages are: 
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two screenings of possibly a lot of compounds have to be done and the combination 
of two high-affinity building blocks will not necessarily result in the best performing 
bidantate receptor. 
 
III.) Kinetically controlled TGS 
The kinetically controlled approach is based on three principles in which it 
fundamentally differs from 1): an irreversible reaction between pairs of building blocks 
is influenced by the target molecule, which acts like a catalyst, leading to the 
formation of the kinetic product. The target accelerates most the formation of the 
product that best fits its binding pockets, as it lowers the energy of its transition state. 
In principle, hit discovery becomes independent of the actual function of the target 
because it relies solely on its ability to bind reagents and hold them in close proximity 
until they become connected through an “arranged” chemical reaction. 
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NN
binding
site
protein
protein surface
binding
site
binding
sitebinding
site
react if in close proximity
functional group exposed
at the surface
N
NN
binding
site binding
site
the bidentate
receptor
shows high binding constant
due to fitting distance
between single binding sites.
 
Figure 1: Model to synthesize high affinity receptors using the click-chemistry approach and the 
target molecule as template. 
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So far, several successful applications of the kinetically controlled approach to TGS 
have been reported. For example, Benkovic and Boger have developed 
multisubstrate adduct inhibitors (MAI) of the enzyme glycinamide ribonucleotide 
transformylase (GAR Tfase). In this case, the enzyme-templated alkylation of one of 
its substrates with a folate-derived electrophile led to highly potent inhibitors.26,27 
Recently, Huc reported about a similar approach, in which inhibitors of carbonic 
anhydrase were generated by alkylation of a thiol with R-chloroketones in the 
presence of the Zn(II)-enzyme.28 The template-effect of the enzyme on the reaction 
favoured the formation of the alkylation product with the highest affinity for the target, 
which was revealed by competition-experiments. 
Nicolaou and co-workers have utilized the kinetically controlled variant of TGS in 
combinatorial synthesis to develop dimeric derivatives of vancomycin.29 Appropriately 
functionalized monomeric vancomycin derivatives were connected via olefin 
metathesis or disulfide formation in the presence of vancomycin’s target, Ac-D-Ala-D-
Ala or Ac2-L-Lys-D-Ala-D-Ala. This resulted in the formation of highly potent dimers. 
 
The scope of most TGS methods is rather limited, because highly reactive reagents 
(strong electrophiles or nucleophiles, metathesis catalysts etc.) are used. As high 
reactivity usually goes hand in hand with low selectivity, those reagents can react in 
several pathways, including ones that even destroy the protein target. In contrast, the 
recently developed in situ click-chemistry approach to kinetically controlled TGS24 
uses bioorthogonal reactions and reagents, for example, the [1,3]-dipolar 
cycloaddition reaction33 between azides and acetylenes. For four reasons this system 
is especially well-suited for TGS: 
1) The reaction is extremely slow at room temperature (activation enthalpy of 
approx. 25 kcal/mol), despite the very high driving force that makes it 
irreversible (reaction enthalpy > 50 kcal/mol).34 
2) Certain catalysts strongly stabilize the transition state and therefore 
dramatically lower the activation enthalpy.35  
3) It does not involve components that might disturb the binding sites 
(external reagents, catalysts, byproducts).36 
4)  The reactants are inert to biological molecules.  
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Mock et al. had previously provided proof-of-concept by demonstrating that the 
triazole formation is accelerated by 4 to 5 orders of magnitude by the synthetic 
receptor cucurbituril to give exclusively the anti-triazole regioisomer.37 
 
2.1.2. The “Click-Chemistry” Approach in Target-Guided Synthesis 
 
The method to synthesize high affinity receptors is based on the well known Huisgen 
reaction. The 1,3-dipolar cycloaddition between azides and alkynes leads to 1,4- and 
1,5-substituted triazoles.33 The groups of Sharpless and Meldal separately 
discovered the Cu(I)-catalyzed variation of this reaction, which allows very fast and 
efficient formation of exclusively 1,4-triazoles at mild reaction conditions.38 This 
reaction can be used to obtain well fitting receptors. Sharpless and Finn et al. 
obtained inhibitors acetylcholineesterase (AChE) in the presence of the enzyme as 
template.39,40,41 The reaction between receptor precursors was accelerated when the 
reactive groups (azide and alkyne) were in close proximity to each other. Therefore, 
this reaction corresponds to the selection of receptors from a virtual library of 
substances.42 
The working groups of Sharpless and Kolb managed to go one step further by using 
the target molecule itself as the catalytic species in a kinetically controlled TGS-
approach to yield high affinity inhibitors of AChE (mouse or electric eel AChE).30 
They synthesized a building block library of azides and acetylenes based on the 
known site-specific inhibitor tacrine (binding to the active site) and 
phenylphenanthridinium (PP) or phenyltetrahydro-isoquinolines (PIQ) (binding to the 
peripheral site). A series of binary mixtures of these reagents was incubated with the 
enzyme as template (several hours at room temperature) in order to test, whether it 
would combine selected pairs of complementary reagents to synthesize its “divalent” 
inhibitors (figure 2).24 Analysis of the crude reaction mixtures by desorption/ionization 
on silicon mass spectrometry (DIOS-MS)43 revealed only one product for the 
combination of tacrine with PP and two for the combination of tacrine with PIQ. All 
inhibitors showed dissociation constants in the femtomolar region. 
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Figure 2: In situ click chemistry between tacrine (active site binder) and PP or PIQ derivatives to 
screen for highly potent AChE-inhibitors. 
A more interesting result was, that in all 3 cases HPLC showed only the 1,5-
disubstituted triazole (“syn-triazole”). The corresponding 1,4-isomers turned out to be 
less active by two orders of magnitude. Further, studies of X-ray structures revealed 
that the triazole unit, created by the azide/alkyne cycloaddition, engages in hydrogen 
bonding and stacking interactions with amino acid residues in the wall of the gorge.44 
The important conclusion that can be drawn from this observation is that triazoles are 
not just passive linkers, but rather active pharmacophores that may contribute 
significantly to protein binding. 
This approach was also used to obtain inhibitors for bovine carbonic anhydrase II 
(bCA II).31 The building blocks to derive divalent receptors were 4-acetylene-
benzenesulfonamide (binding to bCA II with nanomolar affinity) and several azide 
substituted alkanes, aminoalkanes, carbonic acids, stilbenes and benzenes. The 
choice of building blocks was related to the work of Whitesides.45 Results of 
incubation experiments with the enzyme as template showed that 11 of 24 possible 
triazoles were formed. Analysis by LC-MS revealed that all of them were 1,4-
triazoles. In contrast to AChE, the enzyme-catalyzed reaction by bCA II was highly 
anti-selective. Results of binding experiments showed an increase for all 11 “hits”. 
Compared to 4-acetylene-benzenesulfonamide, binding affinities were higher up to 
two orders of magnitude (KD = 0.2 – 7.1 nM). 
 
In situ 
click reaction 
Tacrine 
(active site ligand) 
Library of PP- or 
PIQ-derivatives 
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Dervan et al. demonstrated that this method is not limited to proteins.32 The 
azide/acetylene cycloaddition was used to explore the double-stranded DNA-
templated interconnection of hairpin polyamides in the minor groove. This gave 
hairpin dimers in site-specific fashion, which are capable of targeting longer DNA-
sequences. 
 
2.1.3. Scope 
 
The aim of this chapter is the synthesis of new bidentate metal-complex receptors 
with high binding affinities for peptides and small proteins. The synthesis is based on 
the Cu(I)-catalyzed cycloaddition and shall be done following two different 
approaches: 
• the kinetically controlled TGS at physiological conditions using the target 
molecule as template. Hit detection will be done in situ, using mass 
spectroscopy. Binding constants will be determined using standard 
spectroscopical methods like NMR or UV/Vis. 
• the stepwise TGS in order to build up bidentate receptors which cannot be 
derived from the kinetically controlled TGS. Hit detection and determination of 
binding constants will be done in a screening assay. 
 
The following receptor molecules with binding sites for certain functional groups of 
peptides shall be synthesized: Zinc(II)-cyclen complexes for imide groups,46 bis-
zinc(II)-cyclen complexes for phosphate groups,47 copper(II)- and zinc(II)- 
nitrilotriaceticacid (NTA) complexes for (N-terminal) histidines,48 guanidines for 
carboxylate anions 49 and porphyrins for non polar regions on the protein surface.50 
The receptors as well as the precursors have to be soluble in water. Every receptor 
precursor has to contain either an azide or an alkyne group. 
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2.2. Kinetically Controlled Target Guided Synthesis 
 
After synthesis of the receptor precursors, different types of precursors were 
connected using the template effect of the target molecule. Synthesis was done 
following standard peptide coupling-, SN- and complexation-reactions. The target was 
a biologically active pentapeptide 51 with following AA-sequence: H-LHis-LLeu-LLeu-
LVal-LPhe-OLi. In order to detect the in situ formed high affinity receptors, a simple 
mixture of receptor precursors and the peptide in buffered solution was analyzed with 
mass spectroscopy. 
 
2.2.1. Synthesis of Receptor Building Blocks 
2.2.1.1. Synthesis of Zn(II)-Cyclen Complexes 
 
The synthesis of Zn(II)-Cyclen complexes with an azide functionality started as usual 
with threefold Boc-protected cyclen (1). Compound 1 was reacted with 1,3-
Dibromoethane, or α,α-Dibromo-paraxylol, in a typical SN-reaction. The use of 
potassium iodide would yield a mixture of bromides und iodides and, therefore, 
cannot be used. In order to avoid twofold substitution, the bromides were used in 
large excess. The reactions gave the desired bromides in acceptable yields of 67 % 
for 2 and 74 % for 3 (scheme 1). The corresponding bis-Cyclen compounds, formed 
after twofold substitution, were isolated as side products. 
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Scheme 1: Synthesis of substituted Boc-cyclen compounds 2 and 3. 
The next reaction step was the transformation of the bromides into azides. This was 
achieved in two different ways. 
The first one was the use of a strongly basic anion exchanger, which was loaded with 
azide ions. The general advantage of this method is that a suitable bromide dissolved 
in any organic solvent simply has to be shaken with an according amount of ion 
exchanger for some hours at room temperature. After the reaction, the exchanger is 
filtered and washed. Repeating this procedure several times, a quantitative 
conversion can be achieved without using large excesses of ion exchanger. 
However, experimental results showed that compounds 2 and 3 were adsorbed by 
the polymer material of the exchanger beads. Further, organic solvents partly 
dissolved unidentified compounds from the exchanger material, which were detected 
as impurities in the NMR spectra of the raw products. For this reason, purification 
with column chromatography was necessary. This gave the azides 4 and 5 in yields 
of 92 %. 
The second method proved to be the better one. The bromides 2 and 3 were 
dissolved in MeOH and a saturated solution of NaN3 was added. After a reaction time 
of 24 h and a very simple workup (extraction and drying in vacuum), the desired 
azides were obtained in nearly quantitative yields and in sufficient purity. Compounds 
4 and 5 were not stable at room temperature and decomposed slowly while 
becoming yellow. Storage in the freezer is recommended but will not stop the 
decomposition process. 
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Scheme 2: Synthesis of azides 4 and 5. 
After the introduction of the desired azide functionality the Boc-protecting groups had 
to be cleaved. This was achieved with TFA in DCM, which yielded the trifluoro 
acetate salts 6 and 7 as yellow oils in sufficient purity. Both compounds decomposed 
slowly as well as the precursors. 
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Scheme 3: Cleavage of the Boc-protecting groups with TFA in DCM. 
The last two reaction steps were deprotonation of the cyclen ligand with a strongly 
basic anion exchanger (loaded with OH-) and the following complexation with 
Zn(ClO4)2 x 6 H2O in a mixture of MeOH/water. In order to achieve nearly quantitative 
precipitation of the complexes 8 and 9, EtOH was added to the reaction mixture. 
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Scheme 4: Formation of the Zn(II)-cyclen complexes 8 and 9. 
The synthesis of a Zn(II)-cyclen complex with an alkyne functionality started with 1 
and propargyl bromide. As propargyl bromide is quite volatile the reaction 
temperature was limited to 50 °C. In order to support reaction conversion, catalytic 
amounts of potassium iodide and 18-C-6 were added to the reaction mixture. The 
alkyne 10 was obtained in a good yield of 90 %. 
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Scheme 5: Synthesis of alkyne 10. 
Following, the Boc-protecting groups were cleaved using TFA in DCM. This gave 
compound 11 in quantitative yield. Recrystallisation of the raw product from MeCN 
gave colourless crystals of the TFA salt (see exp. section for structure). 
Deprotonation was achieved with a strongly basic anion exchanger, loaded with OH-. 
For complexation of Zn2+ water-free reaction conditions had to be chosen. Therefore, 
the reaction was carried out in dry acetonitrile using ZnCl2. This gave the Zn(II)-
cyclen complex 12 in a yield of 75 %. 
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Scheme 6: Cleavage of the Boc-protecting groups with TFA and complexation of Zn2+ under water-
free conditions in dry MeCN. 
When the complexation reaction was carried out in aqueous solutions of MeOH or 
EtOH, the already formed 12 catalyzed the addition of water to the triple bond, in 
analogy to the mercury catalyzed reaction leading to enoles which tautomerize to 
ketones. 52 
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Scheme 7: Complexation in aqueous solutions led to a ketone, due to Zn2+ catalyzed addition of 
water to the triple bond. 
 
2.2.1.2. Synthesis of Bis-Zn(II)-Cyclen Complexes 
 
For the synthesis of bis-Zn(II)-cyclen-complexes the Boc-protected Bis-cyclen 13 was 
used as starting compound. A nucleophilic aromatic substitution reaction with the 
ammonium-salt 14 or 15 introduced the desired azide-group. Afterwards the Boc-
groups were cleaved using a saturated solution of HCl in diethylether. 
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Scheme 8: Synthesis of Boc-protected Bis-cyclen-compounds 16 and 17 with azide-group and 
following cleavage of the Boc-groups.a 
Following the treatment of 18 and 19 with a strongly basic anion-exchanger (loaded 
with OH-) in aqueous solution and the reaction of the free amines with zinc 
perchlorate in methanol gave the desired compexes 20 and 21 in good yields. 
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Scheme 9: Synthesis of Zn(II)-complexes 20 and 21. 
The synthesis of the complex 24 was done in the same way as the synthesis of 20 
and 21, but using propargylamine in the first reaction-step. It is remarkable that this 
time the triple bond was not attacked by water. This proves that only mono-Zn(II)-
                                                 
a
 For details about the synthesis of 14 and 15 please see experimental part of chapter 1. 
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cyclen comlexes are able to catalyze this reaction, but neither uncomplexed Zn2+ nor 
bis-Zn(II)-cyclen-complexes. 
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Scheme 10: Synthesis of bis-Zn(II)-cyclen-complex 24. 
 
2.2.1.3. Synthesis of NTA-Complexes 
 
Natural amino-acids are suitable precursors for the synthesis of NTA-complexes. The 
choice which one to use depends on the functional group one wants to connect to the 
side-chain and on the way it should be introduced. As it is easy to synthesize 
carbonic acids or amines, functionalized with an alkyne- or azide-group (some are 
even commercially available), it makes sense to use lysine (Lys), aspartic acid (Asp) 
or glutamic acid (Glu) and peptide-coupling reactions to build the desired NTA-
complexes. However, Asp always forms imides in peptide-couplings, so its use is 
senseless. 
For the synthesis of lysine based NTA-complexes, bearing an alkyne or azide group, 
the twofold alkylated lysine methylester 25 was used. After a peptide-coupling 
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reaction with 4-pentynoic acid the amide 26 was obtained in moderate, but 
acceptable yield. 
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Scheme 11: Synthesis of peptide 26 using 4-pentynoic acid and standard coupling reagents. 
The following reaction step was the cleavage of the ester-protection-groups using 
LiOH in a mixture of water and acetone. This gave the free carbonic acid without 
purification in quantitative yield. In order to form the desired metal-complexes 27 and 
28 either Cu2(OH)2CO3 or a mixture of ZnCl2 and 5ZnO.2CO3 x 4 H2O was used in 
aqueous solution. 
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Scheme 12: Synthesis of the NTA-complexes 27 and 28. 
In the same way another NTA-complex, bearing an azide group, should be 
synthesized, simply using 3-azido-propionic acid instead of pentynoic acid. A peptide-
coupling led to 29 in comparable yield, but the cleavage of the ester-groups yielded 
the elimination-product 30 instead of the desired azido compound. For this reason no 
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Lys based NTA-complex bearing an azide group was synthesized. Further the use of 
Boc-Glu-OBzl as building block for various NTA-complexes proved to be the better 
choice. 
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Scheme 13: Synthesis of 29 and failed synthesis after cleavage of the ester-groups and simultanous 
elimination of HN3. 
The protected Glu 31 is commercial available and a suitable compound to start the 
synthesis of NTA-complexes. In order to introduce an azide group the amines 14 and 
15 were used in peptide-coupling reactions using common coupling reactants and 
reaction conditions. This gave the desired amides 32 and 33 in excellent yields after 
precipitation from the reaction solution with water. It was even possible to use the raw 
products in the following reaction step without any further purification. 
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Scheme 14: Synthesis of amides 32 and 33. 
The cleavage of the Boc-group was achieved by using a saturated solution of HCl in 
diethylether. This gave 34 and 35 in quantitative yields. Alternatively, this reaction 
was performed with TFA in DCM, but the resulting ammonium-salt could not be used 
in the following alkylation reaction with bromo-ethylacetate. 
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Compounds 34 and 35 were not stable at basic conditions (like any other comparable 
glutamic acid compound),53 as the free amino-group formed a five-membered 
lactame by attacking the amide-C. On the other hand it was not possible to alkylate 
the NH2-group when it was protonated. Therefore it was necessary to adjust a 
suitable pH-value to make this reaction possible. This was achieved by using NaF as 
a weak base. SiO2 was added to react with the HF that was formed in the acidic 
solution. Phase transfer catalysts for cations and anions, 18-crown-6 and TBA+Br- 
were also essential for this reaction. Despite the quite complex reaction mixture, the 
desired products 36 and 37 were obtained in very good yields. 
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Scheme 15: Cleavage of the Boc-group gave compounds 34 and 35. The following alkylation at 
slightly acidic conditions yielded the ester-protected NTA-building blocks 36 and 37. 
Table 1 shows the dependence of the yield on the amount of NaF used. It should 
also be noted that a longer reaction time than 20 h will cause a lower yield (estimated 
3 % per 24 h). 
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Table 1: Dependence of the yield on the amount of NaF. 
The subsequent reaction steps were the cleavage of the ester-groups and the 
complexation of the metal cation. Both steps were carried out in the same way as 
already described for compounds 27 and 28. This gave the desired zinc(II)-
complexes 40 and 41 or the corresponding copper(II)-complexes 42 and 43 in good 
yields. 
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Scheme 16: Synthesis of the complexes 40, 41, 42 and 43. 
The synthesis of the complexes (48) and (49) worked as well as described above. 
Propargylamine was used in the first reaction-step. 
92 % 81 % 30 % 13 % 0 % yield 
NaF (9) NaF (7.5) NaF (2.5) NaF (1) K2CO3 base (eq) 
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Scheme 17: Synthesis of NTA-complexes 48 and 49. 
 
2.2.1.4. Synthesis of Guanidines 
 
The Synthesis of the Boc-protected guanidinium precursors 50 and 51 started with 
N,N’-Di-Boc-S-methyl-isothiourea and the ammonium salts 14 and 15. Triethylamine 
was used in excess, in order to liberate the azido-amines from their hydrochloride 
salts. The nucleophilic substitution yielded 50 and 51 in acceptable 81 %. As 50 and 
51 were not stable under the reaction conditions, the reaction had to be stopped after 
7 h, what caused a lower yield.  
The deprotection was done with TFA in DCM. In order to remove surplus TFA and 
transform the resulting TFA-salts into hydrochlorides the crude product was treated 
with 36% aqueous HCl and methanol (to form volatile methyl-trifluoroacetate). This 
gave the azido-substituted guanidines 52 and 53 in quantitative yields. 
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Caution! As the share of nitrogen in these compounds is almost 50 %, they have to 
be handled with care! Heating or shaking might result in an explosive decomposition! 
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Scheme 18: Synthesis of guanidines 52 and 53. 
The synthesis of the guanidinum salt 55 worked as described for 52/53. 
Propargylamine was used without supplementary base in the first reaction-step. 
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Scheme 19: Synthesis of alkyne substituted guanidine 55. 
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2.2.1.5. Synthesis of Zn(II)-Porphyrins 
 
The basic structure of a porphyrin consists of four pyrrole units, which are connected 
to a cyclic conjugated C20-skeleton (fig. 3). This skeleton is a plane aromatic 
macrocycle with 22 pi-electrons of which only 18 belong to the perimeter of a 
1,16-diaza[18]annulene (according to Hückel rule: 4n + 2 = 18 pi electrons [n = 4]). 
This also explains why chlorins and bacteriochlorins are aromatic as well (fig. 3).54  
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Figure 3: Structures of a porphin, a chlorine and a bacteriochlorin and number of π-electrons. 
Porphyrins are formed by oxidation of porphyrinogenes, which can be derived from 
an acid catalyzed cascade reaction between pyrrol and aldehydes. Acid catalysts can 
be strong inorganic or organic acids like HCl and TFA, or even Lewis acids like 
BF3.OEt2. Entropic effects favour the ring closure after the 4th step of the cascade 
leading to the non-aromatic porphyrinogen. Otherwise this approach would only lead 
to poly-pyrrols, which can also be isolated from the reaction mixture. The oxidation of 
porphyrinogens can be done with weak oxidisers as the resulting porphyrin is an 
aromatic system. The common oxidants for this reaction are either molecular oxygen 
(O2) or electron poor chinones like 2,3,5,6-tetrachloro chinone (p-chloranil). 
Due to the extended pi -system porphyrins are coloured (red to purple, depending on 
substituents) and show a very strong absorption at approx. 400 nm (lg ε = 5.0 – 6.0) 
which is called the “B-band” or “soret-band”. The absorption spectrum shows 3 
further absorption bands between 500 nm and 600 nm (called Q-bands [lg ε = 3.5 – 
4.5]) which are responsible for the colour. When excited at the soret band, porphyrins 
show an intensive fluorescence at approx. 600 nm. This makes identification of 
porphyrins in the crude reaction mixture with TLC very easy and therefore enables 
separation from other coloured side products. 
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Synthesis of symmetric porphyrins is easy, as a 1:1 mixture of pyrrole and aldehyde 
leads to exceptional one porphyrin. However, synthesis of asymmetric substituted 
porphyrins with 2 – 4 different substituents is more difficult, as the reaction will yield a 
statistical mixture of all possible combinations. In order to favor the formation of one 
porphyrin, the right stoichiometric relation between pyrrole and the two different 
aldehydes has to be chosen. Further, the statistic mixture of porphyrins and isomers 
has to be purified.  
Porphyrin 56 was synthesized from pyrrol, 4-((trimethylsilyl)-ethinyl)-benzaldehyde 
and 4-(methoxy-carbonyl)-benzaldehyde in a stoichiometric relation of 4:0.5:3.5 
(scheme 20). This relation was chosen as it revealed to give 56 in a higher yield 
(related to the TMS-ethinyl-benzaldehyde). The reaction led to the formation of a 
mixture of 6 possible porphyrins (0 – 4 methoxy groups). Due to differences in 
polarity, purification with column chromatography was possible. Tertiary mixtures of 
PE/DCM/EE proved to be suitable eluents. DCM was necessary to guarantee 
solubilty of the porphyrins in the mixture and EE was necessary to raise polarity. The 
porphyrin with 4 TMS groups revealed to be the most non-polar one. Even the two 
isomers 57 and 58 could be separated and identified via the shape of signals in the 
1H-NMR spectrum (figure 4).  
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Scheme 20: Synthesis of asymmetric alkyne-substituted porphyrin 56. 
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Figure 4: Identification of isomers 57 (α,γ “trans”) and 58 (α,δ “cis”) via the shape of the signals of 
the hydrogens of the porphyrin-core in the 1H-NMR spectrum. Assignment of signals to 
corresponding hydrogens 1 – 4 is given. 
Porphyrin 59 was synthesized in the same way like 56. However, 4-hydroxy-
benzaldehyde was used instead of 4-((trimethylsilyl)ethinyl)-benzaldehyde in order to 
introduce a phenolic OH-group which enables further functionalisation (scheme 21). 
This OH-group also increased the polarity of the product (compared to 56 and side-
products). Therefore, the porphyrin with 4 methoxy groups revealed to be the most 
non-polar one of the mixture of 6, followed by 59. 
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Scheme 21: Synthesis of asymmetric OH-substituted porphyrin 59. 
In order to introduce an alkyne group into 59, the phenol was deprotonated with 
potassium carbonate and reacted with propargyl bromide. Catalytic amounts of 
potassium iodide and 18-C-6 were essential for this reaction. This gave the phenol 
ether 60 in a high yield of 92 %. 
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Scheme 22: Functionalisation of 59 with propargyl bromide. 
For binding affinity studies the porphyrin needed to be soluble in water. This was 
achieved by cleaving the methyl-ester groups, which yielded the threefold carboxylic 
acid 61 (scheme 23). In order to achieve complete cleavage of all ester groups, LiOH 
had to be used in an excess of 10 eq per ester function. Further, the reaction mixture 
had to be heated. As 61 was not soluble in water at a pH lower than 5, the product 
could be obtained directly from the reaction solution by precipitation of the 
carboxylate with aq. HCl. Despite the high polarity of 61 a further purification by 
column chromatography with mixtures of CHCl3/MeOH/AcOH was possible (see exp. 
section). Although this procedure caused a loss of product, 61 was obtained in 
almost quantitative yield. 
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Scheme 23: Cleavage of methyl-esters to obtain the water soluble threefold carboxylic acid 61. 
The 2 NH-groups in the porphyrin-core can act as weak bases and therefore can be 
protonated (pKa1 ≈ 7, pKa2 ≈ 4) resulting in the so called 1H- and 2H-form. This 
causes a change of the colour from red to green. 
The NH-protons also react acidic and can be replaced by metal-cations. As the 2 
further pyrrole-N-atoms also participate as electron donating ligands in binding 
interactions, this leads to a tetra-dentate chelate ligand. For this reason, porphyrins 
show high binding constants for a lot of metal cations. Especially Fe2+/3+, Cu2+, Mg2+ 
and Zn2+ are bound tightly by porphyrines and form biological relevant complexes. 
Removal of these cations is only possible by treatment with strong acids like TFA or 
H2SO4.54  
Therefore, connection of 61 to another binding site building block (bearing an azide 
group) via the Cu(I)-catalyzed click-reaction was only possible when an 
over-stoichiometric amount of Cu(II)-salt was used.55 
The incorporation of a metal cation also causes changes in the spectroscopical 
characteristics. The Q-bands are reduced from 3 to 2, whereas new absorption 
bands (N,M,L-bands) arise between 210 nm and 330 nm. Diamagnetic cations like 
Zn2+ show almost no effect on the intensity of the fluorescence, while paramagnetic 
cations like Cu2+ show an efficient quenching of the porphyrin emission. Thus, a 
Cu(II)-porphyrin complex cannot be used to follow the binding process to a protein 
via fluorescence titration, though it still is a suitable receptor for non-polar regions in a 
polar medium. This problem can be solved by blocking the porphyrin core with Zn2+. 
The zinc cation is bound strongly enough to prevent replacement by Cu2+ and 
therefore works like a protecting group. Further, it does not influence the 
fluorescence. 
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For this reason, the Zn(II)-complex of 61 (62) was synthesized as this avoided 
complexation of Cu2+ and therefore enabled click-reactions with catalytic amounts of 
a Cu(II) salt and the investigation of binding processes with fluorescence 
spectroscopy.  
For complexation of Zn2+ the choice of Zn(II)-salt and adjustment of the right pH 
value was important. First, 61 was transformed into the sodium carboxylate, in order 
to achieve solubility in water. This was done by addition of a saturated solution of 
NaHCO3 to a suspension of 61 in water until the acid was dissolved completely. The 
pH-value of the solution was 7. Then, an aqueous solution of zinc acetate (pH 7) was 
added. The complexation of Zn2+ by 61 resulted in a lowering of the pH to 4.5 as the 
2 protons of the porphyrin core were replaced by the metal cation. This caused the 
precipitation of 62 as the carboxylate was reprotonated. Centrifugation of the 
suspension gave the Zn(II)-porphyrin complex 62 in quantitative yield (scheme 24). If 
an excess of NaHCO3 was used, this resulted in precipitation of Zn(OH)2 due to the 
high pH. If a more acidic Zn(II)-salt like ZnCl2, Zn(NO3)2 or Zn(ClO4)2 was used, this 
caused only precipitation of 61, as the reprotonation reaction was much faster than 
the complexation and as there was no buffering effect. 
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Scheme 24: Synthesis of Zn(II)-complex 62. 
The Zn(II)-porphyrin complex 62 can be used in any kind of click-reaction with 
suitable azides to obtain bidentate receptors with high binding affinities to non-polar 
areas on protein-surfaces in polar media. 
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2.2.2. Induced Fit “Click-Reaction” to Identify High Affinity Receptors 
 
In order to test if the synthesized single binding site receptors can be used in 
kinetically controlled TGS a suitable combination of receptors and target molecule 
had to be used. As histidine (His) and carboxylate groups are quite common 
functionalities on protein surfaces, receptors for these two groups – NTA-complexes 
and guanidines – were the first choice. The target which was chosen was a 
pentapeptide with the following sequence: H-LHis-LLeu-LLeu-LVal-LPhe-OLi (63). As 
this peptide bears a terminal histidine and a carboxylate group separated by a not too 
flexible spacer in a defined distance, this seemed to be a suitable target. It was 
synthesized from the corresponding methyl ester, which was commercially available 
and shows biological activity (scheme 25).51 
H2N-His-Leu-Leu-Val-Phe-OMe . 2 HCl
LiOH
MeCN, H2O
r.t., 24 h H2N-His-Leu-Leu-Val-Phe-COOLi
100 %
63
 
Scheme 25: Synthesis of the target molecule 63 from the commercially available methyl ester. 
In a simple screening assay the synthesized NTA-complexes 27, 28, 40, 41, 42, 43, 
48, 49 were mixed with the guanidines (G) 52, 53, 55 and the target 63 in buffered 
solution (phosphate buffer, pH 7, c = 5 mM) in all possible combinations (see table 
2). In order to guarantee reproducable and comparable mixtures, stock solutions of 
each compound in buffer were prepared (approx. 3 mM solutions), of which aliquots 
of 300 µl were taken and mixed. This gave equimolar mixtures of target, azide and 
alkyne with a concentration of each compound of approx 1 mmol/l. The mixtures 
were shaken at r.t. for 24 h and then analyzed by mass spectroscopy (pos. and neg. 
ESI in mixtures of MeOH/water/NH4OAc) to check, whether the triazole was formed 
or not (scheme 26). 
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Scheme 26: Exemplary reaction mixture of guanidine 55, NTA-complex 41 and the peptide 63 in 
phosphate buffer, leading to 64 which was analyzed by mass spectroscopy. 
This method is very sensitive and allows detection of even very small amounts. 
However, it is just a qualitative method and does not give information about the 
reaction conversion or quantities. Results are given in table 2. MS-spectra of a 
positive tested mixture (63 + 41 + 55) and a negative tested one (63 + 43 + 55) are 
shown in figure 5. 
 
G 
   NTA 27 28 40 41 42 43 48 49 
52 O O     O  
53 O O     O  
55   O  O O   
Table 2: Hit detection via MS-spectroscopy of 12 possible combinations of NTA-complexes and 
guanidines. Hits are marked with a tick. Fields marked with a cross are impossible 
combinations (azide + azide / alkyne + alkyne). Fields marked with a circle are negative 
tested combinations. Blue filled fields mark Cu(II)-NTA-complexes. 
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Figure 5: MS-spectrum (neg. ESI) of a positive tested mixture (63 + 41 + 55) on the left side and a 
negative tested one (63 + 43 + 55) on the right. The black arrow on the left marks the 
signal of the formed triazole 64 (m/z = 488.3), whereas the white arrow on the right marks 
the area where the signal for the triazole (which was not formed) is missing. 
In both MS-spectra (neg. ESI) the major peaks could be assigned: The peaks with 
m/z = 603.6 and 627.6 were assigned to the peptide 63. The peak with m/z = 457.2 
(left side) was assigned to [(41 + LiOAc)-]. Peak with m/z = 471.2 (right side) was 
assigned to [(43 + LiOAc)-]. Both peaks show the typical characteristic isotope 
pattern of compounds containing copper. The same is true for the peak with m/z = 
488.3 (left side) which was assigned to the triazole 64. However, on the right side the 
corresponding peak for the triazole-anion was expected to arise at m/z = 502, but the 
spectrum clearly shows no peak there. 
Results presented in table 2 show that only 3 of 12 possible combinations led to the 
formation of the triazole. First conclusions that could be drawn from these results 
were: 
• only Cu(II)-NTA-complexes formed triazoles. This was expected, as Cu(II)-
NTA-complexes show higher binding affinities towards terminal histidines than 
Zn(II)-NTA-complexes.48 
• the triazole formation was not catalyzed by the Cu(II)-complexes themselves, 
as 2 of 4 complexes (28 and 43) showed no triazole-formation.56 The two 
complexes which were reactive, were tested again (see table 3). 
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• the formed triazoles were the shortest ones that were possible. Neither the 
Lys-based Cu(II)-NTA-complex 28 showed reactivity nor the longer Glu-based 
43. This suggests that there is a relation between reactivity and structure. Only 
the formation of the short and less flexible receptor was induced by the 
pentapeptide 63. 
 
In a simple control experiment it was tested whether the triazole-formation was also 
possible when the pentapeptide was not present in the mixture. Only the Cu(II)-NTA-
complexes were tested (table 3). The experimental procedure was the same as 
described on page 67, except adding 300 µl buffer instead of peptide solution. 
G 
   NTA 28 41 43 49 
52 O    
53 O    
55  O O  
Table 3: Hit detection via MS-spectroscopy of 8 possible combinations of Cu(II)-NTA-complexes 
and guanidines without 63. Hits are marked with a tick.  
MS-spectroscopy of the mixtures revealed that the Cu(II)-complex 49 shows triazole-
formation even in the absence of 63. A possible explanation for this is that the alkyne 
group of 49 is coordinated to the metal cation and therefore is already activated for 
the cycloaddition. As the colour of 49 is brown and not blue or green like complexes 
28, 41, 43 this observation strengthens this assumption. 
In order to check if the remaining hit 64 really shows the highest binding affinity 
towards the target 63 and if there is a relation beween structure and affinity, a 
fluorescence-assay was established. 
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2.2.3. Binding Affinities of Receptors 
2.2.3.1. Investigation of the Binding Process with 1H-NMR Spectroscopy 
 
First, the 6 triazoles from 41+55, 43+55, 49+52, 49+53, 28+52 and 28+53 were 
synthesized using a common click-reaction procedure (scheme 27): To an aq. 
solution of the alkyne and the azide (1:1 relation) catalytic amounts of CuSO4 x 
5 H2O and sodium ascorbate were added. The resulting triazoles 64 – 69 were 
precipitated from solution with EtOH (see exp. section GP 8 for details). 
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Scheme 27: Synthesis of Cu(II)-NTA-guanidine-complexes 64 – 69. 
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Neither the receptors, nor the target bear functional groups, which allowed direct 
visualisation of the binding process via UV/Vis or fluorescence spectroscopy. Further, 
it was not possible to observe a change in the structure of 63 with CD-spectroscopy, 
when one of the receptors was added. The reason for this is that 63 is too small to 
assume a definite shape and therefore cannot give defined signals in the CD-
spectrum. Visualisation of the binding process with 1H-NMR-spectroscopy was only 
possible via the interaction of the His – sidechain residue with the paramagnetic 
Cu2+. However, this allowed only a qualitative conclusion and no determination of a 
binding constant. According to Arnesano et al. who investigated type II copper(II) 
proteins (CopC from Pseudomonas Syringae), the characterisation of such proteins 
represents a challenge, as Cu(II) has a long electron relaxation time. This causes all 
NMR-signals of nuclei, which are in close proximity to the metal ion, to broaden.57 
The nuclear longitudinal realxation rate (R1) of Cu(II)-complexes strongly depends on 
the electronic relaxation time (τ) which is expressed by the Solomon Bloemenberg 
equation: 
 
 
 
Solomon-Bloemenberg equation: dependence of the nuclear longitudinal realxation rate (R1) on the 
electronic relaxation time (τ) and the distance (r) between the 
NMR-active nucleus and the electron of the paramagnetic metal 
center. 
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Using this equation, it is possible to calculate the distance between the NMR-active 
nucleus and the Cu(II)-center after determination of R1. Figure 6 shows the spherical 
areas, within which NMR-active nuclei cannot be detected due to signal-broadening.b 
According to Aresano et al. signal-broadening in 1H-NMR occurs, when the distance 
(r) between the Cu(II) center and a hydrogen is smaller than 110 pm. Hetero-nuclei 
like 13C, 15N or 31P cannot be detected within a spherical area of 120 pm (r = 60 pm) 
around the Cu2+. 
 
 
 
Figure 6: Detection limits through NMR are shown as concentric spheres centered on the copper 
ion in the Cu(II)-CopC stucture. The red sphere (r = 110 pm) represents the region in 
which detection of 1H signals is not possible. Broadening of signals of hetero-nuclei is 
restricted to the blue sphere (r = 60 pm). 
A 1H-NMR investigation of a 2:1 mixture of 63 and 66 in buffered aqueous solution 
confirmed theses results (see figure 7 and 8). 
                                                 
b
 Figure 6 and calculation of distances were taken from: Arnesano et al. in JACS 2003, 125, 7200. 
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Figure 7: 1H-NMR spectrum of 63 in aq. borate buffer pH 9.2. Assignments and integrals of signals 
are given. 
 
Figure 8: 1H-NMR spectrum of a mixture of 63 and 0.5 eq 66 in aq. borate buffer pH 9.2. 
Assignments and integrals of signals are given. A strong broadening of all His-signals and 
a weaker broadening of Leu-signals was observed due to interaction with Cu2+. 
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Figure 7 shows the 1H-NMR spectrum (between 2.7 and 8.1 ppm) of 63 in borate 
buffer at pH 9.2. The assignments of the His-hydrogens are given, as well as the 
assignment of all chiral hydrogens (C*H), and the hydrogens of the benzylic CH2 
group of Phe. Figure 8 shows the same detail of the 1H-NMR spectrum of 63 after 
addition of 0.5 eq 66. It was observed that all signals broaden under the influence of 
the present Cu2+. However, the signals of the His-hydrogens, as well as the Leu-
hydrogens, showed a stronger broadening than the other signals. This was also valid 
for the signals of the sidechain hydrogens of Leu between 0.6 and 0.8 ppm, which 
are not shown in figure 7/8 for better clarity. 
This specific signal-broadening can only be caused by the closer proximity to Cu2+, 
due to binding interactions. Distance-calculations with Spartan confirmed that only 
the H2N-His-Leu-Leu- moiety of the pentapeptide is inside an area of 10 Å around the 
Cu(II)-cation, while the -Val-Phe-OH residue is outside. The conformer with the 
lowest energy was calculated. This revealed a distance between Cu2+ and the Val-
C*H of 10.4 Å and a distance of 11.1 Å between the Phe-C*H and the copper center. 
All hydrogens of the His-Leu-Leu- moiety were within an area of 8.5 Å (fig. 9). 
 
Figure 9: Spartan-calculation (lowest energy conformer) of the structure of a Cu(II)-complex of 63 
in the gas-phase. Colors of elements: Cu (green), C (black), H (grey), N (violet), O (red). 
The green background marks the His, the orange background marks the two Leu and the 
blue background marks the –Val-Phe-OH residue. Ticks of the scale at the bottom 
represent 1 Å. 
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Figure 9 clearly shows that the amino acids His, Leu-Leu and Val-Phe are arranged 
like shells with distances of approx. 3.5 Å, 7.5 Å and 10.5 Å. This corresponds to the 
different signal broadening in the 1H-NMR spectrum. 
 
2.2.3.2. Investigation of the Binding Process with Mass Spectroscopy 
 
Aqueous buffered solutions (phosphate buffer, pH 8.0, c = 5 mM) of the receptors 
64 – 69 (c = 4 mM) and the peptide 63 (c = 4 mM) were prepared and mixed in a 1:1 
ratio. The mixtures were investigated by MS-spectroscopy. The used method was 
electro spray injection (ESI) with a mixture of MeCN/H2O. The detection of cations 
gave too complex spectra, due to multipile exchange of protons by Na+ or K+. 
Therefore, only negative ESI-spectra were evaluated. 
Each spectrum showed peaks for the peptide, the receptor and the formed complex 
between both. Assignments and intensities of signals (relative abundance, all anions 
were single negatively charged) were: 
1. deprotonated peptide 63;    int.: 100 % 
2. deprotonated receptors 64 – 69;   int.: 5 – 10 % 
3. deprotonated complex of peptide+receptor; int.: < 0.5 % 
No further anions were detected. 
These results confirm binding interactions between all receptors and the peptide 
target. A quantification of the binding strength from mass spectroscopic results was 
not possible. 
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2.2.4. Fluorescent Labelled Histidines 
 
As the direct determination of the binding constant between receptors 64 – 69 and 
the target 63 was not possible, an indirect one had to be used. One promising 
approach was the visualisation of binding process in an indicator displacement 
assay. This was already done with a similar system by Anslyn et al.58 The 
competitive binding of a guanidinium to a receptor and 5-carboxyfluorescein was 
followed via the changes in the absorption spectrum of the fluorophore. However, a 
titration of the receptors 64 – 69 with 5-carboxyfluoresceine showed no changes in 
the absorption spectra. 
In order to visualize the binding process of the NTA-moiety in a competitive 
fluorescence binding assay fluorescent labelled N-terminal histidines were 
synthesized. The principle of this assay is depicted in in figure 10. 
The left side shows a mixture of the indicator (active fluorophore = yellow ellipse) and 
one of the receptors 64 – 69. Due to the binding between both, the fluorescence is 
quenched (grey ellipse) by Cu2+ (middle). After addition of the target 63 the 
fluorescence returns as the receptor shows a higher binding affinity towards the 
target (2 binding interactions) than towards the indicator (one interaction). 
       
Figure 10: Principle of the competitive fluorescence assay with target 63, receptors 64 – 69, and 
fluorescent indicator 73. The blue circle represents the Cu(II)-NTA-complex, the red one 
the guanidine moiety. The active fluorophore (F) is represented by a yellow ellipse, whilst 
the inactive is grey. 
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2.2.4.1. Synthesis of Fluorescent Indicators 
 
Two different fluoropheres – a dansyl- and a fluoresceine-unit – were connected to 
the C-terminus of a histidine. A literature known procedure could be used to 
synthesize a dansyl-functionalized histidine.59 However, an alternative synthesis 
using the click-chemistry approach was used, as the necessary dansyl-building block 
71 was already synthesized (scheme 28).c 
The synthesis of the dansyl-labelled His started with a peptide coupling of propargyl 
amine to twofold Boc-protected His (di-cyclohexylamine salt). Coupling reagents 
were TBTU and HOBt. The use of EDC instead of TBTU did not lead to the formation 
of 70. After column chromatography (CC) 70 was obtained in acceptable yield. The 
connection of 70 to 71 was done in MeCN with CuI as direct Cu+-source and 2,4-
lutidine as base. Purification with CC beared problems, due to the different behaviour 
of 72 on TLC-plates and on the column. The last step of synthesis was the cleavage 
of the Boc-groups. This was achieved using HCl-saturated diethyl ether. As it was not 
possible to determine the degree of protonation of the ammonium salt of 73 it was 
necessary to deprotonate the ammonium salt to obtain the free base. This was done 
with aq. NaHCO3 and extraction with methylene chloride. As 73 showed amphiphile 
behaviour, this resulted in a lower yield.  
                                                 
c
 For details about the synthesis of 71 please see experimental part of chapter 1, compound 7. 
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Scheme 28: Synthesis of the dansyl labelled N-terminal histidine 73. 
UV/Vis and fluorescence spectra of 73 were as expected. Merely the emission 
maximum was shifted to longer wavelengths (from 523 nm to 561 nm) compared to 
71 (figure 11). Explanations for this observation are a more polar solvent (aq. buffer) 
and a possible interaction of the naphtalene system with the triazole. 
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Figure 11: Fluorescence spectrum of 71 in MeOH (c = 1.13 x 10-4 mol/L) on the left with the 
maximum at 523 nm and fluorescence spectrum of 73 in aq. buffer (hepes [pH 7.5, 
50 mM], c = 2.69 x 10-4 mol/L) on the right. Different intensities of emissions were due to 
different settings of the spectrometer’s internal photomultiplier. 
In order to connect a fluorescein group to the C-terminus of His, first an isomeric 
mixture of 5- and 6-carboxy fluorescein was reacted with Boc-protected ethylene 
diamine. After cleavage of the protection group, 75 was coupled to Nα,Nim-di-Boc-L-
histidine (di-cyclohexylamine salt). Following, the Boc-groups of 76 were removed 
with HCl saturated diethyl ether. This yielded a mixture of isomers of the fluorescein 
labelled N-terminal His hydrochloride salt 77 in an overall yield of 38 % (scheme 29). 
The degree of protonation of 77 was considered to be 2 and therefore the HCl-salt 
was not converted into the corresponding free amine. 
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Scheme 29: Synthesis of the fluorescein labelled N-terminal histidine 77. 
 
UV/Vis and fluorescence spectrum of 77 are given in figure 12. Compound 77 
showed a very intensive emission signal (λEx= 488 nm), which was still detectable at 
a concentration of 10 nM.  
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Figure 12: On the left: Absorption spectrum of 77 (c = 1.08 x 10-4 mol/L) in hepes buffer (pH 7.5, 
c = 50 mM) with the maximum absorbance at 495 nm. On the right: corresponding 
fluorescence spectrum (λEx= 488 nm). 
 
2.2.4.2. Binding Properties of Fluorescent Indicators 
 
In order to verify that a Cu(II)-NTA unit is able to quench the fluorescence of the 
dansyl labelled His, the emission of 73 was measured in a titration experiment with 
the not functionalized Cu(II)-NTA complex 78. 
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Figure 13: Cu(II)-NTA (78) which was used in a first titration experiment with 73. 
Figure 14 shows the decrease of the fluorescence of 73 (c = 26.9 µM) upon addition 
of 78 (c = 2.69 mM) in buffered solution (50 mM hepes buffer, pH 7.5). The steep 
decrease after addition of 0.3 eq of 78 is remarkable and suggests a 2:1 
stoichiometry of 73:78. This was confirmed by a Job’s plot (figure 15) and a manual 
fitting of the titration curve (figure 16). The latter gave an unexpected high binding 
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constant of 2.1 (± 0.2) x 1010 L2/mol2. However, a 2:1 stoichiometry between 73 and 
78 seems not possible, as 78 can bind only 1 further bidentate ligand.  
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Figure 14: Quenching of fluorescence of 73 by 78. 
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Figure 15: Job’s plot of titration of 73 with 78. 
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Figure 16: Measured and calculated curve of titration of 73 with 78. 
One possible explanation for this observation is that 73 shows a comparable high 
binding affinity towards Cu2+ like 78, therefore partially decomplexes 78 and forms a 
2:1 complex with Cu2+. This assumption was confirmed by MS-spectroscopy of a 
mixture of 73 and 78. The spectrum showed besides a 1:1 complex of 73:78 also a 
2:1 complex of 73:Cu2+. 
Due to these observations, the binding affinities of 73 towards Cu2+, Zn2+ and Ni2+ 
were investigated with fluorescence titrations. Figure 17 shows the results of the 
fluorescence titration for Cu2+ and figure 18 for Zn2+. Table 4 gives the association 
constants (Ka) and the stoichiometries. 
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Figure 17: Measured and calculated curve of titration of 73 with CuSO4 x 5 H2O in 50 mM hepes 
buffer, pH 7.5 (left). Job’s plot of titration showed a 2:1 stoichiometry (right). 
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Figure 18: Measured and calculated curve of titration of 73 with Zn(OAc)2 x 2 H2O in 50 mM hepes 
buffer, pH 7.5 (left). Job’s plot of titration showed a 1:1 stoichiometry (right). 
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73 + cation from log b (±) Ka (±) 73 : K2+ 
CuSO4 x 5 H2O 11.9 (± 0.2) 7.9 (± 2.5) x 1011 L2/mol2 2:1 
Zn(OAc)2 x 2 H2O 4.8 (± 0.1) 6.5 (± 0.7) x 104 L/mol 1:1 
NiCl2 x 6 H2O 7.1 (± 0.3) 1.4 (± 1.0) x 107 L2/mol2 2:1 
 
Table 4: Binding affinities of 73 towards cations Cu2+, Zn2+ and Ni2+. Stoichiometry of complexes 
was derived from job’s plots. 
The results showed a much lower affinity of 73 towards Ni2+ and Zn2+. Further, the 
Job’s plots of the titrations gave different stoichiometries for Zn2+ and Cu2+ or Ni2+. A 
1:1 stoichiometry of 73:Zn2+ was also confirmed by MS-spectroscopy. The spectrum 
of an equimolar mixture of 73 and zinc(II) acetate showed besides the free ligand the 
corresponding complex. 
Similar dansyl labelled peptide systems containing His are reported in literature which 
show comparable behaviour towards heavy metal cations.60 
Ligand 73 bears up to 5 possible donor groups: an imidazole, a primary amine, an 
amide, a triazole and a sulfonamide. Ligand quality ranking of these groups is 
estimated to be: amine > imidazole > triazole > sulfonamide > amide.61 Due to these 
multiple binding interactions 73 is a suitable chelate ligand for metal cations and 
further shows high binding affinities towards Cu(II)-NTA complexes. However, it is 
unsuitable in an indicator displacement assay. 
In comparison with these results, the fluorescein labelled His 77 was investigated in 
equal experiments. First, the binding of Cu2+ by 77 was measured (fig. 19). 
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Figure 19: Measured and calculated curve of titration of 77 (c = 10.8 µM) with CuSO4 x 5 H2O 
(c = 1.08 mM) in 50 mM hepes buffer, pH 7.5 (left). Job’s plot of titration showed a 2:1 
stoichiometry (right). 
The measurements revealed a binding affinity of 1.45 x 1012 L2/mol2 and a 
stoichiometry of 2:1. This value is only insignificant higher than the association 
constant of 73 towards Cu2+. 
Further titration experiments were performed with 77 and the Cu(II)-NTA complexes 
78 and 67 (fig. 20 and 21). The titration of 77 with 78 gave an association constant of 
3.89 x 1012 L2/mol2. This value is even a hundred times higher than the binding 
constant between 73 and 78 (2.1 x 1010 L2/mol2). The binding constant between 
indicator 77 and the bidentate receptor 67 was a little bit lower, but in the same 
range. Measurements revealed a value of 7.2 x 1011 L2/mol2. 
Mass-spectroscopy of a 1:1 mixture of 77 and 78 gave the same result as for 
indicator 73. The spectrum showed besides a 1:1 complex of 77:78 also a 2:1 
complex of 77:Cu2+. 
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Figure 20: Measured and calculated curve of titration of 77 (c = 1.08 µM) with 78 (c = 108 µM) in 
50 mM hepes buffer, pH 7.5 (left). Job’s plot of titration showed a 2:1 stoichiometry (right). 
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Figure 21: Measured and calculated curve of titration of 77 (c = 1.08 µM) with 67 (c = 108 µM) in 
50 mM hepes buffer, pH 7.5 (left). Job’s plot of titration showed a 2:1 stoichiometry (right). 
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Although the synthesized fluorescent indicators 73 and 77 prooved to be unsuitable 
in an indicator displacement assay, these compounds can be used for the detection 
of Cu2+ and Cu(II)-NTA complexes in aqueous solution. Especially 77 would allow 
detection of Cu(II) even at nano molar concentrations, due to its intensive 
fluorescence. 
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2.3. Stepwise Target Guided Synthesis 
2.3.1. Synthesis of Bidentate Receptors 
2.3.1.1. Synthesis of Zn(II)-NTA-Bis-Zn(II)-Cyclen Complexes 
 
For the synthesis of compounds 80, 81, 82, 83, 84 the NTA-building block precursors 
26, 36, 37, 46, 79 and the cyclen building block precursors 16, 17, 22 were used. 79 
was synthesized from 25 and γ-azido butyric acid (scheme 30) like 26 and 29. 
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Scheme 30: Synthesis of NTA-building block precursor 79. 
The precursors were connected in a common Cu(I) catalyzed “click-reaction” with 
sodium ascorbate and CuSO4 x 5 H2O.62 Scheme 31 shows exemplary the synthesis 
of 80, the following schemes show the subsequent reaction steps. Table 5 gives the 
yield for the synthesis of compounds 80 – 84. For details about carrying out reactions 
and the structures of these compounds, as well as their subsequent steps, please 
see experimental section chapter 2.5.3.2. 
N N
N
N
NN
N
BocBoc
Boc
N N
NN
Boc
BocBoc
N
H
N
NN N
H
O
N
BnOOC COOEt
COOEt
acetate-buffer
EtOH / tBuOH
CuSO4
Na-ascorbate
94 %
17 46+
80
 
Scheme 31: Connection of precursors 17 and 46 using the “click-chemistry” approach. 
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Precursors Triazole Yield 
17 + 46 80 94 % 
22 + 36 81 96 % 
22 + 37 82 93 % 
16 + 26 83 91 % 
22 + 79 84 90 % 
 
Table 5: Combination of precursors and resulting triazole. 
The copper as well as the ascorbate salt were not used in catalytic amounts as this 
proved to give higher yields after shorter reaction times. As the the reduction of Cu(II) 
by sodium ascorbate causes a lowering of the pH-value, the reaction was carried out 
in buffered solution (acetate buffer, pH 5, c = 500 mM). Further, a simple workup with 
aqueous solutions of H2O2 and EDTA was necessary, due to complexation of Cu2+ by 
the formed triazole.63 This gave the triazoles 80 – 84 in high yields (table 5, for details 
see experimental section chapter 2.5.3.1 GP 9). 
Following, the Boc-protecting groups were cleaved with a saturated solution of HCl in 
diethylether. Compounds 85, 86, 87, 88 and 89 precipitated from solution 
quantitatively and were used directly in the next reaction step (see experimental 
section GP 10). Scheme 32 shows exemplary the synthesis of 85. Compound 86 was 
derived from 81, 87 from 82, 88 from 83 and 89 from 84. 
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Scheme 32: Removal of Boc-protecting groups with HCl saturated diethyl ether. 
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The ammonium salts 85 – 89 were deprotonated using a strongly basic anion 
exchanger in its OH–-form. Cleavage of the ester groups during this procedure was 
not observed. The obtained aqueous solutions of the free amines were treated with a 
stoichiometric amount of LiOH in order to cleave the ester functionalities (Bn-ester as 
well as Me- and Et-ester, see experimental section GP 11). Lyophilisation of these 
solutions gave the polydentate ligands 90, 91, 92, 93, 94 (derived from 85, 86, 87, 
88, 89 in this sequence) in quantitative yield, ready for complexation with Zn2+ 
(scheme 33). 
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Scheme 33: Deprotonation of the ammonium salt 85 with a strongly basic anion exchanger (OH–-form) 
and cleavage of ester groups with LiOH. 
Complexation was carried out in a refluxing mixture of MeOH and water. Important 
was the control of the pH value, which had to be kept at approx. 8. This was 
necessary in order to prevent protonation of the ligand by the lewis acidic Zn(II)-
solution or precipitation of polymeric Zn(OH)2 by the basic solution of the amine 
ligand. Complexation at stable pH value was achieved by simultaneous addition of 
methanol solutions of ligands 90 – 94 and Zn(ClO4)2 x 6 H2O to water at 80 °C. 
Further, zinc perchlorate was used only in a small excess. Precipitation after addition 
of EtOH gave the threefold Zn(II)-complexes 95, 96, 97, 98, 99 (derived from 90, 91, 
92, 93, 94 in this sequence) in good yields of 75 % as colourless solids (scheme 34, 
see experimental section GP 12). 
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Scheme 34: Complexation of Zn2+ yields the bidentate receptor 95. 
 
2.3.1.2. Synthesis of Guanidine-Bis-Zn(II)-Cyclen Complexes 
 
For the synthesis of compounds 100, 101 and 102 the guanidine precursors 50, 51, 
54 and the cyclen building block precursors 16, 17, 22 were used. The precursors 
were connected in a common Cu(I) catalyzed “click-reaction” according to the 
synthesis of compounds 80 – 84 (GP 13, scheme 35). 
Subsequently, the Boc-protecting groups were cleaved using the established 
procedure with HCl saturated diethyl ether (GP 10, scheme 36). This yielded 
quantitatively the ammonium salts 103, 104 and 105. 
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Scheme 35: Connection of the precursors using the Cu(I) catalyzed “click”-reaction. 
N
N
N
NN
+
N N
+
N
N
+
N
N
+
N
H
N
NN
N
H
N
+
N
H
H
H
H
H
H
H
HH
H
H
H
H
H
+
 
N
N
N
NN
+
N N
+
N
N
+
N
N
+
N
H
N N
N N
H
N
+
N
H
n
 
H
H
H
H
H
H
H
H
H
H
H
H
H
+
 
HCl / Et2O
r.t., 48 h
100
103
101 / 102
104 n = 2
105 n = 3
HCl / Et2O
r.t., 48 h
quant.
6+
6+
(Cl-)6
(Cl-)6
quant.
 
Scheme 36: Cleavage of the Boc-groups with HCl saturated diethyl ether. 
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After deprotonation with a strongly basic anion exchanger (OH–-form), the resulting 
amines were ready for complexation of Zn2+. The synthesis of Zn(II)-complexes 106, 
107 and 108 was done like the synthesis of complexes 95 – 99, however with one 
major difference: As the amine-ligands tended to precipitate after protonation, the pH 
value of the reaction mixture had to be kept as basic as possible. This was achieved 
by addition of 0.1 M aq. LiOH to the reaction mixture until Zn(OH)2 began to 
precipitate (scheme 37, for details see experimental section GP 14). 
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Scheme 37: Complexation of Zn2+ in basic solution using Zn(ClO4)2 x 6 H2O and LiOH. 
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2.3.1.3. Synthesis of a Cu(II)-NTA-Zn(II)-Porphyrin Complex 
 
The tetraphenyl-porphyrin (TPP) unit is well-suited for protein surface recognition due 
to its large hydrophobic surface area of more than 300 Å2. More importantly, TPP 
derivatives are highly fluorescent and can show emission intensity changes on 
binding to a protein target. In order to synthesize a bidentate receptor with a 
porphyrin and a NTA-moiety, compounds 62 and 41 were connected in a typical 
“click-reaction”. The Cu(II)-NTA complex 41 was used in slight excess of 
1.1 equivalents. As 62 was soluble only in basic aqueous solutions it was first treated 
with sat. aq. solution of NaHCO3. After addition of the NTA-complex 41, aliquots of 
aq. stock solutions of copper sulfate and sodium ascorbate were added to generate 
the essential Cu+ in situ. The Zn2+ in 62 worked like a protecting group and avoided 
complexation of Cu2+. After 24 h stirring at room temperature, the reaction was 
expected to be complete. Thus, the solution was acidified with 1 N HCl to precipitate 
the product in pure form. All other compounds like copper- and ascorbate salts, as 
well as remaining 41 stayed in solution. This gave 109 in a high yield of 90 %.  
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Scheme 38: Connection of the Cu(II)-NTA complex 41 and the Zn(II)-porphyrin 62 in a typical “click-
reaction”. 
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The use of an asymmetric substituted tetra-phenyl-Zn(II)-porphyrin like 62 in “click-
reactions” bears two major advantages: 
• a water-soluble fluorescent receptor with a high affinity for non-polar binding 
sites can be connected easily to any suitable substrate. 
• as its solubility strongly depends on the pH, this enables a simple purification 
by precipitation and therefore allows the use of an excess of reaction partner 
which results in high reaction yields. 
 
2.3.2. Binding Affinities of Receptors 
 
The binding affinities of receptors 95 – 99 and 106 – 108 towards different 
phosphorylated peptides were investigated.d The used peptides had following 
sequences: 
• 5-Carboxyfluorescein-Gly-pTyr-Asp-Lys-Pro-His-Val-Leu-OH (P1)  
• 5-Carboxyfluorescein-Gly-Phe-Asp-pThr-Tyr-Leu-Ile-Arg-Arg-OH (P2)  
• 5-Carboxyfluorescein-Gly-pTyr-Glu-Glu-Ile-Pro-OH (P3) 
 
These peptide sequences revealed to be potent binding partners for proteins of the 
STAT – family.64 Signal tranducers and activators of transcription (STATs) are latent 
cytoplasmic transcription factors which transmit signals from the cell membrane to 
the nucleus.65 STAT3, for example, is active in a lot of primary human tumors and 
tumor-derived cell lines. Further, it seems to be an essential mediator of the abberant 
activity of upstream tyrosine kinases.66 Inhibition of active STAT3 results in growth 
inhibition and apoptosis of tumor cells.67 In common with other STAT proteins, the 
STAT3 SH2 domain shows binding interactions to phosphotyrosine domains in two 
processes: first in the binding of the activated upstream kinase (prior to 
phosphorylation) and then in the dimerisation of two phophorylated STAT3 
molecules. Therefore, small molecules like peptides P1 – P3 are potential inhibitors 
of STAT1, STAT3 and other members of this protein family. 
                                                 
d
 Peptides were synthesized by Dr. F. Freudenmann. Binding investigations were performed by Bianca 
  Sperl under the supervision of Dr. Thorsten Berg (Max Planck Institute of Biochemistry, Martinsried). 
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The spectroscopical method which was used to investigate the binding between the 
Peptides P1 – P3 and different STAT proteins was a homogenous fluorescence 
polarisation assay.64 This method is well suited for the investigation of binding 
between small fluorescence labelled molecules and a significantly larger binding 
partner.68 
Complexes 95 – 99 are potential receptors for P1 as the peptide provides two 
complementary binding sites: the phosphorylated tyrosine for the bis-Zn-cyclen 
moiety and the imidazole ring of the histidine sidechain for the Cu-NTA moiety. 
Whereas, complexes 106 – 108 are potential receptors for all three peptides, as each 
provides one or two carboxylate groups (Asp, Glu) in proximity to the phosphorylated 
amino acid (Tyr, Thr), which enables binding interactions with the guanidinium 
moiety. 
 
2.3.2.1. Binding Affinities of Zn(II)-NTA-Bis-Zn(II)-Cyclen Complexes 
 
The influence of the metal complex receptors 95 – 99 on the binding between P1 and 
STAT1 was investigated by detection of the polarisation of the fluoresceine emission. 
The diagrams in figures 23 and 24 show the dependence of the peptide – protein 
binding on the concentration of added receptor. The y-axis shows the ratio of 
P1-STAT1-complex in %, the x-axis shows the receptor concentration in µmol/L. The 
bis-Zn(II)-cyclen 110 (fig. 22) was used as reference compound. It provides no 
second binding site and therefore should show an influence on the P1 – STAT1 
binding at higher concentrations compared to the bidentate receptors 95 – 99.  
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Figure 22: bis-Zn(II)-cyclen 110 which was used as reference compound in titration experiments. 
 99
 
Figure 23: Titration curves of the receptors 95 – 97 and the reference compound 110 in the 
fluorescence polarisation assay with the P1-STAT1-complex.  
 
Figure 24: Titration curves of the receptors 98, 99 and the reference compound 110 in the 
fluorescence polarisation assay with the P1-STAT1-complex.  
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Measurements revealed that receptors 95 – 99 influence the STAT1 – P1 binding at 
a concentration of approx. 450 µmol/L while the reference compound 110 shows the 
same effect at approx. 900 µmol/L. Further, all bidentate receptors show more or less 
the same binding behaviour. This indicates that the different structural chracteristics 
like the distance between the binding sites or the position of certain functionalities 
(triazole, amide groups) have no influence on the binding properties 
Titration experiments of receptors 95 – 97 with peptide P2 showed nearly the same 
results as for P1. The bidentae receptors showed an influence on the STAT3 – P2 
binding at half concentration (300 µmol/L) compared to 110 (600 µmol/L). This was 
unexpected, as P2 beared no His in its sequence and therefore provided no second 
binding site for the receptors. 
 
Figure 25: Titration curves of the receptors 95 – 97 and the reference compound 110 in the 
fluorescence polarisation assay with the P2-STAT3-complex. 
These results showed that not the additional NTA-binding site increased the binding 
affinity by a factor of 2, but the whole substituent at the triazine ring in 95 – 99. The 
insignificantly higher binding affinity of the bidentate receptors compared to 110 is 
likely due to unspecific interactions. 
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2.3.2.2. Binding Affinities  of Guanidine-Bis-Zn(II)-Cyclen Complexes 
 
The titration experiments with bidentate receptors 106 – 108 and the peptides P1 –
P3 were performed in analogy to the investigations with complexes 95 – 99 described 
in the previous chapter 2.3.2.1. First, the influence of the guanidines on the binding 
between GST-Lck and peptide P3 was determined (fig. 26). 
 
Figure 26: Titration curves of the receptors 106 – 108 and the reference compound 110 in the 
fluorescence polarisation assay with the P3-GST-Lck-complex. 
First, peptide P3, bearing two carboxylate groups in proximity to the phosphorylated 
Tyr and a further one at the free C-terminus, was used. Consequently, it was 
expected to be a suitable binding partner for the receptors 106 – 108. However, the 
measurement revealed almost no increase of the binding affinity of the bidentate 
receptors, compared to 110.  
Additional measurements were performed with the peptides P1 and P2. Both contain 
a carboxylate group next to the phosphorylated Tyr- or Thr-sidechain. However, a 
more or less distinct effect on the protein-peptide binding can only be detected for 
STAT1 - P1 (fig. 27 and 28). 
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Figure 27: Titration curves of the receptors 106 – 108 and the reference compound 110 in the 
fluorescence polarisation assay with the P1-STAT1-complex. 
 
Figure 28: Titration curves of the receptors 106 – 108 and the reference compound 110 in the 
fluorescence polarisation assay with the P2-STAT3-complex. 
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In conclusion the results of the titration experiments showed that the bidentate 
receptors 95 – 99 and 106 – 108 show an insignificant higher binding affinity than the 
reference compound 110. Further, no specific binding or any relationship between 
the structure of the receptors and the binding affinity could be determined. 
However, one aspect should be taken into consideration: all measurements were 
based on the influence of the receptor molecules on the interactions between the 
peptides P1 – P3 and their natural binding partners (STAT1, STAT3 and GST-Lck). 
Consequently, the binding interactions between the receptors and the peptide targets 
were investigated in an indirect way. Furthermore, the inhibition of peptide-protein 
interactions by artificial receptors is still a very challenging task. Therefore it would be 
quite possible that the synthesized bidentate receptors show a high and specific 
binding towards suitable peptide targets if the binding interactions were investigated 
directly. 
 
2.3.2.3. Binding Affinities  of a Cu(II)-NTA-Zn(II)-Porphyrin Complex 
 
As the porphyrin moiety of 109 showed a strong fluorescence, which was expected to 
change during the binding process,69 first the spectroscopic characteristics of 109 
were investigated and compared with 62. The UV/Vis-spectrum of 109 did not show 
any significant changes compared to 62 – the soret band was neither shifted nor was 
there a change of the extinction coefficient. However, the fluorescence spectrum of 
109 showed a decrease of emission intensity by nearly 50 %, compared to 62. This 
was due to the Cu(II)-NTA moiety which quenched the emission of the Zn(II)-
porphyrin moiety (fig. 29). 
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Figure 29: UV/Vis spectrum of 109 in buffer (hepes [pH 7.5, 50 mM], c = 2.69 x 10-4 mol/l) on the left 
with the strong absorption maximum (B-band) at 423 nm and 2 weak absorption bands 
(Q-bands) at 520 nm and 600 nm (enlarged). Fluorescence spectrum of 109 and 62 in 
buffer (hepes [pH 7.5, 50 mM], c = 2.69 x 10-6 mol/l) on the right. 
 
1) Binding affinities to single amino acids: 
 
In a first series of experiments, the binding of single amino acids to 109 was 
investigated. The tested amino-acids were: H-His-OMe, Boc-His-OH, H-Lys-OH, 
H-Gly-OH, H-Ser-OH. Experiments were performed in hepes buffer pH 7.5 (c = 
50 mmol/L). Results revealed that only H-His-OMe was bound by 109 with an 
association constant of Ka = 1.5 x 105 L/mol (1:1 stoichiometry).70 This was expected 
as Cu(II)-NTA complexes selectively bind terminal histidines, whereas Zn(II)-
porphyrins show only a weak binding of amines by the zinc cation.71 During the 
titration of 109 (c = 2.7 µM) with H-His-OMe (c = 270 µM) the fluorescence increased 
and reached in the end almost the intensity of 62 (fig. 30).72 This showed that, after 
binding of a terminal histidine, the copper-NTA complex no longer quenched the 
fluorescence of the zinc porphyrin. Thus, the Zn(II)-porphyrin moiety also can be 
used to investigate binding-events of the Cu(II)-NTA moiety. 
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Figure 30: Measured and calculated curve of titration of 109 with H-His-OMe in 50 mM hepes buffer, 
pH 7.5 (left). Job’s plot of titration showed a 1:1 stoichiometry (right). 
 
2) Binding affinity to pentapeptide 63: 
 
In order to check the influence of a hydrophobic peptide residue, connected to a N-
terminal His, on the binding to 109, the binding affinity of the pentapeptide 63 to 109 
was investigated. It was expected that 63 shows a higher binding affinity than H-His-
OMe because of interactions between the non-polar amino acid sequence –Leu-Leu-
Val-Phe-OH and the porphyrin. 
The fluorescence titration of 109 with 63 in hepes buffer was performed under the 
same conditions like the titration of 109 with H-His-OMe. However, results revealed 
only an insignificant higher binding affinity of 2.1 x 105 L/mol (1:1 stoichiometry). 
Therefore, the influence of the non-polar Leu-Leu-Val-Phe-OH moiety has to be 
considered rather low. 
Maybe, a longer non-polar peptide residue with more aromatic side chain 
functionalities (π- π interactions with the porphyrin) would result in a significant 
stronger binding to 109. However, it has to be noted that an elongation of the non-
polar peptide moiety is restricted due to decreasing solubility in aqueous solution. 
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3) Binding affinity to Proteins: 
 
Porphyrin 109 was synthesized in order to achieve selective bindings to non-polar 
regions on a protein surface with a nearby exposed histidine. Proteins which fulfill 
these criteria are for example hen eggwhite lysozyme (HEL) or myoglobine (horse 
muscle myoglobine, Myo). Figure 31 shows the titration curve of 109 vs. HEL and 
figure 32 shows the titration of 109 with Myo. Results revealed in both cases a 
decrease of fluorescence, a 1:1 binding of the receptor to the protein and high 
binding affinities of 1.7 x 105 L/mol for HEL respectively 4.1 x105 L/mol for Myo. 
Compared to HEL, the decrease of fluorescence of 109, after binding to Myo, was 
stronger, because Myo contains a paramagnetic FeII in its active center, which 
quenches the fluorescence more effectively. 
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Figure 31: Measured and calculated curve of titration of 109 with HEL in 50 mM hepes buffer, pH 7.5 
(left). Job’s plot of titration showed a 1:1 stoichiometry (right). 
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Figure 32: Measured and calculated curve of titration of 109 with Myo in 50 mM hepes buffer, pH 7.5 
(left). Job’s plot of titration showed a 1:1 stoichiometry (right). 
As both, HEL and Myo, have got several hydrophobic areas on their surface a non-
specific binding of the porphyrin moiety was expected. An enhancement of binding 
affinity as well as specificity should be achieved by the additional binding site of the 
Cu(II)-NTA moiety. Figure 33 shows a 3D illustraion of HEL with depiction of the 
polarity on its surface. One can see the predominant hydrophobic areas. Only a few 
polar amino acid side chain residues (e.g. of Lys [basic, blue] or Asp [acidic, red]) 
increase the polarity. A comparison with 109 with matching scale shows that, after 
binding of the Cu(II)-NTA moiety to His 15, there are several non polar areas, where 
the porphyrin moiety can bind to. 
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Figure 33: Electrostatic representation of HEL. Hydrophobic patches are represented in white, acidic 
patches in red and basic patches in blue. Locations of amino acid residues of His 15 and 
nearby Asp 87, Lys 96 and Lys 97 are assigned. A depiction of 109 with matching scale 
is added in overlaid fashion. 
In order to confirm that the additional binding site in 109 results in an enhancement of 
binding affinity, the titration experiments were repeated with 62. The measurements 
had to be performed in solutions saturated with Ar.73 Otherwise it was not possible to 
obtain constant values of fluorescence intensity.74 A possible explanation for this is 
the formation of singlet oxygen by 62.75 This was not observed for 109, as the copper 
complex quenches the energy of the excited zinc-poprphyrin.76 
However, the binding constants of 62 to HEL or Myo did not differ significantly from 
values obtained for 109. The association constant (Ka) for 62 to HEL was 1.9 x 
105 L/mol, for 62 to Myo Ka was 4.9 x 105 L/mol. A possible explanation for the slight 
increase of binding affinity of 62 to the proteins compared to 109 is the higher 
hydrophilicity of 109, due to the copper-NTA moiety. The final conclusion that can be 
drawn from this observation is that the additional Cu(II)-NTA binding site results in no 
enhancement of binding affinity towards the tested proteins. 
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2.4. Summary and Conclusions 
 
Novel receptor building blocks for different binding motifs have been synthesized. 
Zn(II)-cyclen complexes for imide groups, bis-Zn(II)-cyclen complexes for phosphate 
groups, Zn(II) and Cu(II) nitrilo-triacetic acid complexes for N-terminal histidines, 
guanidines for carboxylic acids and a Zn(II)-porphyrin for non-polar regions on a 
protein surface. All compounds bear either an azide or an alkyne function and 
therefore can be connected in any combination using the Cu(I)-catalyzed 
cycloaddition. 
 
A biological relevant pentapeptide, with a histidine and a carboxyl-group as possible 
binding motifs, has been used as target in a kinetically controlled target guided 
reaction. In order to identify a bidentate receptor with a high binding constant for the 
target, combinations of Zn(II)- and Cu(II)-NTA complexes and guanidines have been 
tested in this reaction. Hit-detection was performed in situ with MS-spectroscopy. 
Results revealed one possible high affinity receptor out of 12 combinations. 
Six bidentate receptors have been synthesized and their binding interactions with the 
peptide target have been investigated with NMR- MS- and fluorescence-
spectroscopy. All methods confirmed binding interactions. 
Results of NMR-investigations allowed a prediction of the structural relations of the 
formed complex between target and receptor. This prediction was confirmed by 
Spartan-calculations. 
Further, the association constant of this complex was determined with fluorescence 
spectroscopy to be in the micro molar range. However, a definite determination, as 
well as a comparison of the association constants of these six receptors was not 
possible. 
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Fluorescent labelled N-terminal histidines, with a dansyl- or a fluorescein group have 
been synthesized. The binding interactions between the histidine-moiety and heavy 
metal cations as well as Cu(II)-NTA complexes has been investigated with 
fluorescence spectroscopy. Results revealed high association constants 
(> 1011 L2/mol2) of these indicators towards Cu2+ and Cu(II)-NTA complexes. 
Therefore, these indicators can be used in very sensitive detection assays for Cu(II) 
and corresponding complexes. 
 
Using the Cu(I)-catalyzed cycloaddition, several bidentate receptor molecules with 
different binding sites have been synthesized. Combinations of receptor building 
blocks were: bis-Zn(II)-cyclen-complexes with Zn(II)-NTA-complexes or guanidine 
compounds and further a Cu(II)-NTA- with a Zn(II)-porphyrin complex. 
The binding interactions between the bis-Zn(II)-cyclen compounds and 
phosphorylated peptides were investigated with a fluorescence polarisation assay. 
Results confirmed a slight increase of the binding affinity (factor 2) compared to a 
monodentate bis-Zn(II)-cyclen reference compound. 
The binding interactions between the Zn(II)-porphyrin-Cu(II)-NTA complex and amino 
acids, a pentapeptide and two His-containing proteins (HEL and Myo) were 
investigated with fluorescence titrations. Results showed a specific binding of 
histidine as well as of peptides with an N-terminal His. Binding affinities were in the 
micromolar range. The binding affinities of the porphyrine receptor towards His-
containing proteins revealed to be also in the micromolar range, but unspecific. 
 
These results not only show the possibilities, but also emphasize the importance of 
the Cu(I)-catalyzed “click-reaction” for the “Target Guided Synthesis”-approach in the 
field of drug-discovery.  
Further, this work shows that the Cu(I)-catalyzed “click-reaction” is a valuable tool to 
connect diverse kinds of building blocks in any way, which enables the easy 
synthesis of polydentate receptors with increased affinity for various target 
molecules. 
 
 
 111
2.5. Experimental Part 
2.5.1. General Information 
 
All reactions were performed under an inert atmosphere of N2 using standard 
Schlenk techniques if not otherwise stated. 
 
2.5.1.1. Spectroscopy 
 
Emission Spectroscopy 
Fluorescence measurements were performed with UV-grade solvents (Baker or 
Merck) at 20 °C in 1 cm quartz cuvettes (Hellma) and recorded on a Varian ‘Cary 
Eclipse’ fluorescence spectrophotometer. 
 
Absorption Spectroscopy 
Varian Cary BIO 50 UV/VIS/NIR Spectrometer. Use of a 1 cm quartz cell (Hellma) 
and Uvasol solvents (Merck or Baker). 
 
NMR Spectra 
Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 K), Bruker Avance 400 
(1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), Bruker Avance 300 (1H: 300.1 MHz, 
13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ [ppm] relative to 
external standards (solvent residual peak). The spectra were analysed by first order, 
the coupling constants are given in Hertz [Hz]. Characterisation of the signals: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet, psq = 
pseudo quintet, dd = double doublet, dt = double triplet, ddd = double double doublet. 
Integration is determined as the relative number of atoms. Assignment of signals in 
13C-spectra was determined with DEPT-technique (pulse angle: 135 °) and given as 
(+) for CH3 or CH, (-) for CH2 and (Cquat) for quaternary C. Error of reported values: 
chemical shift: 0.01 ppm for 1H-NMR, 0.1 ppm for 13C-NMR and 0.1 Hz for coupling 
constants. The solvent used is reported for each spectrum. 
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Mass Spectra 
Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD), Finnigan MAT TSQ 7000 
(ESI). Xenon serves as the ionisation gas for FAB. 
 
IR Spectra 
Recorded with a Bio-Rad FTS 2000 MX FT-IR and Bio-Rad FT-IR FTS 155. 
 
2.5.1.2. Synthesis 
 
Melting Points were determined on a Tottoli micro melting point apparatus and are 
uncorrected. TLC analyses were performed on silica gel 60 F-254 with a 0.2 mm 
layer thickness. Detection via UV light at 254 nm / 366 nm or through discolouration 
with ninhydrin in EtOH. For preparative column-chromatography, Merck Geduran SI 
60 silica gel was used. Commercially available solvents of standard quality were 
used. If otherwise stated, purification and drying was done according to accepted 
general procedures.77 Elemental analyses were carried out by the Center for 
Chemical Analysis of the Faculty of Natural Sciences of the University Regensburg. 
 
2.5.2. Synthesis of Building Blocks for Kinetically Controlled TGS 
2.5.2.1. General Procedures 
 
GP 1 – Conversion of bromides into azides using an ion-exchanger loaded with N3-: 
The bromide was dissolved in MeCN and 4 eq of the N3- - loaded anion-exchanger 
was added. The mixture was shaken 18 h at 40 °C. The ion-exchanger was filtered 
and washed with MeCN and MeOH. After evaporation of the solvents the remaining 
oil was treated a second time with the ion-exchanger in the same way. This gave the 
crude product as a yellowish oil. 
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GP 2 – Conversion of alkyl halides into azides in aqueous methanol solution: 
The bromide was dissolved MeOH and a saturated aqueous solution of NaN3 was 
added. Further addition of MeOH was necessary to give a clear solution. A reflux 
condenser was put on and the solution was heated to 70 °C for 24 h. After cooling to 
r.t. 50 ml water were added and the MeOH was evaporated at reduced pressure. The 
remaining suspension was extracted with EE (100 ml, twice). The organic layers 
were combined, washed with brine (50 ml), dried over NaSO4 and filtered. Removal 
of the solvent yielded the azide in sufficient purity of > 98 % (determined with 
1H-NMR). 
 
GP 3 – Cleavage of Boc protecting-groups with TFA in DCM: 
The azide was dissolved in DCM and TFA was added (30 eq). The solution was 
stirred at r.t. for 24 h. The solvent was removed at reduced pressure and 50 ml of 
MeOH were added. All volatile compounds were removed at reduced pressure and 
the remaining oil was dried in vacuum over KOH. 
 
GP 4 – Cleavage of Boc protecting-groups with HCl-saturated diethyl ether: 
The Boc-protected compound was dissolved in diethyl ether (20 ml per mmol). A 
saturated solution of HCl in diethyl ether was added (1 ml per 0.15 mmol Boc). After 
a few minutes a white precipitate appeared. The mixture was stirred at r.t. under an 
atmosphere of N2 for 48 h. The solvent was removed at reduced pressure and the 
remaining colourless solid was dried in vacuum. 
 
GP 5 – Synthesis of bis-Zn(II)-cyclen complexes: 
The ammonium-salt was dissolved in water and eluted over a strongly basic anion-
exchanger (OH- -form, loading: 0.9 mmol/ml, 12 eq). The ion-exchanger resin was 
washed well with water. After lyophilisation of the aqueous solution, the amine was 
obtained as a colourless frothy solid. The amine was dissolved in as much methanol 
as necessary and added dropwise to a 0.15 M solution of Zn(ClO4)2 x 6 H2O (2 – 
3 eq) in aqueous MeOH (MeOH:H2O = 25:1). After a few minutes, the product 
precipitated from the solution. The suspension was stirred at r.t. for 14 h and then 
heated to reflux for 4 h. If necessary, boiling water was added dropwise, until the 
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solid dissolved completely. Then, boiling ethanol was added until a precepitate began 
to form. In order to achieve complete precipitation the suspension was cooled to 
- 20 °C for 16 h. The solid was filtered, washed with EtOH and dried in vacuum. 
 
GP 6 – Alkylation of glutamines under acidic conditions: 
The ammonium chloride was dissolved in acetonitrile (4 ml per mmol). Following, 
bromo-ethylacetate (60 eq), NaF (9 eq) and SiO2 (5 eq) were added. Further, 
phasetransfer-catalysts TBABr und 18-crown-6 (each approx. 100 mg) were added. 
The mixture was refluxed under an atmosphere of N2 for 20 h. After cooling to r.t. 
potassium carbonate (1 eq) was added. After stirring the suspension at r.t. for 1 h 
and filtration, the residue was washed thoroughly with EE. The solvents were 
evaporated at reduced pressure and the excess bromo-ethylacetate was removed in 
vacuum. This gave the crude product as dark brown oil, which was purified by 
column chromatography twice. First EE:PE in a ration of 2:3 and then DCM:MeOH 
98:2. 
 
GP 7 – Synthesis of asymmetric porphyrins: 
Freshly distilled Pyrrol (280 µl, 268 mg, 4.00 mmol, 8 eq) was dissolved in 900 ml 
DCM in a 1000 ml round bottom flask under an atmosphere of N2. After addition of 
the two different benzaldehydes, a catalytic amount of BF3.OEt2 was added and the 
solution changed its colour to red. The mixture was stirred in the dark at r.t. for 20 h 
and concentrated to 500 ml at reduced pressure. In order to oxidise the formed 
porphyrinogen, p-chloranil was added and the mixture was refluxed for 1 h. After 
concentration and drying in vacuum, the dark brown solid was treated with DCM in 
order to separate all insoluble polymeric compounds. The suspension was filtered 
and the filtrate was concentrated at reduced pressure to perform purification by CC.  
 
GP 8 – Synthesis of bidentate Cu(II)-NTA-guanidine-complexes: 
The Cu(II)-NTA-complex and the guanidinium chloride were dissolved in water (10 ml 
per mmol). Aqueous solutions (0.5 ml each) of catalytic amounts of CuSO4 x 5 H2O 
(5 mol%) and sodium ascorbate (20 mol%) were added. The mixture was stirred at 
r.t. for 16 h and then heated to boiling. No reflux condenser was put on, in order to 
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concentrate the solution to a volume less than 1 ml. Boiling EtOH was added very 
slowly until the product started to precipitate. After cooling to r.t. the suspension was 
cooled to – 20 °C for 3 h and the suspension was filtered. The residue was washed 
with EtOH and dried in vacuum. 
 
2.5.2.2. Synthesis of New Compounds 
 
N
NN
N
BocBoc
Boc
Br
 
10-(2-Bromo-ethyl)-1,4,7,10tetraaza-cyclododecane-1,4,7-tricarboxylic acid tri-tert-
butyl ester (2): 
The dibromide (4.01 ml, 8.74 g, 46.55 mmol, 22 eq), K2CO3 (1170 mg, 8.46 mmol, 
4 eq) and 1 (1000 mg, 2.12 mmol) were heated to 100 °C for 24 h. TLC control after 
that time showed almost complete conversion of 1 and one side product which could 
be identified as the two fold substitution product. The suspension was filtered and the 
residue was washed thoroughly with EE. After evaporation of the EE and 
removement of the surplus 1,2-dibromo ethane in vacuum the remaining oil was 
purified with CC (EE:PE = 3:2). This gave 2 as colourless solid in a yield of 823 mg 
(1.42 mmol, 67 %). Rf (EE:PE = 1:1) = 0.67.  
Mp: 84 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.38 (s, 18 H, Boc-CH3), 1.40, (s, 
9 H, Boc-CH3), 2.64 – 2.72 (m, 4 H, 2 cyclen-CH2), 2.95 (t, 3J = 7.5 Hz, 2 H, CH2), 
3.23 – 3.48 (m + t, 14 H, 6 cyclen-CH2 + CH2, δ [ppm] = 3.37, 3J = 7.4 Hz); 13C-NMR 
(75.5 MHz, CDCl3): δ [ppm] = 27.6 (–, 1 C), 28.4 (+, 6 C, Boc-CH3), 28.6 (+, 3 C, 
Boc-CH3), 47.6 (–, 1 C),  47.9 (–, 2 C), 48.2 (–, 1 C), 50.0 (–, 2 C), 53.7 (–, 1 C), 54.6 
(–, 1 C), 54.9 (–, 1 C), 79.3  (Cquat, 1 C, Boc), 79.6 (Cquat, 1 C, Boc), 79.6 (Cquat, 1 C, 
Boc), 155.3 (Cquat, urethane), 155.7 (Cquat, urethane), 156.1 (Cquat, urethane); MS (CI, 
NH3): m/z (%) = 579.3 [MH+] (100); EA (C25H47N4O6Br) calc.: C 51.81, H 8.17, N 
9.67, found: C 51.42, H 8.21, N 9.39; IR (KBr): ν  [cm-1] = 2972, 2931, 1687, 1462, 
1416, 1171; MF: C25H47N4O6Br; MW = 579.58 g/mol. 
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10-(4-Bromomethyl-benzyl)-1,4,7,10tetraaza-cyclododecane-1,4,7-tricarboxylic acid 
tri-tert-butyl ester (3): 
The α,α’-Dibrom-paraxylol (870 mg, 3.30 mmol, 6 eq) was dissolved in 14 ml dry 
THF at 50 °C. Following, potassium carbonate (456 mg, 3.30 mmol, 6 eq) and 1 
(260 mg, 0.55 mmol) were added. The suspension was refluxed for 22 h. All 
inorganic compounds were filtered off and washed thoroughly with MeCN. The 
solution was concentrated at reduced pressure. The resulting oil was purified with 
column chromatography (gradient of PE:EE from 4:1 to 3:2). This yielded 267 mg of 3 
as colourless solid (0.41 mmol, 74 %) and 26 mg of 1 (0.06 mmol, 8 %). Rf (EE:PE = 
1:1) = 0.78. 
Mp: 101 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 1.39 (s, 18 H, Boc-CH3), 1.45 (s, 
9 H, Boc-CH3), 2.54 – 2.60 (m, 4 H, cyclen-CH2), 3.25 – 3.38 (m, 8 H, cyclen-CH2), 
3.52 – 3.58 (m, 4 H, cyclen-CH2), 3.74 (s, 2 H, Bn-CH2), 4.56 (s, 2 H, Bn-CH2), 7.25 
(d, 3J = 7.8 Hz, 2 H, arom.), 7.36 (d, 3J = 7.8 Hz, 2 H, arom.); 13C-NMR (100.1 MHz, 
CDCl3): δ [ppm] = 28.5 (+, 6 C, Boc-CH3), 28.7 (+, 3 C, Boc-CH3), 33.2 (–, Bn), 47.5 – 
48.0 (–, 4 C, cyclen), 49.9 (–, 2 C, cyclen), 54.9 (–, 1 C, cyclen), 55.8 (–, 1 C, cyclen), 
56.8 (–, 1 C, Bn), 79.4  (Cquat, 1 C, Boc), 79.4 (Cquat, 1 C, Boc), 79.5 (Cquat, 1 C, Boc), 
128.9 (+, 2 C, arom.), 130.6 (+, 2 C, arom.), 136.8 (Cquat, 1 C, arom.), 137.3 (Cquat, 
1 C, arom.), 155.4 (Cquat, urethane), 155.7 (Cquat, urethane), 156.1 (Cquat, urethane); 
MS (FD, CH2Cl2): m/z (%) = 654.2 [M+.] (100); EA (C31H51N4O6Br) calc.: C 56.79, H 
7.84, N 8.54, gef.: C 56.38, H 7.92, N 8.24; UV/Vis (CH3CN): λ (lg ε) = 238 nm 
(3.945); IR (KBr): ν  [cm-1] = 3025, 2974, 2930, 2810, 1688, 1460, 1416, 1172, 797; 
MF: C31H51N4O6Br; MW = 655.67 g/mol. 
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10-(2-Azido-ethyl)-1,4,7,10tetraaza-cyclododecane-1,4,7-tricarboxylic acid tri-tert-
butyl ester (4): 
Synthesis followed GP 1 using bromide 2 (388 mg, 0.67 mmol), 10 ml of MeCN and 
5.96 ml (0.9 mmol/ml, 5.36 mmol) of the N3- - loaded anion-exchanger. The raw 
product was purified with CC (EE:PE = 2:3). This gave the azide 4 as colourless oil in 
a yield of 335 mg (0.61 mmol, 92 %). Rf (EE:PE = 1:1) = 0.66. 
Alternative synthesis followed GP 2 using bromide 2 (500 mg, 0.86 mmol), 5 ml of 
MeOH and NaN3 (1402 mg, 21.57 mmol, 25 eq). This yielded 4 as colourless oil 
(457 mg, 0.84 mmol, 98 %).  
The azide was not stable at r.t. and decomposed slowly. Storage in the freezer is 
recommended.  
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.38 (s, 18 H, Boc-CH3), 1.40 (s, 9 H, 
Boc-CH3), 2.60 – 2.64 (m, 4 H, 2 cyclen-CH2), 2.68 (t, 3J = 6.4 Hz, 2 H, CH2), 3.22 – 
3.51 (m + t, 14 H, 6 cyclen-CH2 + CH2, δ [ppm] = 3.39, 3J = 6.4 Hz); 13C-NMR 
(75.5 MHz, CDCl3): δ [ppm] = 27.5 (+, 6 C, Boc-CH3), 27.7 (+, 3 C, Boc-CH3), 46.5 - 
47.2 (–, 5 C), 49.0 (–, 2 C), 50.6 (–, 1 C), 53.3 (–, 1 C), 54.3 (–, 1 C), 78.3  (Cquat, 1 C, 
Boc), 78.6 (Cquat, 1 C, Boc), 78.7 (Cquat, 1 C, Boc), 154.4 (Cquat, urethane), 154.7 (Cquat, 
urethane), 155.2 (Cquat, urethane); MS (ESI, CH2Cl2/MeOH): m/z (%) = 542.3 [MH+] 
(100); MS-HR (EI): [M.] calc.: 541.3588, found: 541.3587 (± 0.54 ppm); IR (KBr): 
ν  [cm-1] = 2975, 2935, 2147, 1686, 1460, 1415, 1172; MF: C25H47N7O6; 
MW = 541.69 g/mol; 
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10-(4-Azidomethyl-benzyl)-1,4,7,10tetraaza-cyclododecane-1,4,7-tricarboxylic acid 
tri-tert-butyl ester (5): 
Synthesis followed GP 1 using bromide 3 (544 mg, 0.83 mmol), 12 ml of MeCN and 
7.38 ml (0.9 mmol/ml, 6.64 mmol) of the N3- - loaded anion-exchanger. The raw 
product was purified with CC (EE:PE = 2:3). This gave the azide 5 as colourless solid 
in a yield of 472 mg (0.76 mmol, 92 %). Rf (EE:PE = 1:1) = 0.68. 
Alternative synthesis followed GP 2 using bromide 3 (1081 mg, 1.65 mmol), 5 ml of 
MeOH and NaN3 (1072 mg, 16.49 mmol, 10 eq). This yielded 5 as colourless solid 
(1020 mg, 1.65 mmol, 100 %).  
The azide was not stable at r.t. and decomposed slowly. Storage in the freezer is 
recommended. 
Mp: 99 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.36 (s, 18 H, Boc-CH3), 1.40 (s, 
9 H, Boc-CH3), 2.55 – 2.63 (m, 4 H, cyclen-CH2), 3.16 – 3.51 (m, 12 H, cyclen-CH2), 
3.66 (s, 2 H, Bn-CH2), 4.24 (s, 2 H, Bn-CH2), 7.17 (d, 3J = 8.2 Hz, 2 H, arom.), 7.21 
(d, 3J = 8.2 Hz, 2 H, arom.); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 28.5 (+, 6 C, 
Boc-CH3), 28.7 (+, 3 C, Boc-CH3), 47.4 – 48.1 (–, 4 C), 49.9 (–, 2 C), 54.5 (–, 1 C, 
Bn), 55.1 (–, 1 C), 56.0 (–, 1 C), 57.0 (–, 1 C), 79.4  (Cquat, 1 C, Boc), 79.5 (Cquat, 2 C, 
Boc), 128.1 (+, 2 C, arom.), 130.7 (+, 2 C, arom.), 134.3 (Cquat, 1 C, arom.), 137.2 
(Cquat, 1 C, arom.), 155.4 (Cquat, urethane), 155.7 (Cquat, urethane), 156.1 (Cquat, 
urethane); MS (ESI, MeCN/MeOH): m/z (%) = 618.4 [MH+] (100); MS-HR (EI): 
[M.] calc.: 617.3901, found: 617.3897 (± = 0.73 ppm); UV/Vis (CH3CN): λ (lg ε) = 
238 nm (3.943); IR (KBr): ν  [cm-1] = 3305, 2977, 2932, 2817, 2100, 1694, 1460, 
1366, 1251, 1172, 772; MF: C31H51N7O6; MW = 617.79 g/mol.  
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4-(2-Azido-ethyl)-4,10-diaza-1,7-diazonia-cyclododecane di-trifluoro acetate (6): 
Synthesis followed GP 3 using azide 4 (360 mg, 0.66 mmol), 10 ml of DCM and TFA 
(1.53 ml, 19.94 mmol). This yielded 310 mg of 6 (0.66 mmol, 100 %) as yellowish oil. 
1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.67 (t, 3J = 5.6 Hz, 2 H, CH2), 2.84 – 2.95 
(m, 8 H, cyclen-CH2), 3.05 – 3.11 (m, 8 H, cyclen-CH2), 3.60 (t, 3J = 5.6 Hz, 2 H, 
CH2); 13C-NMR (300 MHz, CD3CN): δ [ppm] = 42.9 (–, 2 C, cyclen), 43.3 (–, 2 C, 
cyclen), 45.3 (–, 2 C, cyclen), 49.3 (–, 2 C, cyclen), 49.8 (–, 1 C), 51.5 (–, 1 C); MS 
(ESI, H2O/CH3CN): m/z (%) = 242.1 [MH+] (100); MF: [C10H25N7]2+(CF3COO-)2 = 
C14H25N7O4F6; MW = 469.39 g/mol. 
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4-(4-Azidomethyl-benzyl)-4,10-diaza-1,7-diazonia-cyclododecane di-trifluoro acetate 
(7): 
Synthesis followed GP 3 using azide 5 (853 mg, 1.38 mmol), 10 ml of DCM and TFA 
(2.26 ml, 29.59 mmol). This yielded 360 mg of 7 (1.38 mmol, 100 %) as yellowish oil. 
1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.81 – 3.13 (m, 16 H, cyclen-CH2), 3.82 (s, 
2 H, Bn-CH2), 4.38 (s, 2 H, Bn-CH2), 7.32 – 7.36 (m, 4 H, arom. CH); 13C-NMR 
(300 MHz, CD3CN): δ [ppm] = 43.1 (–, 2 C, cyclen), 43.2 (–, 2 C, cyclen), 45.5 (–, 
2 C, cyclen), 48.9 (–, 2 C, cyclen), 54.9 (–, 1 C, Bn), 57.2 (–, 1 C, Bn), 129.7 (+, 2 C, 
arom.), 131.4 (+, 2 C, arom.), 136.2 (Cquat, 1 C), 136.7 (Cquat, 1 C); MS (ESI, CH3CN): 
m/z (%) = 179.9 [(M+2H++CH3CN)2+] (32), 200.4 [(M+2H++2CH3CN)2+] (28), 318.0 
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[MH+] (100), 749.5 [(2M+2H++CF3COO-)+] (7); MF: [C16H29N7]2+(CF3COO-)2 = 
C20H29N7O4F6; MW = 545.49 g/mol. 
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Zn[1-(2-Azido-ethyl)-1,4,7,10tetraaza-cyclododecane] di-perchlorate (8): 
The TFA-salt 6 (310 mg, 0.66 mmol) was dissolved in little MeOH and treated with 
2.9 ml (2.64 mmol, 4 eq) of a strongly basic anion-exchanger (OH- -form, loading 
0.9 mmol/ml). The ion-exchanger resin was washed well with MeOH. The solvent 
was removed at reduced pressure. The remaining yellow oil was dissolved in 8 ml of 
a mixture of MeOH/water (9:1) and added dropwise to a solution of Zn(ClO4)2 x 
6 H2O (492 mg, 1.32 mmol, 2 eq) in 8 ml MeOH. A reddish precipitate occurred. The 
mixture was stirred at r.t. for 24 h and then heated to reflux for 1 h. To the boiling 
mixture EtOH (20 ml) was added. After cooling to r.t. the reddish solid was filtered, 
washed with EtOH and dissolved in very little MeCN. All insoluble compounds were 
removed with centrifugation. The solvent was removed at reduced pressure and the 
remaining oil was dried in vacuum. This yielded 327 mg of 8 (0.65 mmol, 98 %) as 
reddish solid. 
Mp: > 220 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.63 – 3.08 (m, 18 H, CH2 + 
cyclen-CH2), 3.17 – 3.24 (m, 1 H, NH), 3.42 – 3.57 (m, 2 H, NH), 3.68 (t, 3J = 6.0 Hz, 
2 H, CH2); 13C-NMR (300 MHz, CD3CN): δ [ppm] = 43.6 (–, 2 C, cyclen), 44.8 (–, 2 C, 
cyclen), 45.9 (–, 2 C, cyclen), 47.3 (–, 1 C), 51.2 (–, 2 C, cyclen), 51.6 (–, 1 C); MS 
(ESI, H2O/CH3CN): m/z (%) = 152.4 [K2+] (75), 172.9 [(K2++CH3CN)2+] (100), 364.0 
[(K2++Ac-)+] (80); MF: [C10H23N7Zn]2+(ClO4-)2 = C10H23N7O8Cl2Zn; MW = 505.62 g/mol. 
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Zn[1-(4-Azidomethyl-benzyl)-1,4,7,10tetraaza-cyclododecane] di-perchlorate (9): 
The TFA-salt 7 (254 mg, 0.47 mmol) was dissolved in little MeOH and treated with 
2.1 ml (1.86 mmol, 4 eq) of a strongly basic anion-exchanger (OH- - form, loading 
0.9 mmol/ml). The ion-exchanger resin was washed well with MeOH. The solvent 
was removed at reduced pressure. The remaining yellow oil was dissolved in 7 ml of 
a mixture of MeOH/water (9:1) and added dropwise to a solution of Zn(ClO4)2 x 
6 H2O (347 mg, 0.93 mmol, 2 eq) in 7 ml MeOH. A reddish precipitate occurred. The 
mixture was strirred at r.t. for 24 h and then heated to reflux for 1 h. To the boiling 
mixture EtOH (20 ml) was added. After cooling to r.t. the reddish solid was filtered, 
washed with EtOH and dissolved in very little MeCN. All insoluble compounds were 
removed with centrifugation. The solvent was removed at reduced pressure and the 
remaining oil was dried in vacuum. This yielded 268 mg of 9 (0.46 mmol, 98 %) as 
reddish solid. 
Mp: > 220 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.41 – 3.63 (m, 19 H, NH + 
cyclen-CH2), 4.02 (s, 2 H, Bn-CH2), 4.48 (s, 2 H, Bn-CH2), 7.31 – 7.51 (m, 4 H, arom. 
CH); 13C-NMR (300 MHz, CD3CN): δ [ppm] = 43.3 (–, 2 C, cyclen), 44.8 (–, 2 C, 
cyclen), 45.6 (–, 2 C, cyclen), 50.0 (–, 2 C, cyclen), 54.8 (–, 1 C, Bn), 56.2 (–, 1 C, 
Bn), 129.7 (+, 2 C, arom.), 132.4 (Cquat, 1 C), 132.8 (+, 2 C, arom.), 137.6 (Cquat, 1 C); 
MS (ESI, H2O/CH3CN): m/z (%) = 190.4 [K2+] (30), 210.9 [(K2++CH3CN)2+] (100), 
416.0 [(K2++Cl-)+] (15), 480.0 [(K2++ClO4-)+] (15), 494.1 [(K2++CF3COO-)+] (15); 
MF: [C16H27N7Zn]2+(ClO4-)2 = C16H27N7O8Cl2Zn; MW = 581.72 g/mol. 
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10-Prop-2-ynyl-1,4,7,10tetraaza-cyclododecane-1,4,7-tricarboxylic acid tri-tert-butyl 
ester (10): 
Compound 1 (473 mg, 1.00 mmol) was dissolved in 10 ml of MeCN and K2CO3 
(182 mg, 1.32 mmol) and catalytic amounts of KI were added. After addition of 195 µl 
of a 80 % solution of propargyl bromide in toluene (215 mg, 1.80 mmol), the 
suspension was stirred at 50 °C for 48 h. TLC control of the reaction mixture showed 
almost complete conversion. The suspension was filtered and the residue was 
washed with MeCN. The solution was concentrated at reduced pressure and purified 
with CC (PE:EE = 7:3 to 1:1). This gave alkyne 10 as colourless solid (485 mg, 
0.95 mmol, 95 %). Rf (EE:PE = 1:1) = 0.82. 
Mp: 104 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.37 (s, 18 H, Boc-CH3), 1.39 (s, 
9 H, Boc-CH3), 2.14 (s, 1 H, CH), 2.66 – 2.81 (m, 4 H, cyclen-CH2), 3.24 – 3.45 (m, 
14 H, 7 CH2); 13C-NMR (300 MHz, CDCl3): δ [ppm] = 28.5 (+, 6 C, Boc-CH3), 28.7 (+, 
3C, Boc-CH3), 39.1 (–), 46.5 (–, cyclen), 47.0 (–, cyclen), 47.6 (–, cyclen), 47.8 (–, 
cyclen), 49.8 (–, cyclen), 49.9 (–, cyclen), 53.1 (–, cyclen), 54.3 (–, cyclen), 73.6 (+, 
CH), 77.6 (Cquat, alkyne), 79.2 (Cquat, Boc), 79.4 (Cquat, Boc), 79.7 (Cquat, Boc), 155.2 
(Cquat, urethane), 155.7 (Cquat, urethane), 156.0 (Cquat, urethane); MS (ESI, 
CH2Cl2/MeOH): m/z (%) = 511.2 [MH+] (100); MS-HR (FAB, CH2Cl2): [MH+] calc.: 
510.3417, found: 510.3415 (± = 0.73 ppm); IR (KBr): ν [cm-1] = 3252, 2957, 2929, 
2841, 2106, 1682, 1456, 1415, 1366, 1251, 1153; MF: C26H46N4O6; MW = 
510.67 g/mol; 
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4-Prop-2-ynyl-4,10-diaza-1,7-diazonia-cyclododecane di-trifluoro acetate (11): 
Synthesis followed GP 3 using 10 (870 mg, 1.70 mmol), 10 ml of DCM and TFA 
(3.9 ml, 5.8 g, 51.1 mmol, 30 eq). This gave 11 as yellow crystals in a yield of 747 mg 
(1.70 mmol, 100 %). In order to obtain 11 in pure form for X-ray structure analysis 
and EA the solid was recrystallized from MeCN/PE. This yielded colourless crystals 
(635 mg, 85 %). 
Mp: 235 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.58 (t, 4J = 2.3 Hz, 1 H, CH), 
2.81 – 3.18 (m, 16 H, Cyclen-CH2), 3.53 (d, 4J = 2.3 Hz, 2 H, CH2); 13C-NMR 
(300 MHz, CD3CN): δ [ppm] = 42.6 (–), 43.0 (–, 2 C, cyclen), 43.2 (–, 2 C, cyclen), 
45.4 (–, 2 C, cyclen), 48.2 (–, 2 C, cyclen), 75.7 (+, CH), 77.9 (Cquat); MS (ESI, 
CH3CN): m/z (%) = 105.7 [(M+2H+)2+] (7), 126.3 [(M+2H++CH3CN)2+] (35), 146.8 
[(M+2H++2CH3CN)2+] (30), 210.7 [MH+] (100); EA (C15H24N4O4F6) calc.: C 41.10, 
H 5.52, N 12.78, found: C 40.74, H 5.50, N 12.72; IR (KBr): ν [cm-1] = 3323, 3266, 
3030, 2856, 2812, 2102, 1681, 1554, 1412, 1199, 1173, 1123; MF: [C11H24N4]2+ 
(CF3COO-)2 = C15H24N4O4F6; MW = 438.37 g/mol; 
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X-Ray structure and crystal data of 11: 
Triclinic; space group: P -1; cell dimensions: a = 9.2944(11) Å, α = 95.692°, b = 
10.2766 Å, β = 107.826°, c = 11.2758 Å, γ = 94.101°; V = 1014.3 Å3; Z = 2, Dx = 
1.435 Mg/m3; µ = 0.139 mm-1; F(000) = 456. Data collection: T = 173 K; graphite 
monochromator. A translucent colorless crystal with dimensions of 0.500 x 0.360 x 
0.240 mm was used to measure 7895 reflections (3591 unique reflections, Rint = 
0.0170) from 2.32° to 25.94° on a STOE-IPDS diffractometer with the rotation 
method. Structure refinement: The F2 value was refined using the full-matrix least 
squares refinement method, with a goodness-of-fit 0f 1.077 for all reflections and 358 
parameters. 
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Table of atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2 x 103) for 11. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor: 
Atom x y z U(eq) 
N(1) 879(1) 2931(1) 7497(1) 26(1)  
N(2) 1823(1) 1518(1) 5528(1) 25(1)  
N(3) 4336(1) 857(1) 7530(1) 29(1)  
N(4) 3544(1) 2391(1) 9545(1) 27(1)  
C(1) 575(2) 3325(2) 6228(2) 30(1)  
C(2) 1865(2) 2987(1) 5722(2) 27(1)  
C(3) 3180(2) 992(2) 5281(2) 30(1)  
C(4) 4602(2) 1309(2) 6419(2) 30(1)  
C(5) 5464(2) 1474(2) 8709(2) 32(1)  
C(6) 4930(2) 2736(2) 9180(2) 30(1)  
C(7) 2610(2) 3494(2) 9691(2) 31(1)  
C(8) 1814(2) 3988(1) 8456(2) 29(1)  
C(9) -526(2) 2470(2) 7750(2) 32(1)  
C(10) -1601(2) 3476(2) 7704(2) 33(1)  
C(11) -2453(2) 4292(2) 7626(2) 40(1)  
F(1) -1124(2) 7672(1) 7537(2) 70(1)  
F(2) 891(2) 7592(1) 9065(1) 79(1)  
F(3) 816(2) 6991(1) 7164(2) 70(1)  
O(1) 1656(1) 10017(1) 8724(1) 39(1)  
O(2) 512(1) 9556(1) 6636(1) 34(1)  
C(12) 389(2) 7888(2) 7907(2) 41(1)  
C(13) 921(2) 9312(1) 7754(2) 29(1)  
F(4) 2738(1) 5830(1) 5482(1) 48(1)  
F(5) 4995(1) 6437(1) 5451(1) 54(1)  
F(6) 3447(1) 7875(1) 5545(1) 50(1)  
O(3) 4608(1) 5784(1) 7829(1) 34(1)  
O(4) 5004(1) 7997(1) 7975(1) 39(1)  
C(14) 3917(2) 6754(1) 5969(2) 32(1)  
C(15) 4560(2) 6858(1) 7413(2) 27(1)  
 
Table of bond legths [Å] and angles [deg] for 11: 
Bond Length Bond Angle Bond Angle 
F(1)-C(12) 1.334(2)  C(1)-N(1)-C(8) 110.88(12)  C(3)-C(4)-H(4B) 110.6(11)  
F(2)-C(12) 1.319(2)  C(1)-N(1)-C(9) 112.40(13)  H(4A)-C(4)-H(4B) 105.3(16)  
F(3)-C(12) 1.347(2)  C(8)-N(1)-C(9) 112.57(12)  N(3)-C(5)-H(5A) 112.4(11)  
F(4)-C(14) 1.335(2)  C(2)-N(2)-C(3) 116.21(12)  N(3)-C(5)-H(5B) 108.6(12)  
F(5)-C(14) 1.348(2)  C(4)-N(3)-C(5) 113.02(13)  C(6)-C(5)-H(5A) 109.4(11)  
F(6)-C(14) 1.3421(19)  C(6)-N(4)-C(7) 116.42(12)  C(6)-C(5)-H(5B) 107.8(12)  
O(1)-C(13) 1.226(2)  H(2N)-N(2)-H(2O) 106.5(19)  H(5A)-C(5)-H(5B) 108.7(16)  
O(2)-C(13) 1.257(2)  C(2)-N(2)-H(2O) 107.2(13)  N(4)-C(6)-H(6A) 105.3(12)  
O(3)-C(15) 1.2403(19)  C(3)-N(2)-H(2N) 109.9(13)  N(4)-C(6)-H(6B) 107.7(11)  
O(4)-C(15) 1.2515(19)  C(2)-N(2)-H(2N) 108.1(13)  C(5)-C(6)-H(6A) 112.2(11)  
N(1)-C(1) 1.474(2)  C(3)-N(2)-H(2O) 108.6(13)  C(5)-C(6)-H(6B) 110.5(11)  
N(1)-C(9) 1.476(2)  C(5)-N(3)-H(3N) 109.9(13)  H(6A)-C(6)-H(6B) 111.9(16)  
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N(1)-C(8) 1.470(2)  C(4)-N(3)-H(3N) 110.0(13)  N(4)-C(7)-H(7A) 105.6(11)  
N(2)-C(2) 1.4999(19)  C(6)-N(4)-H(4N) 109.4(13)  N(4)-C(7)-H(7B) 106.1(12)  
N(2)-C(3) 1.497(2)  C(7)-N(4)-H(4N) 110.6(13)  C(8)-C(7)-H(7A) 112.8(12)  
N(3)-C(5) 1.467(2)  C(7)-N(4)-H(4O) 107.1(13)  C(8)-C(7)-H(7B) 110.7(12)  
N(3)-C(4) 1.461(2)  C(6)-N(4)-H(4O) 104.8(13)  H(7A)-C(7)-H(7B) 108.1(16)  
N(4)-C(6) 1.497(2)  H(4N)-N(4)-H(4O) 108.2(19)  N(1)-C(8)-H(8A) 107.9(10)  
N(4)-C(7) 1.502(2)  N(1)-C(1)-C(2) 109.36(13)  N(1)-C(8)-H(8B) 110.3(12)  
N(2)-H(2O) 0.90(2)  N(2)-C(2)-C(1) 108.18(12)  C(7)-C(8)-H(8A) 108.6(11)  
N(2)-H(2N) 0.88(2)  N(2)-C(3)-C(4) 111.90(13)  C(7)-C(8)-H(8B) 107.5(12)  
N(3)-H(3N) 0.88(2)  N(3)-C(4)-C(3) 110.74(13)  H(8A)-C(8)-H(8B) 109.8(15)  
N(4)-H(4O) 0.87(2)  N(3)-C(5)-C(6) 109.89(13)  N(1)-C(9)-H(9A) 108.9(11)  
N(4)-H(4N) 0.91(2)  N(4)-C(6)-C(5) 109.02(13)  N(1)-C(9)-H(9B) 107.5(11)  
C(1)-C(2) 1.523(2)  N(4)-C(7)-C(8) 113.15(13)  C(10)-C(9)-H(9A) 109.1(11)  
C(3)-C(4) 1.523(2)  N(1)-C(8)-C(7) 112.69(12)  C(10)-C(9)-H(9B) 108.5(11)  
C(5)-C(6) 1.525(2)  N(1)-C(9)-C(10) 114.24(13)  H(9A)-C(9)-H(9B) 108.4(16)  
C(7)-C(8) 1.519(2)  C(9)-C(10)-C(11) 177.46(19)  C(10)-C(11)-H(11) 178.6(7)  
C(9)-C(10) 1.482(2)  N(1)-C(1)-H(1A) 110.2(11)  F(1)-C(12)-F(2) 107.21(17)  
C(10)-C(11) 1.185(3)  N(1)-C(1)-H(1B) 114.0(12)  F(1)-C(12)-F(3) 104.75(15)  
C(1)-H(1B) 1.01(2)  C(2)-C(1)-H(1A) 108.5(12)  F(1)-C(12)-C(13) 111.11(14)  
C(1)-H(1A) 0.974(19)  C(2)-C(1)-H(1B) 108.9(11)  F(2)-C(12)-F(3) 107.51(15)  
C(2)-H(2B) 0.95(2)  H(1A)-C(1)-H(1B) 105.7(16)  F(2)-C(12)-C(13) 114.33(15)  
C(2)-H(2A) 0.97(2)  N(2)-C(2)-H(2A) 109.9(11)  F(3)-C(12)-C(13) 111.38(15)  
C(3)-H(3A) 0.95(2)  N(2)-C(2)-H(2B) 109.0(12)  O(1)-C(13)-O(2) 130.23(14)  
C(3)-H(3B) 0.976(19)  C(1)-C(2)-H(2A) 109.2(11)  O(1)-C(13)-C(12) 116.05(14)  
C(4)-H(4B) 0.970(19)  C(1)-C(2)-H(2B) 113.2(12)  O(2)-C(13)-C(12) 113.72(14)  
C(4)-H(4A) 0.99(2)  H(2A)-C(2)-H(2B) 107.3(16)  F(4)-C(14)-F(5) 106.99(13)  
C(5)-H(5B) 0.97(2)  N(2)-C(3)-H(3A) 107.8(12)  F(4)-C(14)-F(6) 106.53(14)  
C(5)-H(5A) 0.98(2)  N(2)-C(3)-H(3B) 103.6(11)  F(4)-C(14)-C(15) 112.72(13)  
C(6)-H(6B) 0.975(19)  C(4)-C(3)-H(3A) 110.7(12)  F(5)-C(14)-F(6) 106.26(14)  
C(6)-H(6A) 0.98(2)  C(4)-C(3)-H(3B) 110.5(11)  F(5)-C(14)-C(15) 110.06(14)  
C(7)-H(7B) 0.98(2)  H(3A)-C(3)-H(3B) 112.2(16)  F(6)-C(14)-C(15) 113.84(13)  
C(7)-H(7A) 0.964(19)  N(3)-C(4)-H(4A) 113.3(12)  O(3)-C(15)-O(4) 130.18(16)  
C(8)-H(8A) 0.997(19)  N(3)-C(4)-H(4B) 109.2(11)  O(3)-C(15)-C(14) 114.19(13)  
C(8)-H(8B) 0.98(2)  C(3)-C(4)-H(4A) 107.5(12)  O(4)-C(15)-C(14) 115.57(13) 
C(9)-H(9B) 1.01(2)          
C(9)-H(9A) 1.03(2)          
C(11)-H(11) 0.93(2)          
C(12)-C(13) 1.554(2)          
C(14)-C(15) 1.543(2)         
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Zn[1-Prop-2-ynyl-1,4,7,10tetraaza-cyclododecane] di-chloride (12): 
The TFA-salt 11 (732 mg, 1.67 mmol) was dissolved in 20 ml of water and eluted 
over 7.4 ml of a strongly basic anion exchanger (OH--form, loading: 0.9 mmol/ml, 
6.68 mmol, 2 eq). The ion-exchanger resin was washed with water and MeOH. The 
solution was lyophilized and the obtained frothy solid was dissolved under an 
atmosphere of N2 in 8 ml of dry MeCN. A solution of 683 mg ZnCl2 (5.01 mmol, 3 eq) 
in 25 ml of dry MeCN was added and the solution was heated to reflux for 24 h. The 
solvent was removed at reduced pressure. The residue was suspended in 4 ml dry 
EtOH, treated with ultra sound for 30 min, filtered and washed with dry EtOH. Drying 
in vacuum yielded the zinc-complex as colourless hygroscopic solid (434 mg, 
1.25 mmol, 75 %). 
Mp: > 250 °C, 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.68 (t, 4J = 2.3 Hz, 1 H, CH), 
2.64 – 3.04 (m, 16 H, cyclen-CH2), 3.05 – 3.09 (m, 1 H, NH), 3.14 – 3.20 (m, 2 H, 
NH), 3.61 (d, 4J = 2.4 Hz, 2 H, CH2); 13C-NMR (300 MHz, CD3CN): δ [ppm] = 43.4 (–, 
2 C, cyclen), 44.2 (–, 1 C), 44.9 (–, 2 C, cyclen), 45.6 (–, 2 C, cyclen), 50.9 (–, 2 C, 
cyclen), 76.7 (Cquat), 77.1 (+, CH); MS (ESI, H2O/CH3CN): m/z (%) = 308.9 [(K2++    
Cl-)+] (100); MS-HR (PI-LSIMS, H2O/MeCN/glycerine): [(K2++Cl-)+] calc.: 309.0824, 
found: 309.0825 (± = 1.12 ppm); IR (KBr): ν [cm-1] = 3492, 3269, 3216, 2945, 2886, 
2107, 1616, 1468, 1442, 1299, 1087, 974; MF: C11H22N4Cl2Zn; MW = 346.61 g/mol; 
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(2-Azido-ethyl)-[4,6-bis-(4,7,10-tri-tert-butoxycarbonyl-1,4,7,10tetraaza-cyclododec-1-
yl)-[1,3,5]triazin-2-yl]-amine (16): 
The chloride 13 (1000 mg, 0.95 mmol) was dissolved in 40 ml of dioxane. Following, 
potassium carbonate (1962 mg, 14.19 mmol, 15 eq) and 2-Azido-ethylamine 
hydrochloride (14) (580 mg, 4.73 mmol, 5 eq) were added. The suspension was 
stirred at 90 °C for 3 d. The suspension was filtered and the residue was washed 
thoroughly with EE. After evaporation of the solvent in vacuum, the obtained brown 
oil was purified by column chromatography twice. First with PE:EE = 7:3 and then 
with DCM:MeOH = 98:2. This gave the azide 16 as a colourless solid in a yield of 
998 mg (0.90 mmol, 95 %). Rf (EE:PE = 1:1) = 0.73. 
Mp: 142 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.37 – 1.39 (m, 54 H, Boc-CH3), 
3.24 – 3.58 (m, 36 H, 2 CH2 + cyclen-CH2), 4.93 (bs, 1 H, NH); 13C-NMR (75.5 MHz, 
CDCl3): δ [ppm] = 28.4 (+, Boc-CH3), 28.5 (+, Boc-CH3), 40.1 (–, 1 C), 50.3 (–, 16 C, 
cyclen), 51.2 (–, 1 C), 79.7 (Cquat, 4 C, Boc), 79.8 (Cquat, 2 C, Boc), 156.3 (Cquat, 6 C, 
urethane), 165.3 (Cquat, 1 C, triazine), 166.1 (Cquat, 2 C, triazine); MS (ESI, 
CH2Cl2/MeOH): m/z (%) = 1107.0 [MH+] (100), 1129.0 [M+Na+] (8); 
EA (C51H91N15O12) calc.: C 55.37, H 8.29, N 18.99, found: C 55.76, H 8.50, N 18.51; 
UV/Vis (CH3CN): λ (lg ε) = 231 nm (4.562); IR (KBr): ν  [cm-1] = 3402, 3255, 2976, 
2932, 2138, 1680, 1539, 1479, 1411, 1367, 1249, 1178, 777; MF: C51H91N15O12; MW 
= 1106.38 g/mol; 
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(3-Azido-propyl)-[4,6-bis-(4,7,10-tri-tert-butoxycarbonyl-1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-yl]-amine (17): 
The chloride 13 (1000 mg, 0.95 mmol) was dissolved in 40 ml of dioxane. Following, 
potassium carbonate (1962 mg, 14.19 mmol, 15 eq) and 3-Azido-propylamine 
hydrochloride (15) (646 mg, 4.73 mmol, 5 eq) were added. The suspension was 
stirred at 90 °C for 3 d. The suspension was filtered and the residue was washed 
thoroughly with EE. After evaporation of the solvent in vacuum the obtained brown oil 
was purified by column chromatography twice. First with PE:EE = 7:3 and then with 
DCM:MeOH = 98:2. This gave the azide 17 as a colourless solid in a yield of 
1011 mg (0.90 mmol, 95 %). Rf (EE:PE = 1:1) = 0.74. 
Mp: 140 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.37 – 1.39 (m, 54 H, Boc-CH3), 
1.76 (tt, 3J = 6.6 Hz, 2 H, CH2), 3.24 – 3.58 (m, 36 H, 2 CH2 + cyclen-CH2), 4.78 (bs, 
1 H, NH); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 28.4 (+, Boc-CH3), 28.5 (+, Boc-
CH3), 29.2 (–, 1 C), 37.9 (–, 1 C), 49.0 (–, 1 C), 50.3 (–, 16 C, cyclen), 79.7  (Cquat, 
4 C, Boc), 79.8 (Cquat, 2 C, Boc), 156.3 (Cquat, 6 C, urethane), 165.8 (Cquat, 1 C, 
triazine), 166.5 (Cquat, 2 C, triazine); MS (ESI, CH2Cl2/MeOH): m/z (%) = 1121.0 [MH+] 
(100); EA (C52H93N15O12) calc.: C 55.75, H 8.37, N 18.75, found: C 56.02, H 8.60, N 
18.48; UV/Vis (CH3CN): λ (lg ε) = 231 nm (4.559); IR (KBr): ν  [cm-1] = 3402, 3255, 
2976, 2932, 2138, 1680, 1539, 1479, 1411, 1367, 1249, 1178, 777; 
MF: C52H93N15O12; MW = 1120.40 g/mol; 
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(2-Azido-ethyl)-[4,6-bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-yl]-amine 
tetra hydrochloride (18): 
Synthesis followed GP 4 using 16 (550 mg, 0.50 mmol) and 20 ml of a saturated 
solution of HCl in Et2O. This yielded 323 mg of 18 as a colourless solid (0.50 mmol, 
100 %). 
1H-NMR (300 MHz, D2O): δ [ppm] = 3.08 – 3.26 (m, 24 H, cyclen-CH2), 3.40 (t, 3J = 
3.5 Hz, 2 H, CH2), 3.55 (t, 3J = 3.6 Hz, 2 H, CH2), 3.79 (bs, 8 H, cyclen-CH2); 
13C-NMR (75.5 MHz, D2O): δ [ppm] = 40.0 (–, 1 C), 44.2 (–, 8 C, cyclen), 46.2 (–, 
4 C, cyclen), 47.9 (–, 4 C, cyclen), 49.9 (–, 1 C), 155.4 (Cquat, 3 C, triazine); MS (ESI, 
H2O/MeCN + TFA): m/z (%) = 196.7 [(M+3H++2MeCN)3+] (26), 253.6 [(M+2H+)2+] 
(100), 506.4 [MH+] (24), 542.4 [(M+H++HCl)+] (5); UV/Vis (H2O): λ (lg ε) = 220 nm 
(4.637); IR (KBr): ν  [cm-1] = 3428, 2964, 2940, 2811, 2142, 1678, 1542, 1416, 1352, 
1179, 780; MF: C21H47N15Cl4; MW = 651.52 g/mol; 
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(3-Azido-propyl)-[4,6-bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-yl]-amine 
tetra hydrochloride (19): 
Synthesis followed GP 4 using 17 (560 mg, 0.50 mmol) and 20 ml of a saturated 
solution of HCl in Et2O. This yielded 333 mg of 19 as colourless solid (0.50 mmol, 
100 %). 
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1H-NMR (300 MHz, D2O): δ [ppm] = 1.80 (tt, 3J = 3.6 Hz, 2 H, CH2), 3.16 – 3.37 (m, 
26 H, CH2 + cyclen-CH2), 3.49 (t, 3J = 3.6 Hz, 2 H, CH2), 3.85 (bs, 8 H, cyclen-CH2); 
13C-NMR (75.5 MHz, D2O): δ [ppm] = 27.6 (–, 1 C), 38.3 (–, 1 C), 44.3 (–, 8 C, 
cyclen), 46.3 (–, 4 C, cyclen), 48.0 (–, 4 C, cyclen), 48.7 (–, 1 C), 155.2 (Cquat, 3 C, 
triazine); MS (ESI, H2O/MeCN): m/z (%) = 260.7 [(M+2H+)2+] (100); UV/Vis (H2O): 
λ (lg ε) = 220 nm (4.637); IR (KBr): ν  [cm-1] = 3428, 2964, 2940, 2811, 2142, 1678, 
1542, 1416, 1352, 1179, 780; MF: C22H49N15Cl4; MW = 665.53 g/mol; 
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Zn2[(2-Azido-ethyl)-[4,6-bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-yl]-
amine] tri-perchlorate hydroxide (20): 
Synthesis followed GP 5 using the ammonium-salt 18 (280 mg, 0.43 mmol), 5.7 ml of 
the anion-exchanger (5.16 mmol) and Zn(ClO4)2 x 6 H2O (528 mg, 1.29 mmol, 3 eq). 
This gave 20 as pale orange solid (382 mg, 0.39 mmol, 90 %). 
Mp: 263 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.71 – 4.40 (m, 42 H), 6.42 (t, 
3J = 5.9 Hz, 1 H, NH); 13C-NMR (75.5 MHz, CD3CN): δ [ppm] = 41.0 (–, 1 C), 44.5 (–, 
4 C, cyclen), 46.5 (–, 2 C, cyclen), 46.7 (–, 2 C, cyclen), 47.5 (–, 2 C, cyclen), 47.5 (–, 
2 C, cyclen), 47.7 (–, 2 C, cyclen), 47.9 (–, 2 C, cyclen), 51.6 (–, 1 C), 167.1 (Cquat, 
1 C, triazine), 170.9 (Cquat, 1 C, triazine), 171.2 (Cquat, 1 C, triazine); MS (ESI, 
H2O/MeCN): m/z (%) = 360.7 [(K4++H2O+2Cl-)2+] (100); EA (C21H48N15O15Cl3Zn2) 
calc.: C 25.53, H 4.90, N 21.27, found: C 25.66, H 4.92, N 21.15; UV/Vis (CH3CN): λ 
(lg ε) = 221 nm (4.578); IR (KBr): ν  [cm-1] = 3405, 3305, 3255, 2942, 2148, 1562, 
1343; MF: [C21H43N15Zn2] (OH) (ClO4)3 x 2 H2O = C21H48N15O15Cl3Zn2; MW = 
987.82 g/mol; 
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Zn2[(3-Azido-propyl)-[4,6-bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-yl]-
amine] tri-perchlorate hydroxide (21): 
Synthesis followed GP 5 using the ammonium-salt 19 (579 mg, 0.87 mmol), 11.6 ml 
of the anion-exchanger (10.4 mmol) and Zn(ClO4)2 x 6 H2O (972 mg, 2.61 mmol, 
3 eq). This gave 21 as pale orange solid (784 mg, 0.78 mmol, 90 %). 
Mp: 258 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 1.83 (tt, 3J = 6.7 Hz, 2 H, CH2), 
2.65 – 4.42 (m, 42 H), 6.32 (t, 3J = 5.8 Hz, 1 H, NH); 13C-NMR (75.5 MHz, CD3CN): 
δ [ppm] = 29.6 (–, 1 C), 39.0 (–, 1 C), 44.5 (–, 5 C, cyclen + CH2), 46.3 (–, 2 C, 
cyclen), 46.5 (–, 2 C, cyclen), 47.4 (–, 2 C, cyclen), 47.4 (–, 2 C, cyclen), 47.8 (–, 2 C, 
cyclen), 47.9 (–, 2 C, cyclen), 167.0 (Cquat, 1 C, triazine), 170.8 (Cquat, 1 C, triazine), 
171.4 (Cquat, 1 C, triazine); MS (ESI, MeCN): m/z (%) = 372.6 [(K4+-H++ClO4-)2+] (65), 
381.6 [(K4++OH-+ClO4-)2+] (100), 862.3 [(K4++OH-+2ClO4-)+] (35); 
EA (C22H50N15O15Cl3Zn2) calc.: C 26.38, H 5.03, N 20.97, found: C 26.71, H 5.16, N 
21.03; UV/Vis (CH3CN): λ (lg ε) = 221 nm (4.558); IR (KBr): ν  [cm-1] = 3405, 3305, 
3255, 2942, 2148, 1562, 1343; MF: [C22H45N15Zn2] (OH) (ClO4)3 x 2 H2O = 
C22H50N15O15Cl3Zn2; MW = 1001.85 g/mol; 
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[4,6-Bis-(4,7,10-tri-tert-butoxycarbonyl-1,4,7,10tetraaza-cyclododec-1-yl)-
[1,3,5]triazin-2-yl]-prop-2-ynyl-amine (22): 
The chloride 13 (815 mg, 0.77 mmol) was dissolved in 25 ml of dioxane. Following, 
potassium carbonate (533 mg, 3.86 mmol, 5 eq) and propargyl amine (247 µl, 
212 mg, 3.86 mmol, 5 eq) were added. The suspension was stirred at 90 °C in the 
dark for 3 d. The suspension was filtered and the residue was washed thoroughly 
with EE. After evaporation of the solvent in vacuum the obtained brown oil was 
purified by CC twice. First with PE:EE = 7:3 and then with DCM:MeOH = 98:2. This 
gave the alkyne 22 as a colourless solid in a yield of 780 mg (0.73 mmol, 94 %). 
Rf (EE:PE = 1:1) = 0.74. 
Mp: 149 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.37 – 1.39 (m, 54 H, Boc-CH3), 
2.09 (t, 4J = 2.3 Hz, 1 H, CH), 3.22 – 3.58 (m, 32 H, cyclen-CH2), 4.07 – 4.10 (m, 2 H, 
CH2), 4.86 (bs, 1 H, NH); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 28.4 (+, Boc-CH3), 
28.5 (+, Boc-CH3), 30.4 (–, 1 C), 50.3 (–, 16 C, cyclen), 70.5 (+, 1 C, CH), 79.7  
(Cquat, 4 C, Boc), 79.8 (Cquat, 2 C, Boc), 81.1 (Cquat, 1 C, alkyne), 156.3 (Cquat, 6 C, 
urethane), 165.4 (Cquat, 1 C, triazine), 166.1 (Cquat, 2 C, triazine); MS (ESI, 
CH2Cl2/MeOH): m/z (%) = 1075.8 [MH+] (100); EA (C52H90N12O12): calc.: C 58.08, H 
8.44, N 15.63, found: C 57.76, H 8.80, N 15.45; UV/Vis (CH3CN): λ (lg ε) = 231 nm 
(4.564); IR (KBr): ν  [cm-1] = 3402, 3314, 3255, 2976, 2932, 2102, 1680, 1539, 1479, 
1411, 1367, 1249, 1178, 777; MF: C52H90N12O12; MW = 1075.36 g/mol; 
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[4,6-Bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-yl]-prop-2-ynyl-amine 
tetra-trifluoro acetate (23): 
The Boc-protected compound 22 (327 mg, 0.30 mmol) was dissolved in 20 ml of dry 
DCM and TFA was added (1.968 ml, 2912 mg, 25.54 mmol, 84 eq). The solution was 
stirred at r.t. under an atmosphere of N2 for 24 h. The solvent and excess TFA were 
removed in vacuum. This gave a yellow oil, which was dissolved in MeOH and dried 
in vacuum several times. This yielded 278 mg of 23 as yellow hygroscopic solid 
(0.30 mmol, 100 %). 
Mp: 58 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.47 (t, 4J = 2.5 Hz, 1 H, CH), 3.00 
– 3.25 (m, 32 H, cyclen-CH2), 3.78 (d, 4J = 2.5 Hz, 2 H, CH2); 13C-NMR (75.5 MHz, 
CD3CN): δ [ppm] = 30.9 (–), 43.3 (–, cyclen), 43.8 (–, cyclen), 45.4 (–, cyclen), 46.1 
(–, cyclen), 47.0 (–, cyclen), 47.6 (–, cyclen), 72.1 (+, CH), 81.9 (Cquat, alkyne), 164.6 
(Cquat, triazine), 166.6 (Cquat, triazine), 168.1 (Cquat, triazine); MS (ESI, MeCN): m/z (%) 
= 238.1 [MH22+] (100), 475.4 [MH+] (27), 589.4 [(MH++CF3COOH)+] (24); UV/Vis 
(CH3CN): λ (lg ε) = 219 nm (4.637); MF: C30H46N12O8F12; MW = 930.75 g/mol; 
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Zn2[4,6-Bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-yl]-prop-2-ynyl-amine 
tri-perchlorate hydroxide (24): 
Synthesis followed GP 5 using the TFA-salt 23 (2317 mg, 2.49 mmol), 33.2 ml of the 
anion-exchanger (29.9 mmol) and Zn(ClO4)2 x 6 H2O (1946 mg, 5.23 mmol, 2.1 eq). 
This gave 24 as pale orange solid (2192 mg, 2.29 mmol, 92 %).  
Mp: 268 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.54 (t, 4J = 2.5 Hz, 1 H, CH), 
2.68 – 3.63 (m, 32 H, cyclen-CH2), 3.94 – 4.10 (m, 2 H, NH), 4.17 (dd, 3J = 5.8 Hz, 
4J = 2.5 Hz, 2 H, CH2), 4.30 – 4.39 (m, 2 H, NH), 4.45 – 4.54 (m, 2 H, NH), 6.46 (t, 
3J = 5.8 Hz, 1 H, NH); 13C-NMR (75.5 MHz, CD3CN): δ [ppm] = 31.2 (–, 1 C), 44.4 (–, 
4 C, cyclen), 46.8 (–, 2 C, cyclen), 47.1 (–, 2 C, cyclen), 47.5 (–, 4 C, cyclen), 47.7 (–, 
4 C, cyclen), 72.2 (+, 1 C, CH), 82.1 (Cquat, 1 C, alkyne), 166.7 (Cquat, 1 C, triazine), 
170.9 (Cquat, 1 C, triazine), 170.9 (Cquat, 1 C, triazine); MS (ESI, MeCN): m/z (%) = 
213.9 [(K4+-H++MeCN)3+] (32), 227.7 [(K4+-H++2MeCN)3+] (44), 233.7 [(K4++OH-
+2MeCN)3+] (40), 350.1 [(K4+-H++OH-+2MeCN)2+] (40), 359.1 [(K4++OH-+ClO4-)2+] 
(100), 817.2 [(K4++OH-+2ClO4-)+] (50); EA (C22H47N12O15Cl3Zn2) calc.: C 27.62, H 
4.95, N 17.57, found: C 27.77, H 5.19, N 17.88; UV/Vis (CH3CN): λ (lg ε) = 221 nm 
(4.565); IR (KBr): ν  [cm-1] = 3405, 3305, 3255, 2942, 2118, 1562, 1343; 
MF: [C22H42N12Zn2] (OH) (ClO4)3 x 2 H2O = C22H47N12O15Cl3Zn2; MW = 956.81 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-6-pent-4-ynoylamino-hexanoic acid 
methyl ester (26): 
The 4-pentynoic acid (338 mg, 2.65 mmol, 1.3 eq) was dissolved in 5 ml of dry DCM 
and cooled to 0 °C in an icebath. Following, HOBt (512 mg, 3.79 mmol, 1.43 eq), 
EDC (670 µl, 588 mg, 3.79 mmol, 1.43 eq) and DIEA (346 µl, 489 mg, 3.79 mmol, 
1.43 eq) were added in this sequence (important). The solution was stirred at 0 °C for 
30 min. Then, the amine 25 (880 mg, 2.65 mmol, 1 eq), dissolved in 10 ml of dry 
DCM, was added dropwise. The solution was stirred at r.t. under an atmosphere of 
N2 for 24 h. After that time 50 ml of DCM were added and the solution was washed 
with 30 ml of a 0.1 N aqueous solution of citric acid and 30 ml water. The organic 
layer was dried with MgSO4, filtered and concentrated in vacuum. The crude product 
was purified by CC with EE:PE = 3:2 to 4:1. This gave 26 as a colourless oil in a yield 
of 656 mg (1.59 mmol, 60 %). Rf (EE:PE = 1:1) = 0.21. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.06 (t, 3J = 7.1 Hz, 6 H, CH3), 1.19 – 1.41 (m, 
4 H, CH2), 1.46 – 1.53 (m, 2 H, CH2), 1.84 (t, 4J = 2.5 Hz, 1 H, alkyne-CH), 2.19 – 
2.24 (m, 2 H, CH2), 2.27 – 2.33 (m, 2 H, CH2), 2.97 – 3.10 (m, 2 H, CH2), 3.22 (t, 3J = 
7.6 Hz, 1 H, C*H), 3.41 (s, 4 H, N-CH2), 3.47 (s, 3 H, CH3), 3.95 (q, 3J = 7.1 Hz, 4 H, 
CH2), 6.58 (t, 3J = 5.2 Hz, 1 H, NH); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 14.2 (+, 
2 C, CH3), 15.0 (–, 1 C), 22.7 (–, 1 C), 28.3 (–, 1 C), 29.6 (–, 1 C), 35.3 (–, 1 C), 39.2 
(–, 1 C), 51.5 (+, 1 C, C*H), 52.8 (–, 2 C), 60.7 (–, 2 C), 64.2 (+, 1 C, CH3), 69.1 (+, 
CH, alkyne), 83.3 (Cquat, 1 C, alkyne), 171.1 (Cquat, 1 C), 171.5 (Cquat, 2 C, Et-ester), 
173.24 (Cquat, 1 C, amide); MS (ESI, MeOH): m/z (%) = 413.2 [MH+] (100), 435.2 
[MNa+] (7); IR (KBr): ν  [cm-1] = 3311, 3264, 2971, 2107, 1735, 1689, 1646, 1534, 
1450, 1282, 1166; MF: C20H32N2O7; MW = 412.48 g/mol; 
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Li[Zn(2-(Bis-carboxylate-methyl-amino)-6-pent-4-ynoylamino-hexanoate)] 
di-hydrate (27): 
Compound 26 (429 mg, 1.04 mmol) was dissolved in a mixture of 10 ml of acetone 
and 7 ml water. Then, LiOH (74.8 mg, 3.12 mmol, 3 eq) was added and the solution 
was stirred at r.t. for 24 h. The acetone was evaporated and the water was removed 
by lyophilisation. This yielded 375 mg of the carboxylate as colourless solid 
(1.04 mmol, 100 %, MF: C15H19N2O7Li3; MW = 360.15 g/mol). NMR- and MS-
spectroscopy confirmed the complete cleavage of all ester-groups. The lithium-salt 
was dissolved in 15 ml water and ZnCl2 (142 mg, 1.04 mmol, 1 eq) and 5ZnO.2CO3 x  
4 H2O (623 mg, 1.04 mmol, 1 eq) were added. The solution was stirred at r.t. for 16 h 
and then heated to 60 °C for 2 h. All inorganic compounds were removed by filtration 
and the aqueous solution was dried by lyophilisation. The crude product was purified 
by recrystallisation in EtOH/water. Diethyl ether was added to complete precipitation. 
This yielded 421 mg of 27 as colourless solid (0.94 mmol, 90 %). 
1H-NMR (300 MHz, D2O): δ [ppm] = 1.29 – 1.65 (m, 6 H, 3 CH2), 2.27 – 2.43 (m, 5 H, 
2 CH2 + alkyne-CH), 3.02 – 3.44 (m, 7 H, 3 CH2 + C*H); 13C-NMR (75.5 MHz, D2O): 
δ [ppm] = 14.7 (–, 1 C), 24.7 (–, 1 C), 27.0 (–, 1 C), 28.4 (–, 1 C), 34.6 (–, 1 C), 39.0 
(–, 1 C), 55.3 (–, 1 C), 60.7 (–, 1 C), 69.2 (+, 1 C, C*H), 70.2 (+, alkyne-CH), 82.9 
(Cquat, 1 C, alkyne), 174.5 (Cquat, 1 C), 177.9 (Cquat, 1 C), 178.2 (Cquat, 1 C), 179.5 
(Cquat, 1 C); MS (neg. ESI, H2O/MeOH/MeCN + NH4Ac): m/z (%) = 403.1 [A-] (100), 
469.2 [(A-+LiOAc)-] (55), 535.3 [(A-+2LiOAc)-] (50), 601.3 [(A-+3LiOAc)-] (28); IR 
(KBr): ν  [cm-1] = 3443, 3253, 2940, 2870, 1640, 1412, 1138; MF: C15H19N2O7ZnLi x 
2 H2O; MW = 447.68 g/mol; 
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Li[Cu(2-(Bis-carboxylate-methyl-amino)-6-pent-4-ynoylamino-hexanoate)] 
di-hydrate (28): 
Compound 26 (429 mg, 1.04 mmol) was dissolved in a mixture of 10 ml acetone and 
7 ml water. Then, LiOH (74.8 mg, 3.12 mmol, 3 eq) was added and the solution was 
stirred at r.t. for 24 h. The acetone was evaporated and the water is removed by 
lyophilisation. This yielded 375 mg of the carboxylate as a colourless solid (1.04 
mmol, 100 %, MF: C15H19N2O7Li3; MW = 360.15 g/mol). NMR- and MS-spectroscopy 
confirmed the complete cleavage of all ester-groups. The lithium-salt was dissolved 
in 15 ml water and CuSO4 x 5 H2O (260 mg, 1.04 mmol, 1 eq) was added. The 
solution was stirred at r.t. for 16 h and then heated to 60 °C for 2 h. The aqueous 
solution was dried by lyophilisation. The bluish-green crude product was purified by 
recrystallisation in EtOH/water. Diethyl ether was added to complete precipitation. 
This yielded 419 mg of 28 as a bluish-green solid (0.94 mmol, 90 %). 
Mp: > 250 °C; MS (neg. ESI, H2O/MeCN): m/z (%) = 402.0 [A-] (100); IR (KBr): 
ν  [cm-1] = 3443, 3253, 2940, 2870, 1640, 1412, 1138; MF: C15H19N2O7CuLi x 2 H2O; 
MW = 445.84 g/mol; 
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6-(3-Azido-propionylamino)-2-(bis-ethoxycarbonylmethyl-amino)-hexanoic acid 
methyl ester (29): 
The β-azido-propionic acid (336 mg, 2.93 mmol, 1.3 eq) was dissolved in 5 ml of dry 
DCM under an atmosphere of N2 and cooled to 0 °C in an icebath. Following, HOBt 
(434 mg, 3.21 mmol, 1.43 eq), EDC (569 µl, 499 mg, 3.21 mmol, 1.43 eq) and DIEA 
(294 µl, 415 mg, 3.21 mmol, 1.43 eq) were added in this sequence. The solution was 
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stirred at 0 °C for 30 min. Then, the amine 25 (747 mg, 2.25 mmol, 1 eq), dissolved 
in 10 ml dry DCM, was added dropwise. The solution was stirred at r.t. for 24 h. After 
that time 50 ml DCM were added and the solution was washed with 30 ml of a 0.1 N 
aqueous solution of citric acid and 30 ml water. The organic layer was dried with 
MgSO4, filtered and concentrated at reduced pressure. The crude product was 
purified by CC. EE:PE in a ratio of 3:2 to 4:1. This gave 29 as colourless oil in a yield 
of 531 mg (1.24 mmol, 55 %). Rf (EE:PE = 1:1) = 0.21. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.14 (t, 3J = 7.2 Hz, 6 H, CH3), 1.32 – 1.47 (m, 
4 H, CH2), 1.54 – 1.62 (m, 2 H, CH2), 2.35 (t, 3J = 6.6 Hz, 2 H, CH2), 3.07 – 3.20 (m, 
2 H, CH2), 3.31 (t, 3J = 7.6 Hz, 1 H, C*H), 3.46 – 3.50 (m, 6 H, CH2 + 2 N-CH2), 3.56 
(s, 3 H, CH3), 4.03 (q, 3J = 7.2 Hz, 4 H, CH2), 6.54 – 6.57 (m, 1 H, NH); 13C-NMR 
(75.5 MHz, CDCl3): δ [ppm] = 14.1 (+, 2 C, CH3), 22.6 (–, 1 C), 28.0 (–, 1 C), 29.4 (–, 
1 C), 35.5 (–, 1 C), 39.2 (–, 1 C), 47.4 (–, 1 C), 51.3 (+, 1 C, C*H), 52.6 (–, 2 C), 60.6 
(–, 2 C), 64.0 (+, 1 C, O-CH3), 170.0 (Cquat, 1 C, ester), 171.4 (Cquat, 2 C, ester), 
173.13 (Cquat, 1 C, amide); MS (ESI, MeOH): m/z (%) = 430.3 [MH+] (100), 452.3 
[M+Na+] (15); IR (KBr): ν  [cm-1] = 3311, 3264, 2971, 2146, 1735, 1689, 1646, 1534, 
1450, 1282, 1166; MF: C18H31N5O7; MW = 429.47 g/mol; 
 
N
N
O
LiO
2
H
O
O
OLi
 
Li3[6-Acryloylamino-2-(bis-carboxylate-methyl-amino)-hexanoate] (30): 
The azide 29 (429 mg, 1.00 mmol) was dissolved in aqueous acetone (40 Vol% H2O) 
and 71.9 mg LiOH (3.00 mmol, 3 eq) were added. The solution was stirred at r.t. for 
24 h. After that time the acetone was evaporated and the water was removed by 
lyophilisation. This yielded 334 mg of 30 as colourless solid (1.00 mmol, 100 %). 
1H-NMR (300 MHz, D2O): δ [ppm] = 1.13 – 1.64 (m, 6 H, 3 CH2), 2.86 – 3.14 (m, 7 H, 
C*H + 3 CH2), 5.59 (dd, 3J = 1.8 Hz, 3J = 9.7 Hz, 1 H, CH), 6.00 (dd, 3J = 1.8 Hz, 2J = 
17.2 Hz, 1 H, CH2), 6.11 (dd, 2J = 17.2 Hz, 3J = 9.7 Hz, 1 H, CH2); MS (pos. ESI, 
H2O/MeOH + NH4Cl): m/z (%) = 317.0 [(A3-+4H+)+] (70), 323.1 [(A3-+Li++3H+)+] (100), 
329.1 [(A3-+2Li++2H+)+]; MF: C13H17N2O7Li3; MW = 334.11 g/mol; 
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4-(2-Azido-ethylcarbamoyl)-2-tert-butoxycarbonyl-amino-butyric acid 
benzyl ester (32): 
The protected glutamic acid 31 (500 mg, 1.48 mmol) was dissolved in 2 ml of dry 
DMF and cooled in an ice bath. Following, EDC (317 µl, 278 mg, 1.79 mmol, 
1.21 eq), HOBt (242 mg, 1.79 mmol, 1.21 eq), DIEA (298 µl, 421 mg, 3.26 mmol, 
2.2 eq) and 14 (200 mg, 1.63 mmol, 1.1 eq) were added. The ice bath was removed 
and the solution was stirred at r.t. for 24 h. After that time the solution was cooled to 
0 °C and water at 0 °C was added. A pale yellow oil separated. The aqueous solution 
was discarded. The oil was dissolved in 50 ml DCM. The solution was washed with 
30 ml water, 30 ml 1 M aqueous citric acid, 30 ml water and 30 ml brine. The organic 
layer was dried with Na2SO4 and the solvent was removed in vacuum. This yielded 
588 mg of 32 (1.45 mmol, 98 %) as a pale yellow crystalline solid in sufficient purity 
for the following reaction steps. For analytical data the crude product was purified by 
column chromatography with EE:PE in a ratio of 2:3. This gave pure 32 in a yield of 
576 mg (1.42 mmol, 96 %). Rf (EE:PE = 1:1) = 0.36. 
Mp: 118 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.33 (s, 9 H, Boc-CH3), 1.82 – 
1.94 (m, 1 H, CH2), 2.02 – 2.13 (m, 1 H, CH2), 2.19 (t, 3J = 7.0 Hz, 2 H, CH2), 3.27 – 
3.28 (m, 4 H, 2 CH2), 4.19 – 4.25 (m, 1 H, C*H), 5.02 (d, 2J = 12.4 Hz, 1 H, Bn-CH2), 
5.09 (d, 2J = 12.4 Hz, 1 H, Bn-CH2), 5.66 (d, 3J = 8.0 Hz, 1 H, NH), 6.85 – 6.88 (m, 
1 H, NH), 7.22 – 7.25 (m, 5 H, arom. CH); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 
28.1 (–, 1 C), 28.3 (+, 3 C, Boc-CH3), 32.3 (–, 1 C), 38.9 (–, 1 C), 50.5 (–, 1 C), 53.3 
(+, C*H), 67.1 (–, 1 C, Bn), 79.9 (Cquat, Boc), 128.2 (+, 2 C, arom.), 128.4 (+, 1 C, 
arom.), 128.6 (+, 2 C, arom.), 135.3 (Cquat, 1 C, arom.), 155.9 (Cquat, urethane), 172.2 
(Cquat), 172.6 (Cquat); MS (ESI, DCM/MeOH): m/z (%) = 306.1 [(M-C5H9O2-)+] (15), 
350.1 [(MH+-C4H8)+] (20), 406.2 [MH+] (100); EA (C19H27N5O5) calc.: C 56.28, H 6.71, 
N 17.27, found: C 56.40, H 6.81, N 17.33; IR (KBr): ν  [cm-1] = 3344, 3028, 2970, 
2148, 1734, 1688, 1647, 1535, 1455, 1283; MF: C19H27N5O5; MW = 405.45 g/mol; 
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4-(3-Azido-propylcarbamoyl)-2-tert-butoxycarbonylamino-butyric acid 
benzyl ester (33): 
The protected glutamic acid 31 (900 mg, 2.67 mmol) was dissolved in 2 ml of dry 
DMF and cooled in an ice bath. Following, EDC (571 µl, 501 mg, 2.93 mmol, 
1.21 eq), HOBt (436 mg, 3.23 mmol, 1.21 eq), DIEA (537 µl, 759 mg, 5.87 mmol, 
2.2 eq) and 15 (401 mg, 2.93 mmol, 1.1 eq) were added. The ice bath was removed 
and the solution was stirred at r.t. for 24 h. Then the solution was cooled to 0 °C and 
water at 0 °C was added. A pale yellow oil separated. The aqueous solution was 
discarded. The oil was dissolved in 50 ml DCM. The solution was washed with 30 ml 
water, 30 ml 1 M aqueous citric acid, 30 ml water and 30 ml brine. The organic layer 
was dried with Na2SO4 and the solvent was removed in vacuum. This yielded 
1098 mg of 33 (2.62 mmol, 98 %) as a pale yellow crystalline solid in sufficient purity 
for the following reaction steps. For analytical data the crude product was purified by 
column chromatography with EE:PE in a ratio of 2:3. This gave pure 33 as white 
crystalline solid in a yield of 1074 mg (2.56 mmol, 96 %). Rf (EE:PE = 1:1) = 0.37. 
Mp: 116 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.42 (s, 9 H, Boc-CH3), 1.72 – 
1.81 (m, 2 H, CH2), 1.85 – 1.98 (m, 1 H, CH2), 2.11 – 2.24 (m, 3 H, CH2), 3.27 – 3.36 
(m, 4 H, CH2), 4.26 – 4.33 (m, 1 H, C*H), 5.11 (d, 2J = 12.1 Hz, 1 H, Bn-CH2), 5.20 
(d, 2J = 12.1 Hz, 1 H, Bn-CH2), 5.35 (d, 3J = 7.7 Hz, 1 H, NH), 6.28 – 6.33 (m, 1 H, 
NH), 7.32 – 7.37 (m, 5 H, arom. CH); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 28.3 (+, 
3 C, Boc-CH3), 28.8 (–, 1 C), 29.1 (–, 1 C), 32.6 (–, 1 C), 37.1 (–, 1 C), 49.3 (–, 1 C), 
53.1 (+, C*H), 67.3 (–, 1 C, Bn), 80.3 (Cquat, Boc), 128.4 (+, 2 C, arom.), 128.6 (+, 1 C, 
arom.), 128.7 (+, 2 C, arom.), 135.2 (Cquat, 1 C, arom.), 155.9 (Cquat, 1 C, urethane), 
172.1 (Cquat, 2 C, amide + ester); MS (pos. ESI, DCM/MeOH): m/z (%) = 320.1 [(M-
C5H9O2-)+] (30), 364.1 [(MH+-C4H8)+] (40), 420.2 [MH+] (100); MS (neg. ESI, 
DCM/MeOH): m/z (%) = 236.0 [(M-H+-BnOH-tBuOH)-] (35), 310.1 [(M-H+-BnOH)-] 
(75), 454.3 [M+Cl-] (20), 478.3 [M+Ac-] (100); EA (C20H29N5O5) calc.: C 57.27, H 
6.97, N 16.70, found: C 57.29, H 7.08, N 16.65;  IR (KBr): ν  [cm-1] = 3344, 3028, 
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2970, 2148, 1734, 1688, 1647, 1535, 1455, 1283; MF: C20H29N5O5; MW = 
419.48 g/mol; 
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3-(2-Azido-ethylcarbamoyl)-1-benzyloxycarbonyl-propyl-ammonium chloride (34): 
The amide 32 (1220 mg, 3.01 mmol) was dissolved in little dry EE and 20 ml of a 
saturated solution of HCl in dry diethyl ether were added (1 ml per 0.15 mmol Boc). 
The mixture was stirred at r.t. under an atmosphere of N2 for 15 h. After 30 min the 
product began to separate as a colourless oil. The solvent was removed in vacuum. 
This gave 34 as a pale yellow hygroscopic solid in quantitative yield (1028 mg, 
3.01 mmol). 
1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.29 – 2.35 (m, 2 H, CH2), 2.46 – 2.63 (m, 
2 H, CH2), 3.25 – 3.35 (m, 4 H, CH2), 4.28 – 4.34 (m, 1 H, C*H), 5.22 (s, 2 H, 
Bn-CH2), 7.29 – 7.42 (m, 5 H, arom. CH), 7.76 – 7.80 (m, 1 H, NH), 8.82 (bs, 3 H, 
NH3+); 13C-NMR (75.5 MHz, CD3CN): δ [ppm] = 27.0 (–, 1 C), 32.5 (–, 1 C), 39.8 (–, 1 
C), 51.2 (–, 1 C), 53.8 (+, C*H), 69.0 (–, 1 C, Bn), 129.5 (+, 2 C, arom.), 129.6 (+, 1 
C, arom.), 129.7 (+, 2 C, arom.), 136.3 (Cquat, 1 C, arom.), 170.4 (Cquat), 173.9 (Cquat); 
MS (ESI, MeCN): m/z (%) = 306.1 [MH+] (100), 611.4 [(2 MH+-H+)+] (7); IR (KBr): 
ν  [cm-1] = 3324, 3069, 3028, 2970, 2142, 2118, 1731, 1681, 1643, 1533, 1449; MF: 
C14H20N5O3Cl; MW = 341.80 g/mol; 
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3-(3-Azido-propylcarbamoyl)-1-benzyloxycarbonyl-propyl-ammonium chloride (35): 
The amide 33 (1401 mg, 3.34 mmol) was dissolved in little dry EE and 22 ml of a 
saturated solution of HCl in dry diethyl ether were added (1 ml per 0.15 mmol Boc). 
The mixture was stirred at r.t. under an atmosphere of N2 for 15 h. After 30 min the 
product began to separate as a colourless oil. The solvent was removed in vacuum. 
This gave 35 as a pale yellow hygroscopic solid in quantitative yield (1188 mg, 
3.34 mmol).  
1H-NMR (300 MHz, CD3CN): δ [ppm] = 1.69 (tt, 3J = 6.7 Hz, 2 H, CH2), 2.33 – 2.42 
(m, 2 H, CH2), 2.61 – 2.67 (m, 2 H, CH2), 3.16 – 3.21 (m, 2 H, CH2), 3.30 (t, 3J = 
6.7 Hz, 2 H, CH2), 4.31 – 4.37 (m, 1 H, C*H), 5.24 (s, 2 H, Bn-CH2), 7.29 – 7.44 (m, 
5 H, arom. CH), 8.21 – 8.27 (m, 1 H, NH), 8.89 (bs, 3 H, NH3+); 13C-NMR (75.5 MHz, 
CD3CN): δ [ppm] = 27.2 (–, 1 C), 29.2 (–, 1 C), 32.2 (–, 1 C), 38.1 (–, 1 C), 49.9 (–, 
1 C), 53.8 (+, C*H), 69.1 (–, 1 C, Bn), 129.5 (+, 2 C, arom.), 129.6 (+, 1 C, arom.), 
129.7 (+, 2 C, arom.), 136.2 (Cquat, 1 C, arom.), 170.4 (Cquat), 174.3 (Cquat); MS (ESI, 
MeCN): m/z (%) = 320.1 [MH+] (100), 639.4 [(2 MH+-H+)+] (7); IR (KBr): ν  [cm-1] = 
3334, 3069, 3028, 2967, 2141, 2118, 1732, 1681, 1642, 1533, 1450; MF: 
C15H22N5O3Cl; MW = 355.82 g/mol. 
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4-(2-Azido-ethylcarbamoyl)-2-(bis-ethoxycarbonylmethyl-amino)-butyric acid 
benzyl ester (36): 
Synthesis followed GP 6 using 34 (1136 mg, 3.32 mmol), bromo-ethylacetate 
(22.1 ml, 33.3 g, 0.2 mol), NaF (1256 mg, 29.9 mmol), SiO2 (999 mg, 16.62 mmol) 
and potassium carbonate (459 mg, 3.32 mmol). This yielded 1458 mg of 36 
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(3.05 mmol, 92 %) as colourless oil. Compound 36 was not stable at r.t. and 
decomposed within a few days, turning yellow. 
1H-NMR (600 MHz, CDCl3): δ [ppm] = 1.10 (t, 3J = 7.2 Hz, 6 H, CH3), 1.80 – 1.88 (m, 
1 H, Glu-CH2), 1.95 – 2.01 (m, 1 H, Glu-CH2), 2.27 (ddd, 3J = 6.3 Hz, 2J = 14.1 Hz, 
1 H, Glu-CH2), 2.35 (ddd, 3J = 6.0 Hz, 3J = 8.8 Hz, 2J = 14.1 Hz, 1 H, Glu-CH2), 3.20 
– 3.28 (m, 4 H, 2 CH2), 3.39 (dd, 3J = 11.2 Hz, 3J = 4.2 Hz, 1 H, C*H), 3.45 (d, 2J = 
17.5 Hz, 2 H, N-CH2), 3.48 (d, 2J = 17.5 Hz, 2 H, CH2), 3.98 (q, 3J = 7.2 Hz, 4 H, 
CH2), 4.96 (d, 2J = 12.3 Hz, 1 H, CH2), 4.99 (d, 2J = 12.3 Hz, 1 H, CH2), 6.97 – 6.99 
(m, 1 H, NH), 7.15 – 7.22 (m, 5 H, arom. CH); 13C-NMR (150.9 MHz, CDCl3): 
δ [ppm] = 14.0 (+, 2 C, CH3), 25.8 (–, 1 C, Glu), 32.2 (–, 1 C, Glu), 38.7 (–, 1 C), 50.5 
(–, 1 C, N3-CH2), 52.8 (–, 2 C, N-CH2), 60.5 (–, 2 C, Et-ester-CH2), 64.0 (+, 1 C, C*H), 
66.3 (–, 1 C, Bn-CH2), 128.1 (+, 2 C, arom.), 128.1 (+, 1 C, arom.), 128.4 (+, 2 C, 
arom.), 135.6 (Cquat, 1 C, arom.), 171.3 (Cquat, 2 C, Et-ester), 171.8 (Cquat, 1 C, 
Bn-ester), 173.0 (Cquat, 1 C, amide); MS (ESI, DCM/MeOH): m/z (%) = 478.1 [MH+] 
(100); MS-HR (EI-MS): [M+.] calc.: 477.2223, found: 477.2223 (± 0.69 ppm); IR (KBr): 
ν  [cm-1] = 3342, 3311, 3267, 3026, 2968, 2139, 1741, 1737, 1642, 1531, 1449; MF: 
C22H31N5O7; MW = 477.52 g/mol. 
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4-(3-Azido-propylcarbamoyl)-2-(bis-ethoxycarbonylmethyl-amino)-butyric acid 
benzyl ester (37): 
Synthesis followed GP 6 using 35 (631 mg, 1.77 mmol), bromo-ethylacetate (11.8 ml, 
17.8 g, 0.1 mol), NaF (671 mg, 16.0 mmol), SiO2 (533 mg, 8.87 mmol) and potassium 
carbonate (245 mg, 1.77 mmol, 1 eq). This yielded 800 mg of 37 (1.63 mmol, 92 %) 
as a colourless oil. Compound 37 was not stable at r.t. and decompose slowly within 
a few days turning yellow. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.16 (t, 3J = 7.2 Hz, 6 H, CH3), 1.68 (tt, 3J = 
6.9 Hz, 2 H, CH2), 1.79 – 1.93 (m, 1 H, Glu-CH2), 1.99 – 2.10 (m, 1 H, Glu-CH2), 2.24 
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– 4.42 (m, 2 H, Glu-CH2), 3.13 – 3.27 (m, 4 H, 2 CH2), 3.40 (dd, 3J = 11.1 Hz, 3J = 
4.5 Hz, 1 H, C*H), 3.47 (d, 2J = 18.1 Hz, 2 H, N-CH2), 3.53 (d, 2J = 18.1 Hz, 2 H, 
CH2), 4.05 (q, 3J = 7.2 Hz, 4 H, CH2), 5.00 (d, 2J = 12.4 Hz, 1 H, Bn-CH2), 5.05 (d, 
2J = 12.4 Hz, 1 H, Bn-CH2), 6.75 (t, 3J = 5.9 Hz, 1 H, NH), 7.22 – 7.28 (m, 5 H, 
arom. CH); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 14.1 (+, 2 C, CH3), 25.9 (–, 1 C, 
Glu), 28.8 (–, 1 C), 32.4 (–, 1 C, Glu), 36.8 (–, 1 C), 49.1 (–, 1 C, N3-CH2), 52.9 (–, 
2 C, N-CH2), 60.7 (–, 2 C, Et-ester-CH2), 64.1 (+, 1 C, C*H), 66.4 (–, 1 C, Bn-CH2), 
128.2 (+, 2 C, arom.), 128.3 (+, 1 C, arom.), 128.5 (+, 2 C, arom.), 135.6 (Cquat, 1 C, 
arom.), 171.5 (Cquat, 2 C, Et-ester), 172.0 (Cquat, 1 C, Bn-ester), 172.9 (Cquat, 1 C, 
amide); MS (ESI, DCM/MeOH): m/z (%) = 492.4 [MH+] (100), 983.8 [(2M+H+)+] (5); 
EA (C23H33N5O7) calc.: C 56.20, H 6.77, N 14.25, found: C 55.86, H 6.61, N 14.07; IR 
(KBr): ν  [cm-1] = 3344, 3310, 3268, 3025, 2968, 2139, 1742, 1737, 1642, 1532, 
1449; MF: C23H33N5O7; MW = 491.54 g/mol; 
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Li[Zn(4-(2-Azido-ethylcarbamoyl)-2-(bis-carboxylate-methyl-amino)-butanoate)] 
di-hydrate (40): 
This procedure can be used as a general procedure for the synthesis of NTA-
complexes: 
The ester-protected compound 36 (1357 mg, 2.84 mmol) was dissolved in 50 ml of a 
3:2 mixture of THF/water. After addition of LiOH (204 mg, 8.53 mmol, 3 eq) the 
solution was stirred at r.t. for 24 h. The THF was evaporated and the water was 
removed by lyophilisation. This yielded 1000 mg of the carboxylate 38 as a colourless 
solid (2.84 mmol, 100 %, MF: C11H14N5O7Li3; MW = 349.08 g/mol). NMR- and MS-
spectroscopy confirmed the complete cleavage of all ester-groups. The lithium-salt 
was dissolved in 25 ml water and ZnCl2 (387 mg, 2.84 mmol, 1 eq) and 5ZnO.2CO3 x 
4 H2O (1701 mg, 2.84 mmol, 5 eq) were added. The solution was stirred at r.t. for 
16 h and then heated to 60 °C for 3 h. All inorganic compounds were removed by 
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filtration and the aqueous solution was dried by lyophilisation. The white crude 
product was purified by recrystallisation from EtOH/water. Diethyl ether was added in 
order to complete precipitation. This yielded 1118 mg of 40 as colourless hygroscopic 
solid (2.56 mmol, 90 %). 
MS (neg. ESI, H2O/MeCN): m/z (%) = 392.0 [A-] (100); IR (KBr): ν  [cm-1] = 3448, 
3250, 2940, 2870, 2143, 1641, 1413; MF: C11H14N5O7ZnLi x 2 H2O; MW = 
436.61 g/mol; 
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Li[Cu(4-(2-Azido-ethylcarbamoyl)-2-(bis-carboxylate-methyl-amino)-butanoate)] 
di-hydrate (41): 
Procedure was the same as for the synthesis of 40 using 36 (1357 mg, 2.84 mmol), 
LiOH (204 mg, 8.53 mmol, 3 eq) and Cu2(OH)2CO3 (628 mg, 2.84 mmol, 2 eq). The 
blue crude product was purified by recrystallisation from EtOH/water. Diethylether 
was added in order to complete precipitation. This yielded 1113 mg of 41 as blue 
hygroscopic solid (2.56 mmol, 90 %). 
MS (neg. ESI, H2O/MeOH): m/z (%) = 390.9 [A-] (100); IR (KBr): ν  [cm-1] = 3448, 
3252, 2939, 2869, 2142, 1641, 1413; MF: C11H14N5O7CuLi x 2 H2O; MW = 
434.78 g/mol;  
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Li[Zn(4-(3-Azido-propylcarbamoyl)-2-(bis-carboxylate-methyl-amino)-butanoate)] 
di-hydrate (42): 
Procedure was the same as for the synthesis of 40 using 37 (1396 mg, 2.84 mmol), 
LiOH (204 mg, 8.53 mmol, 3 eq), ZnCl2 (387 mg, 2.84 mmol, 1 eq) and 5ZnO.2CO3 x 
4 H2O (1701 mg, 2.84 mmol, 5 eq). This yielded 1031 mg of the carboxylate 39 as a 
colourless solid (2.84 mmol, 100 %, MF: C12H16N5O7Li3; MW = 363.10 g/mol) and 
then 1153 mg of 42 as colourless hygroscopic solid (2.56 mmol, 90 %). 
MS (neg. ESI, H2O/MeCN): m/z (%) = 406.0 [A-] (100); IR (KBr): ν  [cm-1] = 3448, 
3250, 2940, 2870, 2143, 1641, 1413; MF: C12H16N5O7ZnLi x 2 H2O; MW = 
450.63 g/mol; 
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Li[Cu(4-(3-Azido-propylcarbamoyl)-2-(bis-carboxylate-methyl-amino)-butanoate)] 
di-hydrate (43): 
Procedure was the same as for the synthesis of 40 using 37 (1396 mg, 2.84 mmol), 
LiOH (204 mg, 8.53 mmol, 3 eq), and Cu2(OH)2CO3 (628 mg, 2.84 mmol, 2 eq). This 
yielded 1031 mg of the carboxylate 39 as a colourless solid (2.84 mmol, 100 %, MF: 
C12H16N5O7Li3; MW = 363.10 g/mol) and then 1149 mg of 43 as blue hygroscopic 
solid (2.56 mmol, 90 %). 
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MS (neg. ESI, H2O/MeCN): m/z (%) = 405.0 [A-] (100); IR (KBr): ν  [cm-1] = 3448, 
3252, 2939, 2869, 2142, 1641, 1413; MF: C12H16N5O7CuLi x 2 H2O; MW = 
448.80 g/mol; 
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2-tert-Butoxycarbonylamino-4-prop-2-ynylcarbamoyl-butyric acid benzyl ester (44): 
The protected glutamic acid 31 (1000 mg, 2.96 mmol) was dissolved in 2 ml of dry 
DMF and cooled in an ice-bath. Following, EDC (634 µl, 551 mg, 3.58 mmol, 
1.21 eq), HOBt (484 mg, 3.58 mmol, 1.21 eq), DIEA (327 µl, 463 mg, 3.58 mmol, 
1.21 eq) and propargylamine (209 µl, 179 mg, 3.26 mmol, 1.1 eq) were added. The 
ice bath was removed and the solution was stirred in the dark at r.t. for 24 h. The 
solution was cooled to 0 °C and water at 0 °C was added in order to precipitate the 
product. After filtration, the white solid was dissolved in 50 ml DCM. The solution was 
washed with 30 ml water, 30 ml 1 M aqueous citric acid, 30 ml water and 30 ml brine. 
The organic layer was dried with Na2SO4 and the solvent was removed in vacuum. 
This yielded 1086 mg of 44 (2.90 mmol, 98 %) as a white crystalline solid in sufficient 
purity for the following reaction steps. For analytical data the crude product was 
purified by column chromatography with EE:PE in a ratio of 2:3. This gave pure 44 in 
a yield of 1066 mg (2.85 mmol, 96 %). Rf (EE:PE = 1:1) = 0.37. 
Mp: 122 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.42 (s, 9 H, Boc-CH3), 1.91 – 
2.03 (m, 1 H, CH2), 2.11 – 2.19 (m, 1 H, CH2), 2.22 (t, 4J = 2.5 Hz, 1 H, CH), 2.25 – 
2.30 (m, 2 H, CH2), 3.98 (dd, 4J = 2.5 Hz, 3J = 5.2 Hz, 2 H, propargyl-CH2), 4.27 – 
4.34 (m, 1 H, C*H), 5.12 (d, 2J = 12.4 Hz, 1 H, Bn-CH2), 5.18 (d, 2J = 12.4 Hz, 1 H, 
Bn-CH2), 5.63 (d, 3J = 8.2 Hz, 1 H, NH), 6.85 (t, 3J = 5.2 Hz, 1 H, NH), 7.31 – 7.36 
(m, 5 H, arom. CH); 13C-NMR (300 MHz, CDCl3): δ [ppm] = 28.3 (+, 3 C, Boc-CH3), 
29.0 (–, 1 C), 29.2 (–, 1 C), 32.3 (–, 1 C), 53.0 (+, C*H), 67.3 (–, 1 C, Bn), 71.5 (+, 
alkyne-CH),
 
79.5 (Cquat, alkyne), 80.3 (Cquat, Boc), 128.4 (+, 2 C, arom.), 128.6 (+, 
1 C, arom.), 128.7 (+, 2 C, arom.), 135.2 (Cquat, 1 C, arom.), 155.8 (Cquat, urethane), 
171.5 (Cquat), 172.1 (Cquat); MS (CI-MS, NH3): m/z (%) = 275.2 [(M+H+-C4H8+CO2)+] 
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(100), 319.2 [(M+H+-C4H8)+] (65), 336.1 [(M+NH4+-C4H8)+] (20), 375.2 [MH+] (40); 
EA (C20H26N2O5) calc.: C 64.16, H 7.00, N 7.48, found: C 63.85, H 7.03, N 7.40; IR 
(KBr): ν  [cm-1] = 3344, 3313, 3266, 2970, 1736, 1690, 1645, 1535, 1451, 1283, 
1165, 727; MF: C20H26N2O5; MW = 374.44 g/mol; 
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1-Benzyloxycarbonyl-3-prop-2-ynylcarbamoyl-propyl-ammonium chloride (45): 
The amide 44 (1000 mg, 2.67 mmol) was dissolved in little dry EE and 18 ml of a 
saturated solution of HCl in dry diethyl ether were added (1 ml per 0.15 mmol Boc). 
The mixture is stirred at r.t. under an atmosphere of N2 for 15 h. After 30 min the 
product began to separate as a colourless oil. The solvent was removed in vacuum. 
This gave 45 as a colourless hygroscopic solid in quantitative yield (830 mg, 
2.67 mmol). 
1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.27 – 2.34 (m, 2 H, CH2), 2.47 (t, 4J = 
2.5 Hz, 1 H, alkyne), 2.47 – 2.56 (m, 2 H, CH2), 3.86 – 3.88 (m, 4J = 2.5 Hz, 2 H, 
propargyl-CH2), 4.26 – 4.31 (m, 1 H, C*H), 5.19 (d, 2J = 12.5 Hz, 1 H, Bn-CH2), 5.23 
(d, 2J = 12.5 Hz, 1 H, Bn-CH2), 7.31 – 7.42 (m, 5 H, arom. CH), 7.87 (t, 3J = 5.5 Hz, 
1 H, NH), 8.82 (bs, 3 H, NH3+); 13C-NMR (75.5 MHz, CD3CN): δ [ppm] = 26.8 (–, 1 C), 
29.5 (–, 1 C), 32.2 (–, 1 C), 53.7 (+, C*H), 69.1 (–, 1 C, Bn), 72.5 (+, alkyne),
 
81.3 
(Cquat, alkyne), 129.5 (+, 2 C, arom.), 129.6 (+, 1 C, arom.), 129.7 (+, 2 C, arom.), 
136.2 (Cquat, 1 C, arom.), 170.3 (Cquat), 173.2 (Cquat); MS (ESI, H2O): m/z (%) = 275.0 
[MH+] (100); IR (KBr): ν  [cm-1] = 3324, 3069, 3028, 2970, 2121, 1731, 1681, 1643, 
1533, 1449; MF: C15H19N2O3Cl; MW = 310.78 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-4-prop-2-ynylcarbamoyl-butyric acid 
benzyl ester (46): 
Synthesis followed GP 6 using 45 (1602 mg, 5.15 mmol), bromo-ethylacetate 
(34.2 ml, 51.7 g, 0.31 mol), NaF (1949 mg, 46.4 mmol), SiO2 (1549 mg, 25.8 mmol) 
and potassium carbonate (712 mg, 5.15 mmol). This yielded 2116 mg of 46 
(4.74 mmol, 92 %) as colourless oil. 
1H-NMR (600 MHz, CDCl3): δ [ppm] = 1.17 (t, 3J = 7.2 Hz, 6 H, CH3), 1.89 (dddd, 2J = 
14.9 Hz , 3J = 5.5 Hz, 3J = 5.8 Hz, 3J = 11.6 Hz, 1 H, CH2), 2.06 (dddd, 2J = 14.9 Hz, 
3J = 4.5 Hz, 3J = 5.7 Hz, 3J = 10.1 Hz, 1 H, CH2), 2.09 (dd, 4J = 2.6 Hz, 4J = 2.6 Hz, 
1 H, CH), 2.30 (ddd, 3J = 5.5 Hz, 3J = 5.8 Hz, 2J = 13.9 Hz, 1 H, CH2), 2.41 (ddd, 3J = 
5.8 Hz, 3J = 10.1 Hz, 2J = 13.9 Hz, 1 H, CH2), 3.40 (dd, 3J = 11.6 Hz, 3J = 4.5 Hz, 
1 H, C*H), 3.52 (s, 4 H, CH2), 3.83 (ddd, 2J = 17.5 Hz, 3J = 5.0 Hz, 4J = 2.6 Hz, 1 H, 
CH2), 4.00 (ddd, 2J = 17.5 Hz, 3J = 5.9 Hz, 4J = 2.6 Hz, 1 H, CH2), 4.05 (q, 3J = 
7.2 Hz, 4 H, CH2), 5.01 (d, 2J = 12.3 Hz, 1 H, CH2), 5.05 (d, 2J = 12.3 Hz, 1 H, CH2), 
6.88 (dd, 3J = 5.0 Hz, 3J = 6.0 Hz, 1 H, NH), 7.22 – 7.30 (m, 5 H, arom. CH); 
13C-NMR (150.9 MHz, CDCl3): δ [ppm] = 14.1 (+, 2 C, CH3), 25.8 (–, 1 C, Glu), 28.8 
(–, 1 C), 32.3 (–, 1 C, Glu), 53.0 (–, 2 C, N-CH2), 60.8 (–, 2 C, Et-ester-CH2), 64.1 (+, 
1 C, C*H), 66.5 (–, 1 C, Bn-CH2), 70.8 (+, 1 C, alkyne), 80.2 (Cquat, 1 C, alkyne), 
128.2 (+, 2 C, arom.), 128.3 (+, 1 C, arom.), 128.6 (+, 2 C, arom.), 135.4 (Cquat, 1 C, 
arom.), 171.5 (Cquat, 2 C, Et-ester), 171.9 (Cquat, 1 C, Bn-ester), 172.5 (Cquat, 1 C, 
amide); MS (ESI, DCM/MeOH): m/z (%) = 447.1 [MH+] (100); MS-HR (EI-MS): [M+.] 
calc.: 446.2053, found: 446.2053 (± 0.43 ppm); IR (KBr): ν  [cm-1] = 3344, 3313, 
3266, 3030, 2970, 2119, 1742, 1736, 1643, 1533, 1450; MF: C23H30N2O7; MW = 
446.50 g/mol; 
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Li[Zn(2-(Bis-carboxylate-methyl-amino)-4-prop-2-ynylcarbamoyl-butanoate)] 
di-hydrate (48): 
Procedure was the same as for the synthesis of 40 using 46 (1000 mg, 2.24 mmol), 
LiOH (161 mg, 6.72 mmol, 3 eq), ZnCl2 (305 mg, 2.24 mmol, 1 eq) and 5ZnO.2CO3 x 
4 H2O (1341 mg, 2.24 mmol, 5 eq). This yielded 712 mg of the carboxylate 47 as a 
colourless solid (2.24 mmol, 100 %, MF: C12H13N2O7Li3; MW = 318.07 g/mol) and 
then 819 mg of 48 as colourless hygroscopic solid (2.02 mmol, 90 %). 
MS (neg. ESI, H2O/MeOH + NH4Ac): m/z (%) = 361.0 [A-] (100), 427.0 [(A-+LiOAc)-] 
(25); IR (KBr): ν  [cm-1] = 3448, 3250, 2940, 2870, 2112, 1641, 1413; MF: 
C12H13N2O7ZnLi x 2 H2O; MW = 405.60 g/mol; 
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Li[Cu(2-(Bis-carboxylate-methyl-amino)-4-prop-2-ynylcarbamoyl-butanoate)] 
di-hydrate (49): 
Procedure was the same as for the synthesis of 40 using 46 (1000 mg, 2.24 mmol), 
LiOH (161 mg, 6.72 mmol, 3 eq) and Cu2(OH)2CO3 (495 mg, 2.24 mmol, 2 eq). This 
yielded 712 mg of the carboxylate 47 as a colourless solid (2.24 mmol, 100 %, MF: 
C12H13N2O7Li3; MW = 318.07 g/mol) and then 815 mg of 49 as greenish brown 
hygroscopic solid (2.02 mmol, 90 %). 
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MS (neg. ESI, H2O/MeOH + NH4Ac): m/z (%) = 360.0 [A-] (75), 426.0 [(A-+LiOAc)-] 
(100), 492.2 [(A-+2LiOAc)-] (55); IR (KBr): ν  [cm-1] = 3446, 3251, 2937, 2867, 2111, 
1641, 1413; MF: C12H13N2O7CuLi x 2 H2O; MW = 403.76 g/mol; 
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N,N’-Di-Boc-N-(2-azido-ethyl)-guanidine (50): 
The azide 14 (775 mg, 6.32 mmol, 2.5 eq) and NEt3 (1052 µl, 768 mg, 7.59 mmol, 
3 eq) were suspended in 10 ml of dry THF. After addition of N,N’-Di-Boc-S-methyl-
isothiourea (735 mg, 2.53 mmol) the suspension was stirred at 40 °C under an 
atmosphere of N2 for 7 h. TLC control showed incomplete conversion and formation 
of a side product. The solvent and the formed methyl thiole were removed in vacuum. 
The remaining solid was treated with EE in order to dissolve 50. After filtration the 
solvent was evaporated and the crude product was purified by CC. PE:EE in a ratio 
of 9:1 (Rf = 0.25). This yielded 689 mg (2.10 mmol, 83 %) of 50 as colourless 
crystalline solid. 
Mp: 63 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.49 (s, 18 H, Boc-CH3), 3.50 (t, 3J 
= 5.8 Hz, 2 H, CH2), 3.60 (dt, 3J = 6.0 Hz, 3J = 5.8 Hz, 2 H, CH2), 8.56 – 8.60 (m, 1 H, 
NH), 11.47 (s, 1 H, NH) 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 28.1 (+, 3 C, Boc-
CH3), 28.3 (+, 3 C, Boc-CH3), 40.0 (–, 1 C), 50.5 (–, 1 C), 79.5 (Cquat, 1 C, Boc), 83.4 
(Cquat, 1 C, Boc), 153.2 (Cquat, 1 C, urethane), 156.3 (Cquat, 1 C, urethane), 163.4 
(Cquat, 1 C); MS (ESI, DCM/MeOH + NH4Ac): m/z (%) = 329.2 [MH+] (100), 273.0 
[(MH+ - C4H8)+] (40), 216.9 [(MH+ - 2 C4H8)+]; EA (C13H24N6O4) calc.: C 47.55, H 7.37, 
N 25.59, found: C 63.85, H 7.03, N 7.40; UV/Vis (CHCl3): λ (lg ε) = 242 nm (4.258); 
IR (KBr): ν  [cm-1] = 3437, 3326, 3136, 3006, 2977, 2932, 2096, 1737, 1650, 1624, 
1573, 1415, 1368, 1143, 1054; MF: C13H24N6O4; MW = 328.37 g/mol; 
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N,N’-Di-Boc-N-(3-azido-propyl)-guanidine (51): 
The azide 15 (775 mg, 5.67 mmol, 2.5 eq) and NEt3 (944 µl, 689 mg, 6.81 mmol, 
3 eq) were suspended in 10 ml of dry THF. After addition of N,N’-Di-Boc-S-methyl-
isothiourea (659 mg, 2.27 mmol) the suspension was stirred at 40 °C under an 
atmosphere of N2 for 7 h. TLC control showed incomplete conversion and formation 
of a side product. The solvent and the formed methyl thiole were removed in vacuum. 
The remaining solid was treated with EE in order to dissolve 51. After filtration the 
solvent was evaporated and the crude product was purified by CC. PE:EE in a ratio 
of 9:1 (Rf = 0.25). This yielded 630 mg (1.84 mmol, 81 %) of 51 as colourless 
crystalline solid. 
Mp: 65 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.43 (s, 18 H, Boc-CH3), 1.79 (tt, 
3J = 6.7 Hz, 2 H, CH2), 3.32 (t, 3J = 6.7 Hz, 2 H, CH2), 3.45 (dt, 3J = 6.7 Hz, 3J = 
5.8 Hz, 2 H, CH2), 8.36 (t, 3J = 5.8 Hz, 1 H, NH), 11.44 (s, 1 H, NH); 13C-NMR 
(75.5 MHz, CDCl3): δ [ppm] = 28.0 (+, 3 C, Boc-CH3), 28.2 (+, 3 C, Boc-CH3), 28.3 (–, 
1 C), 38.2 (–, 1 C), 49.0 (–, 1 C), 79.2 (Cquat, 1 C, Boc), 83.1 (Cquat, 1 C, Boc), 153.2 
(Cquat, 1 C, urethane), 156.2 (Cquat, 1 C, urethane), 163.5 (Cquat, 1 C); MS (ESI, 
DCM/MeOH + NH4Ac): m/z (%) = 343.1 [MH+] (100); EA (C14H26N6O4) calc.: C 49.11, 
H 7.65, N 24.54, found: C 63.85, H 7.03, N 7.40; UV/Vis (CHCl3): λ (lg ε) = 242 nm 
(4.273); IR (KBr): ν  [cm-1] = 3437, 3326, 3136, 3006, 2977, 2932, 2096, 1737, 1650, 
1624, 1573, 1415, 1368, 1143, 1054; MF: C14H26N6O4; MW = 342.40 g/mol; 
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N-(2-azido-ethyl)-guanidinium chloride (52): 
The Boc-protected compound 50 (356 mg, 1.08 mmol) was dissolved in 10 ml of dry 
DCM and 1.6 ml of TFA (2.46 g, 21.6 mmol, 20 eq) were added. The solution was 
stirred at r.t. under an atmosphere of N2 for 16 h. The solvent was removed in 
vacuum. This gave a pale yellow oil. In order to exchange the anion and to remove 
remaining excess TFA the oil is dissolved in 4 ml of 36 % aqueous HCl and 2 ml 
MeOH. The solution was stirred at r.t. for 1 h. The solvents were removed in vacuum. 
This yielded 178 mg (1.08 mmol, 100 %) of 52 as colourless oil.  
1H-NMR (300 MHz, D2O): δ [ppm] = 3.35 (t, 3J = 5.8 Hz, 2 H, CH2), 3.48 (t, 3J = 
5.8 Hz, 2 H, CH2); 13C-NMR (75.5 MHz, D2O): δ [ppm] = 40.8 (–, 1 C), 50.0 (–, 1 C), 
157.2 (Cquat, 1 C); MS (ESI, H2O/MeCN/TFA): m/z (%) = 129.2 [MH+] (100); 
MF: C3H9N6Cl; MW = 164.60 g/mol; 
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N-(3-azido-propyl)-guanidinium chloride (53): 
The Boc-protected compound 51 (630 mg, 1.84 mmol) was dissolved in 10 ml of dry 
DCM and 2.84 ml of TFA (4.21 g, 36.9 mmol, 20 eq) were added. The solution was 
stirred at r.t. under an atmosphere of N2 for 16 h. The solvent was removed in 
vacuum. This gave a pale yellow oil. In order to exchange the anion and to remove 
remaining excess TFA the oil was dissolved in 4 ml of 36 % aqueous HCl and 2 ml 
MeOH. The solution was stirred at r.t. for 1 h. The solvents were removed in vacuum. 
This yielded 329 mg (1.84 mmol, 100 %) of 53 as colourless oil. 
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1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.84 (tt, 3J = 7.0 Hz, 3J = 6.6 Hz, 2 H, CH2), 
3.30 (t, 3J = 7.0 Hz, 2 H, CH2), 3.45 (t, 3J = 6.6 Hz, 2 H, CH2); 1H-NMR (300 MHz, 
D2O): δ [ppm] = 1.81 (psq, 3J = 6.6 Hz, 2 H, CH2), 3.23 (t, 3J = 6.7 Hz, 2 H, CH2), 3.39 
(t, 3J = 6.6 Hz, 2 H, CH2); 13C-NMR (75.5 MHz, CD3OD): δ [ppm] = 29.3 (–, 1 C), 39.9 
(–, 1 C), 49.8 (–, 1 C), 158.8 (Cquat, 1 C); 13C-NMR (75.5 MHz, D2O): δ [ppm] = 27.3 
(–, 1 C), 38.7 (–, 1 C), 48.5 (–, 1 C), 157.0 (Cquat, 1 C); MS (ESI, H2O/MeCN/TFA): 
m/z (%) = 143.2 [MH+] (100); MF: C4H11N6Cl; MW = 178.62 g/mol; 
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N,N’-Di-Boc-N-(prop-2-ynyl)-guanidine (54): 
In a round bottom flask N,N’-Di-Boc-S-methyl-isothiourea (738 mg, 2.54 mmol) was 
dissolved in 10 ml THF and propargyl amine (436 µl, 350 mg, 6.35 mmol, 2.5 eq) was 
added. The solution was stirred at 40 °C under an atmosphere of N2 for 7 h. The 
solvent and surplus amine were removed in vacuum and the remaining solid was 
purified by CC with PE:EE in a ratio of 9:1 (Rf = 0.25). This yielded 640 mg 
(2.14 mmol, 84 %) of 54 as colourless crystalline solid. 
Mp: 69 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.39 (s, 9 H, Boc-CH3), 1.40 (s, 18 
H, Boc-CH3), 2.22 (t, 4J = 2.6 Hz, 1 H, CH), 4.13 (dd, 3J = 4.9 Hz, 4J = 2.7 Hz, 2 H, 
CH2), 8.36 (t, 3J = 4.9 Hz, 1 H, NH), 11.37 (s, 1 H, NH); 13C-NMR (75.5 MHz, CDCl3): 
δ [ppm] = 28.0 (+, 3 C, Boc-CH3), 28.2 (+, 3 C, Boc-CH3), 30.6 (–, 1 C), 72.3 (+, 1 C, 
CH), 78.8 (Cquat, 1 C, alkyne), 79.4 (Cquat, 1 C, Boc), 83.2 (Cquat, 1 C, Boc), 152.9 
(Cquat, 1 C, urethane), 155.5 (Cquat, 1 C, urethane), 163.2 (Cquat, 1 C); MS (CI): 
m/z (%) = 298.3 [MH+] (100), 242.2 [(M + H+ - C4H8)+] (10); EA (C14H23N3O4) calc.: 
C 56.55, H 7.80, N 14.13, found: C 56.28, H 7.58, N 13.97; UV/Vis (CHCl3): λ (lg ε) = 
242 nm (4.265); IR (KBr): ν  [cm-1] = 3434, 3324, 3135, 3003, 2978, 2935, 2110, 
1737, 1650, 1623, 1573, 1414, 1367, 1143, 1052; MF: C14H23N3O4; 
MW = 297.35 g/mol; 
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N-(prop-2-ynyl)-guanidinium chloride (55): 
The Boc-protected compound 54 (467 mg, 1.57 mmol) was dissolved in 10 ml of dry 
DCM and 2.42 ml of TFA (3.58 g, 31.4 mmol, 20 eq) were added. The solution was 
stirred at r.t. under an atmosphere of N2 for 16 h. The solvent was removed in 
vacuum. This gave a pale yellow oil. In order to exchange the anion and to remove 
remaining excess TFA the oil is dissolved in 4 ml of 36 % aqueous HCl and 2 ml 
MeOH. The solution was stirred at r.t. for 1 h. The solvents were removed in vacuum. 
This yielded 210 mg (1.57 mmol, 100 %) of 55 as colourless oil. 
1H-NMR (300 MHz, D2O): δ [ppm] = 2.72 (t, 4J = 2.5 Hz, 1 H, CH), 4.01 (d, 4J = 
2.5 Hz, 2 H, CH2); 13C-NMR (75.5 MHz, D2O): δ [ppm] = 30.8 (–, 1 C), 73.8 (+, 1 C), 
77.9 (Cquat, 1 C, alkyne), 156.9 (Cquat, 1 C); MS (CI-MS, NH3): m/z (%) = 98.2 [MH+] 
(100); MF: C4H8N3Cl; MW = 133.58 g/mol; 
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Formic acid 4-[15,20-bis-(4-formyloxymethyl-phenyl)-10-(4-trimethylsilanylethynyl-
phenyl)-porphyrin-5-yl]-benzyl ester (56): 
Synthesis followed GP 7 using pyrrole (280 µl, 268 mg, 4.00 mmol, 8 eq), 4-formyl-
bezoicacid-methylester (575 mg, 3.50 mmol, 7 eq), 4-((trimethylsilyl)-ethinyl)-
benzaldehyde (101 mg, 0.50 mmol), 37 µl of BF3.OEt2 and p-chloranil (738 mg, 
3.00 mmol, 6 eq). Identification of the product in the crude mixture was possible using 
TLC which showed 6 red fluorescent spots (ex: 336 nm): spot 1 = 4 TMS groups, 
spot 2 = 3 TMS groups, spots 3 and 4 = 2 TMS groups (isomers), spot 5 = product, 
spot 6 = 4 methoxy groups. Purification by CC had to be done twice. First with 
PE/DCM/EE in a ratio of 80:20:5 to 80:20:12 and then in a ratio of 75:25:5 to 
75:25:10. This gave porphyrin 56 as purple crystals in a yield of 93 mg (0.11 mmol, 
26 %). Rf (PE:DCM:EE = 8:2:1) = 0.28. 
Mp: > 320 °C (decomp.); 1H-NMR (300 MHz, CDCl3): δ [ppm] = - 2.83 (s, 2 H, NH), 
0.38 (s, 9 H, TMS-CH3), 4.12 (s, 9 H, 3 CH3), 7.88 (d, 3J = 8.1 Hz, 2 H, arom. CH), 
8.15 (d, 3J = 8.1 Hz, 2 H, arom. CH), 8.29 (d, 3J = 8.1 Hz, 6 H, arom. CH), 8.45 (d, 
3J = 8.1 Hz, 6 H, arom. CH), 8.80 – 8.85 (m, 8 H, porphyrin-CH); 13C-NMR 
(75.5 MHz, CDCl3): δ [ppm] = 0.0 (+, 3 C, TMS-CH3), 52.4 (+, 3 C, CH3), 95.7 (Cquat, 
1 C, alkyne), 104.8 (Cquat, 1 C, alkyne), 119.1 (Cquat, 1 C, porphyrin), 119.2 (Cquat, 
2 C, porphyrin), 119.9 (Cquat, 1 C, porphyrin), 122.8 (Cquat, 1 C), 127.9 (+, 6 C), 129.7 
(Cquat, 3 C), 130.4 (+, 2 C), 134.3 (+, 2 C), 134.5 (+, 6 C), 142.0 (Cquat, 1 C), 146.6 
(Cquat, 3 C), 167.3 (Cquat, 3 C, ester); MS (PI-EIMS, 70 eV): m/z (%) = 884.0 [M+.] 
(100); UV/Vis (CH3CN): λ (lg ε) = 646 nm (3.599), 591 nm (3.764), 551 nm (3.959), 
516 nm (4.272), 420 nm (5.680), 298 nm (4.271), 260 nm (4.487); Fl (CH3CN, λex= 
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420 nm): λem (a.u.) = 655 nm (90), 720 nm (40); IR (KBr): ν  [cm-1] = 3433, 3319, 
3118, 3036, 2998, 2946, 2708, 2113, 1934, 1812, 1723, 1608, 1436, 965, 802, 760; 
MF: C55H44N4O6Si; MW = 885.07 g/mol; 
Note: due to broadening of signals of pyrrole-CH and –Cquat in the 13C-NMR 
spectrum, these signals are not given for all porphyrin-compounds! 
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5,15-bis-(4-trimethylsilanylethynyl-phenyl)-10,20-bis-(4-formyloxymethyl-phenyl)- 
porphyrin (57): 
Porphyrin 57 was a side-product of the synthesis of 56 and was obtained after CC as 
purple crystals in a yield of 24 mg (0.03 mmol, 5 %). 
Mp: > 320 °C (decomp.); 1H-NMR (300 MHz, CDCl3): δ [ppm] = - 2.84 (s, 2 H, NH), 
0.38 (s, 18 H, TMS-CH3), 4.12 (s, 6 H, 3 CH3), 7.87 (d, 3J = 8.3 Hz, 4 H, arom. CH), 
8.15 (d, 3J = 8.3 Hz, 4 H, arom. CH), 8.29 (d, 3J = 8.3 Hz, 4 H, arom. CH), 8.45 (d, 
3J = 8.3 Hz, 4 H, arom. CH), 8.80 (d, 3J = 4.8 Hz, 4 H, porphyrin-CH), 8.85 (d, 3J = 
4.8 Hz, 4 H, porphyrin-CH); 13C-NMR (150.9 MHz, CDCl3): δ [ppm] = 0.1 (+, 6 C, 
TMS-CH3), 52.4 (+, 2 C, CH3), 95.8 (Cquat, 2 C, alkyne), 104.9 (Cquat, 2 C, alkyne), 
119.2 (Cquat, 2 C, porphyrin), 119.8 (Cquat, 2 C, porphyrin), 122.8 (Cquat, 2 C), 128.0 
(+, 4 C), 129.7 (Cquat, 2 C), 130.4 (+, 4 C), 134.4 (+, 4 C), 134.5 (+, 4 C), 142.1 (Cquat, 
2 C), 146.8 (Cquat, 2 C), 167.3 (Cquat, 2 C, ester); MS (PI-EIMS, 70 eV): m/z (%) = 
922.0 [M+.] (100); UV/Vis (CH3CN): λ (lg ε) = 646 nm (3.599), 591 nm (3.764), 
551 nm (3.959), 516 nm (4.272), 420 nm (5.680), 298 nm (4.271), 260 nm (4.487); Fl 
(CH3CN, λex= 420 nm): λem (a.u.) = 655 nm (90), 720 nm (40); MF: C58H50N4O4Si2; 
MW = 923.23 g/mol; 
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5,10-bis-(4-trimethylsilanylethynyl-phenyl)-15,20-bis-(4-formyloxymethyl-phenyl)- 
porphyrin (58): 
Porphyrin 58 was a side-product of the synthesis of 56 and was obtained after CC as 
purple crystals in a yield of 23 mg (0.03 mmol, 5 %). 
Mp: > 320 °C (decomp.); 1H-NMR (600 MHz, CDCl3): δ [ppm] = - 2.82 (s, 2 H, NH), 
0.38 (s, 18 H, TMS-CH3), 4.11 (s, 6 H, 3 CH3), 7.87 (d, 3J = 8.7 Hz, 4 H, arom. CH), 
8.15 (d, 3J = 8.7 Hz, 4 H, arom. CH), 8.28 (d, 3J = 8.3 Hz, 4 H, arom. CH), 8.44 (d, 
3J = 8.3 Hz, 4 H, arom. CH), 8.80 (d, 3J = 4.8 Hz, 2 H, porphyrin-CH), 8.81 (s, 2 H, 
porphyrin-CH), 8.83 (s, 2 H, porphyrin-CH), 8.84 (d, 3J = 4.8 Hz, 2 H, porphyrin-CH); 
13C-NMR (150.9 MHz, CDCl3): δ [ppm] = 0.1 (+, 6 C, TMS-CH3), 52.5 (+, 2 C, CH3), 
95.8 (Cquat, 2 C, alkyne), 104.9 (Cquat, 2 C, alkyne), 119.1 (Cquat, 2 C, porphyrin), 
119.9 (Cquat, 2 C, porphyrin), 122.8 (Cquat, 2 C), 128.0 (+, 4 C), 129.8 (Cquat, 2 C), 
130.4 (+, 4 C), 134.4 (+, 4 C), 134.5 (+, 4 C), 142.2 (Cquat, 2 C), 146.8 (Cquat, 2 C), 
167.3 (Cquat, 2 C, ester); MS (PI-EIMS, 70 eV): m/z (%) = 922.0 [M+.] (100); UV/Vis 
(CH3CN): λ (lg ε) = 646 nm (3.599), 591 nm (3.764), 551 nm (3.959), 516 nm (4.272), 
420 nm (5.680), 298 nm (4.271), 260 nm (4.487); Fl (CH3CN, λex= 420 nm): λem (a.u.) 
= 655 nm (90), 720 nm (40); MF: C58H50N4O4Si2; MW = 923.23 g/mol; 
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Formic acid 4-[10,15-bis-(4-formyloxymethyl-phenyl)-20-(4-hydroxy-phenyl)-
porphyrin-5-yl]-benzyl ester (59): 
Synthesis followed GP 7 using pyrrole (280 µl, 268 mg, 4.00 mmol, 8 eq), 4-formyl-
bezoicacid-methylester (575 mg, 3.50 mmol, 7 eq), 4-hydroxy-benzaldehyde (61 mg, 
0.50 mmol), 37 µl of BF3.OEt2 and p-chloranil (738 mg, 3.00 mmol, 6 eq). 
Identification of the product in the crude mixture was possible using TLC which 
showed 6 red fluorescent spots (ex: 336 nm) of which the second one revealed to be 
the product. Purification by CC had to be done twice. First with PE/DCM/EE in a ratio 
of 6:3:3 to 6:3:4 and then in a ratio of 60:30:15 to 60:30:25. This gave porphyrin 59 
as purple crystals in a yield of 90 mg (0.11 mmol, 22 %). Rf (PE:DCM:EE = 65:30:40) 
= 0.48. 
Mp: > 320 °C (decomp.); 1H-NMR (300 MHz, CDCl3): δ [ppm] = - 2.80 (s, 2 H, NH), 
4.12 (s, 9 H, 3 CH3), 7.21 (d, 3J = 8.8 Hz, 2 H, arom. CH), 8.06 (d, 3J = 8.8 Hz, 2 H, 
arom. CH), 8.30 (d, 3J = 8.3 Hz, 6 H, arom. CH), 8.45 (d, 3J = 8.3 Hz, 6 H, arom. CH), 
8.79 – 8.81 (m, 8 H, porphyrin-CH); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 52.5 (+, 3 
C, CH3), 113.8 (+, 2 C, phenol), 119.2 (Cquat, 4 C, porphyrin), 128.0 (+, 6 C), 129.7 
(Cquat, 3 C), 134.3 (Cquat, 1 C, phenol), 134.6 (+, 6 C), 135.8 (+, 2 C, phenol), 146.8 
(Cquat, 3 C), 155.7 (Cquat, 1 C, phenol), 167.3 (Cquat, 3 C, ester); MS (PI-EIMS, 70 eV): 
m/z (%) = 803.9 [M+.] (100); EA (C50H38N4O8) calc.: C 72.98 H 4.65 N 6.81, found: C 
73.48 H 4.72 N 6.58; UV/Vis (CH3CN): λ (lg ε) = 647 nm (3.602), 592 nm (3.774), 
553 nm (3.965), 517 nm (4.283), 421 nm (5.697), 299 nm (4.285), 261 nm (4.502); Fl 
(CH3CN, λex= 421 nm): λem (a.u.) = 655 nm (95), 720 nm (43); IR (KBr): ν  [cm-1] = 
3448, 3319, 3118, 3036, 2998, 2946, 2708, 1934, 1812, 1723, 1608, 1436, 1380, 
1140, 965, 802, 760; MF: C50H36N4O7; MW = 804.86 g/mol; 
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Formic acid 4-[10,20-bis-(4-formyloxymethyl-phenyl)-15-(4-prop-2-ynyloxy-phenyl)-
porphyrin-5-yl]-benzyl ester (60): 
The phenol 59 (405 mg, 0.50 mmol) was dissolved in 20 ml of dry THF under an 
atmosphere of N2. After addition of K2CO3 (417 mg, 3.02 mmol, 6 eq), catalytic 
amounts of 18-C-6 and KI (each approx. 25 mg), a solution of propargyl bromide in 
toluene (80 %, 163 µl, 180 mg, 1.51 mmol, 3 eq) was added. The mixture was stirred 
at r.t. for 48 h. TLC control showed almost complete conversion and no side-
products. The suspension was filtered and the filtrate was concentrated at reduced 
pressure. The crude product was purified by CC. PE/DCM/EE in a ratio of 65:25:20. 
This yielded 390 mg of 60 as purple crystals (0.46 mmol, 92 %). Rf (PE:DCM:EE = 
65:25:20) = 0.51. 
Mp: > 320 °C (decomp.); 1H-NMR (300 MHz, CDCl3): δ [ppm] = - 2.80 (s, 2 H, NH), 
2.69 (t, 4J = 2.2 Hz, 1 H, CH), 4.11 (s, 9 H, 3 CH3), 4.97 (d, 4J = 2.2 Hz, 2 H, CH2), 
7.36 (d, 3J = 8.6 Hz, 2 H, arom. CH), 8.12 (d, 3J = 8.6 Hz, 2 H, arom. CH), 8.29 (d, 
3J = 8.3 Hz, 6 H, arom. CH), 8.44 (d, 3J = 8.3 Hz, 6 H, arom. CH), 8.79 – 8.81 (m, 
8 H, porphyrin-CH); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 51.3 (+, 3 C, CH3), 54.9 
(–, 1 C), 74.8 (+, 1 C, CH), 77.5 (Cquat, 1 C, alkyne), 112.0 (+, 2 C, phenol), 117.8 
(Cquat, 1 C, porphyrin), 118.0 (Cquat, 2 C, porphyrin), 119.5 (Cquat, 1 C, porphyrin), 
126.8 (+, 6 C), 128.5 (Cquat, 3 C), 133.4 (+, 6 C), 133.8 (Cquat, 1 C, phenol), 134.4 (+, 
2 C, phenol), 145.6 (Cquat, 3 C), 156.4 (Cquat, 1 C, phenol), 166.1 (Cquat, 3 C, ester); 
MS (ESI, DCM/MeOH): m/z (%) = 843.4 [MH+] (100); EA (C53H38N4O7) calc.: C 75.52 
H 4.54 N 6.65, found: C 75.00 H 4.86 N 6.48; UV/Vis (CH2Cl2): λ (lg ε) = 647 nm 
(3.598), 591 nm (3.772), 552 nm (3.960), 516 nm (4.278), 420 nm (5.690), 305 nm 
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(4.281); Fl (CH3CN, λex= 420 nm): λem (a.u.) = 655 nm (95), 720 nm (43); IR (KBr): 
ν  [cm-1] = 3431, 3320, 3120, 3036, 2996, 2948, 2709, 2113, 1934, 1813, 1722, 
1607, 1435, 1275, 1107, 964, 802, 760; MF: C53H38N4O7; MW = 842.91 g/mol; 
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5,10,15-tris-(4-carboxy-phenyl)-20-(4-prop-2-ynyloxy-phenyl)-porphyrin (61): 
The methyl ester 60 (200 mg, 0.24 mmol) was dissolved in 20 ml of THF. After 
addition of LiOH (170 mg, 7.11 mmol, 30 eq), dissolved in 7 ml H2O, the mixture was 
heated to reflux for 24 h. The solution was acidified with 6 N aq. HCl to pH 2, which 
caused the product to precipitate. The solution was separated by centrifugation and 
discarded. The precipitate was washed with water and dried in vacuum. The crude 
product was purified by CC with CHCl3/MeOH/AcOH in a ratio of 84:15:1. This 
yielded 180 mg of 61 as purple crystals (0.23 mmol, 95 %). Rf (CHCl3:MeOH:AcOH = 
84:15:1) = 0.31. 
Mp: > 320 °C (decomp.); 1H-NMR (300 MHz, acetone-d6): δ [ppm] = - 2.74 (s, 2 H, 
NH), 5.13 (d, 4J = 2.2 Hz, 2 H, CH2), 7.49 (d, 3J = 8.5 Hz, 2 H, arom. CH), 8.22 (d, 
3J = 8.5 Hz, 2 H, arom. CH), 8.41 (d, 3J = 8.3 Hz, 6 H, arom. CH), 8.51 (d, 3J = 
8.3 Hz, 6 H, arom. CH), 8.91 – 8.98 (m, 8 H, porphyrin-CH); Assignment of the signal 
of the alkyne-CH was not possible as it was covered by the H2O-signal. 13C-NMR 
cannot be given as 61 was too poorly soluble in all common deuterated solvents. MS 
(ESI, DCM/MeOH): m/z (%) = 801.3 [MH+] (100); UV/Vis (Hepes-buffer pH 7.5): 
λ (lg ε) = 647 nm (3.586), 591 nm (3.762), 552 nm (3.948), 516 nm (4.270), 420 nm 
(5.678), 305 nm (4.268); MF: C50H32N4O7; MW = 800.83 g/mol; 
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Zn[5,10,15-tris-(4-carboxy-phenyl)-20-(4-prop-2-ynyloxy-phenyl)-porphyrin] (62): 
The porphyrin 61 (285 mg, 0.36 mmol) was suspended in 10 ml water. A saturated 
aq. solution of NaHCO3 was added dropwise until a clear solution was formed. A 
solution of Zn(OAc)2 x 2 H2O (781 mg, 3.56 mmol, 10 eq) in 5 ml water was added 
dropwise. A reddish brown precipitate appeared immediately. The mixture was 
heated to 80 °C for 5 minutes. After cooling to r.t. the product was separated by 
centrifugation and the colourless solution was discarded. The product was washed 
with water and dried in vacuum. This yielded 307 mg of 62 as purple crystalline solid 
(0.36 mmol, 100 %). 
Mp: > 320 °C (decomp.); 1H-NMR (600 MHz, CD3COOD:CDCl3 = 1:1): δ [ppm] = 2.77 
(t, 4J = 2.3 Hz, 1 H, CH), 4.98 (d, 4J = 2.3 Hz, 2 H, CH2), 7.36 (d, 3J = 8.7 Hz, 2 H, 
arom. CH), 8.13 (d, 3J = 8.7 Hz, 2 H, arom. CH), 8.33 (d, 3J = 8.0 Hz, 6 H, arom. CH), 
8.47 (d, 3J = 8.0 Hz, 6 H, arom. CH), 8.67 (d, 3J = 4.6 Hz, 6 H, porphyrin-CH), 8.87 
(s, 4 H, porphyrin-CH), 8.97 (d, 3J = 4.6 Hz, 6 H, porphyrin-CH); 13C-NMR cannot be 
given as 62 was too poorly soluble in all common deuterated solvents. MS (ESI, 
H2O/MeOH): m/z (%) = 865.3 [MH+] (100); UV/Vis (Hepes-buffer, pH 7.5): λ (lg ε) = 
599 nm (3.893), 558 nm (4.151), 423 nm (5.642), 310 nm (4.295); Fl (Hepes-buffer, 
pH 7.5, λex= 423 nm): λem (a.u.) = 610 nm (89), 660 nm (39); IR (KBr): ν  [cm-1] = 
3433, 2925, 2854, 2122, 1697, 1605, 1400, 998; MF: C50H30N4O7Zn; 
MW = 864.19 g/mol; 
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Li[2-[2-(2-{2-[2-Amino-3-(3H-imidazol-4-yl)-propionylamino]-4-methyl-pentanoyl-
amino}-4-methyl-pentanoylamino)-3-methyl-butyrylamino]-3-phenyl-propionate] (63): 
The commercially available peptide H-His-Leu-Leu-Val-Phe-OMe x 2 HCl (71 mg, 
0.1 mmol) was dissolved in 5 ml of a 1:1 mixture of water:acetonitrile. LiOH was 
added (7.2 mg, 0.3 mmol, 3 eq). The solution was stirred at r.t. for 20 h and 
lyophilized. This gave 63 as colourless frothy solid in combination with 2 eq LiCl 
(72 mg, 0.1 mmol, 100 %). 
1H-NMR (300 MHz, D2O): δ [ppm] = 0.68 – 0.79 (m, 18 H), 1.19 – 1.50 (m, 6 H), 1.76 
– 1.83 (m, 1 H), 2.74 – 2.81 (m, 3 H, Phe-CH2 + His-CH2), 3.00 (dd, 2J = 13.9 Hz, 
3J = 4.8 Hz, 1 H, Phe-CH2), 3.53 (t, 3J = 6.2 Hz, 1 H, His-C*H), 3.91 (d, 3J = 8.2 Hz, 
1 H, Val-C*H), 4.12 – 4.23 (m, 2 H), 4.28 – 4.32 (m, 1 H), 6.74 (s, 1 H, His), 7.05 – 
7.20 (m, 5 H, Phe), 7.51 (s, 1 H, His); MS (ESI, H2O/MeCN): m/z (%) = 628.5 [MH+] 
(100), 634.5 [(M+Li+)+] (65); MF: C32H48N7O6Li; MW = 633.72 g/mol; 
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Cu[2-(Bis-carboxylate-methyl-amino)-4-[2-(4-guanidinium-methyl-[1,2,3]triazol-1-yl)-
ethylcarbamoyl]-butanoate] (64): 
Synthesis followed GP 8 using 41 (87 mg, 0.20 mmol), 55 (27 mg, 0.20 mmol), 
sodium ascorbate (8 mg, 0.04 mmol, 20 mol%) and CuSO4 x 5 H2O (2.5 mg, 
0.01 mmol, 5 mol%). This yielded 79 mg (0.15 mmol, 75 %) of 64 as green solid. 
MS (pos. ESI, H2O/MeCN): m/z (%) = 490.0 [MH+] (80), 496.1 [(M+Li+)+] (100), 512.1 
[(M+Na+)+] (60); MS (neg. ESI, H2O/MeCN): m/z (%) = 488.3 [(M-H+)-] (100); 
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IR (KBr): ν  [cm-1] = 3387, 2936, 2873, 2103, 1624, 1388, 1126, 915; 
MF: C15H22N8O7Cu x 2 H2O; MW = 525.97 g/mol; 
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Cu[2-(Bis-carboxylate-methyl-amino)-4-[3-(4-guanidinium-methyl-[1,2,3]triazol-1-yl)-
propylcarbamoyl]-butanoate] (65): 
Synthesis followed GP 8 using 43 (90 mg, 0.20 mmol), 55 (27 mg, 0.20 mmol), 
sodium ascorbate (8 mg, 0.04 mmol, 20 mol%) and CuSO4 x 5 H2O (2.5 mg, 
0.01 mmol, 5 mol%). This yielded 79 mg (0.15 mmol, 73 %) of 65 as green solid. 
MS (pos. ESI, H2O/MeCN): m/z (%) = 504.0 [MH+] (70), 510.1 [(M+Li+)+] (100), 526.1 
[(M+Na+)+] (60); MS (neg. ESI, H2O/MeCN): m/z (%) = 502.2 [(M-H+)-] (100); 
IR (KBr): ν  [cm-1] = 3392, 2932, 2874, 2105, 1622, 1387, 1126, 915; 
MF: C16H24N8O7Cu x 2 H2O; MW = 539.99 g/mol; 
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Cu[2-(Bis-carboxylate-methyl-amino)-4-{[1-(2-guanidinium-ethyl)-1H-[1,2,3]triazol-4-
ylmethyl]-carbamoyl}-butanoate] (66): 
Synthesis followed GP 8 using 49 (84 mg, 0.21 mmol), 52 (34 mg, 0.21 mmol), 
sodium ascorbate (8 mg, 0.04 mmol, 20 mol%) and CuSO4 x 5 H2O (2.6 mg, 
0.01 mmol, 5 mol%). This yielded 78 mg (0.15 mmol, 71 %) of 66 as green solid. 
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MS (neg. ESI, H2O/MeCN): m/z (%) = 488.3 [(M-H+)-] (100); MF: C15H22N8O7Cu x 
2 H2O; IR (KBr): ν  [cm-1] = 3389, 2936, 2872, 2103, 1626, 1388, 1127, 915; 
MW = 525.97 g/mol; 
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Cu[2-(Bis-carboxylate-methyl-amino)-4-{[1-(3-guanidinium-propyl)-1H-[1,2,3]triazol-4-
ylmethyl]-carbamoyl}-butanoate] (67): 
Synthesis followed GP 8 using 49 (84 mg, 0.21 mmol), 53 (37 mg, 0.21 mmol), 
sodium ascorbate (8 mg, 0.04 mmol, 20 mol%) and CuSO4 x 5 H2O (2.6 mg, 
0.01 mmol, 5 mol%). This yielded 85 mg (0.15 mmol, 76 %) of 67 as green solid. 
MS (pos. ESI, H2O/MeCN): m/z (%) = 504.0 [MH+] (60), 510.1 [(M+Li+)+] (100), 526.1 
[(M+Na+)+] (50); MS (neg. ESI, H2O/MeCN): m/z (%) = 502.2 [(M-H+)-] (100); 
IR (KBr): ν  [cm-1] = 3387, 2936, 2873, 2103, 1624, 1388, 1126, 915; 
MF: C16H24N8O7Cu x 2 H2O; MW = 539.99 g/mol; 
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Cu[2-(Bis-carboxylate-methyl-amino)-6-{3-[1-(2-guanidinium-ethyl)-1H-[1,2,3]triazol-
4-yl]-propionylamino}-hexanoate] (68): 
Synthesis followed GP 8 using 28 (75 mg, 0.15 mmol), 52 (25 mg, 0.15 mmol), 
sodium ascorbate (6 mg, 0.03 mmol, 20 mol%) and CuSO4 x 5 H2O (2 mg, 
0.01 mmol, 5 mol%). This yielded 61 mg (0.11 mmol, 72 %) of 68 as green solid. 
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MS (pos. ESI, H2O/MeCN): m/z (%) = 532.3 [MH+] (100); MS (neg. ESI, H2O/MeCN): 
m/z (%) = 530.4 [(M-H+)-] (100); IR (KBr): ν  [cm-1] = 3390, 2938, 2879, 2107, 1625, 
1389, 1128, 916; MF: C18H28N8O7Cu x 2 H2O; MW = 568.05 g/mol; 
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Cu[2-(Bis-carboxylate-methyl-amino)-6-{3-[1-(3-guanidinium-propyl)-1H-[1,2,3]triazol-
4-yl]-propionylamino}-hexanoate] (69): 
Synthesis followed GP 8 using 28 (75 mg, 0.15 mmol), 53 (27 mg, 0.15 mmol), 
sodium ascorbate (6 mg, 0.03 mmol, 20 mol%) and CuSO4 x 5 H2O (2 mg, 
0.01 mmol, 5 mol%). This yielded 61 mg (0.11 mmol, 70 %) of 69 as green solid. 
MS (pos. ESI, H2O/MeCN): m/z (%) = 546.1 [MH+] (90), 552.2 [(M+Li+)+] (100), 568.2 
[(M+Na+)+] (70); MS (neg. ESI, H2O/MeCN): m/z (%) = 544.2 [(M-H+)-] (100); 
IR (KBr): ν  [cm-1] = 3391, 2939, 2881, 2108, 1626, 1389, 1129, 916;  
MF: C19H30N8O7Cu x 2 H2O; MW = 582.07 g/mol; 
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4-(2-tert-Butoxycarbonylamino-2-prop-2-ynylcarbamoyl-ethyl)-imidazole-1-carboxylic 
acid tert-butyl ester (70): 
The twofold Boc-protected histidine (700 mg, 1.3 mmol, di-cyclohexylamine salt) was 
suspended in 5 ml of dry DMF under an atmosphere of N2. The addition of TBTU 
(503 mg, 1.57 mmol, 1.2 eq), HOBt (274 mg, 1.72 mmol, 1.32 eq) and DIEA (290 µl, 
219 mg, 1.70 mmol, 1.3 eq) yielded a clear solution. After addition of propargyl amine 
(358 µl, 287 mg, 5.2 mmol, 4 eq) the solution was stirred at r.t. for 24 h. Water 
(50 ml) was added and the mixture was extracted twice with DCM (100 ml each 
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time). The organic layer was washed with brine, dried over Na2SO4 and concentrated 
at reduced pressure to give a yellow oil. Purification of the crude product by CC with 
EE:PE = 1:1 yielded 383 mg (0.98 mmol, 75 %) of 70 as colourless oil. Rf (EE:PE = 
1:1) = 0.35. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.15 (s, 9 H, CH3), 1.33 (s, 9 H, CH3), 2.97 (t, 
4J = 2.5 Hz, 1 H, alkyne-CH), 2.72 – 2.77 (m, 2 H, His-CH2), 3.72 (dd, 3J = 5.5 Hz, 4J 
= 2.5 Hz, 2 H, propargyl CH2), 4.19 – 4.25 (m, 1 H, C*H),  6.01 (d, 3J = 8.0 Hz, 1 H, 
NH), 6.93 (s, 1 H, His-CH), 7.45 (t, 3J = 5.5 Hz, 1 H, NH), 7.74 (s, 1 H, His-CH); 
13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 27.6 (+, 3 C, CH3), 28.1 (+, 3 C, CH3), 28.6  
(–, 1 C, His), 30.6 (–, 1 C, propargyl), 52.7 (+, 1 C, C*H), 70.9 (+, alkyne-CH), 79.3 
(Cquat, 1 C, Boc), 79.6 (Cquat, 1 C, alkyne), 85.2 (Cquat, 1 C, Boc), 114.5 (+, 1 C, 
imidazole), 136.5 (+, 1 C, imidazole), 138.9 (Cquat, 1 C, imidazole), 146.7 (Cquat, 1 C, 
urethane), 155.4 (Cquat, 1 C, urethane), 171.2 (Cquat, 1 C, amide); MS (ESI, 
DCM/MeOH): m/z (%) = 393.1 [MH+] (100); MF: C19H28N4O5; MW = 392.46 g/mol; 
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4-[2-tert-Butoxycarbonylamino-2-({1-[2-(5-dimethylamino-naphthalene-1-sulfonyl-
amino)-ethyl]-1H-[1,2,3]triazol-4-ylmethyl}-carbamoyl)-ethyl]-imidazole-1-carboxylic 
acid tert-butyl ester (72): 
The alkyne 70 (510 mg, 1.30 mmol) and the azide 71 (415 mg, 1.30 mmol) were 
dissolved in 10 ml of MeCN. After addition of CuI (50 mg, 0.26 mmol, 20 mol%) and 
2,4-lutidine (176 µl, 164 mg, 1.30 mmol, 1 eq) the solution was stirred at r.t. for 16 h. 
An aq. hydrogen peroxide solution (3 %, 20 ml) and a sat. aq. solution of EDTA 
(20 ml) were added and the mixture was stirred strongly for 30 min. After phase 
separation, the aq. phase was extracted with DCM (50 ml). The organic layers were 
combined, dried over Na2SO4 and concentrated at reduced pressure. This yielded a 
green crude product which was purified by CC with DCM:MeOH 96:4. Note: TLC with 
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this eluent shows only a baseline spot. Behaviour of 72 on the column is different 
from that one on TLC plates. Compound 72 was obtained as greenish solid in a yield 
of 85 % (787 mg, 1.11 mmol). 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.36 (s, 9 H, CH3), 1.56 (s, 9 H, CH3), 2.85 (s, 
6 H, 2 CH3), 2.96 (t, 3J = 5.5 Hz, 2 H, CH2), 3.37 – 3.43 (m, 2 H, CH2), 4.27 – 4.44 
(m, 5 H, 2 CH2 + C*H), 6.09 (d, 3J = 6.9 Hz, 1 H, NH), 6.94 (t, 3J = 6.1 Hz, 1 H, NH), 
7.10 (d, 4J = 1.1 Hz, 1 H, His-CH), 7.13 (d, 3J = 7.4 Hz, 1 H, dansyl-CH), 7.41 – 7.51 
(m, 4 H, triazole-CH + NH + 2 dansyl-CH), 7.92 (d, 4J = 1.1 Hz, 1 H, His-CH), 8.18 – 
8.21 (m, 2 H, dansyl-CH), 8.51 (d, 3J = 8.5 Hz, 1 H, dansyl-CH); 13C-NMR (75.5 MHz, 
CDCl3): δ [ppm] = 27.9 (+, 3 C, CH3), 28.3 (+, 3 C, CH3), 30.6 (–, 1 C), 34.8 (–, 1 C), 
42.6 (–, 1 C), 45.4 (+, 2 C), 50.3 (–, 1 C), 54.4 (+, 1 C, C*H), 79.9 (Cquat, 1 C, Boc), 
85.7 (Cquat, 1 C, Boc), 114.7 (+, 1 C, dansyl), 115.3 (+, 1 C, imidazole), 118.9 (+, 1 C, 
dansyl), 123.1 (+, 1 C, dansyl), 123.7 (+, 1 C, triazole), 128.4 (+, 1 C, dansyl), 129.3 
(+, 1 C, dansyl), 129.5 (Cquat, 1 C, dansyl), 129.9 (Cquat, 1 C, dansyl), 130.6 (+, 1 C, 
dansyl), 134.7 (Cquat, 1 C, dansyl), 136.8 (+, 1 C, imidazole), 138.9 (Cquat, 1 C, 
imidazole), 144.6 (Cquat, 1 C, triazole), 146.9 (Cquat, 1 C, urethane), 151.9 (Cquat, 1 C, 
dansyl), 155.6 (Cquat, 1 C, urethane), 171.8 (Cquat, 1 C, amide); MS (ESI, 
DCM/MeOH): m/z (%) = 712.3 [MH+] (100); UV/Vis (CH3CN): λ (lg ε) = 330 nm 
(3.405); MF: C33H45N9SO7; MW = 711.84 g/mol; 
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2-Amino-N-{1-[2-(5-dimethylamino-naphthalene-1-sulfonylamino)-ethyl]-1H-
[1,2,3]triazol-4-ylmethyl}-3-(1H-imidazol-4-yl)-propionamide (73): 
Synthesis followed GP 4 using 72 (270 mg, 0.38 mmol) and 5 ml of HCl saturated 
Et2O. The pale green solid, which was obtained after drying in vacuum was dissolved 
in 10 ml of water. A sat. aq. solution of NaHCO3 was added to adjust the pH value to 
9. The solution was extracted 8 times with DCM (40 ml each time). The organic 
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phases were combined, dried over Na2SO4 and concentrated at reduced pressure. 
Drying in vacuum yielded 185 mg of 73 (0.36 mmol, 95 %) as green solid. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.75 (bs, 2 H, NH2), 2.79 (s, 6 H, 2 CH3), 2.84 
– 2.90 (m, 2 H, CH2), 3.25 – 3.32 (m, 2 H, CH2), 3.56 – 3.62 (m, 1 H, C*H), 4.25 – 
4.36 (m, 4 H, 2 CH2), 6.66 (bs, 1 H, His-CH), 7.04 (d, 3J = 7.4 Hz, 1 H, dansyl-CH), 
7.32 – 7.45 (m, 5 H, triazole-CH + 2 NH + 2 dansyl-CH), 8.12 – 8.25 (m, 3 H, dansyl-
CH + His-CH), 8.45 (d, 3J = 8.8 Hz, 1 H, dansyl-CH); 13C-NMR (75.5 MHz, CDCl3): 
δ [ppm] = 31.0 (–, 1 C), 33.4 (–, 1 C), 41.6 (–, 1 C), 44.3 (+, 2 C), 49.6 (–, 1 C), 54.0 
(+, 1 C, C*H), 114.3 (+, 1 C, dansyl), 117.9 (+, 1 C, dansyl), 122.1 (+, 1 C, dansyl), 
122.5 (+, 1 C, triazole), 127.3 (+, 1 C, dansyl), 128.1 (+, 1 C, dansyl), 128.4 (Cquat, 
1 C, dansyl), 128.8 (Cquat, 1 C, dansyl), 129.4 (+, 1 C, dansyl), 133.7 (Cquat, 1 C, 
dansyl), 134.3 (+, 1 C, imidazole), 143.7 (Cquat, 1 C, triazole), 150.8 (Cquat, 1 C, 
dansyl), 173.9 (Cquat, 1 C, amide); Note: Due to broadening, the signals of the 
imidazole-Cquat and –CH cannot be given. MS (ESI, H2O/MeCN): m/z (%) = 512.2 
[MH+] (100); UV/Vis (Hepes-buffer pH 7.5): λ (lg ε) = 329 nm (3.296), 247 nm 
(3.832); Fl (Hepes-buffer, pH 7.5, λex= 330 nm): λem = 561 nm; IR (KBr): ν  [cm-1] = 
3354, 3140, 3086, 2955, 2858, 2790, 1662, 1573, 1451, 1316, 1258, 1142, 1096, 
796; MF: C23H29N9SO3; MW = 511.60 g/mol; 
 
Note: As compounds 74 – 77 were synthesized from an isomere mixture of 5/6-
carboxy fluorescein (with unknown ratio), assignment of signals in 1H and 13C NMR 
spectra was not possible. 
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5/6-[(2-Amino-ethyl)-carbamic acid tert-butyl ester]-carboxy-fluorescein (74): 
The isomere mixture of 5/6-carboxy fluorescein (1000 mg, 2.66 mmol) was dissolved 
in 15 ml of dry DMF under an atmosphere of N2. Following, TBTU (1033 mg, 
3.22 mmol, 1.21 eq), HOBt (511 mg, 3.22 mmol, 1.21 eq) and DIEA (1.0 ml, 756 mg, 
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5.85 mmol, 2.2 eq) were added. The solution was stirred at r.t. for 15 min. After 
addition of Boc-protected ethylene diamine (468 mg, 2.92 mmol, 1.1 eq) the solution 
was stirred at r.t. for 18 h. An aq. solution of citric acid (100 mg in 40 ml of water) was 
added in order to precipitate the product. After filtration, the residue was washed with 
little water and dried in vacuum. The crude product was purified by CC with EE. This 
yielded 1100 mg (2.12 mmol, 80 %) of 74 as orange solid. Rf (EE:PE = 4:1) = 0.2. 
MS (ESI, MeOH): m/z (%) = 519.2 [MH+] (100); MF: C28H26N2O8; MW = 518.52 g/mol; 
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5/6-(2-Amino-ethylamine)-carboxy-fluorescein hydrochloride (75): 
Synthesis followed GP 4 using 74 (1100 mg, 2.12 mmol) and 14 ml of HCl saturated 
diethyl ether. This yielded 964 mg of 75 (2.12 mmol, quant.) as pale yellow solid. 
MS (ESI, H2O/MeCN/TFA): m/z (%) = 419.1 [MH+] (100); MF: C23H19N2O6Cl; 
MW = 454.87 g/mol; 
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5/6-[4-[2-(2-Amino-ethylcarbamoyl)-2-tert-butoxycarbonylamino-ethyl]-imidazole-1-
carboxylic acid tert-butyl ester]-carboxy-fluorescein (76): 
The twofold Boc-protected histidine (1015 mg, 1.89 mmol, di-cyclohexyl-amine salt) 
was suspended in 20 ml of dry DMF under an atmosphere of N2. The addition of 
TBTU (668 mg, 2.08 mmol, 1.21 eq), HOBt (331 mg, 2.08 mmol, 1.21 eq) and DIEA 
(1236 µl, 933 mg, 7.22 mmol, 4.2 eq) yielded a clear solution. After addition of 75 
(782 mg, 1.72 mmol), the solution was stirred at r.t. for 3 d. An aq. solution of citric 
acid (150 mg in 80 ml of water) was added in order to precipitate the product. After 
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filtration, the residue was washed with water and dried in vacuum. The aqueous 
phases were combined and extracted with 100 ml EE. The organic phase was dried 
with Na2SO4 and concentrated at reduced pressure. Both crude products were 
purified separately by CC with EE:EtOH (from 9:1 to 2:1). Fractions containing the 
product were combined, concentrated and purified a second time with DCM:MeOH = 
4:1. In order to separate silica gel that was dissolved during CC, the product was 
taken up in EE and centrifugated. This yielded 615 mg (0.81 mmol, 47 %) of 76 as 
orange solid. Rf (EE:EtOH = 9:1) = 0.4. Note: As it was very difficult to separate the 
dicyclohexylamine it is recommended to use the twofold Boc-protected histidine 
benzene adduct! 
MS (ESI, MeOH): m/z (%) = 756.3 [MH+] (100); MF: C39H41N5O11; 
MW = 755.78 g/mol; 
1H-NMR spectrum of 76 (300 MHz, methanol-d4): 
The spectrum shows a set of signals for each isomer. δ [ppm] = 1.3 – 1.4 (F, 9 H, 
Boc-CH3), 1.5 – 1.7 (E, 9 H, Boc-CH3), 2.8 – 3.6 (D, 6 H, 3 CH2), 4.1 – 4.3 (C, 1 H, 
C*H), 6.5 – 6.7 (B, 6 H), 7.2 – 8.5 (A, 5 H).   
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5/6-[2-Amino-N-(2-amino-ethyl)-3-(1H-imidazol-4-yl)-propionamide]-carboxy-
fluorescein di-hydrochloride (77): 
Synthesis followed GP 4 using 76 (100 mg, 0.13 mmol) and 2 ml of HCl saturated 
diethyl ether. This yielded 83 mg of 77 (0.13 mmol, quant.) as pale yellow solid. 
MS (ESI, MeOH/H2O): m/z (%) = 556.2 [MH+] (100); MF: C29H27N5O7Cl2; 
MW = 628.47 g/mol; 
1H-NMR spectrum of 77 (300 MHz, methanol-d4): 
 
The spectrum shows a set of signals for each isomer. δ [ppm] = 3.2 – 3.6 (D, 6 H, 
3 CH2), 4.2 – 4.3 (C, 1 H, C*H), 7.1 – 7.6 (B, 6 H), 7.9 – 9.0 (A, 5 H). 
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2.5.3. Synthesis of Receptors for Stepwise TGS 
2.5.3.1. General Procedures 
 
GP 9 – Click-reaction: 
Equimolar amounts of the alkyne and the azide compound were dissolved in a 1:2 
mixture of tBuOH:EtOH (10 ml per mmol alkyne). A solution of sodium ascorbate 
(2 eq) in aqueous acetate buffer (pH 5, c = 0.5 mol/L) was added (4 ml buffer per 
mmol alkyne). Finally an aqueous solution of CuSO4 x 5 H2O (c = 1 mol/L, 1 eq) was 
added. The colour of the mixture turned to brown immediately and then slowly to 
yellow. The mixture was stirred at r.t. for 5 h and diluted with 50 ml of water (an 
orange precipitate occured). The suspension was extracted with EE (3 x 50 ml). The 
organic layers were combined, together with the orange precipitate and washed 
thoroughly with a sat. aq. solution of EDTA until the orange solid dissolved 
completely. The blue aqueous layer was discarded and the organic layer was dried 
with Na2SO4. Filtration and removal of the solvent in vacuum yielded the crude 
product as a white solid, which was purified by column chromatography (CC). 
Chromatography had to be done twice. First with DCM:MeOH and then with EE:EtOH 
(gradient of 98:2 to 96:4 for both mixtures). 
 
GP 10 – Cleavage of Boc protecting-groups with HCl-saturated diethyl ether: 
The Boc-protected compound was dissolved in diethyl ether (20 ml per mmol). A 
saturated solution of HCl in diethyl ether was added (1 ml per 0.15 mmol Boc). After 
a few minutes a white precipitate appeared. The mixture was stirred at r.t. under an 
atmosphere of N2 for 48 h. The solvent was removed at reduced pressure and the 
remaining colourless solid was dried in vacuum. 
 
GP 11 – Deprotonation and cleavage of ester-groups: 
The ammonium salt was dissolved in water (10 ml per mmol) and eluted over a 
strongly basic anion exchanger (OH–-form, loading 0.9 mmol/ml, 16 eq). The resin 
was washed with a little MeOH. Both solutions were combined and LiOH was added 
(3 eq). The solution was stirred at r.t. for 24 h. Lyophilisation yielded the completely 
deprotected compounds. 1H-NMR as well as 13C-NMR spectra of compounds 37 – 41 
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could not be analyzed in detail because of too slow movement of cyclen rings in NMR 
timescale. However, spectra showed no signals that could be assigned to ester 
functions. MS spectroscopy also confirmed the complete cleavage of all ester groups. 
 
GP 12 – complexation of Zn2+: 
The polydentate ligand was dissolved in MeOH (10 ml per mmol). A slight excess of 
Zn(ClO4)2 x 6 H2O (3.3 eq) was dissolved in water (10 ml per mmol). Both solutions 
were added simultaneously drop wise to water (5 ml per mmol) at 80 °C. In the case 
that a precipitate appeared, water was added until the precipitate dissolved. After 
complete addition of both solutions the pH value was checked. If it was lower than 8, 
an aqueous solution of LiOH (0.1 mol/l) was added. The mixture was heated to reflux 
for 6 h. Following, EtOH was added to the boiling solution until the product began to 
precipitate. After cooling to r.t. the suspension was stored at -20 °C over night in 
order to complete precipitation. The product was separated by centrifugation and 
washed with MeOH and EtOH. The solution was concentrated at reduced pressure 
and dried in vacuum. If necessary, the remaining solid was recrystallized from 
water/MeOH/EtOH to raise the yield. 
 
GP 13 – Click-reaction: 
Synthetic procedure was the same like GP 9. Only CC was different: mixtures of 
PE:EE (gradient 1:1 to 1:9) were used to purify the crude product. 
 
GP 14 – complexation of Zn2+: 
The ammonium salt was dissolved in water (10 ml per mmol) and eluted over a 
strongly basic anion exchanger (OH–-form, loading 0.9 mmol/ml, 16 eq). The resin 
was washed with a little MeOH. Both solutions were combined and lyophilized. This 
yielded the amine, which was dissolved in MeOH (10 ml per mmol). A slight excess 
of Zn(ClO4)2 x 6 H2O (3.3 eq) was dissolved in water (10 ml per mmol). Both 
solutions were added simultaneously drop wise to water (5 ml per mmol) at 80 °C. In 
the case that a precipitate appeared, water was added until the precipitate dissolved. 
After complete addition of both solutions an aqueous solution of LiOH (0.1 mol/l) was 
added until Zn(OH)2 began to precipitate. This was done in order to prevent the 
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amine ligand from protonation. The mixture was heated to reflux for 8 h. Following, 
EtOH was added to the boiling solution until the product began to precipitate. After 
cooling to r.t. the suspension was stored at -20 °C over night in order to complete 
precipitation. The product was separated by centrifugation and washed with MeOH 
and EtOH. The solution was concentrated at reduced pressure and dried in vacuum. 
If necessary, the remaining solid was recrystallized from water/MeOH/EtOH to raise 
the yield. 
 
2.5.3.2. Synthesis of New Compounds 
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6-(4-Azido-butyrylamino)-2-(bis-ethoxycarbonylmethyl-amino)-hexanoic acid 
methyl ester (79): 
The γ-azido-butyric acid (321 mg, 2.49 mmol, 1.2 eq) was dissolved in 5 ml of dry 
DCM and cooled to 0 °C in an ice bath. Following, HOBt (370 mg, 2.74 mmol, 
1.32 eq), EDC (484 µl, 425 mg, 2.74 mmol, 1.32 eq) and DIEA (468 µl, 354 mg, 
2.74 mmol, 1.32 eq) were added in this sequence. The solution was stirred at 0 °C 
for 30 min. Then, the amine 25 (689 mg, 2.07 mmol) dissolved in 10 ml dry DCM was 
added drop wise. The solution was stirred at r.t. under an atmosphere of N2 for 24 h. 
After that time 50 ml DCM were added and the solution was washed with 30 ml of a 
0.1 N aqueous solution of citric acid and 30 ml water. The organic layer was dried 
with MgSO4, filtered and concentrated in vacuum. The crude product was purified by 
column chromatography with EE:PE in a ratio of 3:2 to 4:1. This gave 79 as a 
colourless oil in a yield of 550 mg (1.24 mmol, 60 %). Rf (EE:PE = 1:1) = 0.21. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.14 (t, 3J = 7.1 Hz, 6 H, CH3), 1.29 – 1.49 (m, 
4 H, CH2), 1.55 – 1.62 (m, 2 H, CH2), 1.80 (tt, 3J = 6.7 Hz, 3J = 7.3 Hz, 2 H, CH2), 
2.17 (t, 3J = 7.3 Hz, 2 H, CH2), 3.03 – 3.19 (m, 2 H, CH2), 3.23 (t, 3J = 6.7 Hz, 2 H, 
CH2), 3.32 (t, 3J = 7.6 Hz, 1 H, C*H), 3.49 (s, 2 H, N-CH2), 3.50 (s, 2 H, N-CH2), 3.56 
(s, 3 H, Me-ester-CH3), 4.03 (q, 3J = 7.1 Hz, 4 H, CH2), 6.37 (t, 3J = 5.0 Hz, 1 H, NH); 
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13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 14.1 (+, 2 C, CH3), 22.7 (–, 1 C), 24.9 (–, 
1 C), 28.2 (–, 1 C), 29.5 (–, 1 C), 32.9 (–, 1 C), 39.1 (–, 1 C), 50.8 (–, 1 C), 51.3 (+, 1 
C, C*H), 52.6 (–, 2 C), 60.5 (–, 2 C), 64.0 (+, 1 C, CH3), 171.4 (Cquat, 2 C, Et-ester), 
171.9 (Cquat, 1 C, Me-ester), 173.1 (Cquat, 1 C, amide); MS (ESI, MeOH): m/z (%) = 
444.2 [MH+] (100); IR (KBr): ν  [cm-1] = 3309, 3265, 2948, 2888, 2148, 1734, 1688, 
1647, 1535, 1455, 1283; MF: C19H33N5O7; MW = 443.48 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-4-[(1-{3-[4,6-bis-(4,7,10-tri-tert-butoxycarbonyl-
1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-propyl}-1H-[1,2,3]triazol-4-
ylmethyl)-carbamoyl]-butyric acid benzyl ester (80): 
Synthesis followed GP 9 using 17 (1090 mg, 0.97 mmol), 46 (434 mg, 0.97 mmol), 
sodium ascorbate (386 mg, 1.95 mmol) and CuSO4 x 5 H2O (243 mg, 0.97 mmol). 
This yielded 1432 mg of 80 (0.91 mmol, 94 %) as colourless solid. Rf (DCM:MeOH = 
95:5) = 0.30. 
Mp: 110 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.16 (t, 3J = 7.2 Hz, 6 H, Et-
ester-CH3), 1.37 (bs, 36 H, Boc-CH3), 1.39 (bs, 18 H, Boc-CH3), 1.83 – 1.95 (m, 1 H, 
C2H2), 2.00 – 2.10 (m, 3 H, C6H2 + C2H2), 2.28 – 2.47 (m, 2 H, C3H2), 3.22 – 3.62 (m, 
39 H, C*H + C7H2 + C1H2 + cyclen-CH2), 4.04 (q, 3J = 7.2 Hz, 4 H, Et-ester-CH2), 
4.31 – 4.41 (m, 4 H, C4H2 + C5H2), 4.91 – 5.00 (m, 1 H, NH), 5.01 (d, 2J = 12.4 Hz, 
1 H, Bn-CH2), 5.06 (d, 2J = 12.4 Hz, 1 H, Bn-CH2), 7.10 (t, 3J = 5.5 Hz, 1 H, amide-
NH), 7.25 – 7.30 (m, 5 H, arom. CH), 7.53 (bs, 1 H, triazole-CH); 13C-NMR 
(75.5 MHz, CDCl3): δ [ppm] = 14.1 (+, 2 C, Et-ester), 25.9 (–, 1 C, C2), 28.4 (+, Boc-
CH3), 28.5 (+, Boc-CH3), 30.7 (–, 1 C, C6), 32.3 (–, 1 C, C3), 35.0 (–, 1 C, C4), 37.5  
(–, 1 C, C7), 47.6 (–, 1 C, C5), 50.3 (–, broad signal, 16 C, cyclen), 52.9 (–, 2 C, C1), 
60.7 (–, 2 C, Et-ester), 64.1 (+, 1 C, C*H), 66.4 (–, 1 C, Bn-CH2), 79.7 (Cquat, 4 C, 
Boc), 79.9 (Cquat, 2 C, Boc), 122.3 (+, 1 C, triazole), 128.2 (+, 2 C, arom.), 128.3 (+, 
 178
1 C, arom.), 128.6 (+, 2 C, arom.), 135.6 (Cquat, 1 C, arom.), 145.1 (Cquat, 1 C, 
triazole), 156.3 (Cquat, 6 C, urethane), 165.3 (Cquat, 1 C, triazine), 166.1 (very broad 
signal, 2 C, triazine), 171.5 (Cquat, 2 C, Et-ester), 172.0 (Cquat, 1 C, Bn-ester), 172.9 
(Cquat, 1 C, amide); MS (ESI, DCM/MeOH): m/z (%) = 1589.6 [(M+Na+)+] (7), 1567.6 
[MH+] (37), 784.2 [(M+2H+)2+] (100); EA (C75H123N17O19) calc.: C 57.49, H 7.91, N 
15.20, found: C 57.11, H 8.08, N 15.05; IR (KBr): ν  [cm-1] = 3387, 2974, 2933, 1740, 
1691, 1539, 1410, 1366, 1165, 1028, 777; MF: C75H123N17O19; MW = 1566.90 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-4-[2-(4-{[4,6-bis-(4,7,10-tri-tert-butoxycarbonyl-
1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-
ethylcarbamoyl]-butyric acid benzyl ester (81): 
Synthesis followed GP 9 using 22 (901 mg, 0.84 mmol), 36 (400 mg, 0.84 mmol), 
sodium ascorbate (332 mg, 1.68 mmol) and CuSO4 x 5 H2O (209 mg, 0.84 mmol). 
This yielded 1249 mg of 81 (0.81 mmol, 96 %) as colourless solid. Rf (DCM:MeOH = 
95:5) = 0.30. 
Mp: 110 °C; 1H-NMR (400 MHz, CDCl3): δ [ppm] = 1.16 (t, 3J = 7.1 Hz, 6 H, Et-
ester-CH3), 1.36 (bs, 36 H, Boc-CH3), 1.39 (bs, 18 H, Boc-CH3), 1.82 – 1.91 (m, 1 H, 
C2H2), 1.99 – 2.08 (m, 1 H, C2H2), 2.30 (ddd, 2J = 14.0 Hz, 3J = 5.9 Hz, 3J = 5.9 Hz, 
1 H, C3H2), 2.40 (ddd, 2J = 14.0 Hz, 3J = 9.0 Hz, 3J = 5.9 Hz, 1 H, C3H2), 3.20 – 3.70 
(m, 39 H, C*H + C4H2 + C1H2 + cyclen-CH2), 4.03 (q, 3J = 7.1 Hz, 4 H, Et-ester-CH2), 
4.37 – 4.41 (m, 2 H, C5H2), 4.52 – 4.55 (m, 2 H, C6H2), 5.03 (d, 2J = 12.3 Hz, 1 H, Bn-
CH2), 5.07 (d, 2J = 12.3 Hz, 1 H, Bn-CH2), 5.23 – 5.29 (m, 1 H, NH), 6.95 (t, 3J = 
5.5 Hz, 1 H, amide-NH), 7.23 – 7.31 (m, 5 H, arom. CH), 7.63 (bs, 1 H, triazole-CH); 
13C-NMR (100.6 MHz, CDCl3): δ [ppm] = 14.1 (+, 2 C, Et-ester), 25.7 (–, 1 C, C2), 
28.4 (+, Boc-CH3), 28.5 (+, Boc-CH3), 32.3 (–, 1 C, C3), 36.3 (–, 1 C, C6), 39.4 (–, 
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1 C, C4), 49.4 (–, 1 C, C5), 50.2 (–, broad signal, 16 C, cyclen), 53.0 (–, 2 C, C1), 60.7 
(–, 2 C, Et-ester), 64.0 (+, 1 C, C*H), 66.5 (–, 1 C, Bn-CH2), 79.7 (Cquat, 4 C, Boc), 
79.8 (Cquat, 2 C, Boc), 122.4 (+, 1 C, triazole), 128.2 (+, 2 C, arom.), 128.3 (+, 1 C, 
arom.), 128.6 (+, 2 C, arom.), 135.6 (Cquat, 1 C, arom.), 146.0 (Cquat, 1 C, triazole), 
156.3 (Cquat, 6 C, urethane), 165.6 (Cquat, 1 C, triazine), 166.1 (Cquat, very broad 
signal, 2 C, triazine), 171.5 (Cquat, 2 C, Et-ester), 172.0 (Cquat, 1 C, Bn-ester), 173.3 
(Cquat, 1 C, amide); MS (ESI, DCM/MeOH): m/z (%) = 1553.5 [MH+] (40), 777.3 
[(M+2H+)2+] (100); EA (C74H121N17O19) calc.: C 57.24, H 7.85, N 15.33, found: 
C 56.94, H 8.09, N 15.07; IR (KBr): ν  [cm-1] = 3389, 2973, 2933, 1741, 1691, 1538, 
1410, 1366, 1166, 1029, 777; MF: C74H121N17O19; MW = 1552.88 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-4-[3-(4-{[4,6-bis-(4,7,10-tri-tert-butoxycarbonyl-
1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-
propylcarbamoyl]-butyric acid benzyl ester (82): 
Synthesis followed GP 9 using 22 (1009 mg, 0.94 mmol), 37 (452 mg, 0.94 mmol), 
sodium ascorbate (372 mg, 1.88 mmol) and CuSO4 x 5 H2O (234 mg, 0.94 mmol). 
This yielded 1371 mg of 82 (0.87 mmol, 93 %) as colourless solid. Rf (DCM:MeOH = 
95:5) = 0.31. 
Mp: 110 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.16 (t, 3J = 7.1 Hz, 6 H, Et-
ester-CH3), 1.36 (bs, 36 H, Boc-CH3), 1.38 (bs, 18 H, Boc-CH3), 1.82 – 1.94 (m, 1 H, 
C2H2), 1.96 – 2.11 (m, 3 H, C2H2 + C5H2), 2.28 – 2.45 (m, 2 H, C3H2), 3.06 – 3.64 (m, 
39 H, C*H + C4H2 + C1H2 + cyclen-CH2), 4.04 (q, 3J = 7.1 Hz, 4 H, Et-ester-CH2), 
4.30 (t, 3J = 6.9 Hz, 2 H, C6H2), 4.52 – 4.56 (m, 2 H, C7H2), 5.01 (d, 2J = 12.4 Hz, 1 H, 
Bn-CH2), 5.06 (d, 2J = 12.4 Hz, 1 H, Bn-CH2), 5.16 – 5.24 (m, 1 H, NH), 6.83 (t, 3J = 
5.9 Hz, 1 H, amide-NH), 7.21 – 7.31 (m, 5 H, arom. CH), 7.66 (bs, 1 H, triazole-CH); 
13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 14.1 (+, 2 C, Et-ester), 25.9 (–, 1 C, C2), 28.4 
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(+, Boc-CH3), 28.5 (+, Boc-CH3), 30.3 (–, 1 C, C5), 32.4 (–, 1 C, C3), 36.2 (–, 2 C, C4 
+ C7), 47.6 (–, 1 C, C6), 50.2 (–, broad signal, 16 C, cyclen), 52.9 (–, 2 C, C1), 60.7  
(–, 2 C, Et-ester), 64.1 (+, 1 C, C*H), 66.5 (–, 1 C, Bn-CH2), 79.7 (Cquat, 4 C, Boc), 
79.8 (Cquat, 2 C, Boc), 122.3 (+, 1 C, triazole), 128.3 (+, 2 C, arom.), 128.3 (+, 1 C, 
arom.), 128.6 (+, 2 C, arom.), 135.5 (Cquat, 1 C, arom.), 145.8 (Cquat, 1 C, triazole), 
156.3 (Cquat, 6 C, urethane), 165.5 (Cquat, 1 C, triazine), 166.6 (Cquat, broad signal, 
2 C, triazine), 171.5 (Cquat, 2 C, Et-ester), 172.0 (Cquat, 1 C, Bn-ester), 173.2 (Cquat, 
1 C, amide); MS (ESI, DCM/MeOH): m/z (%) = 1576.6 [MH+] (45), 784.2 [(M+2H+)2+] 
(100); EA (C75H123N17O19) calc.: C 57.49, H 7.91, N 15.20, found: C 57.15, H 8.07, N 
15.01; IR (KBr): ν  [cm-1] = 3387, 2974, 2933, 1740, 1691, 1539, 1410, 1366, 1165, 
1028, 777; MF: C75H123N17O19; MW = 1566.90 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-6-[3-(1-{2-[4,6-bis-(4,7,10-tri-tert-
butoxycarbonyl-1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-ethyl}-1H-
[1,2,3]triazol-4-yl)-propionylamino]-hexanoic acid methyl ester (83): 
Synthesis followed GP 9 using 16 (1218 mg, 1.10 mmol), 26 (454 mg, 1.10 mmol), 
sodium ascorbate (463 mg, 2.20 mmol) and CuSO4 x 5 H2O (275 mg, 1.10 mmol). 
This yielded 1519 mg of 83 (1.00 mmol, 91 %) as colourless solid. Rf (DCM:MeOH = 
95:5) = 0.31. 
Mp: 108 °C; 1H-NMR (400 MHz, CDCl3): δ [ppm] = 1.22 (t, 3J = 7.1 Hz, 6 H, Et-ester-
CH3), 1.37 – 1.50 (m, 58 H, C2H2, C3H2, Boc-CH3), 1.62 – 1.68 (m, 2 H, C1H2), 2.57 
(t, 3J = 7.3 Hz, 2 H, C5H2), 3.00 (t, 3J = 7.3 Hz, 2 H, C6H2), 3.12 – 3.23 (m, 2 H, C4H2), 
3.23 – 3.74 (m, 33 H, C*H + Cyclen-CH2), 3.576 (s, 2 H, N-CH2), 3.583 (s, 2 H, N-
CH2), 3.64 (s, 3 H, Me-ester-CH3), 3.76 – 3.81 (m, 2 H, C8H2), 4.10 (q, 3J = 7.1 Hz, 
4 H, Et-ester-CH2), 4.46 – 4.49 (m, 2 H, C7H2), 4.88 – 4.93 (m, 1 H, NH), 6.29 – 6.31 
(m, 1 H, amide-NH), 7.50 (bs, 1 H, triazole-CH); 13C-NMR (75.5 MHz, CDCl3): 
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δ [ppm] = 14.2 (+, 2 C, Et-ester-CH3), 21.6 (–, 1 C, C6), 23.0 (–, 1 C, C2), 28.5 (+, 
18 C, Boc-CH3), 28.7 (–, 1 C, C3), 29.8 (–, 1 C, C1), 35.6 (–, 1 C, C5), 39.2 (–, 1 C,  
C4), 41.0 (–, 1 C, C8), 49.8 (–, 1 C, C7), 50.3 (–, 16 C, cyclen), 51.4 (+, 1 C, 
Me-ester), 52.7 (–, 2 C, N-CH2), 60.6 (–, 2 C, Et-ester), 64.4 (+, 1 C, C*H), 79.8 
(Cquat, 4 C, Boc), 80.0 (Cquat, 2 C, Boc), 122.3 (+, 1 C, triazole), 146.7 (Cquat, 1 C, 
triazole), 156.5 (Cquat, 6 C, urethane), 165.7 (Cquat, 1 C, triazine), 166.6 (very broad 
signal, Cquat, 2 C, triazine), 171.4 (Cquat, 2 C, Et-ester), 172.0 (Cquat, 1 C, amide), 
173.1 (Cquat, 1 C, Me-ester); MS (ESI, DCM/MeOH): m/z (%) = 1541.3 [(M+Na+)+] 
(20), 1519.3 [MH+] (60), 760.2 [(M+2H+)2+] (100), 710.2 [(M+3H+-CO2-(C4H8)+)2+] (60), 
660.2 [(M+4H+-2CO2-2(C4H8)+)2+] (40); EA (C71H123N17O19) calc.: C 56.15, H 8.16, N 
15.68, found: C 56.05, H 8.21, N 15.60; IR (KBr): ν  [cm-1] = 3391, 2978, 2935, 1739, 
1690, 1538, 1411, 1366, 1166, 1028; MF: C71H123N17O19; MW = 1518.86 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-6-[4-(4-{[4,6-bis-(4,7,10-tri-tert-butoxycarbonyl-
1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-
butyrylamino]-hexanoic acid methyl ester (84): 
Synthesis followed GP 9 using 22 (749 mg, 0.70 mmol), 79 (309 mg, 0.70 mmol), 
sodium ascorbate (276 mg, 1.39 mmol) and CuSO4 x 5 H2O (174 mg, 0.70 mmol). 
This yielded 953 mg of 84 (0.63 mmol, 90 %) as colourless solid. Rf (DCM:MeOH = 
95:5) = 0.31. 
Mp: 108 °C; 1H-NMR (400 MHz, CDCl3): δ [ppm] = 1.19 (t, 3J = 7.1 Hz, 6 H, Et-ester-
CH3), 1.37 – 1.52 (m, 58 H, C2H2, C3H2, Boc-CH3), 1.61 – 1.67 (m, 2 H, C1H2), 2.12 – 
2.18 (m, 4 H, C5H2, C6H2), 3.11 – 3.73 (m, 35 H, C*H, C4H2, cyclen-CH2), 3.546 (s, 
2 H, N-CH2), 3.552 (s, 2 H, N-CH2), 3.62 (s, 3 H, Me-ester-CH3), 4.07 (q, 3J = 7.1 Hz, 
4 H, Et-ester-CH2), 4.34 (t, 3J = 6.1 Hz, 2 H, C7H2), 4.56 – 4.58 (m, 2 H, C8H2), 5.20 – 
5.26 (m, 1 H, NH), 6.35 – 6.38 (m, 1 H, amide-NH), 7.63 (bs, 1 H, triazole); 13C-NMR 
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(100.6 MHz, CDCl3): δ [ppm] = 14.2 (+, 2 C, Et-ester-CH3), 22.9 (–, 1 C, C2), 26.3 (–, 
1 C, C6), 28.4 – 28.5 (19 C, C3 and Boc-CH3), 29.7 (–, 1 C, C1), 32.6 (–, 1 C, C5), 
36.3 (–, 1 C,  C8), 39.2 (–, 1 C, C4), 49.3 (–, 1 C, C7), 50.2 (–, 16 C, cyclen), 51.4 (+, 
1 C, Me-ester), 52.7 (–, 2 C, N-CH2), 60.6 (–, 2 C, Et-ester), 64.3 (+, 1 C, C*H), 79.8 
(Cquat, 4 C, Boc), 79.8 (Cquat, 2 C, Boc), 122.0 (+, 1 C, triazole), 146.1 (Cquat, 1 C, 
triazole), 156.3 (Cquat, 6 C, urethane), 165.6 (Cquat, 1 C, triazine), 166.4 (broad signal, 
Cquat, 2 C, triazine), 171.4 (Cquat, 2 C, Et-ester), 171.5 (Cquat, 1 C, amide), 173.1 
(Cquat, 1 C, Me-ester); MS (ESI, DCM/MeOH): m/z (%) = 1519.4 [MH+] (22), 760.1 
[(M+2H+)2+] (100), 710.2 [(M+3H+-CO2-(C4H8)+)2+] (20); EA (C71H123N17O19) calc.: 
C 56.15, H 8.16, N 15.68, found: C 56.01, H 8.23, N 15.57; IR (KBr): ν  [cm-1] = 3390, 
2978, 2934, 1739, 1689, 1538, 1411, 1366, 1166, 1028; MF: C71H123N17O19; 
MW = 1518.86 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-4-[(1-{3-[4,6-bis-(1,4,7,10tetraaza-cyclododec-1-
yl)-[1,3,5]triazin-2-ylamino]-propyl}-1H-[1,2,3]triazol-4-ylmethyl)-carbamoyl]-butyric 
acid benzyl ester hexa-hydrochloride (85): 
Synthesis followed GP 10 using 80 (625 mg, 0.40 mmol) and 16 ml of HCl/Et2O. This 
yielded 474 mg of 85 (0.40 mmol, quant.) as colourless hygroscopic solid. 
Mp: > 250 °C; 1H-NMR (300 MHz, D2O): δ [ppm] = 1.01 (t, 3J = 7.1 Hz, 6 H, Et-ester-
CH3), 1.79 – 1.92 (m, 2 H, C2H2), 2.04 (tt, 3J = 6.7 Hz, 2 H, C6H2), 2.26 (t, 3J = 6.9 Hz, 
2 H, C3H2), 3.05 – 3.35 (m, 26 H, C7H2 + cyclen-CH2), 3.51 (t, 3J = 7.6 Hz, 1 H, C*H), 
3.57 (s, 4 H, C1H2), 3.67 – 3.79 (m, 8 H, cyclen-CH2), 3.93 (q, 3J = 7.1 Hz, 4 H, Et-
ester-CH2), 4.25 (s, 2 H, C4H2), 4.32 (t, 3J = 6.7 Hz, 2 H, C5H2), 4.90 – 4.98 (m, 2 H, 
Bn-CH2), 7.16 – 7.21 (m, 5 H, arom. CH), 7.83 (s, 1 H, triazole); 13C-NMR (75.5 MHz, 
D2O): δ [ppm] = 13.3 (+, 2 C, Et-ester), 24.7 (–, 1 C, C2), 28.7 (–, 1 C, C6), 31.6 (–, 
1 C, C3), 34.0 (–, 1 C, C4), 37.8 (–, 1 C, C7), 44.3 (–, broad signal, 8 C, cyclen), 46.4 
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(–, 4 C, cyclen), 48.1 (–, broad signal, 4 C, cyclen), 48.4 (–, 1 C, C5), 53.2 (–, 2 C, 
C1), 62.3 (–, 2 C, Et-ester), 64.6 (+, 1 C, C*H), 67.4 (–, 1 C, Bn-CH2), 124.5 (+, 1 C, 
triazole), 128.3 (+, 2 C, arom.), 128.4 (+, 1 C, arom.), 128.8 (+, 2 C, arom.), 135.0 
(Cquat, 1 C, arom.), 144.0 (Cquat, 1 C, triazole), 155.2 (Cquat, 2 C, triazine), 163.4 
(broad signal, 1 C, triazine), 171.9 (Cquat, 2 C, Et-ester), 172.1 (Cquat, 1 C, Bn-ester), 
174.9 (Cquat, 1 C, amide); MS (ESI, MeCN/H2O): m/z (%) = 966.7 [MH+] (4), 483.9 
[(M+2H+)2+] (100), 323.0 [(M+3H+)3+] (16); IR (KBr): ν  [cm-1] = 3431, 2961, 2938, 
2810, 1736, 1651, 1610, 1531, 1426, 1340, 751; MF: C45H81N17O7Cl6; 
MW = 1184.96 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-4-[2-(4-{[4,6-bis-(1,4,7,10tetraaza-cyclododec-1-
yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-ethylcarbamoyl]-butyric acid 
benzyl ester hexa-hydrochloride (86): 
Synthesis followed GP 10 using 81 (625 mg, 0.40 mmol) and 16 ml of HCl/Et2O. This 
yielded 471 mg of 86 (0.40 mmol, quant.) as colourless hygroscopic solid. 
Mp: > 250 °C; 1H-NMR (300 MHz, D2O): δ [ppm] = 1.04 (t, 3J = 7.1 Hz, 6 H, Et-ester-
CH3), 1.70 – 1.82 (m, 2 H, C2H2), 2.14 (t, 3J = 7.1 Hz, 1 H, C3H2), 3.04 – 3.31 (m, 
24 H, cyclen-CH2), 3.43 – 3.49 (m, 3 H, C*H + C4H2), 3.59 (s, 4 H, C1H2), 3.72 – 3.81 
(m, 8 H, cyclen-CH2), 3.96 (q, 3J = 7.1 Hz, 4 H, Et-ester-CH2), 4.32 – 4.36 (m, 2 H, 
C5H2), 4.55 (s, 2 H, C6H2), 4.95 – 5.01 (m, 2 H, Bn-CH2), 7.21 – 7.24 (m, 5 H, arom. 
CH), 7.86 (s, 1 H, triazole); 13C-NMR (75.5 MHz, D2O): δ [ppm] = 13.3 (+, 2 C, Et-
ester), 24.7 (–, 1 C, C2), 31.7 (–, 1 C, C3), 35.8 (–, 1 C, C6), 39.0 (–, 1 C, C4), 43.9 – 
44.3 (–, broad signal, 8 C, cyclen), 46.1 (–, 4 C, cyclen), 47.7 (–, 2 C, cyclen), 48.2  
(–, 2 C, cyclen), 49.8 (–, 1 C, C5), 53.2 (–, 2 C, C1), 62.3 (–, 2 C, Et-ester), 64.6 (+, 
1 C, C*H), 67.5 (–, 1 C, Bn-CH2), 124.3 (+, 1 C, triazole), 128.4 (+, 2 C, arom.), 128.8 
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(+, 1 C, arom.), 128.8 (+, 2 C, arom.), 135.1 (Cquat, 1 C, arom.), 144.2 (Cquat, 1 C, 
triazole), 155.5 (Cquat, 2 C, triazine), 163.6 (broad signal, Cquat, 1 C, triazine), 172.0 
(Cquat, 2 C, Et-ester), 172.1 (Cquat, 1 C, Bn-ester), 175.1 (Cquat, 1 C, amide); MS (ESI, 
MeCN/H2O): m/z (%) = 952.6 [MH+] (7), 476.9 [(M+2H+)2+] (100); IR (KBr): ν  [cm-1] = 
3433, 2961, 2939, 2810, 1736, 1651, 1611, 1531, 1426, 1340, 752; 
MF: C44H79N17O7Cl6; MW = 1170.94 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-4-[3-(4-{[4,6-bis-(1,4,7,10tetraaza-cyclododec-1-
yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-propylcarbamoyl]-butyric acid 
benzyl ester hexa-hydrochloride (87): 
Synthesis followed GP 10 using 82 (675 mg, 0.43 mmol) and 17 ml of HCl/Et2O. This 
yielded 510 mg of 87 (0.43 mmol, quant.) as colourless hygroscopic solid. 
Mp: > 250 °C; 1H-NMR (300 MHz, D2O): δ [ppm] = 1.05 (t, 3J = 7.1 Hz, 6 H, Et-ester-
CH3), 1.75 – 1.87 (m, 2 H, C2H2), 1.88 – 2.04 (m, 2 H, C5H2), 2.17 (t, 3J = 7.0 Hz, 2 H, 
C3H2), 3.03 – 3.50 (m, 27 H, C*H + C4H2 + cyclen-CH2), 3.58 (s, 4 H, C1H2), 3.70 – 
3.82 (m, 8 H, cyclen-CH2), 3.95 (q, 3J = 7.1 Hz, 4 H, Et-ester-CH2), 4.25 – 4.30 (m, 
2 H, C6H2), 4.55 (s, 2 H, C7H2), 4.92 – 4.99 (m, 2 H, Bn-CH2), 7.18 – 7.22 (m, 5 H, 
arom. CH), 7.85 (s, 1 H, triazole); 13C-NMR (75.5 MHz, D2O): δ [ppm] = 13.3 (+, 2 C, 
Et-ester), 25.0 (–, 1 C, C2), 29.4 (–, 1 C, C5), 31.7 (–, 1 C, C3), 35.5 (–, 2 C, C4), 35.7 
(–, 2 C, C7), 43.9 – 44.4 (–, broad signal, 8 C, cyclen), 46.2 (–, 4 C, cyclen), 47.6 (–, 
2 C, cyclen), 48.1 (–, 2 C, cyclen), 48.4 (–, 1 C, C6), 53.2 (–, 2 C, C1), 62.3 (–, 2 C, 
Et-ester), 64.6 (+, 1 C, C*H), 67.4 (–, 1 C, Bn-CH2), 124.5 (+, 1 C, triazole), 128.3 (+, 
2 C, arom.), 128.4 (+, 1 C, arom.), 128.7 (+, 2 C, arom.), 135.0 (Cquat, 1 C, arom.), 
144.1 (Cquat, 1 C, triazole), 155.3 (Cquat, 2 C, triazine), 163.5 (broad signal, Cquat, 1 C, 
triazine), 171.7 (Cquat, 2 C, Et-ester), 172.0 (Cquat, 1 C, Bn-ester), 174.9 (Cquat, 1 C, 
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amide); MS (ESI, MeCN/H2O): m/z (%) = 966.7 [MH+] (7), 483.9 [(M+2H+)2+] (100), 
323.0 [(M+3H+)3+] (10); IR (KBr): ν  [cm-1] = 3431, 2961, 2938, 2810, 1736, 1651, 
1610, 1531, 1426, 1340, 751; MF: C45H81N17O7Cl6; MW = 1184.96 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-6-[3-(1-{2-[4,6-bis-(1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-ylamino]-ethyl}-1H-[1,2,3]triazol-4-yl)-propionylamino]-hexanoic 
acid methyl ester hexa-hydrochloride (88): 
Synthesis followed GP 10 using 83 (1000 mg, 0.66 mmol) and 26 ml of HCl/Et2O. 
This yielded 749 mg of 88 (0.66 mmol, quant.) as colourless hygroscopic solid. 
Mp: > 250 °C; 1H-NMR (400 MHz, D2O): δ [ppm] = 1.17 (t, 3J = 7.1 Hz, 6 H, Et-ester-
CH3), 1.16 – 1.28 (m, 2 H, C2H2), 1.33 – 1.40 (m, 2 H, C3H2), 1.61 – 1.77 (m, 2 H, 
C1H2), 2.49 (t, 3J = 7.3 Hz, 2 H, C5H2), 2.91 (t, 3J = 7.3 Hz, 2 H, C6H2), 3.03 (t, 3J = 
6.8 Hz, 2 H, C4H2), 3.17 – 3.21 (m, 16 H, cyclen-CH2), 3.28 – 3.32 (m, 4 H, cyclen-
CH2), 3.35 – 3.40 (m, 4 H, cyclen-CH2), 3.67 (s, 3 H, Me-ester), 3.69 – 3.73 (m, 1 H, 
C*H), 3.80 – 3.86 (m, 12 H, cyclen-CH2 + N-CH2), 3.90 – 3.93 (m, 2 H, C8H2), 4.12 
(q, 3J = 7.1 Hz, 4 H, Et-ester-CH2), 4.60 – 4.62 (m, 2 H, C7H2), 7.92 (s, 1 H, triazole); 
13C-NMR (100.6 MHz, D2O): δ [ppm] = 13.3 (+, 2 C, Et-ester-CH3), 20.7 (–, 1 C, C6), 
22.5 (–, 1 C, C2), 28.9 (–, 1 C, C3), 28.2 (–, 1 C, C1), 34.8 (–, 1 C, C5), 38.8 (–, 1 C, 
C4), 40.7 (–, 1 C, C8), 44.1 (–, 2 C, cyclen), 44.4 (–, 4 C, cyclen), 44.6 (–, 2 C, 
cyclen), 46.4 (–, 4 C, cyclen), 47.8 (–, 2 C, cyclen), 48.4 (–, 2 C, cyclen), 50.2 (–, 1 C, 
C7), 52.7 (+, 1 C, Me-ester), 53.5 (–, 2 C, N-CH2), 62.7 (–, 2 C, Et-ester), 65.7 (+, 
1 C, C*H), 124.8 (+, 1 C, triazole), 145.8 (Cquat, 1 C, triazole), 155.7 (Cquat, 1 C, 
triazine), 156.1 (Cquat, 1 C, triazine), 163.4 (Cquat, 1 C, triazine), 171.2 (Cquat, 2 C, Et-
ester), 172.8 (Cquat, 1 C), 174.3 (Cquat, 1 C); MS (ESI, MeCN/H2O/TFA): m/z (%) = 
918.7 [MH+] (4), 460.0 [(M+2H+)2+] (100), 307.0 [(M+3H+)3+] (30); IR (KBr): ν  [cm-1] = 
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3428, 2964, 2940, 2811, 1734, 1651, 1609, 1530, 1426, 1342; MF: C41H81N17O7Cl6; 
MW = 1136.92 g/mol; 
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2-(Bis-ethoxycarbonylmethyl-amino)-6-[4-(4-{[4,6-bis-(1,4,7,10tetraaza-cyclododec-1-
yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-butyrylamino]-hexanoic acid 
methyl ester hexa-hydrochloride (89): 
Synthesis followed GP 10 using 84 (790 mg, 0.52 mmol) and 21 ml of HCl/Et2O. This 
yielded 591 mg of 89 (0.52 mmol, quant.) as colourless hygroscopic solid. 
Mp: > 250 °C; 1H-NMR (300 MHz, D2O): δ [ppm] = 1.12 (t, 3J = 7.1 Hz, 6 H, Et-ester-
CH3), 1.23 – 1.42 (m, 4 H, C2H2 + C3H2), 1.66 – 1.86 (m, 2 H, C1H2), 2.00 – 2.15 (m, 
4 H, C5H2 + C6H2), 2.98 (t, 3J = 6.7 Hz, 2 H, C4H2), 3.08 – 3.33 (m, 24 H, cyclen-
CH2), 3.65 (s, 3 H, Me-ester-CH3), 3.78 – 3.84 (m, 8 H, cyclen-CH2), 3.93 – 3.98 (m, 
1 H, C*H), 4.03 – 4.04 (m, 4 H, N-CH2), 4.11 (q, 3J = 7.1 Hz, 4 H, Et-ester-CH2), 4.32 
(t, 3J = 6.5 Hz, 2 H, C7H2), 4.67 (s, 2 H, C8H2), 7.95 (bs, 1 H, triazole); 13C-NMR 
(75.5 MHz, D2O): δ [ppm] = 13.3 (+, 2 C, Et-ester-CH3), 22.6 (–, 1 C, C2), 25.8 (–, 
1 C, C6), 27.5 (–, 1 C, C3), 27.9 (–, 1 C, C1), 32.5 (–, 1 C,  C5), 35.8 (–, 1 C, C8), 38.8 
(–, 1 C, C4), 44.4 (–, broad signal, 8 C, cyclen), 46.2 (–, 4 C, cyclen), 47.9 (–, broad 
signal, 4 C, cyclen), 50.2 (–, 1 C, C7), 53.2 (+, 1 C, Me-ester), 53.9 (–, 2 C, N-CH2), 
63.3 (–, 2 C, Et-ester), 66.3 (+, 1 C, C*H), 124.4 (+, 1 C, triazole), 144.1 (Cquat, 1 C, 
triazole), 155.6 (Cquat, 2 C, triazine), 163.8 (Cquat, very broad signal, 1 C, triazine), 
169.3 (Cquat, 2 C, Et-ester), 171.0 (Cquat, 1 C), 174.7 (Cquat, 1 C); MS (ESI, 
MeCN/H2O): m/z (%) = 918.7 [MH+] (5), 460.0 [(M+2H+)2+] (100), 307.0 [(M+3H+)3+] 
(40); IR (KBr): ν  [cm-1] = 3428, 2964, 2940, 2811, 1734, 1651, 1609, 1530, 1426, 
1342; MF: C41H81N17O7Cl6; MW = 1136.92 g/mol; 
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Li3[2-(Bis-carboxylate-methyl-amino)-4-[(1-{3-[4,6-bis-(1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-ylamino]-propyl}-1H-[1,2,3]triazol-4-ylmethyl)-carbamoyl]-
butanoate] (90): 
Synthesis followed GP 11 using 85 (730 mg, 0.4 mmol), 7.1 ml of ion-exchanger 
resin (6.4 mmol) and LiOH (29 mg, 1.2 mmol). This yielded 335 mg of 90 (0.4 mmol, 
quant.) as colourless frothy solid. 
MS (pos. ESI, H2O/MeCN/TFA): m/z (%) = 410.8 [(A3-+5H+)2+] (60), 413.8 [(A3-
+Li++4H+)2+] (100), 416.8 [(A3-+2Li++3H+)2+] (80), 419.8 [(A3-+3Li++2H+)2+] (40), 820.7 
[(A3-+4H+)+] (55), 826.7 [(A3-+Li++3H+)+] (40), 832.7 [(A3-+2Li++2H+)+] (35), 826.7 [(A3-
+3Li++H+)+] (25); MS (neg. ESI, H2O/MeCN/TFA): m/z (%) = 932.7 [(A3-+CF3COO-
+3H+)-] (100), 938.7 [(A3-+CF3COO-+Li++2H+)-] (25), 1046.7 [(A3-+2CF3COO-
+Li++3H+)-] (30), 1052.6 [(A3-+2CF3COO-+2Li++2H+)-] (20), 1058.6 [(A3-+2CF3COO-
+3Li++H+)-] (10); MF: C34H58N17O7Li3; MW = 837.76 g/mol; 
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Li3[2-(Bis-carboxylate-methyl-amino)-4-[2-(4-{[4,6-bis-(1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-ethylcarbamoyl]-butanoate] 
(91): 
Synthesis followed GP 11 using 86 (471 mg, 0.4 mmol), 7.1 ml of ion-exchanger 
resin (6.4 mmol) and LiOH (29 mg, 1.2 mmol). This yielded 329 mg of 91 (0.4 mmol, 
quant.) as colourless frothy solid. 
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MS (pos. ESI, H2O/MeCN/TFA): m/z (%) = 403.8 [(A3-+5H+)2+] (65), 406.8 [(A3-
+Li++4H+)2+] (100), 409.8 [(A3-+2Li++3H+)2+] (85), 412.8 [(A3-+3Li++2H+)2+] (35), 806.7 
[(A3-+4H+)+] (50), 812.7 [(A3-+Li++3H+)+] (35), 818.7 [(A3-+2Li++2H+)+] (30), 824.7 [(A3- 
+3Li++H+)+] (20); MS (neg. ESI, H2O/MeCN/TFA): m/z (%) = 918.7 [(A3-+CF3COO-
+3H+)-] (100), 924.7 [(A3-+CF3COO-+Li++2H+)-] (20), 1032.7 [(A3-+2CF3COO-
+Li++3H+)-] (25), 1038.6 [(A3-+2CF3COO-+2Li++2H+)-] (30), 1044.6 [(A3-+2CF3COO-
+3Li++H+)-] (15); MF: C33H56N17O7Li3; MW = 823.74 g/mol; 
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Li3[2-(Bis-carboxylate-methyl-amino)-4-[3-(4-{[4,6-bis-(1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-propylcarbamoyl]-butanoate] 
(92): 
Synthesis followed GP 11 using 87 (510 mg, 0.43 mmol), 7.6 ml of ion-exchanger 
resin (6.88 mmol) and LiOH (31 mg, 1.29 mmol). This yielded 360 mg of 92 
(0.43 mmol, quant.) as colourless frothy solid. 
MS (pos. ESI, H2O/MeCN/TFA): m/z (%) = 410.8 [(A3-+5H+)2+] (65), 413.8 [(A3-
+Li++4H+)2+] (100), 416.8 [(A3-+2Li++3H+)2+] (85), 419.8 [(A3-+3Li++2H+)2+] (35), 820.7 
[(A3-+4H+)+] (50), 826.7 [(A3-+Li++3H+)+] (35), 832.7 [(A3-+2Li++2H+)+] (30), 826.7 [(A3-
+3Li++H+)+] (20); MS (neg. ESI, H2O/MeCN/TFA): m/z (%) = 932.7 [(A3-+CF3COO-
+3H+)-] (100), 938.7 [(A3-+CF3COO-+Li++2H+)-] (20), 1046.7 [(A3-+2CF3COO-
+Li++3H+)-] (25), 1052.6 [(A3-+2CF3COO-+2Li++2H+)-] (30), 1058.6 [(A3-+2CF3COO-
+3Li++H+)-] (15); MF: C34H58N17O7Li3; MW = 837.76 g/mol; 
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Li3[2-(Bis-carboxylate-methyl-amino)-6-[3-(1-{2-[4,6-bis-(1,4,7,10tetraaza-cyclo-
dodec-1-yl)-[1,3,5]triazin-2-ylamino]-ethyl}-1H-[1,2,3]triazol-4-yl)-propionylamino]-
hexanoate] (93): 
Synthesis followed GP 11 using 88 (749 mg, 0.66 mmol), 11.7 ml of ion-exchanger 
resin (10.56 mmol) and LiOH (48 mg, 2.00 mmol). This yielded 571 mg of 93 
(0.66 mmol, quant.) as colourless frothy solid. 
MS (pos. ESI, MeCN/H2O): m/z (%) = 424.8 [(A3-+5H+)2+] (15), 427.8 [(A3-
+Li++4H+)2+] (25), 430.9 [(A3-+2Li++3H+)2+] (100), 433.9 [(A3-+3Li++2H+)2+] (30), 848.7 
[(A3-+4H+)+] (5), 854.7 [(A3-+Li++3H+)+] (4), 860.8 [(A3-+2Li++2H+)+] (4), 866.8 [(A3-
+3Li++H+)+] (3); MS (neg. ESI, H2O/MeCN): m/z (%) = 422.9 [(A3-+H+)2-] (20), 846.8 
[(A3-+2H+)-] (100), 852.8 [(A3-+Li++H+)-] (30), 858.8 [(A3-+2 Li+)-] (20); 
MF: C36H62N17O7Li3; MW = 865.82 g/mol; 
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Li3[2-(Bis-carboxylate-methyl-amino)-6-[4-(4-{[4,6-bis-(1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)butyrylamino]hexanoate] (94): 
Synthesis followed GP 11 using 89 (591 mg, 0.52 mmol), 9.2 ml of ion-exchanger 
resin (8.32 mmol) and LiOH (38 mg, 1.59 mmol). This yielded 450 mg of 94 
(0.52 mmol, quant.) as colourless frothy solid. 
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MS (pos. ESI, MeCN/H2O): m/z (%) = 424.8 [(A3-+5H+)2+] (100), 427.8 [(A3-
+Li++4H+)2+] (75), 430.9 [(A3-+2Li++3H+)2+] (70), 433.9 [(A3-+3Li++2H+)2+] (20), 848.6 
[(A3-+4H+)+] (15), 854.6 [(A3-+Li++3H+)+] (10), 860.7 [(A3-+2Li++2H+)+] (5); MS (neg. 
ESI, H2O/MeCN): m/z (%) = 422.9 [(A3-+H+)2-] (20), 846.8 [(A3-+2H+)-] (100), 852.8 
[(A3-+Li++H+)-] (30), 858.8 [(A3-+2 Li+)-] (20); MF: C36H62N17O7Li3; MW = 865.82 g/mol; 
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Zn3[2-(Bis-carboxylate-methyl-amino)-4-[(1-{3-[4,6-bis-(1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-ylamino]-propyl}-1H-[1,2,3]triazol-4-ylmethyl)-carbamoyl]-
butanoate] te] di-perchlorate hydroxide di-hydrate (95): 
Synthesis followed GP 12 using 90 (335 mg, 0.40 mmol) and Zn(ClO4)2 x 6 H2O 
(492 mg, 1.32 mmol). This yielded 95 (364 mg, 0.29 mmol, 72 %) as colourless solid. 
Mp: > 250 °C; MS (pos. ESI, H2O/MeCN): m/z (%) = 503.8 [(K3+-H+)2+] (100), 512.8 
[(K3++OH-)2+] (70), 553.8 [(K3++ClO4-)2+] (20); UV/Vis (H2O): λ (lg ε) = 222 nm (4.663); 
IR (KBr): ν  [cm-1] = 3422, 3272, 2934, 2889, 2362, 2341, 1596, 1561, 1425, 1347, 
1286, 1090, 978, 805; MF: [C34H58N17O7Zn3]3+(ClO4)2(OH) x 2 H2O; 
MW = 1265.02 g/mol; 
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Zn3[2-(Bis-carboxylate-methyl-amino)-4-[3-(4-{[4,6-bis-(1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-ethylcarbamoyl]-butanoate] 
di-perchlorate hydroxide di-hydrate (96): 
Synthesis followed GP 12 using 91 (329 mg, 0.40 mmol) and Zn(ClO4)2 x 6 H2O 
(492 mg, 1.32 mmol). This yielded 96 (370 mg, 0.30 mmol, 74 %) as colourless solid. 
Mp: > 250 °C; MS (pos. ESI, H2O/MeCN): m/z (%) = 496.8 [(K3+-H+)2+] (100), 505.8 
[(K3++OH-)2+] (25), 992.4 [(K3+-2H+)+] (5), 1092.4 [(K3++ClO4--H+)+] (12); MS (neg. ESI, 
H2O/MeCN): m/z (%) = 544.7 [(K3++ClO4--4 H+)2-] (100); UV/Vis (H2O): λ (lg ε) = 
222 nm (4.655); IR (KBr): ν  [cm-1] = 3424, 3273, 2933, 2890, 2361, 2340, 1596, 
1562, 1426, 1346, 1286, 1091, 978, 806; MF: [C33H56N17O7Zn3]3+(ClO4)2(OH) x 
2 H2O; MW = 1251.00 g/mol; 
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Zn3[2-(Bis-carboxylate-methyl-amino)-4-[3-(4-{[4,6-bis-(1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-propylcarbamoyl]-butanoate] 
di-perchlorate hydroxide di-hydrate (97): 
Synthesis followed GP 12 using 92 (360 mg, 0.43 mmol) and Zn(ClO4)2 x 6 H2O 
(528 mg, 1.42 mmol). This yielded 97 (408 mg, 0.32 mmol, 75 %) as colourless solid. 
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Mp: > 250 °C; MS (pos. ESI, H2O/MeCN): m/z (%) = 503.8 [(K3+-H+)2+] (100), 512.8 
[(K3++OH-)2+] (100), 553.8 [(K3++ClO4-)2+] (15), 1124.3 [(K3++OH-+ClO4-)+] (8); UV/Vis 
(H2O): λ (lg ε) = 222 nm (4.653); IR (KBr): ν  [cm-1] = 3423, 3272, 2934,              
2889, 2361, 2341, 1596, 1561, 1426, 1347, 1286, 1090, 978, 805; 
MF: [C34H58N17O7Zn3]3+(ClO4)2(OH) x 2 H2O; MW = 1265.02 g/mol; 
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Zn3[2-(Bis-carboxylate-methyl-amino)-6-[3-(1-{2-[4,6-bis-(1,4,7,10tetraaza-
cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-ethyl}-1H-[1,2,3]triazol-4-yl)-
propionylamino]-hexanoate] di-perchlorate hydroxide di-hydrate (98): 
Synthesis followed GP 12 using 93 (571 mg, 0.66 mmol) and Zn(ClO4)2 x 6 H2O 
(811 mg, 2.18 mmol). This yielded 98 (648 mg, 0.50 mmol, 76 %) as colourless solid. 
Mp: > 250 °C; MS (pos. ESI, H2O/MeCN): m/z (%) = 517.9 [(K3+-H+)2+] (100), 526.9 
[(K3++OH-)2+] (25), 547.9 [(K3++CH3COO-)2+] (80), 567.9 [(K3++ClO4-)2+] (30); UV/Vis 
(H2O): λ (lg ε) = 222 nm (4.656); IR (KBr): ν  [cm-1] = 3423, 3272, 2934, 2889,    
2361, 2341, 1596, 1561, 1426, 1347, 1286, 1090, 978, 805; 
MF: [C36H62N17O7Zn3]3+(ClO4)2(OH) x 2 H2O; MW = 1293.08 g/mol; 
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Zn3[2-(Bis-carboxylate-methyl-amino)-6-[4-(4-{[4,6-bis-(1,4,7,10tetraaza-cyclododec-
1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-butyrylamino]-hexanoate] di-
perchlorate hydroxide di-hydrate (99): 
Synthesis followed GP 12 using 94 (450 mg, 0.52 mmol) and Zn(ClO4)2 x 6 H2O 
(639 mg, 1.72 mmol). This yielded 99 (497 mg, 0.38 mmol, 74 %) as colourless solid. 
Mp: > 250 °C; MS (pos. ESI, H2O/MeCN): m/z (%) = 517.9 [(K3+-H+)2+] (100), 526.9 
[(K3++OH-)2+] (30), 547.9 [(K3++CH3COO-)2+] (20), 567.9 [(K3++ClO4-)2+] (20); UV/Vis 
(H2O): λ (lg ε) = 222 nm (4.658); IR (KBr): ν  [cm-1] = 3423, 3272, 2934,              
2889, 2361, 2341, 1596, 1561, 1426, 1347, 1286, 1090, 978, 805;  
MF: [C36H62N17O7Zn3]3+(ClO4)2(OH) x 2 H2O; MW = 1293.08 g/mol; 
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N,N’-Di-Boc-N-(1-{3-[4,6-Bis-(4,7,10-tri-tert-butoxycarbonyl-1,4,7,10tetraaza-
cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-propyl}-1H-[1,2,3]triazol-4-ylmethyl)-
guanidine (100): 
Synthesis followed GP 13 using 54 (159 mg, 0.54 mmol), 17 (600 mg, 0.54 mmol), 
sodium ascorbate (212 mg, 1.07 mmol, 2 eq) and CuSO4 x 5 H2O (134 mg, 
0.54 mmol, 1 eq). This yielded 692 mg (0.49 mmol, 91 %) of 100 as a colourless 
solid. Rf (EE:PE = 4:1) = 0.54. 
 194
Mp: 205 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.36 (bs, 36 H, Boc-CH3), 1.38 (s, 
18 H, Boc-CH3), 1.41 (s, 9 H, Boc-CH3), 1.44 (s, 9 H, Boc-CH3), 2.09 (tt, 3J = 6.5 Hz, 
2 H, C3H2), 3.24 – 3.59 (m, 34 H, cyclen-CH2 + C4H2), 4.38 (t, 3J = 6.5 Hz, 2 H, 
C2H2), 4.63 (d, 3J = 5.1 Hz, 2 H, C1H2), 4.83 – 4.88 (m, 1 H, NH), 7.54 (bs, 1 H, 
triazole), 8.72 (t, 3J = 5.0 Hz, 1 H, NH), 11.38 (s, 1 H, Boc-NH); 13C-NMR (75.5 MHz, 
CDCl3): δ [ppm] = 28.0 (+, 3 C, Boc-CH3), 28.3 (+, 3 C, Boc-CH3), 28.5 (2 close 
signals, +, 18 C, Boc-CH3), 30.8 (–, 1 C, C3), 36.5 (–, 1 C, C4), 37.5 (–, 1 C,  C1), 47.8 
(–, 1 C, C2), 50.3 (–, 16 C, cyclen), 79.3 (Cquat, 1 C, Boc), 79.7 (Cquat, 4 C, Boc), 79.9 
(Cquat, 2 C, Boc), 83.2 (Cquat, 1 C, Boc), 122.3 (+, 1 C, triazole), 143.8 (Cquat, 1 C, 
triazole), 152.9 (Cquat, 1 C, urethane), 156.0 (Cquat, 1 C, urethane), 156.3 (Cquat, 6 C, 
urethane), 163.4 (Cquat, 1 C, guanidine), 165.9 (Cquat, 1 C, triazine), 166.4 (Cquat, 2 C, 
triazine); MS (ESI, DCM/MeOH): m/z (%) = 1418.2 [MH+] (100), 709.7 [(M+2H+)2+] 
(75), 659.7 [(M+3H+-CO2-(C4H8)+)2+] (60), 609.7 [(M+4H+-2CO2-2(C4H8)+)2+] (60), 
559.7 [(M+5H+-3CO2-3(C4H8)+)2+] (40); EA (C66H116N18O16) calc.: C 55.91, H 8.25, N 
17.78, found: C 55.61, H 8.49, N 17.53; UV/Vis (CH3CN): λ (lg ε) = 230 nm (4.803); 
IR (KBr): ν  [cm-1] = 3437, 3340, 3137, 2974, 2933, 1693, 1632, 1540, 1478, 1412, 
1367, 1250, 1165; MF: C66H116N18O16; MW = 1417.76 g/mol; 
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N,N’-Di-Boc-N-[2-(4-{[4,6-Bis-(4,7,10-tri-tert-butoxycarbonyl-1,4,7,10tetraaza-cyclo-
dodec-1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-ethyl]-guanidine (101): 
Synthesis followed GP 13 using 50 (214 mg, 0.65 mmol), 22 (700 mg, 0.65 mmol), 
sodium ascorbate (258 mg, 1.30 mmol, 2 eq) and CuSO4 x 5 H2O (163 mg, 
0.65 mmol, 1 eq). This yielded 821 mg (0.58 mmol, 90 %) of 101 as a colourless 
solid. Rf (EE:PE = 4:1) = 0.53. 
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Mp: 211°C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.36 (bs, 36 H, Boc-CH3), 1.38 (s, 
18 H, Boc-CH3), 1.40 (s, 9 H, Boc-CH3), 1.43 (s, 9 H, Boc-CH3), 3.22 – 3.57 (m, 32 H, 
cyclen-CH2), 3.86 (dt, 3J = 5.8 Hz, 2 H, C1H2), 4.48 (t, 3J = 5.9 Hz, 2 H, C2H2), 4.55 – 
4.57 (m, 2 H, C3H2), 5.14 – 5.23 (m, 1 H, NH), 7.63 (bs, 1 H, triazole), 8.51 (t, 3J = 
5.6 Hz, 1 H, NH), 11.38 (s, 1 H, Boc-NH); 13C-NMR (75.5 MHz, CDCl3): δ [ppm] = 
28.0 (+, 3 C, Boc-CH3), 28.2 (+, 3 C, Boc-CH3), 28.4 (2 close signals, +, 18 C, Boc-
CH3), 36.3 (–, 1 C, C3), 40.5 (–, 1 C,  C1), 49.1 (–, 1 C, C2), 50.2 (–, 16 C, cyclen), 
79.4 (Cquat, 1 C, Boc), 79.7 (Cquat, 4 C, Boc), 79.8 (Cquat, 2 C, Boc), 83.3 (Cquat, 1 C, 
Boc), 122.5 (+, 1 C, triazole), 146.0 (Cquat, 1 C, triazole), 152.8 (Cquat, 1 C, urethane), 
156.3 (Cquat, 7 C, urethane), 163.3 (Cquat, 1 C, guanidine), 165.6 (Cquat, 1 C, triazine), 
166.4 (Cquat, 2 C, triazine); MS (ESI, MeCN/H2O): m/z (%) = 1404.2 [MH+] (100), 
702.7 [(M+2H+)2+] (40), 652.7 [(M+3H+-CO2-(C4H8)+)2+] (70), 602.6 [(M+4H+-2CO2-
2(C4H8)+)2+] (90), 552.6 [(M+5H+-3CO2-3(C4H8)+)2+] (50), 502.5 [(M+6H+-4CO2-
4(C4H8)+)2+] (50); EA (C65H114N18O16) calc.: C 55.62, H 8.19, N 17.96, found: C 55.37, 
H 8.43, N 17.69; UV/Vis (CH3CN): λ (lg ε) = 230 nm (4.796); IR (KBr): ν  [cm-1] = 
3437, 3340, 3139, 2976, 2936, 1694, 1633, 1541, 1478, 1412, 1367, 1250, 1165; 
MF: C65H114N18O16; MW = 1403.73 g/mol; 
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N,N’-Di-Boc-N-[3-(4-{[4,6-Bis-(4,7,10-tri-tert-butoxycarbonyl-1,4,7,10tetraaza-
cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-[1,2,3]triazol-1-yl)-propyl]- 
guanidine (102): 
Synthesis followed GP 13 using 51 (172 mg, 0.50 mmol), 22 (541 mg, 0.50 mmol), 
sodium ascorbate (199 mg, 1.01 mmol, 2 eq) and CuSO4 x 5 H2O (126 mg, 
0.50 mmol, 1 eq). This yielded 654 mg (0.46 mmol, 92 %) of 102 as a colourless 
solid. Rf (EE:PE = 4:1) = 0.54. 
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Mp: 205 °C; 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.35 (bs, 36 H, Boc-CH3), 1.38 (s, 
18 H, Boc-CH3), 1.42 (s, 9 H, Boc-CH3), 1.42 (s, 9 H, Boc-CH3), 2.13 (tt, 3J = 6.7 Hz, 
2 H, C2H2), 3.24 – 3.56 (m, 34 H, cyclen-CH2 + C1H2), 4.35 (t, 3J = 6.8 Hz, 2 H, 
C3H2), 4.54 – 4.56 (m, 2 H, C4H2), 5.21 – 5.24 (m, 1 H, NH), 7.82 (bs, 1 H, triazole), 
8.41 (t, 3J = 5.6 Hz, 1 H, NH), 11.41 (s, 1 H, Boc-NH); 13C-NMR (75.5 MHz, CDCl3): 
δ [ppm] = 28.0 (+, 3 C, Boc-CH3), 28.2 (+, 3 C, Boc-CH3), 28.4 (2 close signals, +, 
18 C, Boc-CH3), 30.2 (–, 1 C, C2), 36.3 (–, 1 C, C4), 37.5 (–, 1 C,  C1), 47.5 (–, 1 C, 
C3), 50.2 (–, 16 C, cyclen), 79.2 (Cquat, 1 C, Boc), 79.7 (Cquat, 4 C, Boc), 79.8 (Cquat, 
2 C, Boc), 83.2 (Cquat, 1 C, Boc), 122.4 (+, 1 C, triazole), 145.7 (Cquat, 1 C, triazole), 
153.1 (Cquat, 1 C, urethane), 156.3 (Cquat, 6 C, urethane), 156.4 (Cquat, 1 C, urethane), 
163.4 (Cquat, 1 C, guanidine), 165.5 (Cquat, 1 C, triazine), 166.1 (Cquat, 2 C, triazine); 
MS (ESI, DCM/MeOH): m/z (%) = 1418.2 [MH+] (80), 709.7 [(M+2H+)2+] (100), 659.7 
[(M+3H+-CO2-(C4H8)+)2+] (70), 609.7 [(M+4H+-2CO2-2(C4H8)+)2+] (60), 559.7 [(M+5H+-
3CO2-3(C4H8)+)2+] (30), 509.7 [(M+6H+-4CO2-4(C4H8)+)2+] (25); EA (C66H116N18O16) 
calc.: C 55.91, H 8.25, N 17.78, found: C 55.71, H 8.51, N 17.67; UV/Vis (CH3CN): 
λ (lg ε) = 230 nm (4.809); IR (KBr): ν  [cm-1] = 3437, 3340, 3137, 2974, 2933,     
1693, 1632, 1540, 1478, 1412, 1367, 1250, 1165; MF: C66H116N18O16; 
MW = 1417.76 g/mol; 
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N-(1-{3-[4,6-Bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-propyl}-
1H-[1,2,3]triazol-4-ylmethyl)-guanidinium hexa-hydrochloride (103): 
Synthesis followed GP 10 using 100 (612 mg, 0.43 mmol) and 23 ml of HCl-saturated 
diethylether. This gave 103 as hygroscopic, colourless solid (361 mg, 0.43 mmol, 
100 %). 
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Mp: > 250 °C; 1H-NMR (300 MHz, D2O): δ [ppm] = 2.14 (tt, 3J = 6.7 Hz, 2 H, C3H2), 
3.14 – 3.35 (m, 24 H, cyclen-CH2), 3.40 (t, 3J = 6.7 Hz, 2 H, C4H2), 3.78 – 3.82 (m, 
8 H, cyclen-CH2), 4.42 (t, 3J = 6.7 Hz, 2 H, C2H2), 4.42 (s, 2 H, C1H2), 7.95 (s, 1 H, 
triazole); 13C-NMR (75.5 MHz, D2O): δ [ppm] = 28.8 (–, 1 C, C3), 36.3 (–, 1 C, C4), 
37.9 (–, 1 C,  C1), 44.4 (–, 8 C, cyclen), 46.5 (–, 4 C, cyclen), 48.1 (–, 5 C, cyclen + 
C2), 124.3 (+, 1 C, triazole), 143.1 (Cquat, 1 C, triazole), 155.5 (Cquat, 2 C, triazine), 
157.0 (Cquat, 1 C, guanidine), 163.2 (very broad signal, Cquat, 1 C, triazine); MS (ESI, 
H2O/MeCN): m/z (%) = 309.3 [(M+2H+)2+] (65), 220.2 [(M+MeCN+3H+)3+] (45), 206.6 
[(M+3H+)3+] (100); MF: C26H58N18Cl16; MW = 835.59 g/mol; 
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N-[2-(4-{[4,6-Bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-
[1,2,3]triazol-1-yl)-ethyl]-guanidinium hexa-hydrochloride (104): 
Synthesis followed GP 10 using 101 (600 mg, 0.43 mmol) and 23 ml of HCl-saturated 
diethylether. This gave 104 as hygroscopic, colourless solid (355 mg, 0.43 mmol, 
100 %). 
Mp: > 250 °C; 1H-NMR (300 MHz, D2O): δ [ppm] = 3.12 – 3.33 (m, 24 H, cyclen-CH2), 
3.60 (t, 3J = 5.5 Hz, 2 H, C1H2), 3.80 – 3.85 (m, 8 H, cyclen-CH2), 4.50 (t, 3J = 5.5 Hz, 
2 H, C2H2), 4.67 (s, 2 H, C3H2), 7.97 (s, 1 H, triazole); 13C-NMR (75.5 MHz, D2O): 
δ [ppm] = 35.8 (–, 1 C, C3), 41.0 (–, 1 C,  C1), 44.4 (–, 8 C, cyclen), 46.3 (–, 4 C, 
cyclen), 48.1 (–, 4 C, cyclen), 49.4 (–, 1 C, C2), 124.7 (+, 1 C, triazole), 144.6 (Cquat, 
1 C, triazole), 155.6 (Cquat, 2 C, triazine), 156.9 (Cquat, 1 C, guanidine), 163.7 (very 
broad signal, Cquat, 1 C, triazine); MS (ESI, H2O/MeCN): m/z (%) = 302.3 [(M+2H+)2+] 
(90), 215.6 [(M+MeCN+3H+)3+] (100), 201.9 [(M+3H+)3+] (50); MF: C25H56N18Cl16; 
MW = 821.56 g/mol; 
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N-[3-(4-{[4,6-Bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-methyl}-
[1,2,3]triazol-1-yl)-propyl]-guanidinium hexa-hydrochloride (105): 
Synthesis followed GP 10 using 102 (620 mg, 0.44 mmol) and 24 ml of HCl-saturated 
diethylether. This gave 105 as hygroscopic, colourless solid (365 mg, 0.44 mmol, 
100 %). 
Mp: > 250 °C; 1H-NMR (300 MHz, D2O): δ [ppm] = 2.10 (tt, 3J = 6.7 Hz, 2 H, C2H2), 
3.10 (t, 3J = 6.7 Hz, 2 H, C1H2), 3.11 – 3.40 (m, 24 H, cyclen-CH2), 3.82 – 3.88 (m, 
8 H, cyclen-CH2), 4.41 (t, 3J = 6.7 Hz, 2 H, C3H2), 7.95 (s, 1 H, triazole), the signal of 
C4H2 was overlaid by the H2O-signal (proved by HSQC); 13C-NMR (75.5 MHz, D2O): 
δ [ppm] = 28.4 (–, 1 C, C2), 35.9 (–, 1 C, C4), 38.3 (–, 1 C,  C1), 43.9 – 44.5 (–, 8 C, 
cyclen), 46.2 (–, 4 C, cyclen), 47.8 (–, 1 C, C3), 48.0 (–, 4 C, cyclen), 124.1 (+, 1 C, 
triazole), 144.7 (Cquat, 1 C, triazole), 156.3 (Cquat, 2 C, triazine), 156.8 (Cquat, 1 C, 
guanidine), 164.0 (very broad signal, Cquat, 1 C, triazine); MS (ESI, H2O/MeCN/TFA): 
m/z (%) = 309.2 [(M+2H+)2+] (100), 220.1 [(M+MeCN+3H+)3+] (10), 206.4 [(M+3 H+)3+] 
(15); MF: C26H58N18Cl16; MW = 835.59 g/mol; 
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Zn2[N-(1-{3-[4,6-Bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-
propyl}-1H-[1,2,3]triazol-4-ylmethyl)-guanidinium] tetra-perchlorate hydroxide (106): 
Synthesis followed GP 14, using 103 (350 mg, 0.42 mmol). This gave 106 as a 
hygroscopic, colourless solid (423 mg, 0.35 mmol, 84 %). 
Mp: > 250 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.15 (tt, 3J = 6.7 Hz, 2 H, 
C3H2), 2.70 – 3.15 (m, 24 H, cyclen-CH2), 3.29 – 3.39 (m, 4 H, cyclen-CH2), 3.42 (dt, 
3J = 6.1 Hz, 3J = 6.7 Hz, 2 H, C4H2), 3.50 – 3.57 (bs, 6 H, cyclen-NH), 4.22 – 4.34 (m, 
4 H, cyclen-CH2), 4.42 – 4.46 (m, 4 H, C1H2 + C2H2), 6.34 (bs, 4 H, guanidine-NH), 
6.36 (t, 3J = 6.1 Hz, 1 H, NH), 6.76 (t, 3J = 5.9 Hz, 1 H, NH), 7.88 (s, 1 H, triazole); 
13C-NMR (75.5 MHz, CD3CN): δ [ppm] = 29.4 (–, 1 C, C3), 36.4 (–, 1 C, C4), 37.4 (–, 
1 C, C1), 43.1 (–, 4 C, cyclen), 45.0 (–, 2 C, cyclen), 45.2 (–, 2 C, cyclen), 46.0 (–, 
2 C, cyclen), 46.1 (–, 2 C, cyclen), 46.4 (–, 2 C, cyclen), 46.5 (–, 2 C, cyclen), 47.7 (–, 
1 C, C2), 123.3 (+, 1 C, triazole), 142.1 (Cquat, 1 C, triazole), 157.1 (Cquat, 1 C, 
guanidine), 165.6 (Cquat, 1 C, triazine), 169.4 (Cquat, 1 C, triazine), 169.9 (Cquat, 1 C, 
triazine); MS (ESI, H2O/MeCN): m/z (%) = 247.7 [(K4+-H+-H2O)3+] (20), 253.7 [(K4+-
H+)3+] (20), 421.2 [(K4+-H+-H2O+ClO4-)2+] (100); UV/Vis (CH3CN): λ (lg ε) = 222 nm 
(4.643); IR (KBr): ν  [cm-1] = 3375, 3292, 2940, 2890, 2717, 2022, 1662, 1562, 1474, 
1346; MF: [C26H54N18OZn2]4+ (ClO4-)4 x 2 H2O; MW = 1199.43 g/mol; 
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Zn2[N-[2-(4-{[4,6-Bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-
methyl}-[1,2,3]triazol-1-yl)-ethyl]-guanidinium] tetra-perchlorate hydroxide (107): 
Synthesis followed GP 14, using 104 (350 mg, 0.42 mmol). This gave 107 as a 
hygroscopic, colourless solid (423 mg, 0.36 mmol, 85 %). 
Mp: > 250 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.68 – 3.45 (m, 30 H, cyclen-
NH + cyclen-CH2), 3.60 – 3.70 (m, 4 H, cyclen-CH2 + C1H2), 3.98 – 4.06 (m, 2 H, 
cyclen-CH2), 4.37 – 4.68 (m, 8 H, cyclen-CH2 + C2H2 + C3H2), 6.20 (bs, 4 H, 
guanidine-NH), 6.51 (t, 3J = 6.1 Hz, 1 H, NH), 6.63 (t, 3J = 5.9 Hz, 1 H, NH), 7.84 (s, 
1 H, triazole); 13C-NMR (75.5 MHz, CD3CN): δ [ppm] = 35.3 (–, 1 C, C3), 41.0 (–, 1 C,  
C1), 42.9 (–, 2 C, cyclen), 43.0 (–, 2 C, cyclen), 45.7 (–, 2 C, cyclen), 45.9 – 46.4 (–, 
8 C, cyclen), 46.6 (–, 2 C, cyclen), 48.4 (–, 1 C, C2), 123.5 (+, 1 C, triazole), 145.2 
(Cquat, 1 C, triazole), 156.7 (Cquat, 1 C, guanidine), 165.6 (Cquat, 1 C, triazine), 169.4 
(Cquat, 2 C, triazine); MS (ESI, H2O/MeCN): m/z (%) = 243.1 [(K4+-H+-H2O)3+] (25), 
249.1 [(K4+-H+)3+] (20), 414.2 [(K4+-H+-H2O+ClO4-)2+] (100); UV/Vis (CH3CN): λ (lg ε) 
= 222 nm (4.653); IR (KBr): ν  [cm-1] = 3375, 3296, 2942, 2893, 2719, 2023, 1663, 
1562, 1475, 1346; MF: [C25H52N18OZn2]4+ (ClO4-)4 x 2 H2O; MW = 1185.40 g/mol; 
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Zn2[N-[3-(4-{[4,6-Bis-(1,4,7,10tetraaza-cyclododec-1-yl)-[1,3,5]triazin-2-ylamino]-
methyl}-[1,2,3]triazol-1-yl)-propyl]-guanidinium] tetra-perchlorate hydroxide (108): 
Synthesis followed GP 14, using 105 (365 mg, 0.44 mmol). This gave 108 as a 
hygroscopic, colourless solid (459 mg, 0.38 mmol, 87 %). 
Mp: > 250 °C; 1H-NMR (300 MHz, CD3CN): δ [ppm] = 2.10 (tt, 3J = 6.7 Hz, 2 H, 
C2H2), 2.65 – 3.20 (m, 26 H, C1H2 + cyclen-CH2), 3.29 – 3.39 (m, 4 H, cyclen-CH2), 
3.50 – 3.57 (bs, 6 H, cyclen-NH), 4.22 – 4.34 (m, 4 H, cyclen-CH2), 4.43 (t, 3J = 
6.7 Hz, 2 H, C3H2), 4.71 – 4.85 (m, 2 H, C4H2), 6.34 (bs, 4 H, guanidine-NH), 6.48 (t, 
3J = 5.9 Hz, 1 H, NH), 6.96 (t, 3J = 5.7 Hz, 1 H, NH), 7.81 (s, 1 H, triazole); 13C-NMR 
(75.5 MHz, CD3CN): δ [ppm] = 28.8 (–, 1 C, C2), 37.2 (–, 1 C, C4), 38.4 (–, 1 C,  C1), 
43.2 (–, 4 C, cyclen), 45.1 (–, 2 C, cyclen), 45.3 (–, 2 C, cyclen), 46.0 (–, 2 C, cyclen), 
46.2 (–, 2 C, cyclen), 46.4 (–, 2 C, cyclen), 46.5 (–, 2 C, cyclen), 47.9 (–, 1 C, C3), 
123.5 (+, 1 C, triazole), 142.2 (Cquat, 1 C, triazole), 157.2 (Cquat, 1 C, guanidine), 
165.5 (Cquat, 1 C, triazine), 169.5 (Cquat, 1 C, triazine), 169.8 (Cquat, 1 C, triazine); MS 
(ESI, H2O/MeCN): m/z (%) = 247.7 [(K4+-H+-H2O)3+] (25), 253.7 [(K4+-H+)3+] (25), 
421.2 [(K4+-H+-H2O+ClO4-)2+] (100); UV/Vis (CH3CN): λ (lg ε) = 222 nm (4.648); IR 
(KBr): ν  [cm-1] = 3375, 3292, 2940, 2890, 2717, 2022, 1662, 1562, 1474, 1346; 
MF: [C26H54N18OZn2]4+ (ClO4-)4 x 2 H2O; MW = 1199.43 g/mol; 
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Li[Cu(2-(Bis-carboxylate-methyl-amino)-4-{2-[4-(4-(Zn[10,15,20-tris-(4-carboxy-
phenyl)-porphyrin])-5-yl-phenoxymethyl)-2,3-dihydro-[1,2,3]triazol-1-yl]-
ethylcarbamoyl}-butanoate)] di-perchlorate hydroxide di-hydrate (109): 
The Zn(II)-porphyrin 62 (140 mg, 0.16 mmol) was suspended in water (4 ml). A sat. 
aq. solution of NaHCO3 was added dropwise until 62 was dissolved completely. 
Then, the Cu(II)-NTA-complex 41 (78 mg, 0.18 mmol, 1.1 eq) was added. Aqueous 
stock solutions of CuSO4 x 5 H2O (c = 0.01 mol/l) and sodium ascorbate (c = 
0.04 mol/l) were prepared. Aliquots of 270 µl of both solutions were added to the 
reaction mixture three times in intervals of 3 h. This corresponded to an altogether 
addition of 5 mol% of copper sulfate (0.7 mg, 2.7 µmol) and 20 mol% sodium 
ascorbate (2.1 mg, 10.8 µmol). The mixture was stirred at r.t. for an altogether time of 
24 h and then acidified carefully with 1 N aq. HCl until 109 was precipitated 
completely. Fast addition and excesses of aq. HCl were avoided as this could result 
in a cleavage of the phenyl ether. The product was separated from the solution after 
centrifugation, washed with water and MeOH and dried in vacuum. This yielded 
191 mg (0.15 mmol, 90 %) of 109 as dark red solid. 
MS (neg. ESI, H2O/MeCN): m/z (%) = 626.3 [(M-H+)-] (40), 644.3 [(M+Cl-)-] (50), 
656.3 [(M+CH3COO-)-] (100), 1253.6 [A-] (40); UV/Vis (Hepes-buffer, pH 7.5, 
50 mM): λ (lg ε) = 308 nm (4.342), 423 nm (5.656), 558 nm (4.205), 599 nm (3.969); 
Fl (Hepes-buffer, pH 7.5, λex= 423 nm): λem (a.u.) = 609 nm (59), 660 nm (27); IR 
(KBr): ν  [cm-1] = 3406, 3071, 2966, 2926, 2802, 2523, 2081, 1604, 1384, 1244, 995; 
MF: C61H44N9O14ZnCuNa x 2 H2O; MW = 1314.97 g/mol; 
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3. Novel Bidentate Triazole Ligands and Complexes 
3.1. Introduction 
 
A large number of transition metal complexes (especially ruthenium(II)- and 
platinum(II)-complexes), based on the 2,2’-bipyridine (bpy) ligand and its derivatives 
have been in the focus of many investigations due to their potential as redox- and 
photo-catalysts.1 Because of their kinetic inertness, a large number of well defined 
dinuclear and polynuclear Ru(II)-complexes have been described.2 
Commonly, the [Ru(bpy)3]2+ and related octahedral d6 transition metal complexes are 
employed in studies about the properties of their excited state e.g. in photochemistry, 
chemiluminescence, electrochemiluminescence and electron-transfer chemistry.3 
These complexes are coordinatively saturated and therefore, their interactions and 
photochemical reactions are usually restricted to the outer-sphere. 
One of the most actual scientific investigation of these complexes is their application 
in the OLED-technology (Organic Light Emitting Diods).4 OLEDs have recently 
received increased attention due to their economic and fabrication advantages when 
compared to their inorganic semiconductor counterparts. Especially tris-chelated 
1,2-diimine Ru(II)- and Os(II)-complexes possess attractive advantages over e.g. 
polymers, which have been used for OLED applications so far.5 These advantages 
are: 
• high photoluminescence (PL) quantum yields  
• a large electronic stability 
• long excited state lifetimes 
• and further a facile synthesis and good chemical stability 
 
For example, the PL quantum yield of [Ru(bpy)3]2+ is Φ = 0.061 in MeCN solution at 
room temperature. This value increases up to 0.25, when the complex is used in 
electro-generated chemiluminescence (ECL) cells.6 
Recently, De Cola et. al reported about a white light emitting assembly of Ir(III)- and 
Eu(III)-complexes.7 The combination of the blue light emitting hetero-leptic 
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Ir(III)-pyridine-triazolyl complex8 1 with the red light emitting Eu(III)-terpyridine 
complex 2 in a 2:1 stoichiometry led to the white light emitting complex 3 (fig. 1). 
N
F
F
Ir
N
F F
N
N
N
N
O
OH
N
N N
Br BrO O O O
 
Eu
Cl
N
N N
Br BrO O O O
Eu
N
F
F
Ir
N
F F
N
N
N
N
O
O
N
F
F
Ir
N
FF
N
N
N
N
O
O
 
Na
+
1 2
+
-
3
 
Figure 1: Combination of the blue light emitting Ir(III)-complex 1 with the red light emitting Eu(III)-
complex 2 yields the white light emitting complex 3. 
As a white light emitting system is highly desired for applications in OLED-
applications,9 this kind of combination of two different metal complexes seems to be 
a promising approach. In particular, the exchange of a py- or bpy-ligand by a 
1,2,4-triazolyl-pyridine ligand (like in 1) is highly interesting, as this allows to shift the 
wavelength of the emitted light into the blue region (461 nm). Due to the structural 
 212
similarity, 1,4-disubstituted 1,2,3-triazole-ligands seem to be promising alternatives in 
these kinds of complexes, with interesting photophysical properties (fig. 2). 
N N N N
NN
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N N
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R R
bpy triazolyl-py bitriazole
_
 
Figure 2: The bpy, a triazolyl-py (1 of 5 mesomeric structures) and a bitriazole ligand. 
For this reason, novel bitriazole ligands and corresponding Ru(II)-complexes have 
been synthesized, using the “click-chemistry” approach.10 Further, the 
spectroscopical behaviour of these ligands and complexes has been investigated 
with UV/Vis- and fluorescence spectroscopy. 
 
3.2. Synthesis of [4,4’]-Bitriazole Ligandsa 
 
The desired bitriaziole-ligands were synthesized by a twofold Cu(I)-catalyzed 
cycloaddition between 1,3-butadiyne and organic azides (β-azido-acetic acid, 
benzylazide and phenylazide). The 1,3-butadiyne was freshly prepared from 1,4-
dichloro-butyne11 and reacted immediately with the azide compound in acetonitrile 
solution at basic conditions with catalytic amounts of copper iodide (scheme 1).  
In order to remove the present Cu+, which could form a complex with the synthesized 
bitriazole, a workup with aq. H2O2 (3%) and sat. aq. EDTA was necessary. After 
purification the bitriazole-ligands 4 – 6 were obtained in acceptable yields. 
                                                 
a
 Complex 7 and X-ray crystallographic data of 4 were obtained by Dr. Uwe Monkowius. 
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Scheme 1: Synthesis of the bitriazoles 4, 5 and 6. 
Investigation of the spectroscopic properties of 4 – 6 with UV/Vis and fluorescence 
spectroscopy showed no noticeable results. Compounds 5 and 6 showed absorption 
in the UV region between 220 – 260 nm. UV/Vis-spectrum of 4 was not detected as 
its solubility was limited to CHCl3. Compound 6 showed a very weak emission signal 
at 414 nm (λEx: 267 nm) in the fluorescence spectrum. 
Ligand 4 gave crystals of two different modifications – prisms (monoclinic space 
proup P21/c [Z=2]) and needles (monoclinic space group Cc [Z=4]). Crystallographic 
data for the first modification showed an asymmetric unit consisting of a half 
structural unit as this modification had an inversion center (fig 3). Data of the latter 
modification showed the whole molecule as asymmetric unit, as there was no 
inversion symmetry (fig. 4). 
 
Figure 3: X-ray structure of 4 (prismatic crystals). Carbon is coloured black, nitrogen is blue. 
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Figure 4: X-ray structure of 4 (needle crystals). 
Compounds 5 and 6 were obtained as colourless needles. The X-ray structure of 5 
showed the whole molecule as asymmetric unit (fig. 5), while the crystallographic 
data of 6 revealed an inversion center (fig. 6). 
 
Figure 5: X-ray structure of 5 (needle crystals). 
 
Figure 6: X-ray structure of 6 (needle crystals). Oxygen is coloured orange. 
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3.3. Synthesis of Complexes 
 
The synthesis of homoleptic Ru(II)-complexes from ligands 4 – 6 was carried out with 
RuCl3 x 4 H2O in boiling ethylene glycol solution. Precipitation of the complexes 7 – 9 
was achieved by addition of ethanol (scheme 2).  
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Scheme 2: Synthesis of homoleptic complexes 7, 8 and 9. 
Recrystallisation in ethylene glycol / ethanol yielded the complexes 7 – 9 as light 
yellow crystals, but only the crystals of compound 7 showed sufficient quality for 
X-ray crystallography (fig. 7). 
 
Figure 7: X-ray structure of 7 (counterions and solvent molecules are not shown for better clarity). 
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The UV/Vis-spectrum of compounds 8 and 9 in H2O showed two absorption signals 
between 225 – 240 nm and at approx. 300 nm (see exp. section for details). A weak 
emission signal was detected at 355 nm after excitation at 215 nm or 270 nm (fig. 8 
shows exemplary the spectra of 9). 
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Figure 8: On the left: absorption spectrum of 9 (c = 2.0 x 10-5 mol/L) in water.         
On the right: corresponding emission spectrum (λEx= 270 nm). 
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3.4. Summary and Outlook 
 
New 1,1’-disubstituted [4,4’]-bitriazole compounds have been synthesized using the 
Cu(I)-catalyzed cycloaddition between 1,4-butadiyne and various alkyl- and aryl-
triazoles.  
Ru(II)-complexes of the obtained ligands have been synthesized and their 
characteristics in the UV- and Fl-spectrum have been determined. 
In order to vary the properties of this class of ligands and complexes, several 
synthetical procedures are available: 
• Monosubstituted [4,4’]-bitriazoles can be obtained from 1,4-butadiyne and a 
mixture of alkyl azide and TMS-azide.12 This allows the formation of a 
triazolyl-anion after deprotonation of the unsubstituted triazole. 
• The use of 2,6-diethynyl-pyridine instead of 1,4-butadiyne would yield ligands 
which are comparable to terpyridines 
• The substitution of the triazole-CH allows further functionalisations. 13 
These procedures allow modifications of the ligands and the spectroscopic 
properties. Their transition metal complexes may be of interest for many 
applications. 
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3.5. Experimental Part 
3.5.1. General Information 
 
For all general information about synthesis and spectroscopy see chapter 2.6.1.! 
 
3.5.2. Synthesis of Triazole Ligands and Complexes 
3.5.2.1. General Procedures 
 
GP 1 – Twofold “click-reaction” with 1,3-butadiyne: 
The freshly prepared butadiyne was condensed into 5 ml of acetonitrile at – 40 °C. 
Following, a solution of the azide (2eq), 2,4-lutidine (2.2 eq) and CuI (10 mol %) in 
10 ml of acetonitrile was cooled to – 40 °C and added. The reaction mixture was 
allowed to warm to room temperature. The reaction vessel was stored in a closed 
autoclave to prevent evaporation of the butadiyne. After stirring for 20 h, the mixture 
was poured into 50 ml of an aq. solution of H2O2 (3 %). The mixture was stirred until 
the generation of gas had ended. Following, 50 ml of a sat. aq. solution of EDTA was 
added and the mixture was stirred for further 30 min. Further purification was 
individual for each compound. 
 
GP 2 – Synthesis of homoleptic Ru(II)-complexes: 
In a round bottom flask (25 ml) the bitriazole ligand (3 eq) and RuCl3 x 4 H2O were 
suspended in 10 ml of ethylene glycol. A reflux condenser was put on and the 
mixture was heated (oil bath temperature: 200 °C). This yielded a dark red solution 
which slowly turned to light orange within 20 h. The solution was concentrated in 
vacuum upon heating to 3 ml. Following, boiling ethanol was added to the solution at 
80 °C, until a white precipitate appeared. The mixture was stored in the freezer at 
- 20 °C during the night to complete precipitation. The solid was separated by 
centrifugation and dried in vacuum. 
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3.5.2.2. Synthesis of New Compounds 
 
 
N N
N
N N
N
 
 
1,1’-Dibenzyl-1H,1’H-[4,4’]bi[[1,2,3]bitriazolyl] 4: 
Synthesis followed GP 1 using butadiyne (563 mg, 11.3 mmol), benzyl azide 
(2996 mg, 22.5 mmol, 2 eq), 2,4-lutidine (2652 mg, 2.86 ml, 24.8 mmol, 2.2 eq) and 
CuI (214 mg, 1.13 mmol, 10 mol %). After workup, the aqueous solution was 
extracted with CHCl3 (3 x 100 ml). The organic phase was dried with Na2SO4, filtered 
and concentrated at reduced pressure. The crude product was purified by CC with 
DCM:MeOH from 99:1 to 96:4. This yielded 2931 mg of 4 as colourless crystals 
(9.3 mmol, 82 %). 
Mp: 228 °C; 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 5.67 (s, 4 H, CH2), 7.31 – 7.40 
(m, 10 H, CH), 8.58 (s, 2 H, triazole); 13C-NMR (75.5 MHz, DMSO-d6): δ [ppm] = 52.8 
(–, 2 C), 121.7 (+, 2 C, triazole), 127.9 (+, 4 C), 128.1 (+, 2 C), 128.7 (+, 4 C), 139.2 
(Cquat, 1 C), 142.2 (Cquat, 1 C); MS (ESI, DCM/MeOH): m/z (%) = 317.1 [MH+] (100); 
EA (C18H16N6) calc.: C 68.34, H 5.10, N 26.56, found: C 68.21, H 5.21, N 26.42; 
UV/Vis (CHCl3): no signal detectable; IR (KBr): ν  [cm-1] = 3133, 3101, 3031, 2984, 
2946, 2858, 1673, 1494, 1439, 1410, 1364, 1293, 1231, 1076, 1058, 949, 836, 722; 
MF: C18H16N6; MW = 316.37 g/mol; 
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1,1’-Diphenyl-1H,1’H-[4,4’]bi[[1,2,3]bitriazolyl] (5): 
Synthesis followed GP 1 using butadiyne (335 mg, 6.7 mmol), phenyl azide 
(1598 mg, 13.4 mmol, 2 eq), 2,4-lutidine (1579 mg, 1.70 ml, 14.8 mmol, 2.2 eq) and 
CuI (127 mg, 0.67 mmol, 10 mol %). After workup, the aqueous solution was heated 
to 40 °C and extracted with warm CHCl3 (40 °C, 8 x 80 ml). The organic phase was 
dried with Na2SO4, filtered, concentrated at reduced pressure and dried in vacuum. 
The residue was dissolved in boiling CHCl3, filtered over charcoal and cellite and 
concentrated again. The crude product was purified by recrystallisation from 
CHCl3/PE. This yielded 1468 mg of 5 as colourless crystals (5.1 mmol, 76 %). 
Mp: 236 °C; 1H-NMR (300 MHz, CHCl3): δ [ppm] = 7.49 (t, 3J = 7.7 Hz, 2 H, CH), 7.53 
– 7.59 (m, 4 H, CH), 7.82 (d, 3J = 7.6 Hz, 4 H, CH), 8.59 (s, 2 H, triazole); 13C-NMR 
(75.5 MHz, CHCl3): δ [ppm] = 118.9 (+, 2 C, triazole), 120.6 (+, 4 C), 129.0 (+, 2 C), 
129.9 (+, 4 C), 136.9 (Cquat, 1 C), 140.5 (Cquat, 1 C); MS (ESI, DCM/MeOH): m/z (%) 
= 289.1 [MH+] (100); EA (C16H12N6) calc.: C 66.66, H 4.20, N 29.15, found: C 66.57, 
H 4.31, N 29.01; UV/Vis (CH3CN): λ (lg ε) = 232 nm (4.480), 257 nm (4.366); IR 
(KBr): ν  [cm-1] = 3132, 3093, 3065, 1654, 1597, 1504, 1464, 1396, 1257, 1234, 
1034, 825, 756; MF: C16H12N6; MW = 288.31 g/mol; 
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(1’-Carboxymethyl-1’H-[4,4’]bi[[1,2,3]triazolyl]-1-yl)-acetic acid (6): 
Synthesis followed GP 1 using butadiyne (541 mg, 10.8 mmol), β-azidoacetic acid 
(2183 mg, 21.6 mmol, 2 eq), 2,4-lutidine (2546 mg, 2.75 ml, 23.8 mmol, 2.2 eq) and 
CuI (206 mg, 1.08 mmol, 10 mol %). After workup, the aqueous solution was acidified 
with 6 N aq. HCl to pH 2. The precipitate was filtered, washed with water and 
suspended in 10 ml water. A 0.1 N aq. solution of NaOH was added dropwise until 
the solid was dissolved completely. The solution was lyophilized to yield the sodium 
salt of 6 (2502 mg, 8.4 mmol, 78 %). NMR-, MS- and UV-spectroscopy were 
performed with this salt. The solid was dissolved in water (20 ml), the solution was 
heated to boiling and 0.5 N aq. HCl was added dropwise until a precipitate appeared. 
After cooling to room temperature, 2 N aq. HCl was added until no further product 
precipitated. The solid was filtered, washed with water and dried in vacuum. This 
yielded 2116 mg of 6 as colourless crystals (8.4 mmol, 78 %). 
Mp: > 215 °C (decomp.); 1H-NMR (300 MHz, D2O): δ [ppm] = 5.05 (s, 4 H, CH2), 8.20 
(s, 2 H, triazole); 13C-NMR (75.5 MHz, D2O): δ [ppm] = 53.3 (–, 2 C), 123.9 (+, 2 C, 
triazole), 138.6 (Cquat, 2 C), 173.1 (Cquat, 2 C); MS (ESI, H2O/MeCN): m/z (%) = 253.1 
[MH+] (100); EA (C8H8N6O4) calc.: C 38.10, H 3.20, N 33.32, found: C 37.97, H 3.32, 
N 33.17; UV/Vis (H2O): λ (lg ε) = 225 nm (4.092); IR (KBr): ν  [cm-1] = 3435, 3151, 
3117, 3013, 2947, 2792, 2708, 2594, 2511, 1930, 1794, 1724, 1496, 1420, 1347, 
1295, 1257, 1223, 1151, 1109, 1064, 1011, 976, 896, 795; MF: C8H8N6O4; 
MW = 252.16 g/mol; 
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Ru[tri-(1,1’-Diphenyl-1H,1’H-[4,4’]bi[[1,2,3]bitriazolyl])] di-chloride (8): 
Synthesis followed GP 2 using 5 (250 mg, 0.87 mmol) and RuCl3 x 4 H2O (78 mg, 
0.29 mmol). This yielded 665 mg of 8 as colourless crystals (0.64 mmol, 74 %). 
Mp: >210 °C (decomp.); 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.54 – 7.66 (m, 18 
H, CH), 7.89 (d, 3J = 7.1 Hz, 12 H, CH), 9.76 (s, 6 H, triazole); 13C-NMR (75.5 MHz, 
DMSO-d6): δ [ppm] = 120.1 (+, 2 C, triazole), 120.5 (+, 4 C), 129.9 (+, 2 C), 130.0 (+, 
4 C), 135.6 (Cquat, 1 C), 140.9 (Cquat, 1 C); MS (ESI, H2O/MeCN): m/z (%) = 483.2 
[(L3Ru2+)2+] (100), 1115.4 [(L3Ru2++TfO-)+]; UV/Vis (H2O): λ (lg ε) = 307 nm (4.517), 
239 (5.012); IR (KBr): ν  [cm-1] = 3102, 3062, 1595, 1499, 1464, 1422, 1313, 1271, 
1065, 999, 760; MF: C48H36N18RuCl2; MW = 1036.91 g/mol; 
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Ru[tri-((1’-Carboxymethyl-1’H-[4,4’]bi[[1,2,3]triazolyl]-1-yl)-acetic acid)] di-chloride (9): 
Synthesis followed GP 2 using 6 (250 mg, 0.99 mmol) and RuCl3 x 4 H2O (90 mg, 
0.33 mmol). This yielded 634 mg of 8 as colourless crystals (0.68 mmol, 69 %). 
Mp: >205 °C (decomp.); 1H-NMR (300 MHz, D2O): δ [ppm] = 5.22 (s, 12 H, CH2), 
8.50 (s, 6 H, CH); 13C-NMR (75.5 MHz, D2O): δ [ppm] = 51.5 (–, 6 C), 122.0 (+, 6 C, 
triazole), 138.2 (Cquat, 6 C), 171.0 (Cquat, 6 C); MS (ESI, H2O/MeCN): m/z (%) = 478.2 
(100), 507.2 (100), 521.3 (100), 955.3 (65); UV/Vis (H2O): λ (lg ε) = 299 nm (4.169), 
225 nm (4.721); IR (KBr): ν  [cm-1] =3429. 3136, 2925, 1746, 1629, 1454, 1377, 
1288, 1221, 1021; MF: C24H24N18O12RuCl2; MW = 928.54 g/mol; 
 
For details about the synthesis of complex 7, please contact Dr. Uwe Monkowius at 
J. Kepler University, Linz, Austria. (email: uwe.monkowius@jku.at). 
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3.5.2.3. Crystal Data 
 
Crystal data of 4 (prisms): 
Monoclinic; space group: P21/c; cell dimensions: a = 8.1669 (10) Å, α = 90°, b = 
9.4871 (13) Å, β = 94.135° (14), c = 10.3595 (12) Å, γ = 90°; V = 800.57 (17) Å3; 
Z = 2, Dx = 1.311 Mg/m3; µ = 0.083 mm-1; F(000) = 332. Data collection: T = 123 K; 
graphite monochromator. A translucent colorless prismatic crystal with dimensions of 
0.32 x 0.22 x 0.18 mm was used to measure 5365 reflections (1589 unique 
reflections, Rint = 0.0337) from 2.50° to 26.80° on a STOE-IPDS diffractometer with 
the rotation method. Structure refinement: The F2 value was refined using the full-
matrix least squares refinement method, with a goodness-of-fit of 0.913 for all 
reflections and 109 parameters. Final R indices: [I≥2σ(I)] = 0.0333, wR2 = 0.0805. 
Absolute structure parameters: σfin(max/min)[eÅ-3] = 0.238/-0.137. 
Table of atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2 x 103). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor: 
 
Atom x y z U(eq) 
N(8) 1128(1) 2840(1) 4667(1) 22(1)  
N(9) 739(1) 2801(1) 5909(1) 25(1)  
N(10) 200(1) 1519(1) 6131(1) 25(1)  
C(1) 3573(2) 3887(1) 3761(1) 24(1)  
C(2) 4691(2) 3083(1) 4530(1) 28(1)  
C(3) 6293(2) 2899(1) 4173(2) 35(1)  
C(4) 6791(2) 3529(2) 3058(2) 39(1)  
C(5) 5693(2) 4346(2) 2306(2) 40(1)  
C(6) 4083(2) 4521(1) 2648(1) 32(1)  
C(7) 1837(2) 4122(1) 4143(1) 25(1)  
C(11) 259(1) 740(1) 5028(1) 21(1)  
C(12) 849(1) 1580(1) 4083(1) 22(1)  
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Table of bond legths [Å] and angles [deg]: 
Bond Length Bond Angle Bond Angle 
N(8)-N(9) 1.3476(15)  N(9)-N(8)-C(7) 120.17(10)  C(1)-C(2)-H(2) 120.00  
N(8)-C(7) 1.4677(16)  N(9)-N(8)-C(12) 111.05(10)  C(3)-C(2)-H(2) 120.00  
N(8)-C(12) 1.3522(15)  C(7)-N(8)-C(12) 128.70(11)  C(2)-C(3)-H(3) 120.00  
N(9)-N(10) 1.3195(15)  N(8)-N(9)-N(10) 107.26(10)  C(4)-C(3)-H(3) 120.00  
N(10)-C(11) 1.3643(17)  N(9)-N(10)-C(11) 108.71(10)  C(3)-C(4)-H(4) 120.00  
C(1)-C(2) 1.3954(18)  C(2)-C(1)-C(6) 119.15(12)  C(5)-C(4)-H(4) 120.00  
C(1)-C(6) 1.3910(19)  C(2)-C(1)-C(7) 121.15(12)  C(4)-C(5)-H(5) 120.00  
C(1)-C(7) 1.5156(18)  C(6)-C(1)-C(7) 119.67(11)  C(6)-C(5)-H(5) 120.00  
C(2)-C(3) 1.3957(19)  C(1)-C(2)-C(3) 120.31(13)  C(1)-C(6)-H(6) 120.00  
C(3)-C(4) 1.388(2)  C(2)-C(3)-C(4) 120.21(13)  C(5)-C(6)-H(6) 120.00  
C(4)-C(5) 1.383(2)  C(3)-C(4)-C(5) 119.61(13)  N(8)-C(7)-H(7A) 109.00  
C(5)-C(6) 1.396(2)  C(4)-C(5)-C(6) 120.51(14)  N(8)-C(7)-H(7B) 109.00  
C(11)-C(12) 1.3764(17)  C(1)-C(6)-C(5) 120.20(13)  C(1)-C(7)-H(7A) 109.00  
C(11)-C(11)#1 1.4666(16)  N(8)-C(7)-C(1) 112.10(10)  C(1)-C(7)-H(7B) 109.00  
C(2)-H(2) 0.9500  N(10)-C(11)-C(12) 108.54(10)  H(7A)-C(7)-H(7B) 108.00  
C(3)-H(3) 0.9500  N(10)-C(11)-C(11)#1 121.62(11)  N(8)-C(12)-H(12) 128.00  
C(4)-H(4) 0.9500  C(11)#1-C(11)-C(12) 129.85(11)  C(11)-C(12)-H(12) 128.00  
C(5)-H(5) 0.9500  N(8)-C(12)-C(11) 104.45(11)      
C(6)-H(6) 0.9500          
C(7)-H(7A) 0.9900          
C(7)-H(7B) 0.9900          
C(12)-H(12) 0.9500         
 
 
Crystal data of 4 (needles): 
Monoclinic; space group: Cc; cell dimensions: a = 34.414 (3) Å, α = 90°, b = 5.5439 
(5) Å, β = 102.466° (10), c = 8.4506 (7) Å, γ = 90°; V = 1574.3 (2) Å3; Z = 4, Dx = 
1.335 Mg/m3; µ = 0.085 mm-1; F(000) = 664. Data collection: T = 123 K; graphite 
monochromator. A translucent colorless crystal with dimensions of 0.48 x 0.28 x 
0.02 mm was used to measure 6381 reflections (3264 unique reflections, Rint = 
0.0854) from 2.42° to 26.80° on a STOE-IPDS diffractometer with the rotation 
method. Structure refinement: The F2 value was refined using the full-matrix least 
squares refinement method, with a goodness-of-fit of 0.951 for all reflections and 217 
parameters. Final R indices: [I≥2σ(I)] = 0.0565, wR2 = 0.1401. Absolute structure 
parameters: σfin(max/min)[eÅ-3] = 0.294/-0.248. 
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Table of atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2 x 103). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor: 
 
Atom x y z U(eq) 
N(1) 876(1) 6980(4) -2258(3) 25(1)  
N(2) 864(1) 4560(5) -2200(3) 28(1)  
N(3) 1154(1) 3870(5) -978(3) 26(1)  
N(4) 1863(1) 7664(4) 1914(3) 26(1)  
N(5) 2158(1) 6927(4) 3104(3) 26(1)  
N(6) 2162(1) 4489(4) 3033(3) 24(1)  
C(1) -4(1) 9615(6) -2434(3) 30(1)  
C(2) -393(1) 9321(6) -2235(4) 33(1)  
C(3) -618(1) 7378(6) -2952(4) 34(1)  
C(4) -454(1) 5729(6) -3853(4) 36(1)  
C(5) -67(1) 5997(5) -4038(3) 32(1)  
C(6) 163(1) 7958(5) -3327(3) 25(1)  
C(7) 589(1) 8297(6) -3509(3) 29(1)  
C(8) 1170(1) 7889(6) -1077(3) 24(1)  
C(9) 1347(1) 5885(5) -274(3) 23(1)  
C(10) 1684(1) 5674(5) 1109(3) 22(1)  
C(11) 1873(1) 3640(5) 1814(3) 23(1)  
C(12) 2457(1) 3098(6) 4205(3) 27(1)  
C(13) 2856(1) 2877(5) 3740(3) 25(1)  
C(14) 2938(1) 900(5) 2828(3) 27(1)  
C(15) 3309(1) 665(6) 2459(3) 31(1)  
C(16) 3603(1) 2370(6) 3006(4) 32(1)  
C(17) 3523(1) 4327(6) 3897(4) 34(1)  
C(18) 3151(1) 4592(6) 4253(3) 30(1) 
 
Table of bond legths [Å] and angles [deg]: 
Bond Length Bond Angle Bond Angle 
N(1)-N(2) 1.344(4)  N(2)-N(1)-C(7) 120.0(2)  C(13)-C(18)-C(17) 120.5(3)  
N(1)-C(7) 1.474(4)  N(2)-N(1)-C(8) 111.6(2)  C(2)-C(1)-H(1) 120.00  
N(1)-C(8) 1.356(4)  C(7)-N(1)-C(8) 128.4(2)  C(6)-C(1)-H(1) 120.00  
N(2)-N(3) 1.328(4)  N(1)-N(2)-N(3) 107.0(2)  C(1)-C(2)-H(2) 120.00  
N(3)-C(9) 1.368(4)  N(2)-N(3)-C(9) 108.4(3)  C(3)-C(2)-H(2) 120.00  
N(4)-N(5) 1.331(4)  N(5)-N(4)-C(10) 108.4(2)  C(2)-C(3)-H(3) 120.00  
N(4)-C(10) 1.371(4)  N(4)-N(5)-N(6) 106.7(2)  C(4)-C(3)-H(3) 120.00  
N(5)-N(6) 1.353(3)  N(5)-N(6)-C(11) 111.6(2)  C(3)-C(4)-H(4) 120.00  
N(6)-C(11) 1.354(4)  N(5)-N(6)-C(12) 120.4(2)  C(5)-C(4)-H(4) 120.00  
N(6)-C(12) 1.473(4)  C(11)-N(6)-C(12) 128.0(2)  C(4)-C(5)-H(5) 120.00  
C(1)-C(2) 1.392(4)  C(2)-C(1)-C(6) 120.6(3)  C(6)-C(5)-H(5) 120.00  
C(1)-C(6) 1.389(4)  C(1)-C(2)-C(3) 119.9(3)  N(1)-C(7)-H(7A) 109.00  
C(2)-C(3) 1.388(5)  C(2)-C(3)-C(4) 119.8(3)  N(1)-C(7)-H(7B) 109.00  
C(3)-C(4) 1.385(5)  C(3)-C(4)-C(5) 120.5(3)  C(6)-C(7)-H(7A) 109.00  
C(4)-C(5) 1.382(5)  C(4)-C(5)-C(6) 120.2(3)  C(6)-C(7)-H(7B) 109.00  
C(5)-C(6) 1.401(4)  C(1)-C(6)-C(5) 119.0(3)  H(7A)-C(7)-H(7B) 108.00  
C(6)-C(7) 1.520(4)  C(1)-C(6)-C(7) 119.6(3)  N(1)-C(8)-H(8) 128.00  
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C(8)-C(9) 1.374(4)  C(5)-C(6)-C(7) 121.4(3)  C(9)-C(8)-H(8) 128.00  
C(9)-C(10) 1.463(4)  N(1)-C(7)-C(6) 112.2(2)  N(6)-C(11)-H(11) 128.00  
C(10)-C(11) 1.372(4)  N(1)-C(8)-C(9) 104.1(3)  C(10)-C(11)-H(11) 128.00  
C(12)-C(13) 1.514(4)  N(3)-C(9)-C(8) 108.9(3)  N(6)-C(12)-H(12A) 109.00  
C(13)-C(14) 1.404(4)  N(3)-C(9)-C(10) 120.6(2)  N(6)-C(12)-H(12B) 109.00  
C(13)-C(18) 1.390(4)  C(8)-C(9)-C(10) 130.6(3)  C(13)-C(12)-H(12A) 109.00  
C(14)-C(15) 1.382(4)  N(4)-C(10)-C(9) 121.7(2)  C(13)-C(12)-H(12B) 109.00  
C(15)-C(16) 1.390(5)  N(4)-C(10)-C(11) 109.0(2)  H(12A)-C(12)-H(12B) 108.00  
C(16)-C(17) 1.382(5)  C(9)-C(10)-C(11) 129.2(3)  C(13)-C(14)-H(14) 120.00  
C(17)-C(18) 1.385(4)  N(6)-C(11)-C(10) 104.3(2)  C(15)-C(14)-H(14) 120.00  
C(1)-H(1) 0.9500  N(6)-C(12)-C(13) 113.5(2)  C(14)-C(15)-H(15) 120.00  
C(2)-H(2) 0.9500  C(12)-C(13)-C(14) 120.5(3)  C(16)-C(15)-H(15) 120.00  
C(3)-H(3) 0.9500  C(12)-C(13)-C(18) 120.4(3)  C(15)-C(16)-H(16) 120.00  
C(4)-H(4) 0.9500  C(14)-C(13)-C(18) 119.0(3)  C(17)-C(16)-H(16) 120.00  
C(5)-H(5) 0.9500  C(13)-C(14)-C(15) 120.2(3)  C(16)-C(17)-H(17) 120.00  
C(7)-H(7A) 0.9900  C(14)-C(15)-C(16) 120.2(3)  C(18)-C(17)-H(17) 120.00  
C(7)-H(7B) 0.9900  C(15)-C(16)-C(17) 119.9(3)  C(13)-C(18)-H(18) 120.00  
C(8)-H(8) 0.9500  C(16)-C(17)-C(18) 120.3(3)  C(17)-C(18)-H(18) 120.00  
C(11)-H(11) 0.9500          
C(12)-H(12A) 0.9900          
C(12)-H(12B) 0.9900          
C(14)-H(14) 0.9500          
C(15)-H(15) 0.9500          
C(16)-H(16) 0.9500          
C(17)-H(17) 0.9500          
C(18)-H(18) 0.9500          
 
 
Crystal data of 5: 
Triclinic; space group: P-1; cell dimensions: a = 5.729 (4) Å, α = 101.38(11)°, b = 
11.019 (18) Å, β = 93.17° (7), c = 16.744 (14) Å, γ = 102.51 ° (11); V = 1006 (2) Å3; Z 
= 3, Dx = 1.428 Mg/m3; µ = 0.741 mm-1; F(000) = 450. Data collection: T = 150 K; 
graphite monochromator. A translucent colorless crystal with dimensions of 0.42 x 
0.06 x 0.04 mm was used to measure 5716 reflections (2062 unique reflections, Rint 
= 0.0263) from 2.71° to 50.31° on a Oxford Diffraction Gemini Ultra with the omega-
scan method. Structure refinement: The F2 value was refined using the full-matrix 
least squares refinement method, with a goodness-of-fit of 0.881 for all reflections 
and 298 parameters. Final R indices: [I≥2σ(I)] = 0.0338, wR2 = 0.0754. Absolute 
structure parameters: σfin(max/min)[eÅ-3] = 0.146/-0.213. 
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Table of atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2 x 103) of 5. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor: 
 
Atom x y z U(eq) 
N(1) 4727(3) 5087(2) 3299(1) 32(1)  
N(2) 7099(3) 5203(2) 3510(1) 40(1)  
N(3) 7354(3) 5157(2) 4285(1) 39(1)  
C(1) 3939(4) 5139(2) 2484(1) 31(1)  
C(2) 5573(4) 5696(2) 2012(1) 38(1)  
C(3) 4851(4) 5730(2) 1223(1) 41(1)  
C(4) 2490(4) 5224(2) 903(1) 41(1)  
C(5) 859(4) 4691(2) 1381(1) 40(1)  
C(6) 1568(4) 4637(2) 2174(1) 37(1)  
C(7) 3474(4) 4967(2) 3945(1) 34(1)  
C(8) 5154(4) 5023(2) 4575(1) 33(1)  
N(4) 4082(3) 1779(2) 4064(1) 32(1)  
N(5) 1707(3) 1673(2) 3862(1) 38(1)  
N(6) 1436(3) 1715(2) 3085(1) 40(1)  
N(7) 6065(3) 2150(2) 1641(1) 37(1)  
N(8) 5739(3) 2074(2) 851(1) 38(1)  
N(9) 3324(3) 1759(2) 632(1) 32(1)  
C(9) 4883(4) 1740(2) 4880(1) 30(1)  
C(10) 3216(4) 1197(2) 5351(1) 39(1)  
C(11) 3938(4) 1160(2) 6140(1) 45(1)  
C(12) 6305(4) 1657(2) 6463(1) 44(1)  
C(13) 7945(4) 2176(2) 5988(1) 40(1)  
C(14) 7257(4) 2227(2) 5190(1) 36(1)  
C(15) 5324(4) 1895(2) 3411(1) 34(1)  
C(16) 3632(4) 1852(2) 2787(1) 32(1)  
C(17) 3873(4) 1887(2) 1935(1) 32(1)  
C(18) 2128(4) 1641(2) 1290(1) 36(1)  
C(19) 2429(4) 1566(2) -210(1) 32(1)  
C(20) 3650(4) 971(2) -808(1) 35(1)  
C(21) 2820(4) 800(2) -1620(1) 39(1)  
C(22) 806(4) 1208(2) -1836(1) 40(1)  
C(23) -393(4) 1783(2) -1234(1) 36(1)  
C(24) 396(4) 1959(2) -416(1) 36(1) 
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Table of bond legths [Å] and angles [deg] of 5: 
Bond Length Bond Angle Bond Angle 
N(1)-N(2) 1.357(3)  N(2)-N(1)-C(1) 119.4(2)  C(11)-C(12)-C(13) 119.6(2)  
N(1)-C(1) 1.429(4)  N(2)-N(1)-C(7) 110.5(2)  C(12)-C(13)-C(14) 120.9(2)  
N(1)-C(7) 1.342(4)  C(1)-N(1)-C(7) 130.2(2)  C(9)-C(14)-C(13) 118.8(2)  
N(2)-N(3) 1.310(3)  N(1)-N(2)-N(3) 107.4(2)  N(4)-C(15)-C(16) 105.0(2)  
N(3)-C(8) 1.365(4)  N(2)-N(3)-C(8) 108.7(2)  N(6)-C(16)-C(15) 108.3(2)  
N(4)-C(9) 1.429(4)  N(5)-N(4)-C(15) 110.6(2)  N(6)-C(16)-C(17) 121.2(2)  
N(4)-C(15) 1.348(4)  C(9)-N(4)-C(15) 130.4(2)  C(15)-C(16)-C(17) 130.5(2)  
N(4)-N(5) 1.358(3)  N(5)-N(4)-C(9) 119.1(2)  N(7)-C(17)-C(16) 122.2(2)  
N(5)-N(6) 1.312(3)  N(4)-N(5)-N(6) 107.3(2)  N(7)-C(17)-C(18) 108.1(2)  
N(6)-C(16) 1.368(4)  N(5)-N(6)-C(16) 108.9(2)  C(16)-C(17)-C(18) 129.7(2)  
N(7)-C(17) 1.368(4)  N(8)-N(7)-C(17) 108.9(2)  N(9)-C(18)-C(17) 105.3(2)  
N(7)-N(8) 1.310(3)  N(7)-N(8)-N(9) 107.3(2)  N(9)-C(19)-C(20) 118.6(2)  
N(8)-N(9) 1.362(3)  N(8)-N(9)-C(19) 119.7(2)  N(9)-C(19)-C(24) 120.1(2)  
N(9)-C(19) 1.433(4)  N(8)-N(9)-C(18) 110.4(2)  C(20)-C(19)-C(24) 121.3(2)  
N(9)-C(18) 1.342(4)  C(18)-N(9)-C(19) 129.9(2)  C(19)-C(20)-C(21) 118.9(2)  
C(1)-C(6) 1.380(4)  C(2)-C(1)-C(6) 120.4(2)  C(20)-C(21)-C(22) 120.5(2)  
C(1)-C(2) 1.380(4)  N(1)-C(1)-C(6) 120.3(2)  C(21)-C(22)-C(23) 119.8(2)  
C(2)-C(3) 1.373(4)  N(1)-C(1)-C(2) 119.3(2)  C(22)-C(23)-C(24) 120.9(2)  
C(3)-C(4) 1.379(4)  C(1)-C(2)-C(3) 119.9(2)  C(19)-C(24)-C(23) 118.7(2)  
C(4)-C(5) 1.374(4)  C(2)-C(3)-C(4) 120.3(2)  C(9)-C(10)-H(10) 120.00  
C(5)-C(6) 1.384(4)  C(3)-C(4)-C(5) 119.6(2)  C(11)-C(10)-H(10) 120.00  
C(7)-C(8) 1.372(4)  C(4)-C(5)-C(6) 120.7(2)  C(10)-C(11)-H(11) 120.00  
C(8)-C(8)#1 1.452(4)  C(1)-C(6)-C(5) 119.0(2)  C(12)-C(11)-H(11) 120.00  
C(2)-H(2) 0.9500  N(1)-C(7)-C(8) 105.1(2)  C(11)-C(12)-H(12) 120.00  
C(3)-H(3) 0.9500  C(7)-C(8)-C(8)#1 129.6(2)  C(13)-C(12)-H(12) 120.00  
C(4)-H(4) 0.9500  N(3)-C(8)-C(7) 108.3(2)  C(12)-C(13)-H(13) 120.00  
C(5)-H(5) 0.9500  N(3)-C(8)-C(8)#1 122.1(2)  C(14)-C(13)-H(13) 120.00  
C(6)-H(6) 0.9500  C(1)-C(2)-H(2) 120.00  C(9)-C(14)-H(14) 121.00  
C(7)-H(7) 0.9500  C(3)-C(2)-H(2) 120.00  C(13)-C(14)-H(14) 121.00  
C(9)-C(10) 1.384(4)  C(4)-C(3)-H(3) 120.00  N(4)-C(15)-H(15) 127.00  
C(9)-C(14) 1.379(4)  C(2)-C(3)-H(3) 120.00  C(16)-C(15)-H(15) 128.00  
C(10)-C(11) 1.373(4)  C(5)-C(4)-H(4) 120.00  N(9)-C(18)-H(18) 127.00  
C(11)-C(12) 1.383(4)  C(3)-C(4)-H(4) 120.00  C(17)-C(18)-H(18) 127.00  
C(12)-C(13) 1.369(4)  C(4)-C(5)-H(5) 120.00  C(19)-C(20)-H(20) 121.00  
C(13)-C(14) 1.388(4)  C(6)-C(5)-H(5) 120.00  C(21)-C(20)-H(20) 121.00  
C(15)-C(16) 1.372(4)  C(1)-C(6)-H(6) 120.00  C(20)-C(21)-H(21) 120.00  
C(16)-C(17) 1.449(4)  C(5)-C(6)-H(6) 121.00  C(22)-C(21)-H(21) 120.00  
C(17)-C(18) 1.374(4)  N(1)-C(7)-H(7) 127.00  C(21)-C(22)-H(22) 120.00  
C(19)-C(20) 1.392(4)  C(8)-C(7)-H(7) 127.00  C(23)-C(22)-H(22) 120.00  
C(19)-C(24) 1.377(4)  N(4)-C(9)-C(10) 118.3(2)  C(22)-C(23)-H(23) 120.00  
C(20)-C(21) 1.379(4)  N(4)-C(9)-C(14) 120.9(2)  C(24)-C(23)-H(23) 120.00  
C(21)-C(22) 1.381(4)  C(10)-C(9)-C(14) 120.8(2)  C(19)-C(24)-H(24) 121.00  
C(22)-C(23) 1.379(4)  C(9)-C(10)-C(11) 119.3(2)  C(23)-C(24)-H(24) 121.00 
C(23)-C(24) 1.381(4)  C(10)-C(11)-C(12) 120.6(2)      
C(n)-H(n)           
[n=10-24] 0.9500          
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Crystal data of 6: 
Monoclinic; space group: P21/c; cell dimensions: a = 7.4088 (4) Å, α = 90°, b = 
4.5388 (3) Å, β = 95.767° (5), c = 14.5860 (9) Å, γ = 90°; V = 488.00 (5) Å3; Z = 2, 
Dx = 1.716 Mg/m3; µ = 1.221 mm-1; F(000) = 260. Data collection: T = 123 K; graphite 
monochromator. A translucent colorless crystal with dimensions of 0.44 x 0.02 x 
0.01 mm was used to measure 1756 reflections (748 unique reflections, Rint = 
0.0298) from 6.10° to 62.10° on a Oxford Diffraction Gemini Ultra with the omega-
scan method. Structure refinement: The F2 value was refined using the full-matrix 
least squares refinement method, with a goodness-of-fit of 1.062 for all reflections 
and 85 parameters. Final R indices: [I≥2σ(I)] = 0.0773, wR2 = 0.2273. Absolute 
structure parameters: σfin(max/min)[eÅ-3] = 1.021/-0.299. 
Table of atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(A2 x 103) of 6. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor: 
Atom x y z U(eq) 
O(1) 6329(4) -1046(6) 3132(2) 39(1)  
O(2) 8158(4) 2644(7) 2785(2) 46(1)  
N(1) 7524(4) 4376(8) -159(2) 36(1)  
N(2) 6519(4) 2632(8) 315(2) 35(1)  
N(3) 7674(4) 1282(8) 945(2) 34(1)  
C(1) 9291(5) 4167(9) 188(2) 32(1)  
C(2) 9397(5) 2156(9) 898(2) 34(1)  
C(3) 6952(6) -688(10) 1597(2) 37(1)  
C(4) 7213(5) 541(9) 2575(2) 32(1)  
 
Table of bond legths [Å] and angles [deg] of 6: 
Bond Length Bond Angle Bond Angle 
O(1)-C(4) 1.310(5)  C(4)-O(1)-H(1O) 112(4)  O(1)-C(4)-C(3) 110.8(3)  
O(2)-C(4) 1.205(5)  N(2)-N(1)-C(1) 109.5(3)  O(2)-C(4)-C(3) 122.9(3)  
O(1)-H(1O) 0.80(6)  N(1)-N(2)-N(3) 106.1(3)  O(1)-C(4)-O(2) 126.3(3)  
N(1)-N(2) 1.328(5)  N(2)-N(3)-C(2) 112.0(3)  N(3)-C(2)-H(2) 128.00  
N(1)-C(1) 1.359(5)  C(2)-N(3)-C(3) 129.2(3)  C(1)-C(2)-H(2) 128.00  
N(2)-N(3) 1.339(4)  N(2)-N(3)-C(3) 118.7(3)  N(3)-C(3)-H(3A) 109.00  
N(3)-C(2) 1.345(5)  N(1)-C(1)-C(2) 107.9(3)  N(3)-C(3)-H(3B) 109.00  
N(3)-C(3) 1.447(5)  C(1)#1-C(1)-C(2) 130.0(3)  C(4)-C(3)-H(3A) 109.00  
C(1)-C(1)#1 1.446(5)  N(1)-C(1)-C(1)#1 122.1(3)  C(4)-C(3)-H(3B) 109.00  
C(1)-C(2) 1.377(5)  N(3)-C(2)-C(1) 104.6(3)  H(3A)-C(3)-H(3B) 108.00  
C(3)-C(4) 1.526(4)  N(3)-C(3)-C(4) 111.6(3)      
C(2)-H(2) 0.9500          
C(3)-H(3A) 0.9900          
C(3)-H(3B) 0.9900         
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Crystal data of 7: 
Monoclinic; space group: P21/a; cell dimensions: a = 16.3417 (3) Å, α = 90°, b = 
23.1347 (4) Å, β = 107.787° (3), c = 18.0784 (5) Å, γ = 90°; V = 6508.0 (3) Å3; Z = 4, 
Dx = 1.134 Mg/m3; µ = 2.968 mm-1; F(000) = 2286. Data collection: T = 123 K; 
graphite monochromator. A translucent colorless crystal with dimensions of 0.36 x 
0.11 x 0.06 mm was used to measure 31311 reflections (6840 unique reflections, Rint 
= 0.0455) from 3.20° to 51.54° on a Oxford Diffraction Gemini Ultra with the omega-
scan method. Structure refinement: The F2 value was refined using the full-matrix 
least squares refinement method, with a goodness-of-fit of 15.585 for all reflections 
and 677 parameters. Final R indices: [I≥2σ(I)] = 0.1981, wR2 = 0.3470. Absolute 
structure parameters: σfin(max/min)[eÅ-3] = 3.112/-1.520. 
 
 
 
 232
3.6. References 
                                                 
1
 A. Juris, V. Balzani, F. Barigeletti, S. Campagna, P. Belser, A. v. Zelewsky, 
Coord. Chem. Rev. 1988, 84, 85; K.P. Balashev, M.V. Puzyk, V.S. Kotlyar, M.V. 
Kulikova, Coord. Chem. Rev. 1997, 159, 109; C.E. Housecroft, Compr. Coord. 
Chem. II 2004, 5, 555; O.S. Wolfbeis, L.J. Weis, M.J.P. Leiner, W.E. Ziegler, Anal. 
Chem. 1988, 60, 2028; M. Maestri, D. Sandrini, V. Balzani, L. Chassot, P. Jolliet, 
A. v. Zelewsky, Chem. Phys. Lett. 1985, 122, 375. 
2
 S. Welter, N. Salluce, P. Belser, M. Groeneveld, L. De Cola, Coord. Chem. Rev. 
2005, 249, 1327; R.T.F. Jukes, V. Adamo, F. Hartl, P. Belser, L. De Cola, Coord. 
Chem Rev. 2005, 249, 1327. V. Balzani, F. Scandola, Supramolecular 
Photochemistry, E. Horwood, Chichester, 1991; R. Hage, Coord. Chem. Rev. 
1991, 111, 161; M. Ruben, S. Rau, A. Skirl, K. Krause, H. Gorls, D. Walther, J.G. 
Vos, Inorg. Chim. Acta 2000, 303, 206; V.J. Catalano, T.J. Craig, Inorg. Chem. 
2003, 42, 321; D.M. D’Alessandro, P.H. Dinolfo, J.T. Hupp, P.C. Junk, F.R. 
Keene, Eur. J. Org. Chem. 2006, 4, 772; H. Yersin, C. Kratzer, Coord. Chem. 
Rev. 2002, 229, 75. 
3
 L. De Cola, P. Belser, A. v. Zelewsky, F. Vögtle, Inorg. Chim. Acta 2007, 360, 
775; R.T.F. Jukes, B. Bozic, F, Hartl, P. Belser, L. De Cola, Inorg. Chem. 2006, 
45, 8326; S. Welter, F. Lafolet, E. Cecchetto, F. Vergeer, L. De Cola, 
ChemPhysChem 2005, 6, 2417; W.J. Finkenzeller, P. Stoessel, H. Yersin, Chem. 
Phys. Lett. 2004, 397, 289; C.A. Bignozzi, R. Argazzi, C. Chiorboli, S. Roffia, F. 
Scandola, Coord. Chem. Rev. 1991, 111, 261; D.M. D’Alessandro, F.R. Keene, 
Chem. Rev. 2006, 106, 2270; S. Ranjan, S.K. Dikshit, Trans. Metal Chem. 2002, 
27, 668; E. Tfouni, Coord. Chem. Rev. 2000, 196, 281; D.W. Thompson, J.R. 
Schoonover, T.J. Meyer, R. Argazzi, C.A. Bignozzi, J. Chem. Soc. Dalton Trans.: 
Inorg. Chem. 1999, 21, 3729. 
4
 H. Yersin, Topics in Curr. Chem. 2004, 241, 1; K.W. Lee, J.D. Slinker, A.A. 
Gorodetsky, S. Flores-Torres, H.D. Abruna, P.L: Housten, G.G. Malliaras, 
Physical Chemistry Chemical Physics 2003, 5, 2706; L.J. Stoltzberg, J.D. Slinker, 
S. Flores-Torres, A.D. Bernards, G.G. Malliaras, H.D. Abruna, J.-S. Kim, R.H. 
Friend, M.D. Kaplan, V. Goldberg, J. Am. Chem. Soc. 2006, 128, 7761; C. Zhen, 
Y. Chuai, C. Lao, L. Huang, D. Zou, D.N. Lee, B.H. Kim, Appl. Phys. Lett. 2005, 
 233
                                                                                                                                                         
87, 093508/1; F.W. Vergeer, X. Chen, F. Lafolet, L. De Cola, H. Fuchs, L. Chi, 
Adv. Funct. Mat. 2006, 16, 625. 
5
 K. Kalyanasundaram, Photochemistry of Polypyridine and Porphyrin Complexes, 
Academic Press, London, 1992. 
6
 P. McCord, A.J. Bard, J. Electroanal. Chem. 1991, 318, 91. 
7
 P. Coppo, M. Duati, V.N. Kozhevnikov, J.W. Hofstraat, L. DeCola, Angew. Chem. 
Int. Ed. 2005, 44, 1806. 
8
 P. Coppo, E.A. Plummer, L. De Cola, Chem. Commun. 2004, 1774. 
9
 B.W. D’Andrade, J. Brooks, V. Adamovich, M.E. Thompsom, S.R. Forrest, Adv. 
Mater. 2002, 14, 1032; B.W. D’Andrade, S.R. Forrest, Adv. Mater. 2004, 16, 1585; 
J. Slinker, A.D. Bernards, P.L. Houston, H.D. Abruna, S. Bernhard, G.G. 
Malliaras, Chem. Commun. 2003, 2392. 
10
 The synthesis of a phenyl substituted bitriazole, using the thermal cycloaddition, is 
already reported in literature. However, a mixture of different products was 
obtained and no analytical data for this compound are available. 
 L.V. Sokolyanska, A.N. Volkov, B.A. Trofimov, Khimiya Geterotsiklicheskikh 
Soedinenii 1979, 6, 849. 
 The synthesis of an unsubstituted bitriazole is reported. K. Banert, Chem. Ber. 
1989, 122, 1175. 
11
 H.D. Verkruijsse, L. Brandsma, Synth. Comm. 1991, 21, 657. 
12
 T. Jin, S. Kamijo, Y. Yamamoto, Eur. J. Org. Chem. 2004, 18, 3789. 
13
 Y.-M. Wu, J. Deng, Q.-Y. Chen, Synthesis 2005, 8, 1314. 
 234
 235
4. Abbreviations 
 
A anion 
Ala alanine 
Asp aspartic acid 
aq aqueous 
Bn benzyl 
BnOH benzyl alcohol 
Boc tert-Butoxycarbonyl 
Bu butyl 
tBuOH tert-butanol 
Bzl benzyl 
c concentration 
calc calculated 
CC column chromatography 
CD circular dichroism 
d days 
DCM dichloromethane 
DIEA ethyl diisopropyl amine 
DMAP 4-(dimethylamino) pyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
EA elemental analysis 
EDC 1-ethyl-3-(3-
dimethylaminopropyl) 
carbodiimide 
EDTA ethylenediaminetetraacetic 
acid disodium salt 
 
 
EE ethyl acetate 
EI electronic ionisation 
eq equivalents 
ESI electronic spray ionisation 
Et ethyl 
Et2O diethyl ether 
EtOAc ethyl acetate 
EtOH ethanol 
FAB fast atom bombardment 
Fc ferrocene 
fig figure 
Fl fluorescence 
FRET fluorescent resonance 
energy transfer 
Glu glutamic acid 
Gly glycine 
GP general procedure 
h hour 
HEL hen eggwhite lysozyme 
Hepes 4-(2-hydroxyethyl)-
piperazine-1-ethane 
sulfonic acid 
His histidine 
HNEt2 diethyl amine 
HOBt 1-Hydroxybenzotriazole 
HPLC high performance liquid 
chromatography 
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HR high resolution 
IDA iminodiacetic acid 
IR infrared spectroscopy 
J coupling constant 
K cation 
LC liquid chromatography 
Leu leucine 
Lys lysine 
M molecule 
Me methyl 
MeCN acetonitrile 
MeOH methanol 
min minutes 
MF molecular formular 
Mp melting point 
MS mass spectroscopy 
MW molecular weight 
Myo myoglobine 
NEt3 triethyl amine 
NIR near infrared 
NMR nuclear magnetic 
resonance 
NTA nitrilotriacetic acid 
OAc acetate 
 
 
 
 
PE petrol ether 
Ph phenyl 
Phe phenylalanine 
Rf retention factor 
RNA ribonucleic acid 
r.t. room temperature 
sat saturated 
Ser serine 
SN nucleophilic substitution 
TBABr tetrabutyl ammonium 
bromide 
TBTU 2-(1H-Benzotriazole-1-yl)-
1,1,3,3-tetramethyl-
uronium tetrafluoro borate  
TFA trifluoroacetic acid 
TGS target guided synthesis 
THF tetrahydrofurane 
TLC thin layer chromatography 
TMS trimethylsilyl 
TPP tetraphenyl porphyrin 
UV ultraviolet 
Val valine 
Vis visible 
x mole fraction 
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